{
"company_details": [
{
"company_id": "0000786947",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000786947.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000786947.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000786947.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000786947_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000786947_main_keyfigs.svg",
"name": "Acura Pharmaceuticals INC",
"rank": 1,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000786947.svg",
"report_text": "The relative strengths and weaknesses of Acura Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Acura Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 192% points.The greatest weakness of Acura Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 38% points.
The company's Economic Capital Ratio, given in the ranking table, is 501%, being 267% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000786947_2012_Acura_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.03",
"Assets": "-19.0",
"Liabilities": "142",
"Stockholders Equity": "192",
"ECR before LimitedLiability": "343",
"Intangible Assets": "2.64",
"Assets, Current": "-38.0",
"Other Liabilities": "54.7",
"Liabilities, Non-Current": "24.7",
"Liabilities, Current": "92.8",
"Research and Development": "23.8",
"Expenses": "49.3",
"Revenues": "50.4",
"Net Income": "98.3",
"Other Expenses": "12.6",
"Cost of Goods Sold": "4.72",
"Selling, General and Administrative Expense": "9.44",
"Other Revenues": "50.4",
"Comprehensive Net Income": "97.9",
"Other Net Income": "2.88",
"Economic Capital Ratio": "267"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000786947_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "36,129",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "530",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "147",
"Other Liabilities": "0",
"Other Net Income": "-2.0",
"Other Revenues": "20,466",
"Property and Equipment": "1,044",
"Research and Development": "4,037",
"Selling, General and Administrative Expense": "5,895"
},
"output_variables": {
"Assets": "37,173",
"Liabilities": "530",
"Expenses": "10,079",
"Revenues": "20,466",
"Stockholders Equity": "36,643",
"Net Income": "10,385",
"Comprehensive Net Income": "10,385",
"BaseVar": "34,125",
"ECR before LimitedLiability": "479%",
"Economic Capital Ratio": "501%"
}
}
},
"top_rated": true,
"trend": null,
"value": 5.013609653404872,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000786947.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000786947.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000786947.svg"
},
{
"company_id": "0000875622",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000875622.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000875622.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000875622_main_keyfigs.svg",
"name": "Biospecifics Technologies CORP",
"rank": 2,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000875622.svg",
"report_text": "The relative strengths and weaknesses of Biospecifics Technologies CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biospecifics Technologies CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 152% points.The greatest weakness of Biospecifics Technologies CORP is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 483%, being 249% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000875622_2012_Biospecifics_Technologies_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.15",
"Assets": "-5.40",
"Liabilities": "124",
"Stockholders Equity": "152",
"ECR before LimitedLiability": "324",
"Intangible Assets": "1.28",
"Assets, Current": "-6.08",
"Other Liabilities": "55.1",
"Liabilities, Non-Current": "25.0",
"Liabilities, Current": "69.3",
"Research and Development": "33.8",
"Expenses": "52.1",
"Revenues": "63.1",
"Net Income": "113",
"Other Expenses": "25.8",
"Cost of Goods Sold": "4.92",
"Selling, General and Administrative Expense": "-11.7",
"Other Revenues": "63.1",
"Comprehensive Net Income": "113",
"Other Net Income": "3.67",
"Economic Capital Ratio": "249"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000875622_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,087",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,116",
"Liabilities, Non-Current": "0",
"Other Assets": "3,179",
"Other Compr. Net Income": "0",
"Other Expenses": "-1,338",
"Other Liabilities": "0",
"Other Net Income": "72",
"Other Revenues": "11,396",
"Property and Equipment": "0",
"Research and Development": "972",
"Selling, General and Administrative Expense": "5,232"
},
"output_variables": {
"Assets": "16,265",
"Liabilities": "1,116",
"Expenses": "4,866",
"Revenues": "11,396",
"Stockholders Equity": "15,149",
"Net Income": "6,602",
"Comprehensive Net Income": "6,602",
"BaseVar": "16,857",
"ECR before LimitedLiability": "456%",
"Economic Capital Ratio": "483%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.8269459350535335,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000875622.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000875622.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000875622.svg"
},
{
"company_id": "0000847464",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000847464.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000847464.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000847464_main_keyfigs.svg",
"name": "Spring Pharmaceutical Group INC",
"rank": 3,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000847464.svg",
"report_text": "The relative strengths and weaknesses of Spring Pharmaceutical Group INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Spring Pharmaceutical Group INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 181% points.The greatest weakness of Spring Pharmaceutical Group INC is the variable Other Expenses, reducing the Economic Capital Ratio by 36% points.
The company's Economic Capital Ratio, given in the ranking table, is 472%, being 238% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000847464_2012_Spring_Pharmaceutical_Group_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "-2.85",
"Stockholders Equity": "181",
"ECR before LimitedLiability": "314",
"Intangible Assets": "-4.80",
"Assets, Current": "0.698",
"Other Liabilities": "49.6",
"Liabilities": "126",
"Liabilities, Non-Current": "22.4",
"Liabilities, Current": "78.9",
"Research and Development": "37.7",
"Expenses": "38.9",
"Revenues": "35.2",
"Net Income": "74.3",
"Other Expenses": "-35.9",
"Cost of Goods Sold": "4.46",
"Selling, General and Administrative Expense": "31.0",
"Other Revenues": "35.2",
"Comprehensive Net Income": "75.3",
"Other Net Income": "2.77",
"Other Compr. Net Income": "1.08",
"Economic Capital Ratio": "238"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000847464_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "21,708",
"Cost of Goods Sold": "0",
"Intangible Assets": "40,560",
"Liabilities, Current": "1,914",
"Liabilities, Non-Current": "0",
"Other Assets": "211",
"Other Compr. Net Income": "1,330",
"Other Expenses": "22,241",
"Other Liabilities": "0",
"Other Net Income": "23",
"Other Revenues": "33,465",
"Property and Equipment": "9,630",
"Research and Development": "280",
"Selling, General and Administrative Expense": "752"
},
"output_variables": {
"Assets": "72,109",
"Liabilities": "1,914",
"Expenses": "23,273",
"Revenues": "33,465",
"Stockholders Equity": "70,196",
"Net Income": "10,215",
"Comprehensive Net Income": "10,880",
"BaseVar": "66,057",
"ECR before LimitedLiability": "443%",
"Economic Capital Ratio": "472%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.72228705112978,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000847464.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000847464.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000847464.svg"
},
{
"company_id": "0000926844",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000926844.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000926844.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000926844_main_keyfigs.svg",
"name": "Fuss Brands Corp",
"rank": 4,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000926844.svg",
"report_text": "The relative strengths and weaknesses of Fuss Brands Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fuss Brands Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 129% points.The greatest weakness of Fuss Brands Corp is the variable Other Expenses, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 445%, being 211% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000926844_2012_Fuss_Brands_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "8.10",
"Assets": "5.20",
"Stockholders Equity": "129",
"ECR before LimitedLiability": "287",
"Assets, Current": "-1.50",
"Other Liabilities": "14.6",
"Liabilities": "110",
"Liabilities, Non-Current": "23.2",
"Liabilities, Current": "85.9",
"Research and Development": "37.2",
"Expenses": "37.5",
"Revenues": "50.9",
"Net Income": "88.3",
"Other Expenses": "-36.9",
"Cost of Goods Sold": "4.84",
"Selling, General and Administrative Expense": "30.4",
"Other Revenues": "50.9",
"Comprehensive Net Income": "90.1",
"Other Net Income": "3.12",
"Other Compr. Net Income": "2.05",
"Economic Capital Ratio": "211"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000926844_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,072",
"Cost of Goods Sold": "0",
"Intangible Assets": "17,147",
"Liabilities, Current": "2,098",
"Liabilities, Non-Current": "0",
"Other Assets": "41,677",
"Other Compr. Net Income": "3,852",
"Other Expenses": "39,283",
"Other Liabilities": "8,131",
"Other Net Income": "127",
"Other Revenues": "72,714",
"Property and Equipment": "0",
"Research and Development": "3,593",
"Selling, General and Administrative Expense": "4,046"
},
"output_variables": {
"Assets": "109,896",
"Liabilities": "10,230",
"Expenses": "46,922",
"Revenues": "72,714",
"Stockholders Equity": "99,666",
"Net Income": "25,919",
"Comprehensive Net Income": "27,845",
"BaseVar": "121,870",
"ECR before LimitedLiability": "408%",
"Economic Capital Ratio": "445%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.453172041265832,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000926844.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000926844.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000926844.svg"
},
{
"company_id": "0001052284",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001052284.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001052284.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001052284_main_keyfigs.svg",
"name": "Tongli Pharmaceuticals USA Inc",
"rank": 5,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001052284.svg",
"report_text": "The relative strengths and weaknesses of Tongli Pharmaceuticals USA Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tongli Pharmaceuticals USA Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 122% points.The greatest weakness of Tongli Pharmaceuticals USA Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 62% points.
The company's Economic Capital Ratio, given in the ranking table, is 441%, being 207% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001052284_2012_Tongli_Pharmaceuticals_USA_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "10.8",
"Assets": "2.63",
"Liabilities": "122",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "283",
"Property and Equipment": "8.72",
"Assets, Current": "-6.74",
"Other Liabilities": "56.4",
"Liabilities, Non-Current": "25.8",
"Liabilities, Current": "64.1",
"Research and Development": "46.5",
"Expenses": "30.4",
"Revenues": "65.0",
"Net Income": "95.3",
"Other Expenses": "-62.0",
"Cost of Goods Sold": "5.45",
"Selling, General and Administrative Expense": "35.1",
"Other Revenues": "65.0",
"Comprehensive Net Income": "96.8",
"Other Net Income": "2.89",
"Economic Capital Ratio": "207"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001052284_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,979",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,791",
"Liabilities, Non-Current": "0",
"Other Assets": "7,504",
"Other Compr. Net Income": "562",
"Other Expenses": "9,723",
"Other Liabilities": "0",
"Other Net Income": "-58",
"Other Revenues": "14,655",
"Property and Equipment": "6,384",
"Research and Development": "0",
"Selling, General and Administrative Expense": "614"
},
"output_variables": {
"Assets": "17,867",
"Liabilities": "1,791",
"Expenses": "10,337",
"Revenues": "14,655",
"Stockholders Equity": "16,076",
"Net Income": "4,260",
"Comprehensive Net Income": "4,541",
"BaseVar": "22,635",
"ECR before LimitedLiability": "403%",
"Economic Capital Ratio": "441%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.412907765037316,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001052284.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001052284.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001052284.svg"
},
{
"company_id": "0001059790",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001059790.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001059790.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001059790_main_keyfigs.svg",
"name": "Pozen INC NC",
"rank": 6,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001059790.svg",
"report_text": "The relative strengths and weaknesses of Pozen INC NC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pozen INC NC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 114% points.The greatest weakness of Pozen INC NC is the variable Intangible Assets, reducing the Economic Capital Ratio by 2.4% points.
The company's Economic Capital Ratio, given in the ranking table, is 436%, being 202% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001059790_2012_Pozen_INC_NC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.85",
"Assets": "7.06",
"Liabilities": "91.4",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "278",
"Intangible Assets": "-2.41",
"Assets, Current": "19.5",
"Other Liabilities": "48.1",
"Liabilities, Non-Current": "21.8",
"Liabilities, Current": "35.7",
"Research and Development": "15.7",
"Expenses": "42.8",
"Revenues": "55.0",
"Net Income": "97.4",
"Other Expenses": "12.9",
"Cost of Goods Sold": "4.60",
"Selling, General and Administrative Expense": "10.8",
"Other Revenues": "55.0",
"Comprehensive Net Income": "97.1",
"Other Net Income": "2.99",
"Economic Capital Ratio": "202"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001059790_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "121,450",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "16,055",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "161",
"Other Revenues": "86,951",
"Property and Equipment": "103",
"Research and Development": "23,020",
"Selling, General and Administrative Expense": "21,752"
},
"output_variables": {
"Assets": "121,553",
"Liabilities": "16,055",
"Expenses": "44,772",
"Revenues": "86,951",
"Stockholders Equity": "105,498",
"Net Income": "42,340",
"Comprehensive Net Income": "42,340",
"BaseVar": "134,746",
"ECR before LimitedLiability": "396%",
"Economic Capital Ratio": "436%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.36077529947281,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001059790.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001059790.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001059790.svg"
},
{
"company_id": "0001362718",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001362718.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001362718.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001362718_main_keyfigs.svg",
"name": "Tianyin Pharmaceutical CO INC",
"rank": 7,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001362718.svg",
"report_text": "The relative strengths and weaknesses of Tianyin Pharmaceutical CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tianyin Pharmaceutical CO INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 147% points.The greatest weakness of Tianyin Pharmaceutical CO INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 77% points.
The company's Economic Capital Ratio, given in the ranking table, is 434%, being 199% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001362718_2012_Tianyin_Pharmaceutical_CO_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.82",
"Assets": "-2.66",
"Liabilities": "147",
"Stockholders Equity": "79.3",
"ECR before LimitedLiability": "275",
"Property and Equipment": "7.93",
"Assets, Current": "-5.89",
"Other Liabilities": "65.7",
"Liabilities, Non-Current": "30.5",
"Liabilities, Current": "83.4",
"Research and Development": "54.5",
"Expenses": "12.0",
"Revenues": "84.1",
"Net Income": "101",
"Other Expenses": "-14.1",
"Cost of Goods Sold": "-76.9",
"Selling, General and Administrative Expense": "39.7",
"Other Revenues": "84.1",
"Comprehensive Net Income": "102",
"Other Net Income": "6.47",
"Economic Capital Ratio": "199"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001362718_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "47,396",
"Cost of Goods Sold": "52,698",
"Intangible Assets": "15,339",
"Liabilities, Current": "8,922",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "3,272",
"Other Expenses": "21,803",
"Other Liabilities": "0",
"Other Net Income": "1,641",
"Other Revenues": "95,201",
"Property and Equipment": "27,466",
"Research and Development": "1,073",
"Selling, General and Administrative Expense": "5,645"
},
"output_variables": {
"Assets": "90,201",
"Liabilities": "8,922",
"Expenses": "81,219",
"Revenues": "95,201",
"Stockholders Equity": "81,280",
"Net Income": "15,623",
"Comprehensive Net Income": "17,259",
"BaseVar": "140,228",
"ECR before LimitedLiability": "392%",
"Economic Capital Ratio": "434%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.335065089469718,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001362718.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001362718.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001362718.svg"
},
{
"company_id": "0000887497",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000887497.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000887497.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000887497_main_keyfigs.svg",
"name": "HI TECH Pharmacal CO INC",
"rank": 8,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000887497.svg",
"report_text": "The relative strengths and weaknesses of HI TECH Pharmacal CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of HI TECH Pharmacal CO INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 127% points.The greatest weakness of HI TECH Pharmacal CO INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 51% points.
The company's Economic Capital Ratio, given in the ranking table, is 429%, being 195% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000887497_2012_HI_TECH_Pharmacal_CO_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "57.3",
"Liabilities": "127",
"Stockholders Equity": "92.1",
"ECR before LimitedLiability": "271",
"Liabilities, Non-Current": "26.9",
"Liabilities, Current": "68.0",
"Research and Development": "49.6",
"Expenses": "47.6",
"Net Income": "95.1",
"Other Expenses": "2.72",
"Cost of Goods Sold": "-50.7",
"Selling, General and Administrative Expense": "42.1",
"Other Revenues": "73.9",
"Revenues": "73.9",
"Other Assets": "0.755",
"Property and Equipment": "1.68",
"Assets, Current": "2.38",
"Intangible Assets": "-3.65",
"Comprehensive Net Income": "94.7",
"Other Net Income": "-26.5",
"Economic Capital Ratio": "195"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000887497_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "153,742",
"Cost of Goods Sold": "83,263",
"Intangible Assets": "0",
"Liabilities, Current": "21,607",
"Liabilities, Non-Current": "0",
"Other Assets": "23,632",
"Other Compr. Net Income": "154",
"Other Expenses": "21,082",
"Other Liabilities": "621",
"Other Net Income": "-45,049",
"Other Revenues": "190,848",
"Property and Equipment": "25,866",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "203,240",
"Liabilities": "22,228",
"Expenses": "104,345",
"Revenues": "190,848",
"Stockholders Equity": "181,012",
"Net Income": "41,454",
"Comprehensive Net Income": "41,531",
"BaseVar": "282,932",
"ECR before LimitedLiability": "387%",
"Economic Capital Ratio": "429%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.294675550645115,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000887497.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000887497.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000887497.svg"
},
{
"company_id": "0001178711",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001178711.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001178711.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178711.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178711_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001178711_main_keyfigs.svg",
"name": "Paratek Pharmaceuticals Inc",
"rank": 9,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001178711.svg",
"report_text": "The relative strengths and weaknesses of Paratek Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Paratek Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 177% points.The greatest weakness of Paratek Pharmaceuticals Inc is the variable Other Assets, reducing the Economic Capital Ratio by 1.9% points.
The company's Economic Capital Ratio, given in the ranking table, is 428%, being 194% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001178711_2012_Paratek_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.91",
"Assets": "23.6",
"Liabilities": "94.3",
"Stockholders Equity": "177",
"ECR before LimitedLiability": "269",
"Property and Equipment": "-1.47",
"Assets, Current": "38.6",
"Other Liabilities": "39.0",
"Liabilities, Non-Current": "17.0",
"Liabilities, Current": "52.7",
"Research and Development": "9.90",
"Expenses": "26.5",
"Revenues": "10.4",
"Net Income": "38.4",
"Other Expenses": "10.3",
"Cost of Goods Sold": "3.70",
"Selling, General and Administrative Expense": "3.01",
"Other Revenues": "10.4",
"Comprehensive Net Income": "38.2",
"Other Net Income": "2.04",
"Economic Capital Ratio": "194"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001178711_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "65,837",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,962",
"Liabilities, Current": "3,339",
"Liabilities, Non-Current": "60",
"Other Assets": "38",
"Other Compr. Net Income": "0",
"Other Expenses": "9.0",
"Other Liabilities": "0",
"Other Net Income": "-107",
"Other Revenues": "19,694",
"Property and Equipment": "314",
"Research and Development": "11,273",
"Selling, General and Administrative Expense": "12,185"
},
"output_variables": {
"Assets": "69,151",
"Liabilities": "3,399",
"Expenses": "23,467",
"Revenues": "19,694",
"Stockholders Equity": "65,752",
"Net Income": "-3,880",
"Comprehensive Net Income": "-3,880",
"BaseVar": "57,909",
"ECR before LimitedLiability": "384%",
"Economic Capital Ratio": "428%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.276865969477611,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001178711.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001178711.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001178711.svg"
},
{
"company_id": "0001401667",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001401667.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001401667.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001401667.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001401667_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001401667_main_keyfigs.svg",
"name": "PUMA Biotechnology INC",
"rank": 10,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001401667.svg",
"report_text": "The relative strengths and weaknesses of PUMA Biotechnology INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of PUMA Biotechnology INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 226% points.The greatest weakness of PUMA Biotechnology INC is the variable Other Revenues, reducing the Economic Capital Ratio by 22% points.
The company's Economic Capital Ratio, given in the ranking table, is 427%, being 193% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001401667_2012_PUMA_Biotechnology_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.788",
"Assets": "47.6",
"Liabilities": "80.4",
"Stockholders Equity": "226",
"ECR before LimitedLiability": "269",
"Intangible Assets": "-1.91",
"Assets, Current": "69.9",
"Other Liabilities": "25.5",
"Liabilities, Non-Current": "13.0",
"Liabilities, Current": "51.5",
"Research and Development": "21.7",
"Expenses": "28.1",
"Revenues": "-22.1",
"Net Income": "8.52",
"Other Expenses": "7.65",
"Cost of Goods Sold": "2.74",
"Selling, General and Administrative Expense": "-3.78",
"Other Revenues": "-22.1",
"Comprehensive Net Income": "8.31",
"Other Net Income": "1.47",
"Economic Capital Ratio": "193"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001401667_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "53,663",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "586",
"Liabilities, Non-Current": "0",
"Other Assets": "1,053",
"Other Compr. Net Income": "0",
"Other Expenses": "11",
"Other Liabilities": "439",
"Other Net Income": "-76",
"Other Revenues": "0",
"Property and Equipment": "682",
"Research and Development": "826",
"Selling, General and Administrative Expense": "9,320"
},
"output_variables": {
"Assets": "55,398",
"Liabilities": "1,026",
"Expenses": "10,157",
"Revenues": "0",
"Stockholders Equity": "54,373",
"Net Income": "-10,233",
"Comprehensive Net Income": "-10,233",
"BaseVar": "33,328",
"ECR before LimitedLiability": "384%",
"Economic Capital Ratio": "427%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.272665590590364,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001401667.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001401667.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001401667.svg"
},
{
"company_id": "0001173784",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001173784.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001173784.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001173784_main_keyfigs.svg",
"name": "China Health Resource INC",
"rank": 11,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001173784.svg",
"report_text": "The relative strengths and weaknesses of China Health Resource INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of China Health Resource INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 207% points.The greatest weakness of China Health Resource INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 229% points.
The company's Economic Capital Ratio, given in the ranking table, is 427%, being 193% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001173784_2012_China_Health_Resource_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.09",
"Assets": "-17.4",
"Liabilities": "207",
"Stockholders Equity": "-78.8",
"ECR before LimitedLiability": "268",
"Intangible Assets": "-6.67",
"Assets, Current": "-10.3",
"Other Liabilities": "28.8",
"Liabilities, Non-Current": "46.8",
"Liabilities, Current": "167",
"Research and Development": "89.1",
"Expenses": "-18.8",
"Revenues": "199",
"Net Income": "187",
"Other Expenses": "8.80",
"Cost of Goods Sold": "-229",
"Selling, General and Administrative Expense": "69.5",
"Other Revenues": "199",
"Comprehensive Net Income": "188",
"Other Net Income": "6.53",
"Economic Capital Ratio": "193"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001173784_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,442",
"Cost of Goods Sold": "24,057",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "95",
"Other Compr. Net Income": "426",
"Other Expenses": "2,502",
"Other Liabilities": "2,680",
"Other Net Income": "-0.50",
"Other Revenues": "34,339",
"Property and Equipment": "831",
"Research and Development": "0",
"Selling, General and Administrative Expense": "808"
},
"output_variables": {
"Assets": "14,368",
"Liabilities": "2,680",
"Expenses": "27,367",
"Revenues": "34,339",
"Stockholders Equity": "11,688",
"Net Income": "6,971",
"Comprehensive Net Income": "7,184",
"BaseVar": "39,590",
"ECR before LimitedLiability": "383%",
"Economic Capital Ratio": "427%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.267647392766646,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001173784.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001173784.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001173784.svg"
},
{
"company_id": "0000863894",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000863894.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000863894.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000863894.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000863894_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000863894_main_keyfigs.svg",
"name": "VERU INC",
"rank": 12,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000863894.svg",
"report_text": "The relative strengths and weaknesses of VERU INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of VERU INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 113% points.The greatest weakness of VERU INC is the variable Other Expenses, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 424%, being 189% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000863894_2012_VERU_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "15.0",
"Assets": "0.892",
"Liabilities": "113",
"Stockholders Equity": "82.9",
"ECR before LimitedLiability": "265",
"Intangible Assets": "-4.08",
"Property and Equipment": "0.914",
"Assets, Current": "-5.76",
"Other Liabilities": "47.8",
"Liabilities, Non-Current": "25.6",
"Liabilities, Current": "60.3",
"Research and Development": "47.5",
"Expenses": "25.8",
"Revenues": "73.3",
"Net Income": "100",
"Other Expenses": "-30.2",
"Cost of Goods Sold": "5.57",
"Other Revenues": "73.3",
"Comprehensive Net Income": "99.8",
"Other Net Income": "3.41",
"Economic Capital Ratio": "189"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000863894_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,747",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,293",
"Liabilities, Non-Current": "0",
"Other Assets": "7,716",
"Other Compr. Net Income": "0",
"Other Expenses": "6,866",
"Other Liabilities": "397",
"Other Net Income": "0",
"Other Revenues": "18,502",
"Property and Equipment": "1,979",
"Research and Development": "11",
"Selling, General and Administrative Expense": "6,226"
},
"output_variables": {
"Assets": "19,443",
"Liabilities": "2,690",
"Expenses": "13,103",
"Revenues": "18,502",
"Stockholders Equity": "16,753",
"Net Income": "5,399",
"Comprehensive Net Income": "5,399",
"BaseVar": "26,869",
"ECR before LimitedLiability": "379%",
"Economic Capital Ratio": "424%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.235527345086938,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000863894.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000863894.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000863894.svg"
},
{
"company_id": "0000835887",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000835887.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000835887.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000835887_main_keyfigs.svg",
"name": "Progenics Pharmaceuticals INC",
"rank": 13,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000835887.svg",
"report_text": "The relative strengths and weaknesses of Progenics Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Progenics Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 141% points.The greatest weakness of Progenics Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 78% points.
The company's Economic Capital Ratio, given in the ranking table, is 423%, being 189% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000835887_2012_Progenics_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.19",
"Assets": "-3.29",
"Liabilities": "141",
"Stockholders Equity": "77.5",
"ECR before LimitedLiability": "264",
"Intangible Assets": "-4.74",
"Assets, Current": "6.22",
"Other Liabilities": "54.9",
"Liabilities, Non-Current": "29.2",
"Liabilities, Current": "85.6",
"Research and Development": "53.7",
"Expenses": "7.25",
"Revenues": "83.2",
"Net Income": "93.5",
"Other Expenses": "-78.4",
"Cost of Goods Sold": "6.42",
"Selling, General and Administrative Expense": "17.8",
"Other Revenues": "83.2",
"Comprehensive Net Income": "93.0",
"Other Net Income": "4.03",
"Economic Capital Ratio": "189"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000835887_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "72,540",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,650",
"Liabilities, Non-Current": "0",
"Other Assets": "3,532",
"Other Compr. Net Income": "0",
"Other Expenses": "55,654",
"Other Liabilities": "1,659",
"Other Net Income": "65",
"Other Revenues": "84,796",
"Property and Equipment": "4,038",
"Research and Development": "578",
"Selling, General and Administrative Expense": "18,248"
},
"output_variables": {
"Assets": "80,110",
"Liabilities": "8,309",
"Expenses": "74,480",
"Revenues": "84,796",
"Stockholders Equity": "71,801",
"Net Income": "10,381",
"Comprehensive Net Income": "10,381",
"BaseVar": "123,880",
"ECR before LimitedLiability": "378%",
"Economic Capital Ratio": "423%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.226342389353632,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000835887.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000835887.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000835887.svg"
},
{
"company_id": "0000850693",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000850693.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000850693.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000850693_main_keyfigs.svg",
"name": "Allergan INC",
"rank": 14,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000850693.svg",
"report_text": "The relative strengths and weaknesses of Allergan INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Allergan INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 116% points.The greatest weakness of Allergan INC is the variable Other Expenses, reducing the Economic Capital Ratio by 6.1% points.
The company's Economic Capital Ratio, given in the ranking table, is 416%, being 182% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000850693_2012_Allergan_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "0.767",
"Assets": "1.24",
"Liabilities": "80.4",
"Stockholders Equity": "59.0",
"ECR before LimitedLiability": "76.7",
"Other Assets": "-1.59",
"Intangible Assets": "4.20",
"Property and Equipment": "-1.73",
"Liabilities, Current": "30.3",
"Other Liabilities": "26.0",
"Liabilities, Non-Current": "35.5",
"Expenses": "-11.0",
"Revenues": "10.3",
"Net Income": "-2.12",
"Selling, General and Administrative Expense": "-11.2",
"Other Expenses": "1.40",
"Research and Development": "-1.89",
"Other Revenues": "10.3",
"Comprehensive Net Income": "-2.15",
"Other Net Income": "-1.62",
"Economic Capital Ratio": "77.5"
},
"2010": {
"Liabilities, Current": "0.718",
"Liabilities": "72.9",
"Stockholders Equity": "50.8",
"ECR before LimitedLiability": "88.0",
"Other Liabilities": "42.8",
"Liabilities, Non-Current": "35.0",
"Selling, General and Administrative Expense": "-3.03",
"Expenses": "-6.10",
"Net Income": "10.4",
"Research and Development": "4.71",
"Cost of Goods Sold": "5.80",
"Other Expenses": "-13.7",
"Other Revenues": "16.9",
"Revenues": "16.9",
"Other Assets": "-4.34",
"Assets, Current": "-2.40",
"Property and Equipment": "-2.92",
"Intangible Assets": "11.3",
"Comprehensive Net Income": "10.4",
"Other Net Income": "-0.506",
"Economic Capital Ratio": "81.6"
},
"2011": {
"Other Assets": "-1.27",
"Assets": "10.4",
"Liabilities": "97.2",
"Stockholders Equity": "116",
"ECR before LimitedLiability": "257",
"Intangible Assets": "16.3",
"Property and Equipment": "1.41",
"Assets, Current": "-3.54",
"Other Liabilities": "46.9",
"Liabilities, Non-Current": "21.2",
"Liabilities, Current": "44.6",
"Research and Development": "26.8",
"Expenses": "26.0",
"Revenues": "43.9",
"Net Income": "70.2",
"Other Expenses": "-6.14",
"Cost of Goods Sold": "4.64",
"Other Revenues": "43.9",
"Comprehensive Net Income": "69.9",
"Other Net Income": "1.85",
"Economic Capital Ratio": "182"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000850693_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "3,106,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,355,500",
"Liabilities, Current": "811,600",
"Liabilities, Non-Current": "0",
"Other Assets": "266,700",
"Other Compr. Net Income": "0",
"Other Expenses": "1,172,800",
"Other Liabilities": "0",
"Other Net Income": "-79,500",
"Other Revenues": "4,503,600",
"Property and Equipment": "808,100",
"Research and Development": "706,000",
"Selling, General and Administrative Expense": "1,921,500"
},
"output_variables": {
"Assets": "7,536,600",
"Liabilities": "811,600",
"Expenses": "3,800,300",
"Revenues": "4,503,600",
"Stockholders Equity": "6,725,000",
"Net Income": "623,800",
"Comprehensive Net Income": "623,800",
"BaseVar": "8,365,800",
"ECR before LimitedLiability": "366%",
"Economic Capital Ratio": "414%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "3,993,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,034,600",
"Liabilities, Current": "1,528,400",
"Liabilities, Non-Current": "0",
"Other Assets": "479,200",
"Other Compr. Net Income": "0",
"Other Expenses": "2,004,500",
"Other Liabilities": "0",
"Other Net Income": "-87,800",
"Other Revenues": "4,919,400",
"Property and Equipment": "800,600",
"Research and Development": "804,600",
"Selling, General and Administrative Expense": "2,017,600"
},
"output_variables": {
"Assets": "8,308,100",
"Liabilities": "1,528,400",
"Expenses": "4,826,700",
"Revenues": "4,919,400",
"Stockholders Equity": "6,779,700",
"Net Income": "4,900",
"Comprehensive Net Income": "4,900",
"BaseVar": "9,835,200",
"ECR before LimitedLiability": "301%",
"Economic Capital Ratio": "369%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "4,048,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,253,600",
"Liabilities, Current": "955,000",
"Liabilities, Non-Current": "0",
"Other Assets": "399,700",
"Other Compr. Net Income": "0",
"Other Expenses": "1,266,200",
"Other Liabilities": "0",
"Other Net Income": "-65,400",
"Other Revenues": "5,419,100",
"Property and Equipment": "807,000",
"Research and Development": "902,800",
"Selling, General and Administrative Expense": "2,246,600"
},
"output_variables": {
"Assets": "8,508,600",
"Liabilities": "955,000",
"Expenses": "4,415,600",
"Revenues": "5,419,100",
"Stockholders Equity": "7,553,600",
"Net Income": "938,100",
"Comprehensive Net Income": "938,100",
"BaseVar": "9,681,850",
"ECR before LimitedLiability": "368%",
"Economic Capital Ratio": "416%"
}
}
},
"top_rated": true,
"trend": -8.0,
"value": 4.156141765546227,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000850693.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000850693.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000850693.svg"
},
{
"company_id": "0001232524",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001232524.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001232524.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001232524.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001232524_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001232524_main_keyfigs.svg",
"name": "Jazz Pharmaceuticals plc",
"rank": 15,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001232524.svg",
"report_text": "The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 120% points.The greatest weakness of Jazz Pharmaceuticals plc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 11% points.
The company's Economic Capital Ratio, given in the ranking table, is 415%, being 181% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001232524_2012_Jazz_Pharmaceuticals_plc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "53.3",
"Liabilities": "89.3",
"Stockholders Equity": "56.2",
"ECR before LimitedLiability": "257",
"Liabilities, Non-Current": "24.3",
"Liabilities, Current": "24.4",
"Research and Development": "39.7",
"Expenses": "38.7",
"Net Income": "120",
"Other Expenses": "4.36",
"Cost of Goods Sold": "5.36",
"Selling, General and Administrative Expense": "-11.0",
"Other Revenues": "80.4",
"Revenues": "80.4",
"Other Assets": "-3.65",
"Property and Equipment": "-2.86",
"Assets, Current": "3.40",
"Intangible Assets": "3.53",
"Comprehensive Net Income": "119",
"Other Net Income": "2.73",
"Economic Capital Ratio": "181"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001232524_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "199,131",
"Cost of Goods Sold": "0",
"Intangible Assets": "52,798",
"Liabilities, Current": "52,870",
"Liabilities, Non-Current": "0",
"Other Assets": "87",
"Other Compr. Net Income": "0",
"Other Expenses": "23,065",
"Other Liabilities": "0",
"Other Net Income": "-1,172",
"Other Revenues": "272,277",
"Property and Equipment": "1,557",
"Research and Development": "14,120",
"Selling, General and Administrative Expense": "108,936"
},
"output_variables": {
"Assets": "253,573",
"Liabilities": "52,870",
"Expenses": "146,121",
"Revenues": "272,277",
"Stockholders Equity": "200,703",
"Net Income": "124,984",
"Comprehensive Net Income": "124,984",
"BaseVar": "363,006",
"ECR before LimitedLiability": "367%",
"Economic Capital Ratio": "415%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.151091353086459,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001232524.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001232524.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001232524.svg"
},
{
"company_id": "0001325879",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001325879.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001325879.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001325879.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001325879_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001325879_main_keyfigs.svg",
"name": "AVEO Pharmaceuticals INC",
"rank": 16,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001325879.svg",
"report_text": "The relative strengths and weaknesses of AVEO Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of AVEO Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 121% points.The greatest weakness of AVEO Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 6.0% points.
The company's Economic Capital Ratio, given in the ranking table, is 412%, being 178% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001325879_2012_AVEO_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "5.97",
"Assets": "14.6",
"Liabilities": "87.0",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "254",
"Intangible Assets": "-4.09",
"Property and Equipment": "-1.85",
"Assets, Current": "16.2",
"Other Liabilities": "43.6",
"Liabilities, Non-Current": "19.6",
"Liabilities, Current": "36.4",
"Research and Development": "-5.99",
"Expenses": "29.3",
"Revenues": "36.3",
"Net Income": "65.4",
"Other Expenses": "12.0",
"Cost of Goods Sold": "4.30",
"Selling, General and Administrative Expense": "19.2",
"Other Revenues": "36.3",
"Comprehensive Net Income": "65.1",
"Economic Capital Ratio": "178"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001325879_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "234,395",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "34,609",
"Liabilities, Non-Current": "0",
"Other Assets": "55,184",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-3,299",
"Other Revenues": "164,849",
"Property and Equipment": "5,471",
"Research and Development": "101,735",
"Selling, General and Administrative Expense": "29,167"
},
"output_variables": {
"Assets": "295,050",
"Liabilities": "34,609",
"Expenses": "130,902",
"Revenues": "164,849",
"Stockholders Equity": "260,441",
"Net Income": "30,648",
"Comprehensive Net Income": "30,648",
"BaseVar": "314,354",
"ECR before LimitedLiability": "363%",
"Economic Capital Ratio": "412%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.121872404680852,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001325879.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001325879.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001325879.svg"
},
{
"company_id": "0001092662",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001092662.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001092662.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001092662.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001092662_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001092662_main_keyfigs.svg",
"name": "Chembio Diagnostics INC",
"rank": 17,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001092662.svg",
"report_text": "The relative strengths and weaknesses of Chembio Diagnostics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Chembio Diagnostics INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 121% points.The greatest weakness of Chembio Diagnostics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 20% points.
The company's Economic Capital Ratio, given in the ranking table, is 411%, being 177% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001092662_2012_Chembio_Diagnostics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "13.1",
"Assets": "-6.42",
"Liabilities": "114",
"Stockholders Equity": "39.5",
"ECR before LimitedLiability": "253",
"Intangible Assets": "-5.81",
"Assets, Current": "-8.71",
"Other Liabilities": "57.2",
"Liabilities, Non-Current": "27.7",
"Liabilities, Current": "49.4",
"Research and Development": "17.3",
"Expenses": "23.4",
"Revenues": "94.8",
"Net Income": "121",
"Other Expenses": "-20.3",
"Cost of Goods Sold": "6.21",
"Selling, General and Administrative Expense": "19.8",
"Other Revenues": "94.8",
"Comprehensive Net Income": "120",
"Other Net Income": "3.70",
"Economic Capital Ratio": "177"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001092662_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8,992",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,858",
"Liabilities, Non-Current": "0",
"Other Assets": "5,432",
"Other Compr. Net Income": "0",
"Other Expenses": "4,865",
"Other Liabilities": "133",
"Other Net Income": "-12",
"Other Revenues": "19,388",
"Property and Equipment": "1,062",
"Research and Development": "4,878",
"Selling, General and Administrative Expense": "3,424"
},
"output_variables": {
"Assets": "15,486",
"Liabilities": "2,991",
"Expenses": "13,167",
"Revenues": "19,388",
"Stockholders Equity": "12,495",
"Net Income": "6,209",
"Comprehensive Net Income": "6,209",
"BaseVar": "25,522",
"ECR before LimitedLiability": "362%",
"Economic Capital Ratio": "411%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.114700194018026,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001092662.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001092662.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001092662.svg"
},
{
"company_id": "0001443242",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001443242.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001443242.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001443242_main_keyfigs.svg",
"name": "Bohai Pharmaceuticals Group Inc",
"rank": 18,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001443242.svg",
"report_text": "The relative strengths and weaknesses of Bohai Pharmaceuticals Group Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Bohai Pharmaceuticals Group Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 117% points.The greatest weakness of Bohai Pharmaceuticals Group Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 26% points.
The company's Economic Capital Ratio, given in the ranking table, is 406%, being 172% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001443242_2012_Bohai_Pharmaceuticals_Group_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "57.3",
"Liabilities": "117",
"Stockholders Equity": "62.5",
"ECR before LimitedLiability": "248",
"Liabilities, Non-Current": "10.4",
"Liabilities, Current": "66.8",
"Research and Development": "50.7",
"Expenses": "15.5",
"Net Income": "92.8",
"Other Expenses": "-17.7",
"Cost of Goods Sold": "5.91",
"Selling, General and Administrative Expense": "-26.0",
"Other Revenues": "74.0",
"Revenues": "74.0",
"Other Assets": "42.8",
"Property and Equipment": "-4.01",
"Assets, Current": "-13.9",
"Intangible Assets": "-6.13",
"Comprehensive Net Income": "94.6",
"Other Net Income": "4.40",
"Economic Capital Ratio": "172"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001443242_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "31,818",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,329",
"Liabilities, Non-Current": "2,878",
"Other Assets": "48,297",
"Other Compr. Net Income": "3,099",
"Other Expenses": "22,288",
"Other Liabilities": "0",
"Other Net Income": "514",
"Other Revenues": "81,329",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "45,550"
},
"output_variables": {
"Assets": "80,115",
"Liabilities": "12,207",
"Expenses": "67,838",
"Revenues": "81,329",
"Stockholders Equity": "67,908",
"Net Income": "14,005",
"Comprehensive Net Income": "15,554",
"BaseVar": "122,550",
"ECR before LimitedLiability": "354%",
"Economic Capital Ratio": "406%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.060393732492027,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001443242.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001443242.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001443242.svg"
},
{
"company_id": "0001459450",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001459450.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001459450.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001459450_main_keyfigs.svg",
"name": "Myrexis Inc",
"rank": 19,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001459450.svg",
"report_text": "The relative strengths and weaknesses of Myrexis Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Myrexis Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 212% points.The greatest weakness of Myrexis Inc is the variable Other Revenues, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 403%, being 169% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001459450_2012_Myrexis_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.42",
"Assets": "57.7",
"Liabilities": "81.5",
"Stockholders Equity": "212",
"ECR before LimitedLiability": "245",
"Intangible Assets": "-3.40",
"Assets, Current": "65.3",
"Other Liabilities": "30.8",
"Liabilities, Non-Current": "13.6",
"Liabilities, Current": "47.2",
"Research and Development": "1.24",
"Expenses": "14.1",
"Revenues": "-23.9",
"Net Income": "-5.42",
"Other Expenses": "8.37",
"Cost of Goods Sold": "2.98",
"Selling, General and Administrative Expense": "1.58",
"Other Revenues": "-23.9",
"Comprehensive Net Income": "-5.66",
"Other Net Income": "3.78",
"Economic Capital Ratio": "169"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001459450_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "107,496",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,310",
"Liabilities, Non-Current": "0",
"Other Assets": "10,449",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "1,742",
"Other Revenues": "185",
"Property and Equipment": "3,315",
"Research and Development": "22,296",
"Selling, General and Administrative Expense": "18,339"
},
"output_variables": {
"Assets": "121,260",
"Liabilities": "3,310",
"Expenses": "40,635",
"Revenues": "185",
"Stockholders Equity": "117,950",
"Net Income": "-38,708",
"Comprehensive Net Income": "-38,708",
"BaseVar": "83,566",
"ECR before LimitedLiability": "351%",
"Economic Capital Ratio": "403%"
}
}
},
"top_rated": true,
"trend": null,
"value": 4.034174765857284,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001459450.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001459450.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001459450.svg"
},
{
"company_id": "0001087294",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001087294.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001087294.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001087294.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001087294_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001087294_main_keyfigs.svg",
"name": "Cumberland Pharmaceuticals INC",
"rank": 20,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001087294.svg",
"report_text": "The relative strengths and weaknesses of Cumberland Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cumberland Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 114% points.The greatest weakness of Cumberland Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 399%, being 165% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001087294_2012_Cumberland_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.82",
"Assets": "17.1",
"Liabilities": "79.1",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "240",
"Property and Equipment": "-2.64",
"Assets, Current": "32.0",
"Other Liabilities": "15.3",
"Liabilities, Non-Current": "18.7",
"Liabilities, Current": "53.5",
"Research and Development": "30.0",
"Expenses": "24.9",
"Revenues": "32.1",
"Net Income": "58.9",
"Other Expenses": "-29.6",
"Cost of Goods Sold": "4.18",
"Selling, General and Administrative Expense": "19.2",
"Other Revenues": "32.1",
"Comprehensive Net Income": "58.6",
"Other Net Income": "2.83",
"Economic Capital Ratio": "165"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001087294_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "87,308",
"Cost of Goods Sold": "0",
"Intangible Assets": "7,023",
"Liabilities, Current": "6,600",
"Liabilities, Non-Current": "0",
"Other Assets": "68",
"Other Compr. Net Income": "0",
"Other Expenses": "31,501",
"Other Liabilities": "6,083",
"Other Net Income": "211",
"Other Revenues": "51,143",
"Property and Equipment": "1,119",
"Research and Development": "5,028",
"Selling, General and Administrative Expense": "9,198"
},
"output_variables": {
"Assets": "95,518",
"Liabilities": "12,683",
"Expenses": "45,727",
"Revenues": "51,143",
"Stockholders Equity": "82,835",
"Net Income": "5,627",
"Comprehensive Net Income": "5,627",
"BaseVar": "102,641",
"ECR before LimitedLiability": "344%",
"Economic Capital Ratio": "399%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.9886031633571557,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001087294.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001087294.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001087294.svg"
},
{
"company_id": "0001520512",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001520512.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001520512.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001520512_main_keyfigs.svg",
"name": "il2m International CORP",
"rank": 21,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001520512.svg",
"report_text": "The relative strengths and weaknesses of il2m International CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of il2m International CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 197% points.The greatest weakness of il2m International CORP is the variable Other Expenses, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 396%, being 162% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001520512_2012_il2m_International_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.70",
"Assets": "65.1",
"Liabilities": "62.3",
"Stockholders Equity": "197",
"ECR before LimitedLiability": "237",
"Intangible Assets": "-3.53",
"Assets, Current": "105",
"Other Liabilities": "28.1",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "28.3",
"Research and Development": "23.8",
"Expenses": "21.8",
"Revenues": "-20.9",
"Net Income": "3.25",
"Other Expenses": "-24.7",
"Cost of Goods Sold": "2.74",
"Selling, General and Administrative Expense": "19.0",
"Other Revenues": "-20.9",
"Comprehensive Net Income": "3.04",
"Other Net Income": "1.67",
"Economic Capital Ratio": "162"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001520512_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "160",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "40",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "1.4",
"Property and Equipment": "2.5",
"Research and Development": "0",
"Selling, General and Administrative Expense": "1.5"
},
"output_variables": {
"Assets": "163",
"Liabilities": "10",
"Expenses": "41",
"Revenues": "1.4",
"Stockholders Equity": "153",
"Net Income": "-40",
"Comprehensive Net Income": "-40",
"BaseVar": "108",
"ECR before LimitedLiability": "340%",
"Economic Capital Ratio": "396%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.956580040117757,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001520512.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001520512.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001520512.svg"
},
{
"company_id": "0000891288",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000891288.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000891288.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000891288_main_keyfigs.svg",
"name": "Questcor Pharmaceuticals INC",
"rank": 22,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000891288.svg",
"report_text": "The relative strengths and weaknesses of Questcor Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Questcor Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 88% points.The greatest weakness of Questcor Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 32% points.
The company's Economic Capital Ratio, given in the ranking table, is 394%, being 160% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000891288_2012_Questcor_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.50",
"Assets": "7.34",
"Liabilities": "69.4",
"Stockholders Equity": "73.4",
"ECR before LimitedLiability": "235",
"Intangible Assets": "-5.36",
"Property and Equipment": "-3.42",
"Assets, Current": "27.1",
"Other Liabilities": "44.5",
"Liabilities, Non-Current": "19.7",
"Liabilities, Current": "11.9",
"Research and Development": "32.6",
"Expenses": "32.9",
"Revenues": "53.6",
"Net Income": "88.3",
"Other Expenses": "-31.7",
"Cost of Goods Sold": "4.55",
"Selling, General and Administrative Expense": "26.1",
"Other Revenues": "53.6",
"Comprehensive Net Income": "88.0",
"Economic Capital Ratio": "160"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000891288_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "265,600",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,778",
"Liabilities, Current": "55,721",
"Liabilities, Non-Current": "261",
"Other Assets": "5,460",
"Other Compr. Net Income": "0",
"Other Expenses": "104,684",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "218,796",
"Property and Equipment": "1,970",
"Research and Development": "16,778",
"Selling, General and Administrative Expense": "17,743"
},
"output_variables": {
"Assets": "275,808",
"Liabilities": "55,982",
"Expenses": "139,205",
"Revenues": "218,796",
"Stockholders Equity": "219,826",
"Net Income": "79,591",
"Comprehensive Net Income": "79,591",
"BaseVar": "344,896",
"ECR before LimitedLiability": "337%",
"Economic Capital Ratio": "394%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.9375090597451754,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000891288.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000891288.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000891288.svg"
},
{
"company_id": "0001005201",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001005201.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001005201.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001005201_main_keyfigs.svg",
"name": "Assertio Therapeutics Inc",
"rank": 23,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001005201.svg",
"report_text": "The relative strengths and weaknesses of Assertio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Assertio Therapeutics Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 99% points.The greatest weakness of Assertio Therapeutics Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 393%, being 158% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001005201_2012_Assertio_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "17.0",
"Assets": "8.80",
"Liabilities": "51.4",
"Stockholders Equity": "65.0",
"ECR before LimitedLiability": "234",
"Intangible Assets": "-5.63",
"Property and Equipment": "-3.31",
"Assets, Current": "3.81",
"Other Liabilities": "42.1",
"Liabilities, Non-Current": "18.9",
"Liabilities, Current": "-8.23",
"Research and Development": "27.2",
"Expenses": "42.8",
"Revenues": "54.4",
"Net Income": "99.4",
"Other Expenses": "34.4",
"Cost of Goods Sold": "4.28",
"Selling, General and Administrative Expense": "-23.7",
"Other Revenues": "54.4",
"Comprehensive Net Income": "99.1",
"Economic Capital Ratio": "158"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001005201_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "109,489",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "39,840",
"Liabilities, Non-Current": "0",
"Other Assets": "53,813",
"Other Compr. Net Income": "0",
"Other Expenses": "-34,060",
"Other Liabilities": "0",
"Other Net Income": "424",
"Other Revenues": "132,973",
"Property and Equipment": "1,070",
"Research and Development": "15,187",
"Selling, General and Administrative Expense": "81,544"
},
"output_variables": {
"Assets": "164,372",
"Liabilities": "39,840",
"Expenses": "62,671",
"Revenues": "132,973",
"Stockholders Equity": "124,532",
"Net Income": "70,726",
"Comprehensive Net Income": "70,726",
"BaseVar": "200,140",
"ECR before LimitedLiability": "335%",
"Economic Capital Ratio": "393%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.9257399798077866,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001005201.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001005201.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001005201.svg"
},
{
"company_id": "0001034842",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001034842.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001034842.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001034842.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001034842_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001034842_main_keyfigs.svg",
"name": "Rigel Pharmaceuticals INC",
"rank": 24,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001034842.svg",
"report_text": "The relative strengths and weaknesses of Rigel Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Rigel Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 201% points.The greatest weakness of Rigel Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 392%, being 158% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001034842_2012_Rigel_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.59",
"Assets": "61.9",
"Liabilities": "74.2",
"Stockholders Equity": "201",
"ECR before LimitedLiability": "234",
"Intangible Assets": "-4.01",
"Assets, Current": "99.9",
"Other Liabilities": "30.1",
"Liabilities, Non-Current": "13.3",
"Liabilities, Current": "39.3",
"Research and Development": "-9.48",
"Expenses": "12.8",
"Revenues": "-24.0",
"Net Income": "-6.15",
"Other Expenses": "8.32",
"Cost of Goods Sold": "2.97",
"Selling, General and Administrative Expense": "10.9",
"Other Revenues": "-24.0",
"Comprehensive Net Income": "-6.38",
"Other Net Income": "4.46",
"Economic Capital Ratio": "158"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001034842_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "250,233",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,527",
"Liabilities, Non-Current": "0",
"Other Assets": "1,991",
"Other Compr. Net Income": "0",
"Other Expenses": "25",
"Other Liabilities": "0",
"Other Net Income": "5,170",
"Other Revenues": "0",
"Property and Equipment": "4,882",
"Research and Development": "69,350",
"Selling, General and Administrative Expense": "21,768"
},
"output_variables": {
"Assets": "257,106",
"Liabilities": "11,527",
"Expenses": "91,143",
"Revenues": "0",
"Stockholders Equity": "245,579",
"Net Income": "-85,973",
"Comprehensive Net Income": "-85,973",
"BaseVar": "182,473",
"ECR before LimitedLiability": "335%",
"Economic Capital Ratio": "392%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.921777698250689,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001034842.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001034842.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001034842.svg"
},
{
"company_id": "0000310158",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000310158.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000310158.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000310158.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000310158_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000310158_main_keyfigs.svg",
"name": "Merck Co Inc",
"rank": 25,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000310158.svg",
"report_text": "The relative strengths and weaknesses of Merck Co Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Merck Co Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 114% points.The greatest weakness of Merck Co Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 11% points.
The company's Economic Capital Ratio, given in the ranking table, is 389%, being 155% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000310158_2012_Merck_Co_Inc.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-0.847",
"Assets": "25.1",
"Liabilities": "28.6",
"Stockholders Equity": "102",
"ECR before LimitedLiability": "64.5",
"Intangible Assets": "20.2",
"Property and Equipment": "3.56",
"Liabilities, Current": "-12.0",
"Other Liabilities": "16.9",
"Liabilities, Non-Current": "23.3",
"Cost of Goods Sold": "0.485",
"Expenses": "19.2",
"Revenues": "-13.5",
"Net Income": "5.96",
"Selling, General and Administrative Expense": "4.80",
"Other Expenses": "13.8",
"Research and Development": "0.222",
"Other Revenues": "-13.5",
"Comprehensive Net Income": "5.94",
"Other Net Income": "-0.165",
"Economic Capital Ratio": "65.3"
},
"2010": {
"Other Assets": "-1.65",
"Assets": "11.6",
"Liabilities": "70.0",
"Stockholders Equity": "85.2",
"ECR before LimitedLiability": "105",
"Assets, Current": "-9.35",
"Property and Equipment": "3.19",
"Intangible Assets": "25.5",
"Liabilities, Current": "4.33",
"Other Liabilities": "39.7",
"Liabilities, Non-Current": "32.4",
"Selling, General and Administrative Expense": "6.91",
"Expenses": "2.59",
"Revenues": "7.15",
"Net Income": "10.3",
"Research and Development": "1.62",
"Cost of Goods Sold": "5.18",
"Other Expenses": "-11.2",
"Other Revenues": "7.15",
"Comprehensive Net Income": "10.3",
"Economic Capital Ratio": "98.4"
},
"2011": {
"Assets": "24.2",
"Liabilities": "61.6",
"Stockholders Equity": "114",
"ECR before LimitedLiability": "230",
"Intangible Assets": "31.5",
"Property and Equipment": "6.81",
"Assets, Current": "-9.95",
"Other Liabilities": "37.4",
"Liabilities, Non-Current": "16.6",
"Liabilities, Current": "13.2",
"Research and Development": "23.5",
"Expenses": "28.5",
"Revenues": "24.1",
"Net Income": "54.2",
"Other Expenses": "-11.5",
"Cost of Goods Sold": "3.78",
"Selling, General and Administrative Expense": "12.6",
"Other Revenues": "24.1",
"Comprehensive Net Income": "53.9",
"Other Net Income": "2.31",
"Economic Capital Ratio": "155"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000310158_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "28,428,600",
"Cost of Goods Sold": "0",
"Intangible Assets": "59,578,900",
"Liabilities, Current": "15,750,700",
"Liabilities, Non-Current": "0",
"Other Assets": "5,808,700",
"Other Compr. Net Income": "0",
"Other Expenses": "15,900",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "27,428,300",
"Property and Equipment": "18,273,500",
"Research and Development": "5,845,000",
"Selling, General and Administrative Expense": "8,543,200"
},
"output_variables": {
"Assets": "112,089,700",
"Liabilities": "15,750,700",
"Expenses": "14,404,100",
"Revenues": "27,428,300",
"Stockholders Equity": "96,339,000",
"Net Income": "13,024,200",
"Comprehensive Net Income": "13,024,200",
"BaseVar": "84,836,400",
"ECR before LimitedLiability": "349%",
"Economic Capital Ratio": "402%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "29,064,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "51,834,000",
"Liabilities, Current": "15,641,000",
"Liabilities, Non-Current": "0",
"Other Assets": "7,801,000",
"Other Compr. Net Income": "0",
"Other Expenses": "20,769,000",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "45,987,000",
"Property and Equipment": "17,082,000",
"Research and Development": "10,991,000",
"Selling, General and Administrative Expense": "13,245,000"
},
"output_variables": {
"Assets": "105,781,000",
"Liabilities": "15,641,000",
"Expenses": "45,005,000",
"Revenues": "45,987,000",
"Stockholders Equity": "90,140,000",
"Net Income": "982,000",
"Comprehensive Net Income": "982,000",
"BaseVar": "106,207,000",
"ECR before LimitedLiability": "325%",
"Economic Capital Ratio": "386%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "33,181,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "46,457,000",
"Liabilities, Current": "16,245,000",
"Liabilities, Non-Current": "0",
"Other Assets": "9,193,000",
"Other Compr. Net Income": "0",
"Other Expenses": "19,455,000",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "48,047,000",
"Property and Equipment": "16,297,000",
"Research and Development": "8,467,000",
"Selling, General and Administrative Expense": "13,733,000"
},
"output_variables": {
"Assets": "105,128,000",
"Liabilities": "16,245,000",
"Expenses": "41,655,000",
"Revenues": "48,047,000",
"Stockholders Equity": "88,883,000",
"Net Income": "6,392,000",
"Comprehensive Net Income": "6,392,000",
"BaseVar": "105,537,500",
"ECR before LimitedLiability": "330%",
"Economic Capital Ratio": "389%"
}
}
},
"top_rated": true,
"trend": -21.0,
"value": 3.8889808519527866,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000310158.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000310158.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000310158.svg"
},
{
"company_id": "0001416083",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001416083.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001416083.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001416083_main_keyfigs.svg",
"name": "Catalent Pharma Solutions Inc",
"rank": 26,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001416083.svg",
"report_text": "The relative strengths and weaknesses of Catalent Pharma Solutions Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Catalent Pharma Solutions Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 109% points.The greatest weakness of Catalent Pharma Solutions Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 35% points.
The company's Economic Capital Ratio, given in the ranking table, is 388%, being 154% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001416083_2012_Catalent_Pharma_Solutions_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "16.6",
"Liabilities": "80.1",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "229",
"Intangible Assets": "28.7",
"Property and Equipment": "14.9",
"Assets, Current": "-15.0",
"Other Liabilities": "41.7",
"Liabilities, Non-Current": "18.7",
"Liabilities, Current": "29.6",
"Research and Development": "37.0",
"Expenses": "27.2",
"Revenues": "31.0",
"Net Income": "51.3",
"Other Expenses": "-35.1",
"Cost of Goods Sold": "4.27",
"Selling, General and Administrative Expense": "19.4",
"Other Revenues": "31.0",
"Comprehensive Net Income": "51.0",
"Other Net Income": "-6.50",
"Economic Capital Ratio": "154"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001416083_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "757,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,192,700",
"Liabilities, Current": "385,500",
"Liabilities, Non-Current": "0",
"Other Assets": "159,500",
"Other Compr. Net Income": "0",
"Other Expenses": "1,081,100",
"Other Liabilities": "0",
"Other Net Income": "-212,500",
"Other Revenues": "1,531,800",
"Property and Equipment": "721,300",
"Research and Development": "0",
"Selling, General and Administrative Expense": "288,300"
},
"output_variables": {
"Assets": "2,831,200",
"Liabilities": "385,500",
"Expenses": "1,369,400",
"Revenues": "1,531,800",
"Stockholders Equity": "2,445,700",
"Net Income": "-50,100",
"Comprehensive Net Income": "-50,100",
"BaseVar": "3,165,200",
"ECR before LimitedLiability": "328%",
"Economic Capital Ratio": "388%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.8790803849008366,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001416083.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001416083.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001416083.svg"
},
{
"company_id": "0001100962",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001100962.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001100962.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001100962_main_keyfigs.svg",
"name": "ENDO Health Solutions INC",
"rank": 27,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001100962.svg",
"report_text": "The relative strengths and weaknesses of ENDO Health Solutions INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ENDO Health Solutions INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 122% points.The greatest weakness of ENDO Health Solutions INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 14% points.
The company's Economic Capital Ratio, given in the ranking table, is 386%, being 152% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001100962_2012_ENDO_Health_Solutions_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-5.07",
"Assets": "13.1",
"Liabilities": "52.6",
"Stockholders Equity": "73.2",
"ECR before LimitedLiability": "94.5",
"Assets, Current": "-5.63",
"Property and Equipment": "-4.03",
"Intangible Assets": "38.9",
"Liabilities, Current": "-14.0",
"Other Liabilities": "37.1",
"Liabilities, Non-Current": "30.3",
"Selling, General and Administrative Expense": "4.76",
"Expenses": "10.2",
"Revenues": "7.59",
"Net Income": "17.0",
"Research and Development": "9.01",
"Cost of Goods Sold": "-9.83",
"Other Expenses": "6.14",
"Other Revenues": "7.59",
"Comprehensive Net Income": "17.0",
"Economic Capital Ratio": "88.2"
},
"2011": {
"Other Assets": "-2.73",
"Assets": "31.0",
"Liabilities": "54.0",
"Stockholders Equity": "122",
"ECR before LimitedLiability": "227",
"Intangible Assets": "82.7",
"Property and Equipment": "-0.748",
"Assets, Current": "-12.1",
"Other Liabilities": "34.7",
"Liabilities, Non-Current": "15.4",
"Liabilities, Current": "7.90",
"Research and Development": "27.6",
"Expenses": "32.1",
"Revenues": "16.5",
"Net Income": "47.8",
"Other Expenses": "5.66",
"Cost of Goods Sold": "-14.0",
"Selling, General and Administrative Expense": "12.7",
"Other Revenues": "16.5",
"Comprehensive Net Income": "47.5",
"Economic Capital Ratio": "152"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001100962_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,359,534",
"Cost of Goods Sold": "504,757",
"Intangible Assets": "2,246,765",
"Liabilities, Current": "735,828",
"Liabilities, Non-Current": "0",
"Other Assets": "90,795",
"Other Compr. Net Income": "720",
"Other Expenses": "187,654",
"Other Liabilities": "0",
"Other Net Income": "-44,668",
"Other Revenues": "1,716,229",
"Property and Equipment": "215,295",
"Research and Development": "144,525",
"Selling, General and Administrative Expense": "547,605"
},
"output_variables": {
"Assets": "3,912,389",
"Liabilities": "735,828",
"Expenses": "1,384,541",
"Revenues": "1,716,229",
"Stockholders Equity": "3,176,561",
"Net Income": "287,020",
"Comprehensive Net Income": "287,380",
"BaseVar": "3,897,188",
"ECR before LimitedLiability": "310%",
"Economic Capital Ratio": "376%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,788,096",
"Cost of Goods Sold": "1,065,208",
"Intangible Assets": "5,062,165",
"Liabilities, Current": "1,121,778",
"Liabilities, Non-Current": "0",
"Other Assets": "144,591",
"Other Compr. Net Income": "0",
"Other Expenses": "259,353",
"Other Liabilities": "0",
"Other Net Income": "-156,675",
"Other Revenues": "2,730,121",
"Property and Equipment": "297,731",
"Research and Development": "182,286",
"Selling, General and Administrative Expense": "824,534"
},
"output_variables": {
"Assets": "7,292,583",
"Liabilities": "1,121,778",
"Expenses": "2,331,381",
"Revenues": "2,730,121",
"Stockholders Equity": "6,170,805",
"Net Income": "242,065",
"Comprehensive Net Income": "242,065",
"BaseVar": "6,816,269",
"ECR before LimitedLiability": "326%",
"Economic Capital Ratio": "386%"
}
}
},
"top_rated": true,
"trend": -22.0,
"value": 3.859312734645444,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001100962.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001100962.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001100962.svg"
},
{
"company_id": "0001354071",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001354071.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001354071.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001354071_main_keyfigs.svg",
"name": "China Pediatric Pharmaceuticals INC",
"rank": 28,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001354071.svg",
"report_text": "The relative strengths and weaknesses of China Pediatric Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of China Pediatric Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 199% points.The greatest weakness of China Pediatric Pharmaceuticals INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 83% points.
The company's Economic Capital Ratio, given in the ranking table, is 384%, being 150% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001354071_2012_China_Pediatric_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.50",
"Assets": "-27.1",
"Liabilities": "199",
"Stockholders Equity": "15.6",
"ECR before LimitedLiability": "225",
"Intangible Assets": "-7.83",
"Assets, Current": "-12.7",
"Other Liabilities": "78.7",
"Liabilities, Non-Current": "36.7",
"Liabilities, Current": "121",
"Research and Development": "66.2",
"Expenses": "-53.4",
"Revenues": "84.7",
"Net Income": "72.1",
"Other Expenses": "-51.3",
"Cost of Goods Sold": "-83.0",
"Selling, General and Administrative Expense": "7.73",
"Other Revenues": "84.7",
"Comprehensive Net Income": "73.9",
"Other Net Income": "37.5",
"Economic Capital Ratio": "150"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001354071_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "19,620",
"Cost of Goods Sold": "15,082",
"Intangible Assets": "1,710",
"Liabilities, Current": "1,609",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "883",
"Other Expenses": "12,964",
"Other Liabilities": "0",
"Other Net Income": "5,737",
"Other Revenues": "27,415",
"Property and Equipment": "877",
"Research and Development": "1,856",
"Selling, General and Administrative Expense": "10,216"
},
"output_variables": {
"Assets": "22,207",
"Liabilities": "1,609",
"Expenses": "40,119",
"Revenues": "27,415",
"Stockholders Equity": "20,598",
"Net Income": "-6,967",
"Comprehensive Net Income": "-6,525",
"BaseVar": "48,985",
"ECR before LimitedLiability": "322%",
"Economic Capital Ratio": "384%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.8373484542961798,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001354071.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001354071.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001354071.svg"
},
{
"company_id": "0001274057",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001274057.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001274057.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001274057_main_keyfigs.svg",
"name": "Hospira INC",
"rank": 29,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001274057.svg",
"report_text": "The relative strengths and weaknesses of Hospira INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Hospira INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 93% points.The greatest weakness of Hospira INC is the variable Other Expenses, reducing the Economic Capital Ratio by 55% points.
The company's Economic Capital Ratio, given in the ranking table, is 384%, being 149% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001274057_2012_Hospira_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "0.926",
"Assets": "-5.61",
"Liabilities": "67.3",
"Stockholders Equity": "20.9",
"ECR before LimitedLiability": "50.0",
"Other Assets": "-2.95",
"Intangible Assets": "-6.13",
"Property and Equipment": "2.87",
"Liabilities, Current": "14.0",
"Other Liabilities": "25.5",
"Liabilities, Non-Current": "34.9",
"Cost of Goods Sold": "0.769",
"Expenses": "-18.8",
"Revenues": "14.4",
"Net Income": "-4.52",
"Selling, General and Administrative Expense": "9.16",
"Other Expenses": "-34.8",
"Research and Development": "5.34",
"Other Revenues": "14.4",
"Comprehensive Net Income": "-4.55",
"Economic Capital Ratio": "50.9"
},
"2010": {
"Other Assets": "-4.19",
"Assets": "-0.537",
"Liabilities": "88.2",
"Stockholders Equity": "58.7",
"ECR before LimitedLiability": "108",
"Assets, Current": "-6.29",
"Property and Equipment": "5.03",
"Intangible Assets": "6.52",
"Liabilities, Current": "14.7",
"Other Liabilities": "46.6",
"Liabilities, Non-Current": "38.2",
"Selling, General and Administrative Expense": "12.6",
"Expenses": "-6.22",
"Revenues": "23.7",
"Net Income": "17.9",
"Research and Development": "10.7",
"Cost of Goods Sold": "6.15",
"Other Expenses": "-36.9",
"Other Revenues": "23.7",
"Comprehensive Net Income": "17.9",
"Economic Capital Ratio": "101"
},
"2011": {
"Assets": "6.07",
"Liabilities": "92.7",
"Stockholders Equity": "86.3",
"ECR before LimitedLiability": "225",
"Intangible Assets": "10.2",
"Property and Equipment": "12.7",
"Assets, Current": "-11.5",
"Other Liabilities": "46.7",
"Liabilities, Non-Current": "21.0",
"Liabilities, Current": "37.5",
"Research and Development": "37.2",
"Expenses": "13.4",
"Revenues": "43.9",
"Net Income": "60.9",
"Other Expenses": "-55.0",
"Cost of Goods Sold": "4.88",
"Selling, General and Administrative Expense": "23.0",
"Other Revenues": "43.9",
"Comprehensive Net Income": "59.1",
"Other Net Income": "4.11",
"Economic Capital Ratio": "149"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001274057_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "2,526,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,649,900",
"Liabilities, Current": "881,900",
"Liabilities, Non-Current": "0",
"Other Assets": "179,000",
"Other Compr. Net Income": "0",
"Other Expenses": "2,604,300",
"Other Liabilities": "0",
"Other Net Income": "-11,800",
"Other Revenues": "3,879,300",
"Property and Equipment": "1,147,800",
"Research and Development": "240,500",
"Selling, General and Administrative Expense": "618,800"
},
"output_variables": {
"Assets": "5,502,900",
"Liabilities": "881,900",
"Expenses": "3,463,600",
"Revenues": "3,879,300",
"Stockholders Equity": "4,621,000",
"Net Income": "403,900",
"Comprehensive Net Income": "403,900",
"BaseVar": "6,869,750",
"ECR before LimitedLiability": "328%",
"Economic Capital Ratio": "388%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "2,477,500",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,998,900",
"Liabilities, Current": "931,600",
"Liabilities, Non-Current": "0",
"Other Assets": "290,700",
"Other Compr. Net Income": "0",
"Other Expenses": "2,557,900",
"Other Liabilities": "0",
"Other Net Income": "-26,600",
"Other Revenues": "3,917,200",
"Property and Equipment": "1,279,200",
"Research and Development": "300,500",
"Selling, General and Administrative Expense": "675,000"
},
"output_variables": {
"Assets": "6,046,300",
"Liabilities": "931,600",
"Expenses": "3,533,400",
"Revenues": "3,917,200",
"Stockholders Equity": "5,114,700",
"Net Income": "357,200",
"Comprehensive Net Income": "357,200",
"BaseVar": "7,227,550",
"ECR before LimitedLiability": "330%",
"Economic Capital Ratio": "389%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "2,570,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,438,700",
"Liabilities, Current": "847,800",
"Liabilities, Non-Current": "0",
"Other Assets": "414,700",
"Other Compr. Net Income": "-140,600",
"Other Expenses": "3,225,200",
"Other Liabilities": "0",
"Other Net Income": "54,800",
"Other Revenues": "4,057,100",
"Property and Equipment": "1,355,000",
"Research and Development": "258,800",
"Selling, General and Administrative Expense": "637,300"
},
"output_variables": {
"Assets": "5,779,100",
"Liabilities": "847,800",
"Expenses": "4,121,300",
"Revenues": "4,057,100",
"Stockholders Equity": "4,931,300",
"Net Income": "-9,400",
"Comprehensive Net Income": "-79,700",
"BaseVar": "7,500,350",
"ECR before LimitedLiability": "322%",
"Economic Capital Ratio": "384%"
}
}
},
"top_rated": true,
"trend": -26.0,
"value": 3.835613488566392,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001274057.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001274057.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001274057.svg"
},
{
"company_id": "0000881524",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000881524.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000881524.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000881524_main_keyfigs.svg",
"name": "Vivus INC",
"rank": 30,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000881524.svg",
"report_text": "The relative strengths and weaknesses of Vivus INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Vivus INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 190% points.The greatest weakness of Vivus INC is the variable Other Revenues, reducing the Economic Capital Ratio by 23% points.
The company's Economic Capital Ratio, given in the ranking table, is 383%, being 149% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000881524_2012_Vivus_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.29",
"Assets": "69.2",
"Liabilities": "59.7",
"Stockholders Equity": "190",
"ECR before LimitedLiability": "224",
"Intangible Assets": "-4.31",
"Property and Equipment": "-2.62",
"Assets, Current": "122",
"Other Liabilities": "28.0",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "25.0",
"Research and Development": "4.16",
"Expenses": "16.6",
"Revenues": "-22.5",
"Net Income": "-2.69",
"Other Expenses": "7.70",
"Cost of Goods Sold": "2.79",
"Other Revenues": "-22.5",
"Comprehensive Net Income": "-2.90",
"Other Net Income": "2.65",
"Economic Capital Ratio": "149"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000881524_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "151,736",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "10,972",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "21",
"Other Expenses": "190",
"Other Liabilities": "0",
"Other Net Income": "1,126",
"Other Revenues": "0",
"Property and Equipment": "320",
"Research and Development": "24,604",
"Selling, General and Administrative Expense": "22,472"
},
"output_variables": {
"Assets": "152,056",
"Liabilities": "10,972",
"Expenses": "47,266",
"Revenues": "0",
"Stockholders Equity": "141,084",
"Net Income": "-46,140",
"Comprehensive Net Income": "-46,130",
"BaseVar": "105,720",
"ECR before LimitedLiability": "321%",
"Economic Capital Ratio": "383%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.826640374541914,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000881524.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000881524.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000881524.svg"
},
{
"company_id": "0001087432",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001087432.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001087432.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001087432_main_keyfigs.svg",
"name": "Intermune INC",
"rank": 31,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001087432.svg",
"report_text": "The relative strengths and weaknesses of Intermune INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Intermune INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 183% points.The greatest weakness of Intermune INC is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 380%, being 146% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001087432_2012_Intermune_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "61.4",
"Liabilities": "65.8",
"Stockholders Equity": "183",
"ECR before LimitedLiability": "221",
"Intangible Assets": "-4.81",
"Property and Equipment": "-2.74",
"Assets, Current": "88.9",
"Other Liabilities": "29.9",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "29.3",
"Research and Development": "6.62",
"Expenses": "12.4",
"Revenues": "-17.3",
"Net Income": "-2.70",
"Other Expenses": "4.46",
"Cost of Goods Sold": "3.02",
"Selling, General and Administrative Expense": "-1.62",
"Other Revenues": "-17.3",
"Comprehensive Net Income": "-2.94",
"Other Net Income": "1.82",
"Economic Capital Ratio": "146"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001087432_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "443,138",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "34,091",
"Liabilities, Non-Current": "0",
"Other Assets": "27,144",
"Other Compr. Net Income": "0",
"Other Expenses": "15,137",
"Other Liabilities": "0",
"Other Net Income": "-102",
"Other Revenues": "25,630",
"Property and Equipment": "2,341",
"Research and Development": "74,973",
"Selling, General and Administrative Expense": "90,192"
},
"output_variables": {
"Assets": "472,623",
"Liabilities": "34,091",
"Expenses": "180,302",
"Revenues": "25,630",
"Stockholders Equity": "438,532",
"Net Income": "-154,774",
"Comprehensive Net Income": "-154,774",
"BaseVar": "356,374",
"ECR before LimitedLiability": "316%",
"Economic Capital Ratio": "380%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.796153269548542,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001087432.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001087432.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001087432.svg"
},
{
"company_id": "0001520262",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001520262.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001520262.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001520262.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001520262_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001520262_main_keyfigs.svg",
"name": "Alkermes plc",
"rank": 32,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001520262.svg",
"report_text": "The relative strengths and weaknesses of Alkermes plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alkermes plc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 120% points.The greatest weakness of Alkermes plc is the variable Intangible Assets, reducing the Economic Capital Ratio by 6.1% points.
The company's Economic Capital Ratio, given in the ranking table, is 379%, being 145% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001520262_2012_Alkermes_plc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "13.5",
"Assets": "25.5",
"Liabilities": "70.7",
"Stockholders Equity": "120",
"ECR before LimitedLiability": "221",
"Intangible Assets": "-6.15",
"Property and Equipment": "12.6",
"Assets, Current": "3.77",
"Other Liabilities": "33.8",
"Liabilities, Non-Current": "9.85",
"Liabilities, Current": "34.2",
"Research and Development": "8.75",
"Expenses": "17.2",
"Revenues": "18.3",
"Net Income": "37.3",
"Other Expenses": "-2.56",
"Cost of Goods Sold": "3.89",
"Selling, General and Administrative Expense": "7.18",
"Other Revenues": "18.3",
"Comprehensive Net Income": "37.1",
"Economic Capital Ratio": "145"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001520262_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "252,960",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "48,057",
"Liabilities, Non-Current": "7,536",
"Other Assets": "104,468",
"Other Compr. Net Income": "379",
"Other Expenses": "51,234",
"Other Liabilities": "4,837",
"Other Net Income": "-860",
"Other Revenues": "186,640",
"Property and Equipment": "95,020",
"Research and Development": "97,239",
"Selling, General and Administrative Expense": "82,847"
},
"output_variables": {
"Assets": "452,448",
"Liabilities": "60,430",
"Expenses": "231,320",
"Revenues": "186,640",
"Stockholders Equity": "392,018",
"Net Income": "-45,540",
"Comprehensive Net Income": "-45,350",
"BaseVar": "466,038",
"ECR before LimitedLiability": "316%",
"Economic Capital Ratio": "379%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.7915884180598725,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001520262.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001520262.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001520262.svg"
},
{
"company_id": "0000038074",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000038074.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000038074.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000038074_main_keyfigs.svg",
"name": "Forest Laboratories LLC",
"rank": 33,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000038074.svg",
"report_text": "The relative strengths and weaknesses of Forest Laboratories LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Forest Laboratories LLC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 80% points.The greatest weakness of Forest Laboratories LLC is the variable Other Liabilities, reducing the Economic Capital Ratio by 48% points.
The company's Economic Capital Ratio, given in the ranking table, is 377%, being 143% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000038074_2012_Forest_Laboratories_LLC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "20.4",
"Assets": "-5.80",
"Liabilities": "71.7",
"Stockholders Equity": "19.0",
"ECR before LimitedLiability": "59.3",
"Other Assets": "1.41",
"Intangible Assets": "-14.1",
"Property and Equipment": "-5.31",
"Liabilities, Current": "16.9",
"Other Liabilities": "26.7",
"Liabilities, Non-Current": "36.4",
"Cost of Goods Sold": "0.794",
"Expenses": "-15.5",
"Revenues": "19.4",
"Net Income": "4.15",
"Selling, General and Administrative Expense": "-11.0",
"Research and Development": "-4.46",
"Other Revenues": "19.4",
"Comprehensive Net Income": "3.18",
"Other Compr. Net Income": "-0.977",
"Economic Capital Ratio": "60.2"
},
"2010": {
"Other Assets": "0.970",
"Assets": "-0.813",
"Liabilities": "88.6",
"Stockholders Equity": "57.1",
"ECR before LimitedLiability": "113",
"Assets, Current": "15.5",
"Property and Equipment": "-4.75",
"Intangible Assets": "-8.36",
"Liabilities, Current": "13.9",
"Other Liabilities": "47.4",
"Liabilities, Non-Current": "38.9",
"Selling, General and Administrative Expense": "1.95",
"Expenses": "-3.46",
"Revenues": "26.5",
"Net Income": "23.9",
"Research and Development": "-3.45",
"Cost of Goods Sold": "6.21",
"Other Expenses": "-8.26",
"Other Revenues": "26.5",
"Comprehensive Net Income": "24.4",
"Economic Capital Ratio": "106"
},
"2011": {
"Other Assets": "0.606",
"Assets": "14.2",
"Liabilities": "57.4",
"Stockholders Equity": "80.3",
"ECR before LimitedLiability": "219",
"Property and Equipment": "-1.31",
"Assets, Current": "14.9",
"Other Liabilities": "-47.9",
"Liabilities, Non-Current": "17.8",
"Liabilities, Current": "74.9",
"Research and Development": "24.7",
"Expenses": "28.3",
"Revenues": "38.2",
"Net Income": "68.7",
"Other Expenses": "-8.72",
"Cost of Goods Sold": "4.13",
"Selling, General and Administrative Expense": "8.14",
"Other Revenues": "38.2",
"Comprehensive Net Income": "68.4",
"Other Net Income": "2.53",
"Economic Capital Ratio": "143"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000038074_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "3,785,954",
"Cost of Goods Sold": "0",
"Intangible Assets": "512,862",
"Liabilities, Current": "817,828",
"Liabilities, Non-Current": "0",
"Other Assets": "552,057",
"Other Compr. Net Income": "-81,737",
"Other Expenses": "1,019,471",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,922,782",
"Property and Equipment": "345,935",
"Research and Development": "661,294",
"Selling, General and Administrative Expense": "1,474,274"
},
"output_variables": {
"Assets": "5,196,808",
"Liabilities": "817,828",
"Expenses": "3,155,039",
"Revenues": "3,922,782",
"Stockholders Equity": "4,378,980",
"Net Income": "767,743",
"Comprehensive Net Income": "726,874",
"BaseVar": "6,587,097",
"ECR before LimitedLiability": "342%",
"Economic Capital Ratio": "397%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "4,579,191",
"Cost of Goods Sold": "0",
"Intangible Assets": "481,707",
"Liabilities, Current": "979,646",
"Liabilities, Non-Current": "0",
"Other Assets": "839,349",
"Other Compr. Net Income": "50,840",
"Other Expenses": "1,192,649",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "4,192,862",
"Property and Equipment": "323,284",
"Research and Development": "1,053,561",
"Selling, General and Administrative Expense": "1,264,269"
},
"output_variables": {
"Assets": "6,223,531",
"Liabilities": "979,646",
"Expenses": "3,510,479",
"Revenues": "4,192,862",
"Stockholders Equity": "5,243,885",
"Net Income": "682,383",
"Comprehensive Net Income": "707,803",
"BaseVar": "7,478,679",
"ECR before LimitedLiability": "337%",
"Economic Capital Ratio": "394%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "5,259,673",
"Cost of Goods Sold": "0",
"Intangible Assets": "740,459",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "602,556",
"Other Compr. Net Income": "4,301",
"Other Expenses": "1,254,947",
"Other Liabilities": "1,423,574",
"Other Net Income": "0",
"Other Revenues": "4,419,700",
"Property and Equipment": "319,766",
"Research and Development": "715,872",
"Selling, General and Administrative Expense": "1,402,111"
},
"output_variables": {
"Assets": "6,922,454",
"Liabilities": "1,423,574",
"Expenses": "3,372,930",
"Revenues": "4,419,700",
"Stockholders Equity": "5,498,880",
"Net Income": "1,046,770",
"Comprehensive Net Income": "1,048,920",
"BaseVar": "8,071,480",
"ECR before LimitedLiability": "312%",
"Economic Capital Ratio": "377%"
}
}
},
"top_rated": true,
"trend": -31.0,
"value": 3.770082212746862,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000038074.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000038074.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000038074.svg"
},
{
"company_id": "0001107332",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001107332.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001107332.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001107332_main_keyfigs.svg",
"name": "Dendreon CORP",
"rank": 34,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001107332.svg",
"report_text": "The relative strengths and weaknesses of Dendreon CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Dendreon CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 142% points.The greatest weakness of Dendreon CORP is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 16% points.
The company's Economic Capital Ratio, given in the ranking table, is 376%, being 142% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001107332_2012_Dendreon_CORP.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-6.20",
"Assets": "24.7",
"Liabilities": "86.0",
"Stockholders Equity": "121",
"ECR before LimitedLiability": "44.5",
"Assets, Current": "16.7",
"Property and Equipment": "51.2",
"Intangible Assets": "-20.1",
"Liabilities, Current": "27.7",
"Other Liabilities": "36.2",
"Liabilities, Non-Current": "29.4",
"Selling, General and Administrative Expense": "-25.6",
"Expenses": "-44.3",
"Revenues": "-35.1",
"Net Income": "-81.0",
"Research and Development": "-1.28",
"Cost of Goods Sold": "-0.553",
"Other Expenses": "-16.7",
"Other Revenues": "-35.1",
"Comprehensive Net Income": "-81.0",
"Economic Capital Ratio": "38.1"
},
"2011": {
"Other Assets": "1.44",
"Assets": "26.4",
"Liabilities": "93.7",
"Stockholders Equity": "142",
"ECR before LimitedLiability": "217",
"Intangible Assets": "-6.80",
"Property and Equipment": "17.2",
"Assets, Current": "13.6",
"Other Liabilities": "40.0",
"Liabilities, Non-Current": "17.8",
"Liabilities, Current": "47.8",
"Research and Development": "27.2",
"Expenses": "-1.39",
"Revenues": "9.76",
"Net Income": "11.1",
"Cost of Goods Sold": "-15.9",
"Selling, General and Administrative Expense": "-14.3",
"Other Revenues": "9.76",
"Comprehensive Net Income": "10.8",
"Other Net Income": "2.74",
"Economic Capital Ratio": "142"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001107332_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "330,394",
"Cost of Goods Sold": "28,520",
"Intangible Assets": "0",
"Liabilities, Current": "50,079",
"Liabilities, Non-Current": "0",
"Other Assets": "26,670",
"Other Compr. Net Income": "0",
"Other Expenses": "143,744",
"Other Liabilities": "0",
"Other Net Income": "-3,572",
"Other Revenues": "48,057",
"Property and Equipment": "246,889",
"Research and Development": "75,941",
"Selling, General and Administrative Expense": "235,760"
},
"output_variables": {
"Assets": "603,953",
"Liabilities": "50,079",
"Expenses": "483,965",
"Revenues": "48,057",
"Stockholders Equity": "553,874",
"Net Income": "-439,480",
"Comprehensive Net Income": "-439,480",
"BaseVar": "594,813",
"ECR before LimitedLiability": "235%",
"Economic Capital Ratio": "326%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "670,222",
"Cost of Goods Sold": "159,090",
"Intangible Assets": "0",
"Liabilities, Current": "77,716",
"Liabilities, Non-Current": "0",
"Other Assets": "88,764",
"Other Compr. Net Income": "0",
"Other Expenses": "86,292",
"Other Liabilities": "0",
"Other Net Income": "1,595",
"Other Revenues": "341,613",
"Property and Equipment": "242,505",
"Research and Development": "74,290",
"Selling, General and Administrative Expense": "361,342"
},
"output_variables": {
"Assets": "1,001,491",
"Liabilities": "77,716",
"Expenses": "681,014",
"Revenues": "341,613",
"Stockholders Equity": "923,775",
"Net Income": "-337,806",
"Comprehensive Net Income": "-337,806",
"BaseVar": "1,051,714",
"ECR before LimitedLiability": "311%",
"Economic Capital Ratio": "376%"
}
}
},
"top_rated": true,
"trend": -22.0,
"value": 3.7579260074767378,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001107332.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001107332.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001107332.svg"
},
{
"company_id": "0000934473",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000934473.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000934473.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000934473_main_keyfigs.svg",
"name": "Genvec INC",
"rank": 35,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000934473.svg",
"report_text": "The relative strengths and weaknesses of Genvec INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Genvec INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 102% points.The greatest weakness of Genvec INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.
The company's Economic Capital Ratio, given in the ranking table, is 371%, being 137% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000934473_2012_Genvec_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.14",
"Assets": "8.64",
"Liabilities": "102",
"Stockholders Equity": "101",
"ECR before LimitedLiability": "213",
"Intangible Assets": "-8.29",
"Property and Equipment": "-3.71",
"Assets, Current": "39.1",
"Other Liabilities": "45.8",
"Liabilities, Non-Current": "20.6",
"Liabilities, Current": "48.7",
"Research and Development": "-27.9",
"Expenses": "-3.87",
"Revenues": "32.8",
"Net Income": "32.1",
"Other Expenses": "13.7",
"Cost of Goods Sold": "4.87",
"Selling, General and Administrative Expense": "4.81",
"Other Revenues": "32.8",
"Comprehensive Net Income": "31.7",
"Economic Capital Ratio": "137"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000934473_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "29,067",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,328",
"Liabilities, Non-Current": "0",
"Other Assets": "107",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "41",
"Other Revenues": "17,744",
"Property and Equipment": "692",
"Research and Development": "17,416",
"Selling, General and Administrative Expense": "7,810"
},
"output_variables": {
"Assets": "29,866",
"Liabilities": "3,328",
"Expenses": "25,226",
"Revenues": "17,744",
"Stockholders Equity": "26,538",
"Net Income": "-7,441",
"Comprehensive Net Income": "-7,441",
"BaseVar": "38,102",
"ECR before LimitedLiability": "304%",
"Economic Capital Ratio": "371%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.711665471442732,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000934473.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000934473.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000934473.svg"
},
{
"company_id": "0001322505",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001322505.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001322505.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001322505.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001322505_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001322505_main_keyfigs.svg",
"name": "Albireo Pharma INC",
"rank": 36,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001322505.svg",
"report_text": "The relative strengths and weaknesses of Albireo Pharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Albireo Pharma INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 138% points.The greatest weakness of Albireo Pharma INC is the variable Other Revenues, reducing the Economic Capital Ratio by 30% points.
The company's Economic Capital Ratio, given in the ranking table, is 371%, being 136% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001322505_2012_Albireo_Pharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.03",
"Assets": "34.1",
"Liabilities": "74.6",
"Stockholders Equity": "138",
"ECR before LimitedLiability": "212",
"Intangible Assets": "-6.48",
"Assets, Current": "62.8",
"Other Liabilities": "25.5",
"Liabilities, Non-Current": "16.0",
"Liabilities, Current": "40.8",
"Research and Development": "-7.40",
"Expenses": "7.46",
"Revenues": "-30.2",
"Net Income": "15.1",
"Other Expenses": "10.2",
"Cost of Goods Sold": "3.76",
"Selling, General and Administrative Expense": "0.826",
"Other Revenues": "-30.2",
"Comprehensive Net Income": "14.8",
"Other Net Income": "36.8",
"Economic Capital Ratio": "136"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001322505_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "39,196",
"Cost of Goods Sold": "0",
"Intangible Assets": "49",
"Liabilities, Current": "3,289",
"Liabilities, Non-Current": "0",
"Other Assets": "7.0",
"Other Compr. Net Income": "0",
"Other Expenses": "119",
"Other Liabilities": "1,138",
"Other Net Income": "11,984",
"Other Revenues": "60",
"Property and Equipment": "2,253",
"Research and Development": "13,901",
"Selling, General and Administrative Expense": "9,321"
},
"output_variables": {
"Assets": "41,505",
"Liabilities": "4,427",
"Expenses": "23,341",
"Revenues": "60",
"Stockholders Equity": "37,078",
"Net Income": "-11,297",
"Comprehensive Net Income": "-11,297",
"BaseVar": "40,658",
"ECR before LimitedLiability": "303%",
"Economic Capital Ratio": "371%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.7051091162142176,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001322505.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001322505.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001322505.svg"
},
{
"company_id": "0001375247",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001375247.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001375247.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001375247_main_keyfigs.svg",
"name": "Obagi Medical Products Inc",
"rank": 37,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001375247.svg",
"report_text": "The relative strengths and weaknesses of Obagi Medical Products Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Obagi Medical Products Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 128% points.The greatest weakness of Obagi Medical Products Inc is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 52% points.
The company's Economic Capital Ratio, given in the ranking table, is 370%, being 136% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001375247_2012_Obagi_Medical_Products_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.91",
"Assets": "-23.5",
"Liabilities": "128",
"ECR before LimitedLiability": "212",
"Intangible Assets": "-5.17",
"Property and Equipment": "-5.31",
"Assets, Current": "-9.25",
"Other Liabilities": "59.7",
"Liabilities, Non-Current": "21.7",
"Liabilities, Current": "64.8",
"Research and Development": "58.3",
"Expenses": "-6.46",
"Net Income": "105",
"Other Expenses": "-23.2",
"Cost of Goods Sold": "7.01",
"Selling, General and Administrative Expense": "-51.6",
"Other Revenues": "107",
"Revenues": "107",
"Comprehensive Net Income": "104",
"Other Net Income": "4.34",
"Economic Capital Ratio": "136"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001375247_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "66,471",
"Cost of Goods Sold": "0",
"Intangible Assets": "8,167",
"Liabilities, Current": "14,290",
"Liabilities, Non-Current": "1,570",
"Other Assets": "172",
"Other Compr. Net Income": "0",
"Other Expenses": "30,043",
"Other Liabilities": "919",
"Other Net Income": "35",
"Other Revenues": "114,108",
"Property and Equipment": "2,841",
"Research and Development": "2,192",
"Selling, General and Administrative Expense": "71,888"
},
"output_variables": {
"Assets": "77,651",
"Liabilities": "16,779",
"Expenses": "104,123",
"Revenues": "114,108",
"Stockholders Equity": "60,872",
"Net Income": "10,020",
"Comprehensive Net Income": "10,020",
"BaseVar": "156,348",
"ECR before LimitedLiability": "302%",
"Economic Capital Ratio": "370%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.7018427783635417,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001375247.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001375247.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001375247.svg"
},
{
"company_id": "0000944809",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000944809.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000944809.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000944809.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000944809_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000944809_main_keyfigs.svg",
"name": "OPKO Health INC",
"rank": 38,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000944809.svg",
"report_text": "The relative strengths and weaknesses of OPKO Health INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of OPKO Health INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 131% points.The greatest weakness of OPKO Health INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 365%, being 131% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000944809_2012_OPKO_Health_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "63.9",
"Liabilities": "14.0",
"Stockholders Equity": "131",
"ECR before LimitedLiability": "206",
"Intangible Assets": "55.3",
"Property and Equipment": "-1.38",
"Assets, Current": "6.08",
"Other Liabilities": "25.3",
"Liabilities, Non-Current": "-37.4",
"Liabilities, Current": "20.5",
"Research and Development": "17.3",
"Expenses": "36.3",
"Revenues": "-6.89",
"Net Income": "32.3",
"Other Expenses": "15.0",
"Cost of Goods Sold": "-5.84",
"Selling, General and Administrative Expense": "9.97",
"Other Revenues": "-6.89",
"Comprehensive Net Income": "32.1",
"Other Net Income": "2.82",
"Economic Capital Ratio": "131"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000944809_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "99,582",
"Cost of Goods Sold": "17,243",
"Intangible Assets": "116,545",
"Liabilities, Current": "18,778",
"Liabilities, Non-Current": "25,443",
"Other Assets": "8,004",
"Other Compr. Net Income": "0",
"Other Expenses": "-15,954",
"Other Liabilities": "0",
"Other Net Income": "2,548",
"Other Revenues": "27,979",
"Property and Equipment": "5,358",
"Research and Development": "11,352",
"Selling, General and Administrative Expense": "19,169"
},
"output_variables": {
"Assets": "229,489",
"Liabilities": "44,221",
"Expenses": "31,810",
"Revenues": "27,979",
"Stockholders Equity": "185,268",
"Net Income": "-1,283",
"Comprehensive Net Income": "-1,283",
"BaseVar": "168,024",
"ECR before LimitedLiability": "294%",
"Economic Capital Ratio": "365%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.647615866822452,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000944809.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000944809.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000944809.svg"
},
{
"company_id": "0001260990",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001260990.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001260990.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001260990_main_keyfigs.svg",
"name": "Oncternal Therapeutics Inc",
"rank": 39,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001260990.svg",
"report_text": "The relative strengths and weaknesses of Oncternal Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oncternal Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 157% points.The greatest weakness of Oncternal Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 18% points.
The company's Economic Capital Ratio, given in the ranking table, is 365%, being 131% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001260990_2012_Oncternal_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.29",
"Assets": "41.8",
"Liabilities": "81.5",
"Stockholders Equity": "157",
"ECR before LimitedLiability": "206",
"Intangible Assets": "-6.66",
"Property and Equipment": "-3.31",
"Assets, Current": "87.1",
"Other Liabilities": "35.3",
"Liabilities, Non-Current": "15.6",
"Liabilities, Current": "39.4",
"Other Revenues": "-5.98",
"Revenues": "-5.98",
"Net Income": "-5.21",
"Research and Development": "-18.0",
"Comprehensive Net Income": "-5.50",
"Cost of Goods Sold": "3.70",
"Selling, General and Administrative Expense": "3.20",
"Other Expenses": "8.75",
"Other Net Income": "2.89",
"Economic Capital Ratio": "131"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001260990_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "76,848",
"Cost of Goods Sold": "0",
"Intangible Assets": "240",
"Liabilities, Current": "6,076",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,055",
"Other Liabilities": "0",
"Other Net Income": "398",
"Other Revenues": "14,739",
"Property and Equipment": "1,096",
"Research and Development": "31,938",
"Selling, General and Administrative Expense": "15,438"
},
"output_variables": {
"Assets": "78,184",
"Liabilities": "6,076",
"Expenses": "48,431",
"Revenues": "14,739",
"Stockholders Equity": "72,108",
"Net Income": "-33,294",
"Comprehensive Net Income": "-33,294",
"BaseVar": "73,914",
"ECR before LimitedLiability": "294%",
"Economic Capital Ratio": "365%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.647029987870283,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001260990.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001260990.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001260990.svg"
},
{
"company_id": "0000919722",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000919722.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000919722.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000919722_main_keyfigs.svg",
"name": "Astex Pharmaceuticals Inc",
"rank": 40,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000919722.svg",
"report_text": "The relative strengths and weaknesses of Astex Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Astex Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 115% points.The greatest weakness of Astex Pharmaceuticals Inc is the variable Other Assets, reducing the Economic Capital Ratio by 3.7% points.
The company's Economic Capital Ratio, given in the ranking table, is 362%, being 128% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000919722_2012_Astex_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.68",
"Assets": "49.5",
"Liabilities": "20.8",
"Stockholders Equity": "115",
"ECR before LimitedLiability": "204",
"Intangible Assets": "47.4",
"Assets, Current": "6.90",
"Other Liabilities": "-2.13",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "11.0",
"Research and Development": "8.29",
"Expenses": "33.9",
"Revenues": "3.59",
"Net Income": "39.3",
"Other Expenses": "7.87",
"Cost of Goods Sold": "2.92",
"Selling, General and Administrative Expense": "15.0",
"Other Revenues": "3.59",
"Comprehensive Net Income": "39.1",
"Other Net Income": "1.87",
"Economic Capital Ratio": "128"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000919722_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "136,570",
"Cost of Goods Sold": "0",
"Intangible Assets": "130,992",
"Liabilities, Current": "34,670",
"Liabilities, Non-Current": "0",
"Other Assets": "2,373",
"Other Compr. Net Income": "0",
"Other Expenses": "861",
"Other Liabilities": "22,277",
"Other Net Income": "226",
"Other Revenues": "66,914",
"Property and Equipment": "7,013",
"Research and Development": "43,895",
"Selling, General and Administrative Expense": "16,842"
},
"output_variables": {
"Assets": "276,948",
"Liabilities": "56,947",
"Expenses": "61,598",
"Revenues": "66,914",
"Stockholders Equity": "220,001",
"Net Income": "5,542",
"Comprehensive Net Income": "5,542",
"BaseVar": "231,316",
"ECR before LimitedLiability": "291%",
"Economic Capital Ratio": "362%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.6237095543628066,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000919722.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000919722.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000919722.svg"
},
{
"company_id": "0001096294",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001096294.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001096294.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001096294_main_keyfigs.svg",
"name": "GFR Pharmaceuticals INC",
"rank": 41,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001096294.svg",
"report_text": "The relative strengths and weaknesses of GFR Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of GFR Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 219% points.The greatest weakness of GFR Pharmaceuticals INC is the variable Assets, Current, reducing the Economic Capital Ratio by 23% points.
The company's Economic Capital Ratio, given in the ranking table, is 360%, being 126% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001096294_2012_GFR_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.88",
"Assets": "38.0",
"Liabilities": "12.7",
"Stockholders Equity": "89.4",
"ECR before LimitedLiability": "201",
"Intangible Assets": "-6.13",
"Property and Equipment": "219",
"Assets, Current": "-22.8",
"Other Liabilities": "5.48",
"Liabilities, Non-Current": "13.0",
"Liabilities, Current": "-5.97",
"Research and Development": "27.2",
"Expenses": "39.5",
"Revenues": "15.6",
"Net Income": "57.2",
"Other Expenses": "2.57",
"Cost of Goods Sold": "-7.44",
"Selling, General and Administrative Expense": "17.2",
"Other Revenues": "15.6",
"Comprehensive Net Income": "56.9",
"Economic Capital Ratio": "126"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001096294_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,093",
"Cost of Goods Sold": "1,222",
"Intangible Assets": "0",
"Liabilities, Current": "2,278",
"Liabilities, Non-Current": "0",
"Other Assets": "139",
"Other Compr. Net Income": "0",
"Other Expenses": "716",
"Other Liabilities": "845",
"Other Net Income": "1.5",
"Other Revenues": "4,674",
"Property and Equipment": "11,097",
"Research and Development": "0",
"Selling, General and Administrative Expense": "681"
},
"output_variables": {
"Assets": "12,329",
"Liabilities": "3,123",
"Expenses": "2,618",
"Revenues": "4,674",
"Stockholders Equity": "9,207",
"Net Income": "2,057",
"Comprehensive Net Income": "2,057",
"BaseVar": "11,373",
"ECR before LimitedLiability": "286%",
"Economic Capital Ratio": "360%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.5958392928062923,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001096294.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001096294.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001096294.svg"
},
{
"company_id": "0000949699",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000949699.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000949699.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000949699_main_keyfigs.svg",
"name": "Pharmacyclics INC",
"rank": 42,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000949699.svg",
"report_text": "The relative strengths and weaknesses of Pharmacyclics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pharmacyclics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 156% points.The greatest weakness of Pharmacyclics INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.
The company's Economic Capital Ratio, given in the ranking table, is 358%, being 124% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000949699_2012_Pharmacyclics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.28",
"Assets": "65.5",
"Liabilities": "45.4",
"Stockholders Equity": "156",
"ECR before LimitedLiability": "200",
"Intangible Assets": "-5.90",
"Property and Equipment": "-2.85",
"Assets, Current": "117",
"Other Liabilities": "26.8",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "9.08",
"Research and Development": "-9.02",
"Expenses": "14.8",
"Revenues": "-15.0",
"Net Income": "1.99",
"Other Expenses": "8.26",
"Cost of Goods Sold": "2.93",
"Selling, General and Administrative Expense": "12.6",
"Other Revenues": "-15.0",
"Other Net Income": "1.96",
"Economic Capital Ratio": "124"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000949699_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "114,696",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,268",
"Liabilities, Non-Current": "0",
"Other Assets": "344",
"Other Compr. Net Income": "-15",
"Other Expenses": "0",
"Other Liabilities": "410",
"Other Net Income": "171",
"Other Revenues": "8,233",
"Property and Equipment": "1,312",
"Research and Development": "34,482",
"Selling, General and Administrative Expense": "9,125"
},
"output_variables": {
"Assets": "116,352",
"Liabilities": "14,678",
"Expenses": "43,607",
"Revenues": "8,233",
"Stockholders Equity": "101,674",
"Net Income": "-35,203",
"Comprehensive Net Income": "-35,210",
"BaseVar": "91,528",
"ECR before LimitedLiability": "285%",
"Economic Capital Ratio": "358%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.5836518900645045,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000949699.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000949699.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000949699.svg"
},
{
"company_id": "0001003642",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001003642.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001003642.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001003642_main_keyfigs.svg",
"name": "Impax Laboratories LLC",
"rank": 43,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001003642.svg",
"report_text": "The relative strengths and weaknesses of Impax Laboratories LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Impax Laboratories LLC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 64% points.The greatest weakness of Impax Laboratories LLC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 355%, being 121% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001003642_2012_Impax_Laboratories_LLC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "12.5",
"Liabilities": "48.5",
"Stockholders Equity": "64.4",
"ECR before LimitedLiability": "197",
"Intangible Assets": "-5.86",
"Property and Equipment": "7.12",
"Assets, Current": "14.2",
"Other Liabilities": "31.5",
"Liabilities, Non-Current": "9.45",
"Liabilities, Current": "10.3",
"Research and Development": "25.4",
"Expenses": "23.3",
"Revenues": "36.1",
"Net Income": "62.1",
"Other Expenses": "6.25",
"Cost of Goods Sold": "-30.6",
"Selling, General and Administrative Expense": "21.6",
"Other Revenues": "36.1",
"Comprehensive Net Income": "61.7",
"Other Net Income": "2.33",
"Economic Capital Ratio": "121"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001003642_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "599,935",
"Cost of Goods Sold": "254,624",
"Intangible Assets": "27,574",
"Liabilities, Current": "156,861",
"Liabilities, Non-Current": "16,861",
"Other Assets": "48,192",
"Other Compr. Net Income": "-990",
"Other Expenses": "40,279",
"Other Liabilities": "17,131",
"Other Net Income": "-1,440",
"Other Revenues": "512,919",
"Property and Equipment": "118,158",
"Research and Development": "82,701",
"Selling, General and Administrative Expense": "68,477"
},
"output_variables": {
"Assets": "793,859",
"Liabilities": "190,853",
"Expenses": "446,081",
"Revenues": "512,919",
"Stockholders Equity": "603,006",
"Net Income": "65,398",
"Comprehensive Net Income": "64,903",
"BaseVar": "973,071",
"ECR before LimitedLiability": "280%",
"Economic Capital Ratio": "355%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.5544694892238615,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001003642.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001003642.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001003642.svg"
},
{
"company_id": "0001130591",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001130591.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001130591.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001130591_main_keyfigs.svg",
"name": "Xenoport INC",
"rank": 44,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001130591.svg",
"report_text": "The relative strengths and weaknesses of Xenoport INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Xenoport INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 111% points.The greatest weakness of Xenoport INC is the variable Research and Development, reducing the Economic Capital Ratio by 12% points.
The company's Economic Capital Ratio, given in the ranking table, is 355%, being 120% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001130591_2012_Xenoport_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-7.28",
"Assets": "34.6",
"Liabilities": "74.3",
"Stockholders Equity": "127",
"ECR before LimitedLiability": "45.4",
"Assets, Current": "131",
"Property and Equipment": "-5.27",
"Intangible Assets": "-18.6",
"Liabilities, Current": "19.2",
"Other Liabilities": "33.6",
"Liabilities, Non-Current": "27.3",
"Selling, General and Administrative Expense": "-7.94",
"Expenses": "-36.4",
"Revenues": "-37.7",
"Net Income": "-74.7",
"Research and Development": "-39.4",
"Cost of Goods Sold": "4.79",
"Other Expenses": "6.09",
"Other Revenues": "-37.7",
"Comprehensive Net Income": "-74.7",
"Economic Capital Ratio": "39.1"
},
"2011": {
"Other Assets": "-4.54",
"Assets": "21.0",
"Liabilities": "80.2",
"Stockholders Equity": "111",
"ECR before LimitedLiability": "196",
"Intangible Assets": "-8.65",
"Property and Equipment": "-2.38",
"Assets, Current": "50.7",
"Other Liabilities": "39.4",
"Liabilities, Non-Current": "17.5",
"Liabilities, Current": "31.3",
"Other Revenues": "15.6",
"Revenues": "15.6",
"Net Income": "16.9",
"Research and Development": "-11.8",
"Comprehensive Net Income": "16.5",
"Cost of Goods Sold": "4.24",
"Selling, General and Administrative Expense": "-2.55",
"Other Expenses": "8.67",
"Other Net Income": "2.59",
"Economic Capital Ratio": "120"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001130591_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "110,801",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "11,487",
"Liabilities, Non-Current": "0",
"Other Assets": "3,219",
"Other Compr. Net Income": "0",
"Other Expenses": "5,275",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "3,675",
"Property and Equipment": "7,209",
"Research and Development": "52,546",
"Selling, General and Administrative Expense": "28,323"
},
"output_variables": {
"Assets": "121,229",
"Liabilities": "11,487",
"Expenses": "86,144",
"Revenues": "3,675",
"Stockholders Equity": "109,742",
"Net Income": "-82,469",
"Comprehensive Net Income": "-82,469",
"BaseVar": "111,268",
"ECR before LimitedLiability": "236%",
"Economic Capital Ratio": "326%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "97,452",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,530",
"Liabilities, Non-Current": "0",
"Other Assets": "2,663",
"Other Compr. Net Income": "-10",
"Other Expenses": "2,923",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "43,758",
"Property and Equipment": "3,921",
"Research and Development": "43,788",
"Selling, General and Administrative Expense": "30,427"
},
"output_variables": {
"Assets": "104,036",
"Liabilities": "13,530",
"Expenses": "77,138",
"Revenues": "43,758",
"Stockholders Equity": "90,506",
"Net Income": "-33,380",
"Comprehensive Net Income": "-33,385",
"BaseVar": "119,236",
"ECR before LimitedLiability": "279%",
"Economic Capital Ratio": "355%"
}
}
},
"top_rated": true,
"trend": -33.0,
"value": 3.545715241248095,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001130591.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001130591.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001130591.svg"
},
{
"company_id": "0001379006",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001379006.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001379006.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001379006_main_keyfigs.svg",
"name": "Nanoviricides INC",
"rank": 45,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001379006.svg",
"report_text": "The relative strengths and weaknesses of Nanoviricides INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nanoviricides INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 192% points.The greatest weakness of Nanoviricides INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 34% points.
The company's Economic Capital Ratio, given in the ranking table, is 353%, being 119% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001379006_2012_Nanoviricides_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.29",
"Assets": "68.9",
"Liabilities": "77.2",
"Stockholders Equity": "192",
"ECR before LimitedLiability": "195",
"Intangible Assets": "-3.54",
"Property and Equipment": "2.89",
"Assets, Current": "89.6",
"Other Liabilities": "31.0",
"Liabilities, Non-Current": "13.6",
"Liabilities, Current": "39.8",
"Research and Development": "-19.5",
"Expenses": "-8.81",
"Revenues": "-26.3",
"Net Income": "-33.9",
"Other Expenses": "9.25",
"Cost of Goods Sold": "3.29",
"Selling, General and Administrative Expense": "-1.97",
"Other Revenues": "-26.3",
"Comprehensive Net Income": "-34.1",
"Economic Capital Ratio": "119"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001379006_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,556",
"Cost of Goods Sold": "0",
"Intangible Assets": "399",
"Liabilities, Current": "587",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-48",
"Other Revenues": "0",
"Property and Equipment": "802",
"Research and Development": "4,156",
"Selling, General and Administrative Expense": "2,274"
},
"output_variables": {
"Assets": "10,758",
"Liabilities": "587",
"Expenses": "6,429",
"Revenues": "0",
"Stockholders Equity": "10,171",
"Net Income": "-6,477",
"Comprehensive Net Income": "-6,477",
"BaseVar": "8,911",
"ECR before LimitedLiability": "277%",
"Economic Capital Ratio": "353%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.531376934722502,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001379006.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001379006.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001379006.svg"
},
{
"company_id": "0001235007",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001235007.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001235007.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001235007_main_keyfigs.svg",
"name": "Endocyte INC",
"rank": 46,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001235007.svg",
"report_text": "The relative strengths and weaknesses of Endocyte INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Endocyte INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 159% points.The greatest weakness of Endocyte INC is the variable Other Revenues, reducing the Economic Capital Ratio by 21% points.
The company's Economic Capital Ratio, given in the ranking table, is 352%, being 118% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001235007_2012_Endocyte_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.83",
"Assets": "80.7",
"Liabilities": "33.3",
"Stockholders Equity": "159",
"ECR before LimitedLiability": "194",
"Intangible Assets": "-5.71",
"Property and Equipment": "-2.92",
"Assets, Current": "139",
"Other Liabilities": "-13.7",
"Liabilities, Non-Current": "11.1",
"Liabilities, Current": "34.9",
"Research and Development": "-1.84",
"Expenses": "17.6",
"Revenues": "-21.1",
"Comprehensive Net Income": "-1.74",
"Other Expenses": "5.76",
"Cost of Goods Sold": "2.66",
"Selling, General and Administrative Expense": "11.1",
"Other Revenues": "-21.1",
"Other Net Income": "1.74",
"Economic Capital Ratio": "118"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001235007_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "129,756",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,470",
"Liabilities, Non-Current": "0",
"Other Assets": "811",
"Other Compr. Net Income": "0",
"Other Expenses": "1,988",
"Other Liabilities": "12,833",
"Other Net Income": "129",
"Other Revenues": "155",
"Property and Equipment": "1,108",
"Research and Development": "28,828",
"Selling, General and Administrative Expense": "10,000"
},
"output_variables": {
"Assets": "131,675",
"Liabilities": "18,303",
"Expenses": "40,816",
"Revenues": "155",
"Stockholders Equity": "113,372",
"Net Income": "-40,532",
"Comprehensive Net Income": "-40,532",
"BaseVar": "95,539",
"ECR before LimitedLiability": "276%",
"Economic Capital Ratio": "352%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.523742025196254,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001235007.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001235007.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001235007.svg"
},
{
"company_id": "0001367644",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001367644.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001367644.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001367644.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001367644_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001367644_main_keyfigs.svg",
"name": "Emergent Biosolutions Inc",
"rank": 47,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001367644.svg",
"report_text": "The relative strengths and weaknesses of Emergent Biosolutions Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Emergent Biosolutions Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 77% points.The greatest weakness of Emergent Biosolutions Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 351%, being 117% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001367644_2012_Emergent_Biosolutions_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "6.28",
"Assets": "23.2",
"Liabilities": "36.9",
"Stockholders Equity": "77.1",
"ECR before LimitedLiability": "192",
"Intangible Assets": "-7.18",
"Property and Equipment": "37.5",
"Assets, Current": "-6.57",
"Other Liabilities": "32.9",
"Liabilities, Non-Current": "-24.4",
"Liabilities, Current": "26.0",
"Research and Development": "8.61",
"Expenses": "24.8",
"Revenues": "23.8",
"Net Income": "51.1",
"Cost of Goods Sold": "3.73",
"Selling, General and Administrative Expense": "13.3",
"Other Revenues": "23.8",
"Comprehensive Net Income": "50.8",
"Other Net Income": "2.25",
"Economic Capital Ratio": "117"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001367644_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "254,418",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,502",
"Liabilities, Current": "71,054",
"Liabilities, Non-Current": "56,078",
"Other Assets": "77,971",
"Other Compr. Net Income": "0",
"Other Expenses": "58,001",
"Other Liabilities": "3,005",
"Other Net Income": "-156",
"Other Revenues": "273,384",
"Property and Equipment": "208,973",
"Research and Development": "124,832",
"Selling, General and Administrative Expense": "74,282"
},
"output_variables": {
"Assets": "546,864",
"Liabilities": "130,137",
"Expenses": "257,115",
"Revenues": "273,384",
"Stockholders Equity": "416,727",
"Net Income": "16,113",
"Comprehensive Net Income": "16,113",
"BaseVar": "603,828",
"ECR before LimitedLiability": "273%",
"Economic Capital Ratio": "351%"
}
}
},
"top_rated": true,
"trend": null,
"value": 3.5079269467863865,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001367644.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001367644.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001367644.svg"
},
{
"company_id": "0000001800",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000001800.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000001800.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000001800.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000001800_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000001800_main_keyfigs.svg",
"name": "Abbott Laboratories",
"rank": 48,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000001800.svg",
"report_text": "The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Abbott Laboratories compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points.The greatest weakness of Abbott Laboratories is the variable Other Expenses, reducing the Economic Capital Ratio by 17% points.
The company's Economic Capital Ratio, given in the ranking table, is 348%, being 114% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000001800_2012_Abbott_Laboratories.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "1.92",
"Assets": "-3.13",
"Liabilities": "25.3",
"Stockholders Equity": "7.40",
"ECR before LimitedLiability": "17.4",
"Other Assets": "-3.10",
"Intangible Assets": "-0.953",
"Property and Equipment": "-0.937",
"Liabilities, Current": "-27.0",
"Other Liabilities": "20.7",
"Liabilities, Non-Current": "28.4",
"Cost of Goods Sold": "0.654",
"Expenses": "-6.03",
"Revenues": "3.65",
"Net Income": "0.406",
"Selling, General and Administrative Expense": "2.14",
"Other Expenses": "-12.3",
"Research and Development": "3.40",
"Other Revenues": "3.65",
"Other Net Income": "2.77",
"Economic Capital Ratio": "18.3"
},
"2010": {
"Other Assets": "-8.74",
"Assets": "-1.21",
"Liabilities": "34.8",
"Stockholders Equity": "20.9",
"ECR before LimitedLiability": "55.7",
"Assets, Current": "-12.2",
"Intangible Assets": "27.2",
"Liabilities, Current": "-39.2",
"Other Liabilities": "37.6",
"Liabilities, Non-Current": "30.6",
"Selling, General and Administrative Expense": "4.56",
"Expenses": "1.86",
"Revenues": "14.6",
"Net Income": "17.5",
"Research and Development": "7.94",
"Cost of Goods Sold": "5.31",
"Other Expenses": "-16.0",
"Other Revenues": "14.6",
"Comprehensive Net Income": "17.5",
"Other Net Income": "0.937",
"Economic Capital Ratio": "49.3"
},
"2011": {
"Other Assets": "-2.98",
"Assets": "11.8",
"Liabilities": "43.9",
"Stockholders Equity": "58.2",
"ECR before LimitedLiability": "189",
"Intangible Assets": "37.0",
"Property and Equipment": "5.62",
"Assets, Current": "-16.5",
"Other Liabilities": "38.0",
"Liabilities, Non-Current": "16.8",
"Liabilities, Current": "-10.8",
"Research and Development": "28.1",
"Expenses": "23.8",
"Revenues": "35.0",
"Net Income": "61.9",
"Other Expenses": "-17.2",
"Cost of Goods Sold": "4.13",
"Selling, General and Administrative Expense": "8.61",
"Other Revenues": "35.0",
"Comprehensive Net Income": "60.4",
"Economic Capital Ratio": "114"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000001800_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "23,313,891",
"Cost of Goods Sold": "0",
"Intangible Assets": "19,492,163",
"Liabilities, Current": "13,049,489",
"Liabilities, Non-Current": "0",
"Other Assets": "1,991,080",
"Other Compr. Net Income": "0",
"Other Expenses": "15,346,921",
"Other Liabilities": "0",
"Other Net Income": "1,477,689",
"Other Revenues": "30,764,707",
"Property and Equipment": "7,619,489",
"Research and Development": "2,743,733",
"Selling, General and Administrative Expense": "8,405,904"
},
"output_variables": {
"Assets": "52,416,623",
"Liabilities": "13,049,489",
"Expenses": "26,496,558",
"Revenues": "30,764,707",
"Stockholders Equity": "39,367,134",
"Net Income": "5,745,838",
"Comprehensive Net Income": "5,745,838",
"BaseVar": "62,102,533",
"ECR before LimitedLiability": "280%",
"Economic Capital Ratio": "355%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "22,317,529",
"Cost of Goods Sold": "0",
"Intangible Assets": "28,081,705",
"Liabilities, Current": "17,262,434",
"Liabilities, Non-Current": "0",
"Other Assets": "1,092,076",
"Other Compr. Net Income": "0",
"Other Expenses": "16,618,189",
"Other Liabilities": "0",
"Other Net Income": "178,388",
"Other Revenues": "35,166,721",
"Property and Equipment": "7,970,956",
"Research and Development": "3,724,424",
"Selling, General and Administrative Expense": "10,376,324"
},
"output_variables": {
"Assets": "59,462,266",
"Liabilities": "17,262,434",
"Expenses": "30,718,937",
"Revenues": "35,166,721",
"Stockholders Equity": "42,199,832",
"Net Income": "4,626,172",
"Comprehensive Net Income": "4,626,172",
"BaseVar": "71,394,373",
"ECR before LimitedLiability": "252%",
"Economic Capital Ratio": "337%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "23,768,774",
"Cost of Goods Sold": "0",
"Intangible Assets": "25,695,016",
"Liabilities, Current": "15,480,228",
"Liabilities, Non-Current": "0",
"Other Assets": "2,939,148",
"Other Compr. Net Income": "-1,230,339",
"Other Expenses": "16,540,914",
"Other Liabilities": "0",
"Other Net Income": "-23,165",
"Other Revenues": "38,851,259",
"Property and Equipment": "7,873,955",
"Research and Development": "4,801,914",
"Selling, General and Administrative Expense": "12,756,817"
},
"output_variables": {
"Assets": "60,276,893",
"Liabilities": "15,480,228",
"Expenses": "34,099,645",
"Revenues": "38,851,259",
"Stockholders Equity": "44,796,665",
"Net Income": "4,728,449",
"Comprehensive Net Income": "4,113,280",
"BaseVar": "74,980,764",
"ECR before LimitedLiability": "269%",
"Economic Capital Ratio": "348%"
}
}
},
"top_rated": true,
"trend": -39.0,
"value": 3.4784530088401966,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000001800.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000001800.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000001800.svg"
},
{
"company_id": "0000881464",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000881464.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000881464.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000881464_main_keyfigs.svg",
"name": "Amylin Pharmaceuticals INC",
"rank": 49,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000881464.svg",
"report_text": "The relative strengths and weaknesses of Amylin Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Amylin Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 109% points.The greatest weakness of Amylin Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 33% points.
The company's Economic Capital Ratio, given in the ranking table, is 347%, being 112% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000881464_2012_Amylin_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-7.93",
"Assets": "5.98",
"Liabilities": "35.5",
"Stockholders Equity": "37.7",
"ECR before LimitedLiability": "47.3",
"Assets, Current": "-4.29",
"Property and Equipment": "62.6",
"Intangible Assets": "-19.3",
"Liabilities, Current": "-32.8",
"Other Liabilities": "35.5",
"Liabilities, Non-Current": "28.8",
"Selling, General and Administrative Expense": "1.66",
"Expenses": "-4.10",
"Revenues": "2.18",
"Net Income": "-1.32",
"Research and Development": "1.99",
"Cost of Goods Sold": "5.07",
"Other Expenses": "-12.8",
"Other Revenues": "2.18",
"Comprehensive Net Income": "-1.31",
"Economic Capital Ratio": "40.9"
},
"2011": {
"Other Assets": "32.0",
"Assets": "29.6",
"Liabilities": "61.8",
"Stockholders Equity": "109",
"ECR before LimitedLiability": "188",
"Intangible Assets": "-8.52",
"Property and Equipment": "55.9",
"Assets, Current": "-23.4",
"Other Liabilities": "35.7",
"Liabilities, Non-Current": "15.7",
"Liabilities, Current": "14.9",
"Research and Development": "24.3",
"Expenses": "8.23",
"Revenues": "9.04",
"Net Income": "16.5",
"Other Expenses": "-32.7",
"Cost of Goods Sold": "3.86",
"Selling, General and Administrative Expense": "12.3",
"Other Revenues": "9.04",
"Comprehensive Net Income": "16.2",
"Economic Capital Ratio": "112"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000881464_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "676,395",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "401,595",
"Liabilities, Non-Current": "0",
"Other Assets": "43,289",
"Other Compr. Net Income": "0",
"Other Expenses": "363,862",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "671,511",
"Property and Equipment": "811,745",
"Research and Development": "171,312",
"Selling, General and Administrative Expense": "288,650"
},
"output_variables": {
"Assets": "1,531,429",
"Liabilities": "401,595",
"Expenses": "823,824",
"Revenues": "671,511",
"Stockholders Equity": "1,129,834",
"Net Income": "-152,313",
"Comprehensive Net Income": "-152,313",
"BaseVar": "1,714,180",
"ECR before LimitedLiability": "239%",
"Economic Capital Ratio": "328%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "421,190",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "296,017",
"Liabilities, Non-Current": "0",
"Other Assets": "617,847",
"Other Compr. Net Income": "0",
"Other Expenses": "709,698",
"Other Liabilities": "0",
"Other Net Income": "-51,940",
"Other Revenues": "650,678",
"Property and Equipment": "831,162",
"Research and Development": "161,215",
"Selling, General and Administrative Expense": "271,224"
},
"output_variables": {
"Assets": "1,870,199",
"Liabilities": "296,017",
"Expenses": "1,142,137",
"Revenues": "650,678",
"Stockholders Equity": "1,574,182",
"Net Income": "-543,399",
"Comprehensive Net Income": "-543,399",
"BaseVar": "2,005,486",
"ECR before LimitedLiability": "267%",
"Economic Capital Ratio": "347%"
}
}
},
"top_rated": true,
"trend": -39.0,
"value": 3.465230466166894,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000881464.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000881464.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000881464.svg"
},
{
"company_id": "0001145404",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001145404.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001145404.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001145404_main_keyfigs.svg",
"name": "Cornerstone Therapeutics INC",
"rank": 50,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001145404.svg",
"report_text": "The relative strengths and weaknesses of Cornerstone Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cornerstone Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 79% points.The greatest weakness of Cornerstone Therapeutics INC is the variable Other Expenses, reducing the Economic Capital Ratio by 15% points.
The company's Economic Capital Ratio, given in the ranking table, is 344%, being 110% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001145404_2012_Cornerstone_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.65",
"Assets": "28.7",
"Liabilities": "28.8",
"Stockholders Equity": "78.8",
"ECR before LimitedLiability": "185",
"Intangible Assets": "61.3",
"Property and Equipment": "-4.63",
"Assets, Current": "-5.57",
"Other Liabilities": "20.2",
"Liabilities, Non-Current": "14.4",
"Liabilities, Current": "-5.38",
"Research and Development": "30.7",
"Expenses": "25.1",
"Revenues": "18.0",
"Net Income": "45.5",
"Other Expenses": "-14.6",
"Cost of Goods Sold": "3.55",
"Selling, General and Administrative Expense": "5.41",
"Other Revenues": "18.0",
"Comprehensive Net Income": "45.2",
"Economic Capital Ratio": "110"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001145404_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "107,048",
"Cost of Goods Sold": "0",
"Intangible Assets": "122,178",
"Liabilities, Current": "48,655",
"Liabilities, Non-Current": "0",
"Other Assets": "1,514",
"Other Compr. Net Income": "0",
"Other Expenses": "54,019",
"Other Liabilities": "8,856",
"Other Net Income": "-128",
"Other Revenues": "101,422",
"Property and Equipment": "1,574",
"Research and Development": "1,624",
"Selling, General and Administrative Expense": "46,344"
},
"output_variables": {
"Assets": "232,314",
"Liabilities": "57,511",
"Expenses": "101,987",
"Revenues": "101,422",
"Stockholders Equity": "174,803",
"Net Income": "-693",
"Comprehensive Net Income": "-693",
"BaseVar": "246,681",
"ECR before LimitedLiability": "262%",
"Economic Capital Ratio": "344%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.4376753249903236,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001145404.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001145404.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001145404.svg"
},
{
"company_id": "0000812796",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000812796.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000812796.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000812796.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000812796_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000812796_main_keyfigs.svg",
"name": "Soligenix INC",
"rank": 51,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000812796.svg",
"report_text": "The relative strengths and weaknesses of Soligenix INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Soligenix INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 110% points.The greatest weakness of Soligenix INC is the variable Other Expenses, reducing the Economic Capital Ratio by 96% points.
The company's Economic Capital Ratio, given in the ranking table, is 340%, being 106% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000812796_2012_Soligenix_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.2",
"Assets": "-15.3",
"Liabilities": "110",
"Stockholders Equity": "41.5",
"ECR before LimitedLiability": "182",
"Property and Equipment": "-8.50",
"Assets, Current": "4.63",
"Other Liabilities": "52.3",
"Liabilities, Non-Current": "23.3",
"Liabilities, Current": "46.4",
"Research and Development": "52.9",
"Expenses": "-18.2",
"Revenues": "58.7",
"Net Income": "43.7",
"Other Expenses": "-96.2",
"Cost of Goods Sold": "-23.0",
"Selling, General and Administrative Expense": "44.5",
"Other Revenues": "58.7",
"Comprehensive Net Income": "43.2",
"Other Net Income": "3.71",
"Economic Capital Ratio": "106"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000812796_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,129",
"Cost of Goods Sold": "2,108",
"Intangible Assets": "1,080",
"Liabilities, Current": "1,433",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "7,941",
"Other Liabilities": "0",
"Other Net Income": "7.4",
"Other Revenues": "7,663",
"Property and Equipment": "15",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "8,224",
"Liabilities": "1,433",
"Expenses": "10,049",
"Revenues": "7,663",
"Stockholders Equity": "6,791",
"Net Income": "-2,379",
"Comprehensive Net Income": "-2,379",
"BaseVar": "13,688",
"ECR before LimitedLiability": "257%",
"Economic Capital Ratio": "340%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.4039422332289315,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000812796.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000812796.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000812796.svg"
},
{
"company_id": "0000886744",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000886744.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000886744.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000886744.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000886744_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000886744_main_keyfigs.svg",
"name": "Geron CORP",
"rank": 52,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000886744.svg",
"report_text": "The relative strengths and weaknesses of Geron CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Geron CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 174% points.The greatest weakness of Geron CORP is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 340%, being 106% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000886744_2012_Geron_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "18.8",
"Assets": "67.3",
"Liabilities": "68.4",
"Stockholders Equity": "174",
"ECR before LimitedLiability": "182",
"Intangible Assets": "-7.84",
"Property and Equipment": "-4.27",
"Assets, Current": "58.9",
"Other Liabilities": "30.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "29.6",
"Research and Development": "-23.3",
"Expenses": "-7.96",
"Revenues": "-23.8",
"Net Income": "-31.0",
"Other Expenses": "5.07",
"Cost of Goods Sold": "3.33",
"Selling, General and Administrative Expense": "6.79",
"Other Revenues": "-23.8",
"Comprehensive Net Income": "-31.3",
"Economic Capital Ratio": "106"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000886744_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "125,625",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,444",
"Liabilities, Non-Current": "0",
"Other Assets": "33,181",
"Other Compr. Net Income": "0",
"Other Expenses": "5,686",
"Other Liabilities": "0",
"Other Net Income": "-1,524",
"Other Revenues": "3,462",
"Property and Equipment": "1,241",
"Research and Development": "69,316",
"Selling, General and Administrative Expense": "23,789"
},
"output_variables": {
"Assets": "160,047",
"Liabilities": "13,444",
"Expenses": "98,791",
"Revenues": "3,462",
"Stockholders Equity": "146,603",
"Net Income": "-96,853",
"Comprehensive Net Income": "-96,853",
"BaseVar": "138,634",
"ECR before LimitedLiability": "257%",
"Economic Capital Ratio": "340%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.400073338815619,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000886744.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000886744.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000886744.svg"
},
{
"company_id": "0000831547",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000831547.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000831547.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000831547.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000831547_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000831547_main_keyfigs.svg",
"name": "Spectrum Pharmaceuticals INC",
"rank": 53,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000831547.svg",
"report_text": "The relative strengths and weaknesses of Spectrum Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Spectrum Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 70% points.The greatest weakness of Spectrum Pharmaceuticals INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 16% points.
The company's Economic Capital Ratio, given in the ranking table, is 332%, being 98% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000831547_2012_Spectrum_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.30",
"Assets": "10.8",
"Liabilities": "20.6",
"Stockholders Equity": "36.9",
"ECR before LimitedLiability": "174",
"Intangible Assets": "3.45",
"Property and Equipment": "-5.53",
"Assets, Current": "19.5",
"Other Liabilities": "20.3",
"Liabilities, Non-Current": "15.7",
"Liabilities, Current": "-16.5",
"Research and Development": "25.4",
"Expenses": "31.5",
"Revenues": "37.0",
"Net Income": "70.4",
"Other Expenses": "-2.05",
"Cost of Goods Sold": "3.96",
"Selling, General and Administrative Expense": "4.02",
"Other Revenues": "37.0",
"Comprehensive Net Income": "70.0",
"Economic Capital Ratio": "98.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000831547_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "225,801",
"Cost of Goods Sold": "0",
"Intangible Assets": "41,654",
"Liabilities, Current": "78,537",
"Liabilities, Non-Current": "0",
"Other Assets": "10,644",
"Other Compr. Net Income": "0",
"Other Expenses": "37,558",
"Other Liabilities": "14,336",
"Other Net Income": "-6,615",
"Other Revenues": "192,963",
"Property and Equipment": "2,681",
"Research and Development": "27,720",
"Selling, General and Administrative Expense": "72,553"
},
"output_variables": {
"Assets": "280,780",
"Liabilities": "92,873",
"Expenses": "137,831",
"Revenues": "192,963",
"Stockholders Equity": "187,907",
"Net Income": "48,517",
"Comprehensive Net Income": "48,517",
"BaseVar": "355,531",
"ECR before LimitedLiability": "245%",
"Economic Capital Ratio": "332%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.3241152799257376,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000831547.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000831547.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000831547.svg"
},
{
"company_id": "0000057725",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000057725.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000057725.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000057725.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000057725_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000057725_main_keyfigs.svg",
"name": "Lannett CO INC",
"rank": 54,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000057725.svg",
"report_text": "The relative strengths and weaknesses of Lannett CO INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lannett CO INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Lannett CO INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 53% points.
The company's Economic Capital Ratio, given in the ranking table, is 331%, being 97% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000057725_2012_Lannett_CO_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.86",
"Assets": "3.32",
"Liabilities": "45.3",
"Stockholders Equity": "39.6",
"ECR before LimitedLiability": "172",
"Intangible Assets": "-7.63",
"Property and Equipment": "13.9",
"Assets, Current": "-3.80",
"Other Liabilities": "39.6",
"Liabilities, Current": "5.35",
"Research and Development": "33.7",
"Expenses": "14.8",
"Revenues": "39.5",
"Net Income": "58.4",
"Other Expenses": "11.7",
"Cost of Goods Sold": "-53.0",
"Selling, General and Administrative Expense": "22.2",
"Other Revenues": "39.5",
"Comprehensive Net Income": "58.0",
"Other Net Income": "3.04",
"Economic Capital Ratio": "96.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000057725_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "94,142",
"Cost of Goods Sold": "81,899",
"Intangible Assets": "5,910",
"Liabilities, Current": "34,860",
"Liabilities, Non-Current": "7,193",
"Other Assets": "17,763",
"Other Compr. Net Income": "0",
"Other Expenses": "1,155",
"Other Liabilities": "2.0",
"Other Net Income": "478",
"Other Revenues": "106,835",
"Property and Equipment": "29,929",
"Research and Development": "8,587",
"Selling, General and Administrative Expense": "15,912"
},
"output_variables": {
"Assets": "147,744",
"Liabilities": "42,055",
"Expenses": "107,553",
"Revenues": "106,835",
"Stockholders Equity": "105,689",
"Net Income": "-240",
"Comprehensive Net Income": "-240",
"BaseVar": "202,332",
"ECR before LimitedLiability": "243%",
"Economic Capital Ratio": "331%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.306365940138245,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000057725.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000057725.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000057725.svg"
},
{
"company_id": "0000352998",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000352998.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000352998.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000352998_main_keyfigs.svg",
"name": "Teligent Inc",
"rank": 55,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000352998.svg",
"report_text": "The relative strengths and weaknesses of Teligent Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Teligent Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 94% points.The greatest weakness of Teligent Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 49% points.
The company's Economic Capital Ratio, given in the ranking table, is 330%, being 96% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000352998_2012_Teligent_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "-10.4",
"Liabilities": "93.6",
"Stockholders Equity": "46.0",
"ECR before LimitedLiability": "172",
"Intangible Assets": "-13.3",
"Property and Equipment": "26.3",
"Assets, Current": "-17.0",
"Other Liabilities": "29.3",
"Liabilities, Non-Current": "21.3",
"Liabilities, Current": "51.2",
"Research and Development": "23.8",
"Expenses": "-14.0",
"Revenues": "47.2",
"Net Income": "36.1",
"Other Expenses": "-49.1",
"Cost of Goods Sold": "5.46",
"Selling, General and Administrative Expense": "5.54",
"Other Revenues": "47.2",
"Comprehensive Net Income": "35.7",
"Other Net Income": "3.33",
"Economic Capital Ratio": "96.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000352998_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,686",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,316",
"Liabilities, Non-Current": "0",
"Other Assets": "1,150",
"Other Compr. Net Income": "0",
"Other Expenses": "5,601",
"Other Liabilities": "555",
"Other Net Income": "0",
"Other Revenues": "7,823",
"Property and Equipment": "2,800",
"Research and Development": "2,151",
"Selling, General and Administrative Expense": "3,078"
},
"output_variables": {
"Assets": "9,636",
"Liabilities": "1,871",
"Expenses": "10,830",
"Revenues": "7,823",
"Stockholders Equity": "7,765",
"Net Income": "-3,007",
"Comprehensive Net Income": "-3,007",
"BaseVar": "15,080",
"ECR before LimitedLiability": "242%",
"Economic Capital Ratio": "330%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.302545278062743,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000352998.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000352998.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000352998.svg"
},
{
"company_id": "0001080709",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001080709.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001080709.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001080709_main_keyfigs.svg",
"name": "Arena Pharmaceuticals INC",
"rank": 56,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001080709.svg",
"report_text": "The relative strengths and weaknesses of Arena Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arena Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 160% points.The greatest weakness of Arena Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 326%, being 92% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001080709_2012_Arena_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.83",
"Assets": "54.4",
"Liabilities": "75.6",
"Stockholders Equity": "160",
"ECR before LimitedLiability": "168",
"Intangible Assets": "-1.97",
"Property and Equipment": "108",
"Assets, Current": "-10.9",
"Other Liabilities": "33.4",
"Liabilities, Non-Current": "14.6",
"Liabilities, Current": "33.3",
"Research and Development": "-12.2",
"Expenses": "1.53",
"Revenues": "-19.6",
"Net Income": "-36.2",
"Cost of Goods Sold": "3.73",
"Selling, General and Administrative Expense": "9.17",
"Other Revenues": "-19.6",
"Comprehensive Net Income": "-36.5",
"Other Net Income": "-18.0",
"Economic Capital Ratio": "92.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001080709_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "60,260",
"Cost of Goods Sold": "0",
"Intangible Assets": "11,032",
"Liabilities, Current": "14,360",
"Liabilities, Non-Current": "0",
"Other Assets": "3,771",
"Other Compr. Net Income": "0",
"Other Expenses": "12,564",
"Other Liabilities": "0",
"Other Net Income": "-26,425",
"Other Revenues": "12,719",
"Property and Equipment": "82,066",
"Research and Development": "58,706",
"Selling, General and Administrative Expense": "24,248"
},
"output_variables": {
"Assets": "157,129",
"Liabilities": "14,360",
"Expenses": "95,518",
"Revenues": "12,719",
"Stockholders Equity": "142,769",
"Net Income": "-109,224",
"Comprehensive Net Income": "-109,224",
"BaseVar": "153,076",
"ECR before LimitedLiability": "236%",
"Economic Capital Ratio": "326%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2607045349983688,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001080709.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001080709.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001080709.svg"
},
{
"company_id": "0001070336",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001070336.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001070336.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001070336_main_keyfigs.svg",
"name": "Achillion Pharmaceuticals INC",
"rank": 57,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001070336.svg",
"report_text": "The relative strengths and weaknesses of Achillion Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Achillion Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 152% points.The greatest weakness of Achillion Pharmaceuticals INC is the variable Other Revenues, reducing the Economic Capital Ratio by 24% points.
The company's Economic Capital Ratio, given in the ranking table, is 325%, being 91% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001070336_2012_Achillion_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "40.9",
"Assets": "76.7",
"Liabilities": "43.5",
"Stockholders Equity": "152",
"ECR before LimitedLiability": "167",
"Intangible Assets": "-8.20",
"Property and Equipment": "-3.97",
"Assets, Current": "37.9",
"Other Liabilities": "17.1",
"Liabilities, Non-Current": "11.1",
"Liabilities, Current": "17.4",
"Other Revenues": "-24.0",
"Revenues": "-24.0",
"Net Income": "-22.2",
"Research and Development": "-22.3",
"Comprehensive Net Income": "-22.5",
"Cost of Goods Sold": "3.09",
"Selling, General and Administrative Expense": "10.2",
"Other Expenses": "8.65",
"Other Net Income": "2.14",
"Economic Capital Ratio": "91.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001070336_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "55,092",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,944",
"Liabilities, Non-Current": "229",
"Other Assets": "26,544",
"Other Compr. Net Income": "0",
"Other Expenses": "45",
"Other Liabilities": "2,489",
"Other Net Income": "186",
"Other Revenues": "247",
"Property and Equipment": "994",
"Research and Development": "35,441",
"Selling, General and Administrative Expense": "9,153"
},
"output_variables": {
"Assets": "82,630",
"Liabilities": "11,662",
"Expenses": "44,639",
"Revenues": "247",
"Stockholders Equity": "70,968",
"Net Income": "-44,206",
"Comprehensive Net Income": "-44,206",
"BaseVar": "69,682",
"ECR before LimitedLiability": "234%",
"Economic Capital Ratio": "325%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2527246424301977,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001070336.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001070336.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001070336.svg"
},
{
"company_id": "0001098880",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001098880.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001098880.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001098880.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001098880_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001098880_main_keyfigs.svg",
"name": "Intelgenx Technologies Corp",
"rank": 58,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001098880.svg",
"report_text": "The relative strengths and weaknesses of Intelgenx Technologies Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Intelgenx Technologies Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 137% points.The greatest weakness of Intelgenx Technologies Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 324%, being 90% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001098880_2012_Intelgenx_Technologies_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.03",
"Assets": "57.2",
"Liabilities": "51.9",
"Stockholders Equity": "137",
"ECR before LimitedLiability": "165",
"Intangible Assets": "-6.32",
"Property and Equipment": "-2.32",
"Assets, Current": "103",
"Other Liabilities": "-24.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "60.0",
"Research and Development": "-8.00",
"Expenses": "-3.71",
"Revenues": "-16.1",
"Net Income": "-17.7",
"Other Expenses": "-16.4",
"Cost of Goods Sold": "3.44",
"Selling, General and Administrative Expense": "17.4",
"Other Revenues": "-16.1",
"Comprehensive Net Income": "-17.3",
"Economic Capital Ratio": "89.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001098880_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,296",
"Cost of Goods Sold": "0",
"Intangible Assets": "125",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "49",
"Other Expenses": "1,035",
"Other Liabilities": "666",
"Other Net Income": "0",
"Other Revenues": "440",
"Property and Equipment": "149",
"Research and Development": "1,524",
"Selling, General and Administrative Expense": "333"
},
"output_variables": {
"Assets": "4,570",
"Liabilities": "666",
"Expenses": "2,892",
"Revenues": "440",
"Stockholders Equity": "3,904",
"Net Income": "-2,452",
"Comprehensive Net Income": "-2,428",
"BaseVar": "4,308",
"ECR before LimitedLiability": "232%",
"Economic Capital Ratio": "324%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2393664772384705,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001098880.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001098880.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001098880.svg"
},
{
"company_id": "0001428522",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001428522.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001428522.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001428522_main_keyfigs.svg",
"name": "Radius Health Inc",
"rank": 59,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001428522.svg",
"report_text": "The relative strengths and weaknesses of Radius Health Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Radius Health Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 165% points.The greatest weakness of Radius Health Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 77% points.
The company's Economic Capital Ratio, given in the ranking table, is 323%, being 89% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001428522_2012_Radius_Health_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.75",
"Assets": "72.2",
"Liabilities": "60.8",
"Stockholders Equity": "165",
"ECR before LimitedLiability": "165",
"Intangible Assets": "-8.98",
"Property and Equipment": "-5.50",
"Assets, Current": "159",
"Other Liabilities": "30.0",
"Liabilities, Non-Current": "13.1",
"Liabilities, Current": "21.5",
"Research and Development": "30.0",
"Expenses": "69.0",
"Revenues": "-26.4",
"Net Income": "-36.6",
"Other Expenses": "8.04",
"Selling, General and Administrative Expense": "25.2",
"Other Revenues": "-26.4",
"Comprehensive Net Income": "-36.9",
"Other Net Income": "-77.4",
"Economic Capital Ratio": "89.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001428522_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "63,390",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,783",
"Liabilities, Non-Current": "0",
"Other Assets": "80",
"Other Compr. Net Income": "0",
"Other Expenses": "758",
"Other Liabilities": "0",
"Other Net Income": "-41,718",
"Other Revenues": "0",
"Property and Equipment": "167",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "63,637",
"Liabilities": "6,783",
"Expenses": "758",
"Revenues": "0",
"Stockholders Equity": "56,854",
"Net Income": "-42,476",
"Comprehensive Net Income": "-42,476",
"BaseVar": "56,448",
"ECR before LimitedLiability": "231%",
"Economic Capital Ratio": "323%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2328335613613857,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001428522.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001428522.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001428522.svg"
},
{
"company_id": "0001159019",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001159019.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001159019.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001159019_main_keyfigs.svg",
"name": "Tribute Pharmaceuticals Canada Inc",
"rank": 60,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001159019.svg",
"report_text": "The relative strengths and weaknesses of Tribute Pharmaceuticals Canada Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Tribute Pharmaceuticals Canada Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 154% points.The greatest weakness of Tribute Pharmaceuticals Canada Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 23% points.
The company's Economic Capital Ratio, given in the ranking table, is 321%, being 87% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001159019_2012_Tribute_Pharmaceuticals_Canada_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.86",
"Assets": "60.1",
"Liabilities": "-11.5",
"Stockholders Equity": "83.1",
"ECR before LimitedLiability": "163",
"Intangible Assets": "154",
"Property and Equipment": "1.52",
"Assets, Current": "-19.0",
"Liabilities, Non-Current": "10.9",
"Liabilities, Current": "-23.0",
"Research and Development": "24.6",
"Expenses": "33.9",
"Revenues": "-1.50",
"Net Income": "33.5",
"Other Expenses": "6.33",
"Cost of Goods Sold": "-2.14",
"Selling, General and Administrative Expense": "4.77",
"Other Revenues": "-1.50",
"Comprehensive Net Income": "33.3",
"Other Net Income": "1.15",
"Economic Capital Ratio": "87.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001159019_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,182",
"Cost of Goods Sold": "933",
"Intangible Assets": "13,818",
"Liabilities, Current": "4,311",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "290",
"Other Liabilities": "1,524",
"Other Net Income": "-103",
"Other Revenues": "3,889",
"Property and Equipment": "1,207",
"Research and Development": "50",
"Selling, General and Administrative Expense": "3,035"
},
"output_variables": {
"Assets": "19,208",
"Liabilities": "5,836",
"Expenses": "4,307",
"Revenues": "3,889",
"Stockholders Equity": "13,373",
"Net Income": "-522",
"Comprehensive Net Income": "-522",
"BaseVar": "16,672",
"ECR before LimitedLiability": "229%",
"Economic Capital Ratio": "321%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2148470784375127,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001159019.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001159019.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001159019.svg"
},
{
"company_id": "0001029142",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001029142.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001029142.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001029142.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001029142_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001029142_main_keyfigs.svg",
"name": "Dynavax Technologies CORP",
"rank": 61,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001029142.svg",
"report_text": "The relative strengths and weaknesses of Dynavax Technologies CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Dynavax Technologies CORP compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 111% points.The greatest weakness of Dynavax Technologies CORP is the variable Research and Development, reducing the Economic Capital Ratio by 13% points.
The company's Economic Capital Ratio, given in the ranking table, is 321%, being 87% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001029142_2012_Dynavax_Technologies_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.12",
"Assets": "53.1",
"Liabilities": "32.1",
"Stockholders Equity": "111",
"ECR before LimitedLiability": "163",
"Intangible Assets": "-7.26",
"Assets, Current": "90.9",
"Other Liabilities": "29.6",
"Liabilities, Non-Current": "12.8",
"Liabilities, Current": "-10.6",
"Research and Development": "-12.8",
"Expenses": "8.27",
"Revenues": "-8.42",
"Net Income": "2.60",
"Other Expenses": "7.49",
"Cost of Goods Sold": "3.31",
"Selling, General and Administrative Expense": "10.3",
"Other Revenues": "-8.42",
"Comprehensive Net Income": "2.35",
"Other Net Income": "2.79",
"Economic Capital Ratio": "87.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001029142_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "124,618",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,312",
"Liabilities, Current": "27,219",
"Liabilities, Non-Current": "0",
"Other Assets": "1,009",
"Other Compr. Net Income": "0",
"Other Expenses": "2,256",
"Other Liabilities": "0",
"Other Net Income": "937",
"Other Revenues": "21,614",
"Property and Equipment": "6,163",
"Research and Development": "51,322",
"Selling, General and Administrative Expense": "17,570"
},
"output_variables": {
"Assets": "134,102",
"Liabilities": "27,219",
"Expenses": "71,148",
"Revenues": "21,614",
"Stockholders Equity": "106,883",
"Net Income": "-48,597",
"Comprehensive Net Income": "-48,597",
"BaseVar": "127,510",
"ECR before LimitedLiability": "229%",
"Economic Capital Ratio": "321%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.2146913173346823,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001029142.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001029142.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001029142.svg"
},
{
"company_id": "0001061027",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001061027.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001061027.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001061027.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001061027_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001061027_main_keyfigs.svg",
"name": "Viracta Therapeutics Inc",
"rank": 62,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001061027.svg",
"report_text": "The relative strengths and weaknesses of Viracta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Viracta Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 108% points.The greatest weakness of Viracta Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.
The company's Economic Capital Ratio, given in the ranking table, is 320%, being 86% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001061027_2012_Viracta_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.43",
"Assets": "40.1",
"Liabilities": "48.6",
"Stockholders Equity": "108",
"ECR before LimitedLiability": "162",
"Intangible Assets": "-10.0",
"Property and Equipment": "-6.33",
"Assets, Current": "102",
"Other Liabilities": "32.8",
"Liabilities, Non-Current": "14.3",
"Liabilities, Current": "3.38",
"Other Revenues": "-17.0",
"Revenues": "-17.0",
"Net Income": "-1.65",
"Research and Development": "-22.2",
"Comprehensive Net Income": "-1.89",
"Cost of Goods Sold": "3.70",
"Selling, General and Administrative Expense": "7.38",
"Other Expenses": "10.5",
"Other Net Income": "16.3",
"Economic Capital Ratio": "86.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001061027_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "45,665",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,383",
"Liabilities, Non-Current": "0",
"Other Assets": "130",
"Other Compr. Net Income": "34",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "5,725",
"Other Revenues": "5,000",
"Property and Equipment": "74",
"Research and Development": "22,563",
"Selling, General and Administrative Expense": "8,303"
},
"output_variables": {
"Assets": "45,869",
"Liabilities": "8,383",
"Expenses": "30,866",
"Revenues": "5,000",
"Stockholders Equity": "37,486",
"Net Income": "-20,141",
"Comprehensive Net Income": "-20,124",
"BaseVar": "47,938",
"ECR before LimitedLiability": "227%",
"Economic Capital Ratio": "320%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.20444846898235,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001061027.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001061027.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001061027.svg"
},
{
"company_id": "0001130166",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001130166.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001130166.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001130166_main_keyfigs.svg",
"name": "Bio Green Med Solution Inc",
"rank": 63,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001130166.svg",
"report_text": "The relative strengths and weaknesses of Bio Green Med Solution Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Bio Green Med Solution Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 318% points.The greatest weakness of Bio Green Med Solution Inc is the variable Research and Development, reducing the Economic Capital Ratio by 998% points.
The company's Economic Capital Ratio, given in the ranking table, is 318%, being 84% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001130166_2012_Bio_Green_Med_Solution_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.11",
"Assets": "26.1",
"Liabilities": "34.8",
"Stockholders Equity": "73.1",
"ECR before LimitedLiability": "160",
"Intangible Assets": "-10.5",
"Property and Equipment": "-6.17",
"Assets, Current": "78.2",
"Other Liabilities": "33.8",
"Liabilities, Non-Current": "14.7",
"Liabilities, Current": "-14.5",
"Research and Development": "-998",
"Expenses": "9.76",
"Revenues": "9.57",
"Net Income": "24.2",
"Other Expenses": "318",
"Selling, General and Administrative Expense": "-415",
"Other Revenues": "9.57",
"Comprehensive Net Income": "23.9",
"Other Net Income": "4.71",
"Economic Capital Ratio": "84.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001130166_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,831",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,498",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "-258,764",
"Other Liabilities": "0",
"Other Net Income": "580",
"Other Revenues": "9,769",
"Property and Equipment": "167",
"Research and Development": "185,799",
"Selling, General and Administrative Expense": "89,487"
},
"output_variables": {
"Assets": "25,998",
"Liabilities": "6,498",
"Expenses": "16,522",
"Revenues": "9,769",
"Stockholders Equity": "19,500",
"Net Income": "-6,173",
"Comprehensive Net Income": "-6,173",
"BaseVar": "29,684",
"ECR before LimitedLiability": "224%",
"Economic Capital Ratio": "318%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.1817555492562413,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001130166.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001130166.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001130166.svg"
},
{
"company_id": "0001082554",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001082554.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001082554.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001082554.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001082554_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001082554_main_keyfigs.svg",
"name": "United Therapeutics Corp",
"rank": 64,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001082554.svg",
"report_text": "The relative strengths and weaknesses of United Therapeutics Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of United Therapeutics Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 60% points.The greatest weakness of United Therapeutics Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 25% points.
The company's Economic Capital Ratio, given in the ranking table, is 317%, being 83% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001082554_2012_United_Therapeutics_Corp.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "18.3",
"Assets": "11.4",
"Liabilities": "-6.47",
"Stockholders Equity": "16.0",
"ECR before LimitedLiability": "27.3",
"Assets, Current": "8.10",
"Property and Equipment": "10.8",
"Intangible Assets": "-20.0",
"Liabilities, Current": "-44.9",
"Other Liabilities": "16.8",
"Liabilities, Non-Current": "16.9",
"Selling, General and Administrative Expense": "5.49",
"Expenses": "13.8",
"Revenues": "2.11",
"Net Income": "15.4",
"Research and Development": "0.872",
"Cost of Goods Sold": "4.52",
"Other Expenses": "2.85",
"Other Revenues": "2.11",
"Comprehensive Net Income": "15.4",
"Economic Capital Ratio": "21.0"
},
"2011": {
"Other Assets": "43.4",
"Assets": "27.8",
"Liabilities": "-7.97",
"Stockholders Equity": "42.7",
"ECR before LimitedLiability": "159",
"Intangible Assets": "-9.44",
"Property and Equipment": "21.6",
"Assets, Current": "-15.9",
"Other Liabilities": "-25.4",
"Liabilities, Non-Current": "-3.59",
"Liabilities, Current": "19.2",
"Research and Development": "18.5",
"Expenses": "36.4",
"Revenues": "20.9",
"Net Income": "59.7",
"Other Expenses": "-1.37",
"Cost of Goods Sold": "3.38",
"Selling, General and Administrative Expense": "15.3",
"Other Revenues": "20.9",
"Comprehensive Net Income": "59.4",
"Economic Capital Ratio": "83.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001082554_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "764,487",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "428,686",
"Liabilities, Non-Current": "39,252",
"Other Assets": "361,104",
"Other Compr. Net Income": "0",
"Other Expenses": "115,388",
"Other Liabilities": "68,929",
"Other Net Income": "-16,166",
"Other Revenues": "603,831",
"Property and Equipment": "306,044",
"Research and Development": "166,761",
"Selling, General and Administrative Expense": "199,600"
},
"output_variables": {
"Assets": "1,431,635",
"Liabilities": "536,867",
"Expenses": "481,749",
"Revenues": "603,831",
"Stockholders Equity": "894,768",
"Net Income": "105,916",
"Comprehensive Net Income": "105,916",
"BaseVar": "1,535,124",
"ECR before LimitedLiability": "209%",
"Economic Capital Ratio": "308%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "562,455",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "212,577",
"Liabilities, Non-Current": "80,500",
"Other Assets": "589,578",
"Other Compr. Net Income": "0",
"Other Expenses": "170,778",
"Other Liabilities": "265,632",
"Other Net Income": "-18,665",
"Other Revenues": "743,183",
"Property and Equipment": "366,046",
"Research and Development": "180,015",
"Selling, General and Administrative Expense": "156,482"
},
"output_variables": {
"Assets": "1,518,079",
"Liabilities": "558,709",
"Expenses": "507,275",
"Revenues": "743,183",
"Stockholders Equity": "959,370",
"Net Income": "217,243",
"Comprehensive Net Income": "217,243",
"BaseVar": "1,672,956",
"ECR before LimitedLiability": "222%",
"Economic Capital Ratio": "317%"
}
}
},
"top_rated": false,
"trend": -49.0,
"value": 3.1730906151549894,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001082554.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001082554.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001082554.svg"
},
{
"company_id": "0001413754",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001413754.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001413754.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001413754.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001413754_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001413754_main_keyfigs.svg",
"name": "Marizyme INC",
"rank": 65,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001413754.svg",
"report_text": "The relative strengths and weaknesses of Marizyme INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Marizyme INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 156% points.The greatest weakness of Marizyme INC is the variable Assets, Current, reducing the Economic Capital Ratio by 26% points.
The company's Economic Capital Ratio, given in the ranking table, is 316%, being 82% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001413754_2012_Marizyme_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "32.2",
"Liabilities": "6.45",
"Stockholders Equity": "59.3",
"ECR before LimitedLiability": "158",
"Intangible Assets": "156",
"Property and Equipment": "-5.85",
"Assets, Current": "-26.3",
"Other Liabilities": "30.4",
"Liabilities, Non-Current": "-21.6",
"Liabilities, Current": "-4.94",
"Research and Development": "30.9",
"Expenses": "25.9",
"Revenues": "9.18",
"Net Income": "40.3",
"Other Expenses": "-10.4",
"Cost of Goods Sold": "-15.0",
"Selling, General and Administrative Expense": "20.8",
"Other Revenues": "9.18",
"Comprehensive Net Income": "41.1",
"Other Net Income": "4.65",
"Economic Capital Ratio": "82.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001413754_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "17,875",
"Cost of Goods Sold": "14,082",
"Intangible Assets": "56,204",
"Liabilities, Current": "16,346",
"Liabilities, Non-Current": "7,940",
"Other Assets": "2,488",
"Other Compr. Net Income": "1,528",
"Other Expenses": "15,348",
"Other Liabilities": "0",
"Other Net Income": "1,939",
"Other Revenues": "27,707",
"Property and Equipment": "298",
"Research and Development": "0",
"Selling, General and Administrative Expense": "3,854"
},
"output_variables": {
"Assets": "76,866",
"Liabilities": "24,286",
"Expenses": "33,284",
"Revenues": "27,707",
"Stockholders Equity": "52,580",
"Net Income": "-3,637",
"Comprehensive Net Income": "-2,873",
"BaseVar": "82,805",
"ECR before LimitedLiability": "221%",
"Economic Capital Ratio": "316%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.1639975315245614,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001413754.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001413754.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001413754.svg"
},
{
"company_id": "0001124105",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001124105.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001124105.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001124105.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001124105_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001124105_main_keyfigs.svg",
"name": "GYRE Therapeutics INC",
"rank": 66,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001124105.svg",
"report_text": "The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 59% points.The greatest weakness of GYRE Therapeutics INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 39% points.
The company's Economic Capital Ratio, given in the ranking table, is 314%, being 80% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001124105_2012_GYRE_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "19.9",
"Assets": "34.5",
"Stockholders Equity": "58.5",
"Other Liabilities": "26.0",
"ECR before LimitedLiability": "155",
"Intangible Assets": "-9.59",
"Property and Equipment": "-6.22",
"Assets, Current": "33.7",
"Research and Development": "-7.16",
"Expenses": "26.5",
"Revenues": "11.3",
"Net Income": "41.0",
"Other Expenses": "9.54",
"Cost of Goods Sold": "3.37",
"Selling, General and Administrative Expense": "20.7",
"Other Revenues": "11.3",
"Liabilities, Non-Current": "10.5",
"Liabilities, Current": "-38.8",
"Comprehensive Net Income": "40.8",
"Other Net Income": "2.53",
"Economic Capital Ratio": "79.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001124105_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "198,693",
"Cost of Goods Sold": "0",
"Intangible Assets": "132",
"Liabilities, Current": "78,611",
"Liabilities, Non-Current": "1,986",
"Other Assets": "59,301",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "3,241",
"Other Net Income": "1,216",
"Other Revenues": "97,637",
"Property and Equipment": "0",
"Research and Development": "95,215",
"Selling, General and Administrative Expense": "12,167"
},
"output_variables": {
"Assets": "258,126",
"Liabilities": "83,838",
"Expenses": "107,382",
"Revenues": "97,637",
"Stockholders Equity": "174,288",
"Net Income": "-8,529",
"Comprehensive Net Income": "-8,529",
"BaseVar": "274,100",
"ECR before LimitedLiability": "217%",
"Economic Capital Ratio": "314%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.1392517201301944,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001124105.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001124105.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001124105.svg"
},
{
"company_id": "0001182129",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001182129.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001182129.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001182129_main_keyfigs.svg",
"name": "Auxilium Pharmaceuticals INC",
"rank": 67,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001182129.svg",
"report_text": "The relative strengths and weaknesses of Auxilium Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Auxilium Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Auxilium Pharmaceuticals INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 23% points.
The company's Economic Capital Ratio, given in the ranking table, is 314%, being 79% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001182129_2012_Auxilium_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-11.7",
"Assets": "-31.0",
"Liabilities": "81.3",
"Stockholders Equity": "-19.6",
"ECR before LimitedLiability": "35.4",
"Assets, Current": "17.5",
"Property and Equipment": "-6.55",
"Intangible Assets": "-28.4",
"Liabilities, Current": "-3.99",
"Other Liabilities": "49.1",
"Liabilities, Non-Current": "39.9",
"Selling, General and Administrative Expense": "-39.9",
"Expenses": "-37.9",
"Revenues": "28.6",
"Net Income": "-8.96",
"Research and Development": "-0.958",
"Cost of Goods Sold": "7.32",
"Other Expenses": "-4.31",
"Other Revenues": "28.6",
"Comprehensive Net Income": "-8.94",
"Economic Capital Ratio": "29.1"
},
"2011": {
"Other Assets": "-5.66",
"Assets": "-12.3",
"Liabilities": "58.1",
"Stockholders Equity": "16.0",
"ECR before LimitedLiability": "155",
"Intangible Assets": "-14.2",
"Assets, Current": "7.57",
"Other Liabilities": "44.2",
"Liabilities, Non-Current": "19.4",
"Liabilities, Current": "-3.80",
"Research and Development": "24.6",
"Expenses": "2.14",
"Revenues": "51.0",
"Net Income": "56.9",
"Other Expenses": "-4.50",
"Cost of Goods Sold": "5.13",
"Selling, General and Administrative Expense": "-22.6",
"Other Revenues": "51.0",
"Comprehensive Net Income": "56.5",
"Other Net Income": "3.30",
"Economic Capital Ratio": "79.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001182129_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "202,912",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "64,173",
"Liabilities, Non-Current": "0",
"Other Assets": "11,056",
"Other Compr. Net Income": "0",
"Other Expenses": "50,147",
"Other Liabilities": "0",
"Other Net Income": "167",
"Other Revenues": "211,429",
"Property and Equipment": "29,936",
"Research and Development": "48,005",
"Selling, General and Administrative Expense": "164,675"
},
"output_variables": {
"Assets": "243,904",
"Liabilities": "64,173",
"Expenses": "262,827",
"Revenues": "211,429",
"Stockholders Equity": "179,731",
"Net Income": "-51,231",
"Comprehensive Net Income": "-51,231",
"BaseVar": "391,250",
"ECR before LimitedLiability": "221%",
"Economic Capital Ratio": "316%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "255,143",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "91,072",
"Liabilities, Non-Current": "0",
"Other Assets": "16,205",
"Other Compr. Net Income": "0",
"Other Expenses": "55,898",
"Other Liabilities": "0",
"Other Net Income": "502",
"Other Revenues": "264,315",
"Property and Equipment": "29,623",
"Research and Development": "61,948",
"Selling, General and Administrative Expense": "179,887"
},
"output_variables": {
"Assets": "300,971",
"Liabilities": "91,072",
"Expenses": "297,733",
"Revenues": "264,315",
"Stockholders Equity": "209,899",
"Net Income": "-32,916",
"Comprehensive Net Income": "-32,916",
"BaseVar": "477,296",
"ECR before LimitedLiability": "217%",
"Economic Capital Ratio": "314%"
}
}
},
"top_rated": false,
"trend": -54.0,
"value": 3.1353644170608805,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001182129.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001182129.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001182129.svg"
},
{
"company_id": "0001356857",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001356857.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001356857.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001356857_main_keyfigs.svg",
"name": "Trius Therapeutics Inc",
"rank": 68,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001356857.svg",
"report_text": "The relative strengths and weaknesses of Trius Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Trius Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 52% points.The greatest weakness of Trius Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 35% points.
The company's Economic Capital Ratio, given in the ranking table, is 309%, being 75% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001356857_2012_Trius_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.73",
"Assets": "1.94",
"Liabilities": "52.2",
"Stockholders Equity": "43.3",
"ECR before LimitedLiability": "150",
"Intangible Assets": "-13.4",
"Property and Equipment": "-7.10",
"Assets, Current": "46.6",
"Other Liabilities": "40.0",
"Liabilities, Non-Current": "17.4",
"Liabilities, Current": "-4.04",
"Other Revenues": "27.2",
"Revenues": "27.2",
"Net Income": "32.1",
"Research and Development": "-35.1",
"Comprehensive Net Income": "31.7",
"Cost of Goods Sold": "4.65",
"Selling, General and Administrative Expense": "17.3",
"Other Expenses": "13.2",
"Other Net Income": "5.29",
"Economic Capital Ratio": "74.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001356857_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "66,687",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,234",
"Liabilities, Non-Current": "0",
"Other Assets": "401",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "1,581",
"Other Revenues": "41,011",
"Property and Equipment": "1,037",
"Research and Development": "49,503",
"Selling, General and Administrative Expense": "11,339"
},
"output_variables": {
"Assets": "68,125",
"Liabilities": "18,234",
"Expenses": "60,842",
"Revenues": "41,011",
"Stockholders Equity": "49,891",
"Net Income": "-18,250",
"Comprehensive Net Income": "-18,250",
"BaseVar": "94,896",
"ECR before LimitedLiability": "210%",
"Economic Capital Ratio": "309%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.0886226915471298,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001356857.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001356857.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001356857.svg"
},
{
"company_id": "0001326190",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001326190.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001326190.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001326190.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001326190_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001326190_main_keyfigs.svg",
"name": "Altimmune Inc",
"rank": 69,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001326190.svg",
"report_text": "The relative strengths and weaknesses of Altimmune Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Altimmune Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 105% points.The greatest weakness of Altimmune Inc is the variable Assets, reducing the Economic Capital Ratio by 43% points.
The company's Economic Capital Ratio, given in the ranking table, is 306%, being 72% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001326190_2012_Altimmune_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.0",
"Assets": "-43.3",
"Liabilities": "105",
"Stockholders Equity": "-34.2",
"ECR before LimitedLiability": "148",
"Intangible Assets": "-9.75",
"Property and Equipment": "-9.46",
"Assets, Current": "-20.6",
"Other Liabilities": "28.7",
"Liabilities, Non-Current": "25.8",
"Liabilities, Current": "58.3",
"Research and Development": "-33.2",
"Expenses": "-21.0",
"Revenues": "56.6",
"Net Income": "78.2",
"Other Expenses": "17.8",
"Selling, General and Administrative Expense": "-12.1",
"Other Revenues": "56.6",
"Comprehensive Net Income": "76.9",
"Other Net Income": "41.3",
"Economic Capital Ratio": "72.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001326190_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "19,613",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,348",
"Liabilities, Current": "4,615",
"Liabilities, Non-Current": "0",
"Other Assets": "53",
"Other Compr. Net Income": "-240",
"Other Expenses": "461",
"Other Liabilities": "2,336",
"Other Net Income": "7,928",
"Other Revenues": "24,266",
"Property and Equipment": "789",
"Research and Development": "21,220",
"Selling, General and Administrative Expense": "14,311"
},
"output_variables": {
"Assets": "22,804",
"Liabilities": "6,952",
"Expenses": "35,992",
"Revenues": "24,266",
"Stockholders Equity": "15,852",
"Net Income": "-3,798",
"Comprehensive Net Income": "-3,918",
"BaseVar": "49,091",
"ECR before LimitedLiability": "206%",
"Economic Capital Ratio": "306%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.064065830625535,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001326190.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001326190.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001326190.svg"
},
{
"company_id": "0001135906",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001135906.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001135906.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001135906_main_keyfigs.svg",
"name": "Epirus Biopharmaceuticals Inc",
"rank": 70,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001135906.svg",
"report_text": "The relative strengths and weaknesses of Epirus Biopharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Epirus Biopharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 117% points.The greatest weakness of Epirus Biopharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 19% points.
The company's Economic Capital Ratio, given in the ranking table, is 306%, being 72% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001135906_2012_Epirus_Biopharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.15",
"Assets": "59.0",
"Liabilities": "36.0",
"Stockholders Equity": "117",
"ECR before LimitedLiability": "148",
"Intangible Assets": "28.6",
"Assets, Current": "25.0",
"Other Liabilities": "29.8",
"Liabilities, Non-Current": "12.9",
"Liabilities, Current": "-6.32",
"Research and Development": "-19.1",
"Expenses": "-1.80",
"Revenues": "-15.5",
"Net Income": "-15.0",
"Other Expenses": "3.08",
"Cost of Goods Sold": "3.43",
"Selling, General and Administrative Expense": "11.0",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "-15.2",
"Other Net Income": "2.31",
"Economic Capital Ratio": "72.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001135906_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,207",
"Cost of Goods Sold": "0",
"Intangible Assets": "21,546",
"Liabilities, Current": "15,544",
"Liabilities, Non-Current": "0",
"Other Assets": "1,872",
"Other Compr. Net Income": "0",
"Other Expenses": "4,689",
"Other Liabilities": "0",
"Other Net Income": "156",
"Other Revenues": "8,184",
"Property and Equipment": "5,258",
"Research and Development": "35,294",
"Selling, General and Administrative Expense": "10,400"
},
"output_variables": {
"Assets": "79,883",
"Liabilities": "15,544",
"Expenses": "50,383",
"Revenues": "8,184",
"Stockholders Equity": "64,339",
"Net Income": "-42,043",
"Comprehensive Net Income": "-42,043",
"BaseVar": "77,075",
"ECR before LimitedLiability": "206%",
"Economic Capital Ratio": "306%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.0634130671961852,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001135906.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001135906.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001135906.svg"
},
{
"company_id": "0000859368",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000859368.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000859368.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000859368_main_keyfigs.svg",
"name": "Medicis Pharmaceutical CORP",
"rank": 71,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000859368.svg",
"report_text": "The relative strengths and weaknesses of Medicis Pharmaceutical CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Medicis Pharmaceutical CORP compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 63% points.The greatest weakness of Medicis Pharmaceutical CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 63% points.
The company's Economic Capital Ratio, given in the ranking table, is 303%, being 69% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000859368_2012_Medicis_Pharmaceutical_CORP.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-5.09",
"Assets": "6.07",
"Liabilities": "38.5",
"Stockholders Equity": "41.2",
"ECR before LimitedLiability": "70.6",
"Assets, Current": "25.5",
"Property and Equipment": "-8.52",
"Liabilities, Current": "-32.5",
"Other Liabilities": "36.7",
"Liabilities, Non-Current": "29.9",
"Selling, General and Administrative Expense": "-4.11",
"Expenses": "6.29",
"Revenues": "11.5",
"Net Income": "18.7",
"Research and Development": "9.04",
"Cost of Goods Sold": "5.05",
"Other Expenses": "-3.71",
"Other Revenues": "11.5",
"Comprehensive Net Income": "18.7",
"Other Net Income": "0.904",
"Economic Capital Ratio": "64.2"
},
"2011": {
"Other Assets": "4.55",
"Assets": "23.1",
"Liabilities": "-9.99",
"Stockholders Equity": "30.8",
"ECR before LimitedLiability": "145",
"Intangible Assets": "63.0",
"Property and Equipment": "-5.24",
"Assets, Current": "-19.3",
"Other Liabilities": "30.7",
"Liabilities, Non-Current": "13.3",
"Liabilities, Current": "-63.0",
"Research and Development": "27.5",
"Expenses": "31.4",
"Revenues": "20.0",
"Net Income": "56.9",
"Cost of Goods Sold": "3.56",
"Selling, General and Administrative Expense": "3.12",
"Other Revenues": "20.0",
"Comprehensive Net Income": "56.6",
"Other Net Income": "3.77",
"Economic Capital Ratio": "69.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000859368_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "967,074",
"Cost of Goods Sold": "0",
"Intangible Assets": "287,707",
"Liabilities, Current": "339,892",
"Liabilities, Non-Current": "0",
"Other Assets": "62,491",
"Other Compr. Net Income": "0",
"Other Expenses": "199,137",
"Other Liabilities": "0",
"Other Net Income": "3,860",
"Other Revenues": "699,968",
"Property and Equipment": "24,552",
"Research and Development": "58,282",
"Selling, General and Administrative Expense": "323,074"
},
"output_variables": {
"Assets": "1,341,824",
"Liabilities": "339,892",
"Expenses": "580,493",
"Revenues": "699,968",
"Stockholders Equity": "1,001,932",
"Net Income": "123,335",
"Comprehensive Net Income": "123,335",
"BaseVar": "1,483,018",
"ECR before LimitedLiability": "274%",
"Economic Capital Ratio": "352%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "551,154",
"Cost of Goods Sold": "0",
"Intangible Assets": "705,119",
"Liabilities, Current": "574,797",
"Liabilities, Non-Current": "0",
"Other Assets": "170,605",
"Other Compr. Net Income": "0",
"Other Expenses": "196,875",
"Other Liabilities": "0",
"Other Net Income": "24,038",
"Other Revenues": "721,126",
"Property and Equipment": "25,081",
"Research and Development": "68,370",
"Selling, General and Administrative Expense": "353,379"
},
"output_variables": {
"Assets": "1,451,959",
"Liabilities": "574,797",
"Expenses": "618,624",
"Revenues": "721,126",
"Stockholders Equity": "877,162",
"Net Income": "126,540",
"Comprehensive Net Income": "126,540",
"BaseVar": "1,695,272",
"ECR before LimitedLiability": "201%",
"Economic Capital Ratio": "303%"
}
}
},
"top_rated": false,
"trend": -63.0,
"value": 3.0321688442290213,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000859368.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000859368.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000859368.svg"
},
{
"company_id": "0001484478",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001484478.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001484478.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001484478_main_keyfigs.svg",
"name": "Furiex Pharmaceuticals Inc",
"rank": 72,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001484478.svg",
"report_text": "The relative strengths and weaknesses of Furiex Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Furiex Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 116% points.The greatest weakness of Furiex Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 23% points.
The company's Economic Capital Ratio, given in the ranking table, is 299%, being 65% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001484478_2012_Furiex_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.77",
"Assets": "71.9",
"Liabilities": "22.4",
"Stockholders Equity": "116",
"ECR before LimitedLiability": "141",
"Intangible Assets": "101",
"Property and Equipment": "-6.30",
"Assets, Current": "4.14",
"Other Liabilities": "-3.05",
"Liabilities, Non-Current": "11.1",
"Liabilities, Current": "14.5",
"Research and Development": "-22.8",
"Expenses": "2.23",
"Revenues": "-19.9",
"Net Income": "-15.8",
"Other Expenses": "8.50",
"Cost of Goods Sold": "3.21",
"Selling, General and Administrative Expense": "13.9",
"Other Revenues": "-19.9",
"Comprehensive Net Income": "-16.0",
"Economic Capital Ratio": "65.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001484478_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "45,827",
"Cost of Goods Sold": "0",
"Intangible Assets": "49,116",
"Liabilities, Current": "11,920",
"Liabilities, Non-Current": "232",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "510",
"Other Liabilities": "8,649",
"Other Net Income": "2.0",
"Other Revenues": "4,490",
"Property and Equipment": "181",
"Research and Development": "44,202",
"Selling, General and Administrative Expense": "8,761"
},
"output_variables": {
"Assets": "95,124",
"Liabilities": "20,801",
"Expenses": "53,473",
"Revenues": "4,490",
"Stockholders Equity": "74,323",
"Net Income": "-48,981",
"Comprehensive Net Income": "-48,981",
"BaseVar": "86,945",
"ECR before LimitedLiability": "195%",
"Economic Capital Ratio": "299%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.9907149222687597,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001484478.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001484478.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001484478.svg"
},
{
"company_id": "0000768710",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000768710.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000768710.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000768710.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000768710_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000768710_main_keyfigs.svg",
"name": "Reliv International INC",
"rank": 73,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000768710.svg",
"report_text": "The relative strengths and weaknesses of Reliv International INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Reliv International INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 169% points.The greatest weakness of Reliv International INC is the variable Other Expenses, reducing the Economic Capital Ratio by 204% points.
The company's Economic Capital Ratio, given in the ranking table, is 298%, being 64% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000768710_2012_Reliv_International_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-17.2",
"Assets": "-86.1",
"Liabilities": "158",
"Stockholders Equity": "-190",
"ECR before LimitedLiability": "140",
"Intangible Assets": "-25.5",
"Property and Equipment": "12.3",
"Assets, Current": "-76.6",
"Other Liabilities": "89.8",
"Liabilities, Current": "113",
"Research and Development": "113",
"Expenses": "-56.9",
"Revenues": "169",
"Net Income": "158",
"Other Expenses": "-204",
"Cost of Goods Sold": "-47.3",
"Selling, General and Administrative Expense": "93.0",
"Other Revenues": "169",
"Comprehensive Net Income": "158",
"Other Net Income": "7.16",
"Economic Capital Ratio": "64.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000768710_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,412",
"Cost of Goods Sold": "15,105",
"Intangible Assets": "1,598",
"Liabilities, Current": "6,110",
"Liabilities, Non-Current": "3,823",
"Other Assets": "1,987",
"Other Compr. Net Income": "0",
"Other Expenses": "57,168",
"Other Liabilities": "0",
"Other Net Income": "65",
"Other Revenues": "73,880",
"Property and Equipment": "7,422",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "24,419",
"Liabilities": "9,933",
"Expenses": "72,274",
"Revenues": "73,880",
"Stockholders Equity": "14,486",
"Net Income": "1,671",
"Comprehensive Net Income": "1,671",
"BaseVar": "90,286",
"ECR before LimitedLiability": "194%",
"Economic Capital Ratio": "298%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.9809487658138782,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000768710.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000768710.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000768710.svg"
},
{
"company_id": "0001062822",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001062822.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001062822.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001062822.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001062822_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001062822_main_keyfigs.svg",
"name": "Lexicon Pharmaceuticals INC",
"rank": 74,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001062822.svg",
"report_text": "The relative strengths and weaknesses of Lexicon Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lexicon Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points.The greatest weakness of Lexicon Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 55% points.
The company's Economic Capital Ratio, given in the ranking table, is 295%, being 61% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001062822_2012_Lexicon_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "9.77",
"Assets": "94.1",
"Liabilities": "-20.5",
"Stockholders Equity": "95.1",
"ECR before LimitedLiability": "136",
"Intangible Assets": "4.32",
"Property and Equipment": "8.60",
"Assets, Current": "45.9",
"Other Liabilities": "-1.64",
"Liabilities, Non-Current": "-54.6",
"Liabilities, Current": "29.9",
"Expenses": "24.5",
"Revenues": "-19.9",
"Net Income": "5.50",
"Other Expenses": "5.14",
"Cost of Goods Sold": "2.62",
"Selling, General and Administrative Expense": "15.5",
"Other Revenues": "-19.9",
"Comprehensive Net Income": "5.29",
"Other Net Income": "1.69",
"Economic Capital Ratio": "60.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001062822_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "285,790",
"Cost of Goods Sold": "0",
"Intangible Assets": "44,543",
"Liabilities, Current": "21,390",
"Liabilities, Non-Current": "78,597",
"Other Assets": "53,762",
"Other Compr. Net Income": "0",
"Other Expenses": "9,294",
"Other Liabilities": "32,957",
"Other Net Income": "408",
"Other Revenues": "1,849",
"Property and Equipment": "46,417",
"Research and Development": "91,828",
"Selling, General and Administrative Expense": "17,350"
},
"output_variables": {
"Assets": "430,512",
"Liabilities": "132,944",
"Expenses": "118,472",
"Revenues": "1,849",
"Stockholders Equity": "297,568",
"Net Income": "-116,215",
"Comprehensive Net Income": "-116,215",
"BaseVar": "342,092",
"ECR before LimitedLiability": "189%",
"Economic Capital Ratio": "295%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.9499239936887873,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001062822.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001062822.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001062822.svg"
},
{
"company_id": "0001366541",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001366541.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001366541.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001366541_main_keyfigs.svg",
"name": "Q Therapeutics Inc",
"rank": 75,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001366541.svg",
"report_text": "The relative strengths and weaknesses of Q Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Q Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 152% points.The greatest weakness of Q Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 294%, being 60% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001366541_2012_Q_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.91",
"Assets": "50.1",
"Liabilities": "80.1",
"Stockholders Equity": "152",
"ECR before LimitedLiability": "136",
"Intangible Assets": "-13.3",
"Property and Equipment": "-7.10",
"Assets, Current": "140",
"Other Liabilities": "35.3",
"Liabilities, Non-Current": "15.3",
"Liabilities, Current": "34.2",
"Other Revenues": "-25.1",
"Revenues": "-25.1",
"Net Income": "-57.9",
"Research and Development": "17.9",
"Comprehensive Net Income": "-58.2",
"Cost of Goods Sold": "4.20",
"Selling, General and Administrative Expense": "-36.2",
"Other Expenses": "11.9",
"Other Net Income": "-30.0",
"Economic Capital Ratio": "60.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001366541_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,795",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "294",
"Liabilities, Non-Current": "0",
"Other Assets": "7.5",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-762",
"Other Revenues": "175",
"Property and Equipment": "32",
"Research and Development": "445",
"Selling, General and Administrative Expense": "1,567"
},
"output_variables": {
"Assets": "2,835",
"Liabilities": "294",
"Expenses": "2,012",
"Revenues": "175",
"Stockholders Equity": "2,541",
"Net Income": "-2,599",
"Comprehensive Net Income": "-2,599",
"BaseVar": "3,039",
"ECR before LimitedLiability": "188%",
"Economic Capital Ratio": "294%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.9426992134190817,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001366541.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001366541.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001366541.svg"
},
{
"company_id": "0001267602",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001267602.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001267602.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001267602.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001267602_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001267602_main_keyfigs.svg",
"name": "Alimera Sciences INC",
"rank": 76,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001267602.svg",
"report_text": "The relative strengths and weaknesses of Alimera Sciences INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alimera Sciences INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 152% points.The greatest weakness of Alimera Sciences INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 293%, being 59% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001267602_2012_Alimera_Sciences_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.36",
"Assets": "76.8",
"Liabilities": "31.8",
"Stockholders Equity": "128",
"ECR before LimitedLiability": "134",
"Intangible Assets": "-10.9",
"Property and Equipment": "-6.29",
"Assets, Current": "152",
"Other Liabilities": "28.3",
"Liabilities, Non-Current": "12.2",
"Liabilities, Current": "-8.76",
"Research and Development": "6.13",
"Expenses": "-7.07",
"Revenues": "-25.9",
"Net Income": "-30.8",
"Other Expenses": "-20.7",
"Cost of Goods Sold": "3.34",
"Selling, General and Administrative Expense": "4.47",
"Other Revenues": "-25.9",
"Comprehensive Net Income": "-31.0",
"Economic Capital Ratio": "58.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001267602_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "34,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,718",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "9,229",
"Other Liabilities": "0",
"Other Net Income": "16",
"Other Revenues": "0",
"Property and Equipment": "197",
"Research and Development": "7,100",
"Selling, General and Administrative Expense": "6,203"
},
"output_variables": {
"Assets": "34,698",
"Liabilities": "6,718",
"Expenses": "22,532",
"Revenues": "0",
"Stockholders Equity": "27,980",
"Net Income": "-22,516",
"Comprehensive Net Income": "-22,516",
"BaseVar": "31,982",
"ECR before LimitedLiability": "186%",
"Economic Capital Ratio": "293%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.928263138849328,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001267602.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001267602.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001267602.svg"
},
{
"company_id": "0000816284",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000816284.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000816284.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000816284_main_keyfigs.svg",
"name": "Celgene CORP DE",
"rank": 77,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000816284.svg",
"report_text": "The relative strengths and weaknesses of Celgene CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Celgene CORP DE compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 64% points.The greatest weakness of Celgene CORP DE is the variable Other Liabilities, reducing the Economic Capital Ratio by 53% points.
The company's Economic Capital Ratio, given in the ranking table, is 292%, being 57% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000816284_2012_Celgene_CORP_DE.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.10",
"Assets": "26.9",
"Liabilities": "-28.3",
"Stockholders Equity": "20.8",
"ECR before LimitedLiability": "133",
"Intangible Assets": "63.6",
"Assets, Current": "-14.1",
"Other Liabilities": "-52.9",
"Liabilities, Non-Current": "4.68",
"Liabilities, Current": "16.1",
"Research and Development": "15.3",
"Expenses": "36.7",
"Revenues": "19.0",
"Net Income": "60.1",
"Other Expenses": "2.88",
"Cost of Goods Sold": "3.43",
"Selling, General and Administrative Expense": "14.1",
"Other Revenues": "19.0",
"Comprehensive Net Income": "59.7",
"Other Net Income": "2.27",
"Economic Capital Ratio": "57.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000816284_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,353,225",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,731,918",
"Liabilities, Current": "1,539,972",
"Liabilities, Non-Current": "273,516",
"Other Assets": "414,725",
"Other Compr. Net Income": "0",
"Other Expenses": "717,542",
"Other Liabilities": "2,679,695",
"Other Net Income": "19,506",
"Other Revenues": "4,842,070",
"Property and Equipment": "506,042",
"Research and Development": "1,600,264",
"Selling, General and Administrative Expense": "1,226,314"
},
"output_variables": {
"Assets": "10,005,910",
"Liabilities": "4,493,183",
"Expenses": "3,544,120",
"Revenues": "4,842,070",
"Stockholders Equity": "5,512,727",
"Net Income": "1,317,456",
"Comprehensive Net Income": "1,317,456",
"BaseVar": "11,452,394",
"ECR before LimitedLiability": "184%",
"Economic Capital Ratio": "292%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.915440529580205,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000816284.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000816284.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000816284.svg"
},
{
"company_id": "0000200406",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000200406.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000200406.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000200406.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000200406_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000200406_main_keyfigs.svg",
"name": "Johnson Johnson",
"rank": 78,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000200406.svg",
"report_text": "The relative strengths and weaknesses of Johnson Johnson are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Johnson Johnson compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 65% points.The greatest weakness of Johnson Johnson is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 32% points.
The company's Economic Capital Ratio, given in the ranking table, is 291%, being 57% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000200406_2012_Johnson_Johnson.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-4.05",
"Assets": "-13.5",
"Liabilities": "-7.71",
"Stockholders Equity": "-29.5",
"ECR before LimitedLiability": "5.42",
"Assets, Current": "-17.1",
"Intangible Assets": "8.71",
"Liabilities, Current": "-6.15",
"Other Liabilities": "11.8",
"Liabilities, Non-Current": "-13.8",
"Selling, General and Administrative Expense": "3.15",
"Expenses": "5.77",
"Revenues": "15.1",
"Net Income": "22.4",
"Research and Development": "7.74",
"Cost of Goods Sold": "5.44",
"Other Expenses": "-10.4",
"Other Revenues": "15.1",
"Comprehensive Net Income": "22.4",
"Other Net Income": "1.26",
"Economic Capital Ratio": "-0.917"
},
"2011": {
"Assets": "13.6",
"Liabilities": "-16.6",
"Stockholders Equity": "10.3",
"ECR before LimitedLiability": "133",
"Intangible Assets": "28.1",
"Property and Equipment": "8.90",
"Assets, Current": "-17.6",
"Other Liabilities": "11.7",
"Liabilities, Non-Current": "-32.2",
"Liabilities, Current": "2.49",
"Research and Development": "27.9",
"Expenses": "32.1",
"Revenues": "27.3",
"Net Income": "65.3",
"Other Expenses": "-10.2",
"Cost of Goods Sold": "3.80",
"Selling, General and Administrative Expense": "10.5",
"Other Revenues": "27.3",
"Comprehensive Net Income": "65.0",
"Other Net Income": "3.12",
"Economic Capital Ratio": "56.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000200406_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "39,541,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "31,185,000",
"Liabilities, Current": "21,731,000",
"Liabilities, Non-Current": "14,170,000",
"Other Assets": "9,197,000",
"Other Compr. Net Income": "0",
"Other Expenses": "23,460,000",
"Other Liabilities": "8,193,000",
"Other Net Income": "616,000",
"Other Revenues": "61,897,000",
"Property and Equipment": "14,759,000",
"Research and Development": "6,986,000",
"Selling, General and Administrative Expense": "19,801,000"
},
"output_variables": {
"Assets": "94,682,000",
"Liabilities": "44,094,000",
"Expenses": "50,247,000",
"Revenues": "61,897,000",
"Stockholders Equity": "50,588,000",
"Net Income": "12,266,000",
"Comprehensive Net Income": "12,266,000",
"BaseVar": "125,768,000",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "287%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "47,307,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "32,010,000",
"Liabilities, Current": "23,072,000",
"Liabilities, Non-Current": "15,723,000",
"Other Assets": "9,038,000",
"Other Compr. Net Income": "0",
"Other Expenses": "22,860,000",
"Other Liabilities": "7,534,000",
"Other Net Income": "875,000",
"Other Revenues": "61,587,000",
"Property and Equipment": "14,553,000",
"Research and Development": "6,844,000",
"Selling, General and Administrative Expense": "19,424,000"
},
"output_variables": {
"Assets": "102,908,000",
"Liabilities": "46,329,000",
"Expenses": "49,128,000",
"Revenues": "61,587,000",
"Stockholders Equity": "56,579,000",
"Net Income": "13,334,000",
"Comprehensive Net Income": "13,334,000",
"BaseVar": "130,413,500",
"ECR before LimitedLiability": "183%",
"Economic Capital Ratio": "291%"
}
}
},
"top_rated": false,
"trend": -61.0,
"value": 2.9101174741278943,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000200406.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000200406.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000200406.svg"
},
{
"company_id": "0001001316",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001001316.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001001316.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001001316.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001001316_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001001316_main_keyfigs.svg",
"name": "TG Therapeutics INC",
"rank": 79,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001001316.svg",
"report_text": "The relative strengths and weaknesses of TG Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of TG Therapeutics INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 107% points.The greatest weakness of TG Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 129% points.
The company's Economic Capital Ratio, given in the ranking table, is 290%, being 56% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001001316_2012_TG_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "49.0",
"Assets": "107",
"Liabilities": "-56.4",
"Stockholders Equity": "74.6",
"ECR before LimitedLiability": "131",
"Intangible Assets": "-3.06",
"Property and Equipment": "-4.92",
"Assets, Current": "41.8",
"Other Liabilities": "-129",
"Liabilities, Non-Current": "8.25",
"Liabilities, Current": "38.4",
"Research and Development": "20.4",
"Expenses": "47.8",
"Revenues": "-17.6",
"Net Income": "24.0",
"Other Expenses": "6.35",
"Selling, General and Administrative Expense": "17.1",
"Other Revenues": "-17.6",
"Comprehensive Net Income": "23.8",
"Other Net Income": "-4.06",
"Economic Capital Ratio": "55.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001001316_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,836",
"Cost of Goods Sold": "0",
"Intangible Assets": "630",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "5,442",
"Other Compr. Net Income": "0",
"Other Expenses": "7.1",
"Other Liabilities": "6,271",
"Other Net Income": "-882",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "15,907",
"Liabilities": "6,271",
"Expenses": "7.1",
"Revenues": "0",
"Stockholders Equity": "9,636",
"Net Income": "-889",
"Comprehensive Net Income": "-889",
"BaseVar": "11,534",
"ECR before LimitedLiability": "181%",
"Economic Capital Ratio": "290%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.898152841231407,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001001316.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001001316.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001001316.svg"
},
{
"company_id": "0000792977",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000792977.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000792977.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000792977_main_keyfigs.svg",
"name": "AMAG Pharmaceuticals INC",
"rank": 80,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000792977.svg",
"report_text": "The relative strengths and weaknesses of AMAG Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of AMAG Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points.The greatest weakness of AMAG Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 28% points.
The company's Economic Capital Ratio, given in the ranking table, is 288%, being 54% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000792977_2012_AMAG_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Assets": "27.1",
"Liabilities": "15.3",
"Stockholders Equity": "57.2",
"ECR before LimitedLiability": "29.7",
"Assets, Current": "88.9",
"Property and Equipment": "-8.39",
"Intangible Assets": "-19.1",
"Liabilities, Current": "13.6",
"Other Liabilities": "-24.5",
"Liabilities, Non-Current": "24.2",
"Selling, General and Administrative Expense": "-8.15",
"Expenses": "-1.71",
"Revenues": "-16.7",
"Net Income": "-17.4",
"Research and Development": "-5.24",
"Cost of Goods Sold": "4.36",
"Other Expenses": "7.39",
"Other Revenues": "-16.7",
"Comprehensive Net Income": "-17.4",
"Other Net Income": "0.942",
"Economic Capital Ratio": "23.4"
},
"2011": {
"Other Assets": "-0.378",
"Assets": "46.2",
"Stockholders Equity": "64.3",
"Other Liabilities": "-28.2",
"ECR before LimitedLiability": "129",
"Intangible Assets": "-11.5",
"Property and Equipment": "-3.14",
"Assets, Current": "79.0",
"Research and Development": "7.80",
"Expenses": "14.4",
"Revenues": "-3.31",
"Net Income": "13.8",
"Other Expenses": "4.23",
"Cost of Goods Sold": "3.44",
"Selling, General and Administrative Expense": "-1.17",
"Other Revenues": "-3.31",
"Liabilities, Non-Current": "12.4",
"Liabilities, Current": "14.3",
"Comprehensive Net Income": "13.5",
"Other Net Income": "2.71",
"Economic Capital Ratio": "53.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000792977_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "290,784",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "36,711",
"Liabilities, Non-Current": "0",
"Other Assets": "34,057",
"Other Compr. Net Income": "0",
"Other Expenses": "9,358",
"Other Liabilities": "54,079",
"Other Net Income": "1,361",
"Other Revenues": "66,245",
"Property and Equipment": "11,235",
"Research and Development": "54,462",
"Selling, General and Administrative Expense": "84,939"
},
"output_variables": {
"Assets": "336,076",
"Liabilities": "90,790",
"Expenses": "148,759",
"Revenues": "66,245",
"Stockholders Equity": "245,286",
"Net Income": "-81,153",
"Comprehensive Net Income": "-81,153",
"BaseVar": "321,616",
"ECR before LimitedLiability": "213%",
"Economic Capital Ratio": "311%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "240,031",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "38,994",
"Liabilities, Non-Current": "0",
"Other Assets": "17,987",
"Other Compr. Net Income": "0",
"Other Expenses": "14,039",
"Other Liabilities": "47,634",
"Other Net Income": "1,554",
"Other Revenues": "61,249",
"Property and Equipment": "9,206",
"Research and Development": "58,140",
"Selling, General and Administrative Expense": "68,863"
},
"output_variables": {
"Assets": "267,224",
"Liabilities": "86,628",
"Expenses": "141,042",
"Revenues": "61,249",
"Stockholders Equity": "180,596",
"Net Income": "-78,239",
"Comprehensive Net Income": "-78,239",
"BaseVar": "278,848",
"ECR before LimitedLiability": "178%",
"Economic Capital Ratio": "288%"
}
}
},
"top_rated": false,
"trend": -66.0,
"value": 2.8767399974580643,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000792977.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000792977.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000792977.svg"
},
{
"company_id": "0001048477",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001048477.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001048477.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001048477.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001048477_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001048477_main_keyfigs.svg",
"name": "Biomarin Pharmaceutical INC",
"rank": 81,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001048477.svg",
"report_text": "The relative strengths and weaknesses of Biomarin Pharmaceutical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biomarin Pharmaceutical INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 40% points.The greatest weakness of Biomarin Pharmaceutical INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 57% points.
The company's Economic Capital Ratio, given in the ranking table, is 287%, being 53% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001048477_2012_Biomarin_Pharmaceutical_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "28.3",
"Assets": "28.9",
"Liabilities": "-39.4",
"Stockholders Equity": "18.5",
"ECR before LimitedLiability": "18.5",
"Property and Equipment": "8.23",
"Intangible Assets": "-6.47",
"Liabilities, Current": "23.0",
"Other Liabilities": "-71.6",
"Liabilities, Non-Current": "1.71",
"Selling, General and Administrative Expense": "4.77",
"Expenses": "27.0",
"Revenues": "-4.74",
"Net Income": "22.6",
"Research and Development": "-0.696",
"Cost of Goods Sold": "-1.43",
"Other Expenses": "24.2",
"Other Revenues": "-4.74",
"Comprehensive Net Income": "22.6",
"Other Net Income": "0.605",
"Economic Capital Ratio": "12.1"
},
"2011": {
"Other Assets": "27.5",
"Assets": "39.9",
"Liabilities": "-23.6",
"Stockholders Equity": "38.5",
"ECR before LimitedLiability": "129",
"Intangible Assets": "11.3",
"Property and Equipment": "21.1",
"Assets, Current": "-18.4",
"Other Liabilities": "-56.8",
"Liabilities, Non-Current": "-8.30",
"Liabilities, Current": "35.3",
"Research and Development": "13.2",
"Expenses": "30.0",
"Revenues": "7.14",
"Net Income": "39.9",
"Other Expenses": "7.70",
"Cost of Goods Sold": "-3.01",
"Selling, General and Administrative Expense": "11.5",
"Other Revenues": "7.14",
"Comprehensive Net Income": "39.6",
"Economic Capital Ratio": "53.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001048477_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "504,260",
"Cost of Goods Sold": "70,285",
"Intangible Assets": "157,012",
"Liabilities, Current": "83,844",
"Liabilities, Non-Current": "84,001",
"Other Assets": "379,485",
"Other Compr. Net Income": "0",
"Other Expenses": "-196,846",
"Other Liabilities": "377,521",
"Other Net Income": "2,023",
"Other Revenues": "376,267",
"Property and Equipment": "221,866",
"Research and Development": "147,309",
"Selling, General and Administrative Expense": "151,723"
},
"output_variables": {
"Assets": "1,262,623",
"Liabilities": "545,366",
"Expenses": "172,471",
"Revenues": "376,267",
"Stockholders Equity": "717,257",
"Net Income": "205,819",
"Comprehensive Net Income": "205,819",
"BaseVar": "1,179,375",
"ECR before LimitedLiability": "196%",
"Economic Capital Ratio": "300%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "469,802",
"Cost of Goods Sold": "84,023",
"Intangible Assets": "231,820",
"Liabilities, Current": "94,125",
"Liabilities, Non-Current": "88,179",
"Other Assets": "333,088",
"Other Compr. Net Income": "0",
"Other Expenses": "21,882",
"Other Liabilities": "348,329",
"Other Net Income": "508",
"Other Revenues": "441,358",
"Property and Equipment": "268,971",
"Research and Development": "214,374",
"Selling, General and Administrative Expense": "175,423"
},
"output_variables": {
"Assets": "1,303,681",
"Liabilities": "530,633",
"Expenses": "495,702",
"Revenues": "441,358",
"Stockholders Equity": "773,048",
"Net Income": "-53,836",
"Comprehensive Net Income": "-53,836",
"BaseVar": "1,385,941",
"ECR before LimitedLiability": "178%",
"Economic Capital Ratio": "287%"
}
}
},
"top_rated": false,
"trend": -65.0,
"value": 2.8738222837392966,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001048477.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001048477.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001048477.svg"
},
{
"company_id": "0001369786",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001369786.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001369786.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001369786_main_keyfigs.svg",
"name": "Sagent Pharmaceuticals Inc",
"rank": 82,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001369786.svg",
"report_text": "The relative strengths and weaknesses of Sagent Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sagent Pharmaceuticals Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 48% points.The greatest weakness of Sagent Pharmaceuticals Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 47% points.
The company's Economic Capital Ratio, given in the ranking table, is 287%, being 53% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001369786_2012_Sagent_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "37.0",
"Liabilities": "16.5",
"Stockholders Equity": "12.4",
"ECR before LimitedLiability": "128",
"Liabilities, Non-Current": "10.0",
"Liabilities, Current": "-33.9",
"Research and Development": "35.2",
"Expenses": "12.5",
"Net Income": "48.2",
"Other Expenses": "-46.9",
"Cost of Goods Sold": "4.47",
"Selling, General and Administrative Expense": "22.9",
"Other Revenues": "31.6",
"Revenues": "31.6",
"Other Assets": "0.808",
"Property and Equipment": "-9.13",
"Assets, Current": "26.1",
"Intangible Assets": "-12.1",
"Comprehensive Net Income": "48.1",
"Other Net Income": "2.85",
"Economic Capital Ratio": "52.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001369786_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "200,846",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,426",
"Liabilities, Current": "84,142",
"Liabilities, Non-Current": "4,697",
"Other Assets": "23,352",
"Other Compr. Net Income": "877",
"Other Expenses": "141,200",
"Other Liabilities": "0",
"Other Net Income": "284",
"Other Revenues": "152,405",
"Property and Equipment": "884",
"Research and Development": "12,763",
"Selling, General and Administrative Expense": "25,148"
},
"output_variables": {
"Assets": "230,508",
"Liabilities": "88,839",
"Expenses": "179,111",
"Revenues": "152,405",
"Stockholders Equity": "141,669",
"Net Income": "-26,422",
"Comprehensive Net Income": "-25,984",
"BaseVar": "326,012",
"ECR before LimitedLiability": "177%",
"Economic Capital Ratio": "287%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.868788921247435,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001369786.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001369786.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001369786.svg"
},
{
"company_id": "0001348362",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001348362.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001348362.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001348362.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001348362_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001348362_main_keyfigs.svg",
"name": "Lexaria Bioscience Corp",
"rank": 83,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001348362.svg",
"report_text": "The relative strengths and weaknesses of Lexaria Bioscience Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lexaria Bioscience Corp compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 210% points.The greatest weakness of Lexaria Bioscience Corp is the variable Liabilities, reducing the Economic Capital Ratio by 38% points.
The company's Economic Capital Ratio, given in the ranking table, is 285%, being 51% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001348362_2012_Lexaria_Bioscience_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "210",
"Assets": "77.6",
"Liabilities": "-38.1",
"Stockholders Equity": "63.8",
"ECR before LimitedLiability": "127",
"Intangible Assets": "-9.39",
"Property and Equipment": "-6.04",
"Assets, Current": "-36.6",
"Other Liabilities": "-19.0",
"Liabilities, Non-Current": "9.83",
"Liabilities, Current": "-28.7",
"Research and Development": "24.7",
"Expenses": "32.9",
"Revenues": "-21.1",
"Net Income": "23.1",
"Other Expenses": "-15.1",
"Selling, General and Administrative Expense": "20.6",
"Other Revenues": "-21.1",
"Comprehensive Net Income": "22.9",
"Other Net Income": "12.5",
"Economic Capital Ratio": "51.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001348362_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "264",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,079",
"Liabilities, Non-Current": "0",
"Other Assets": "4,075",
"Other Compr. Net Income": "0",
"Other Expenses": "999",
"Other Liabilities": "599",
"Other Net Income": "466",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "5.2"
},
"output_variables": {
"Assets": "4,339",
"Liabilities": "1,678",
"Expenses": "1,004",
"Revenues": "0",
"Stockholders Equity": "2,661",
"Net Income": "-538",
"Comprehensive Net Income": "-538",
"BaseVar": "3,744",
"ECR before LimitedLiability": "175%",
"Economic Capital Ratio": "285%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.8535931555471206,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001348362.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001348362.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001348362.svg"
},
{
"company_id": "0000749647",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000749647.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000749647.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000749647.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000749647_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000749647_main_keyfigs.svg",
"name": "Imunon Inc",
"rank": 84,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000749647.svg",
"report_text": "The relative strengths and weaknesses of Imunon Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Imunon Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 137% points.The greatest weakness of Imunon Inc is the variable Research and Development, reducing the Economic Capital Ratio by 37% points.
The company's Economic Capital Ratio, given in the ranking table, is 284%, being 50% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000749647_2012_Imunon_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.34",
"Assets": "61.6",
"Liabilities": "39.2",
"Stockholders Equity": "118",
"ECR before LimitedLiability": "126",
"Intangible Assets": "-12.4",
"Property and Equipment": "-4.79",
"Assets, Current": "137",
"Other Liabilities": "28.4",
"Liabilities, Non-Current": "12.6",
"Research and Development": "-36.6",
"Expenses": "-14.1",
"Revenues": "-28.6",
"Net Income": "-33.9",
"Other Expenses": "10.5",
"Cost of Goods Sold": "3.71",
"Selling, General and Administrative Expense": "9.40",
"Other Revenues": "-28.6",
"Comprehensive Net Income": "-34.2",
"Other Net Income": "8.69",
"Economic Capital Ratio": "50.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000749647_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "31,508",
"Cost of Goods Sold": "0",
"Intangible Assets": "36",
"Liabilities, Current": "6,152",
"Liabilities, Non-Current": "65",
"Other Assets": "323",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "238",
"Other Net Income": "1,796",
"Other Revenues": "0",
"Property and Equipment": "783",
"Research and Development": "19,864",
"Selling, General and Administrative Expense": "5,155"
},
"output_variables": {
"Assets": "32,649",
"Liabilities": "6,456",
"Expenses": "25,019",
"Revenues": "0",
"Stockholders Equity": "26,194",
"Net Income": "-23,223",
"Comprehensive Net Income": "-23,223",
"BaseVar": "32,960",
"ECR before LimitedLiability": "173%",
"Economic Capital Ratio": "284%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.8420319483003524,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000749647.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000749647.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000749647.svg"
},
{
"company_id": "0000003116",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000003116.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000003116.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000003116_main_keyfigs.svg",
"name": "Akorn INC",
"rank": 85,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000003116.svg",
"report_text": "The relative strengths and weaknesses of Akorn INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Akorn INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points.The greatest weakness of Akorn INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 126% points.
The company's Economic Capital Ratio, given in the ranking table, is 283%, being 49% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000003116_2012_Akorn_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "26.9",
"Liabilities": "-37.7",
"Stockholders Equity": "12.3",
"ECR before LimitedLiability": "124",
"Intangible Assets": "22.2",
"Property and Equipment": "10.6",
"Assets, Current": "-7.40",
"Other Liabilities": "28.4",
"Liabilities, Non-Current": "-126",
"Liabilities, Current": "32.7",
"Research and Development": "27.5",
"Expenses": "38.8",
"Revenues": "14.9",
"Net Income": "62.0",
"Other Expenses": "9.12",
"Cost of Goods Sold": "-13.8",
"Selling, General and Administrative Expense": "15.7",
"Other Revenues": "14.9",
"Comprehensive Net Income": "61.7",
"Other Net Income": "5.86",
"Economic Capital Ratio": "48.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000003116_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "155,949",
"Cost of Goods Sold": "57,231",
"Intangible Assets": "79,685",
"Liabilities, Current": "28,289",
"Liabilities, Non-Current": "120,648",
"Other Assets": "27,122",
"Other Compr. Net Income": "0",
"Other Expenses": "1,974",
"Other Liabilities": "0",
"Other Net Income": "12,267",
"Other Revenues": "136,920",
"Property and Equipment": "44,389",
"Research and Development": "11,555",
"Selling, General and Administrative Expense": "33,135"
},
"output_variables": {
"Assets": "307,145",
"Liabilities": "148,937",
"Expenses": "103,895",
"Revenues": "136,920",
"Stockholders Equity": "158,208",
"Net Income": "45,292",
"Comprehensive Net Income": "45,292",
"BaseVar": "354,582",
"ECR before LimitedLiability": "171%",
"Economic Capital Ratio": "283%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.8269923401906585,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000003116.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000003116.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000003116.svg"
},
{
"company_id": "0001095858",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001095858.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001095858.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001095858_main_keyfigs.svg",
"name": "ERBA Diagnostics Inc",
"rank": 86,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001095858.svg",
"report_text": "The relative strengths and weaknesses of ERBA Diagnostics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ERBA Diagnostics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 58% points.The greatest weakness of ERBA Diagnostics Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 41% points.
The company's Economic Capital Ratio, given in the ranking table, is 282%, being 48% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001095858_2012_ERBA_Diagnostics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "2.82",
"Assets": "-27.1",
"Liabilities": "49.4",
"Stockholders Equity": "-15.3",
"ECR before LimitedLiability": "123",
"Intangible Assets": "-11.2",
"Property and Equipment": "-12.2",
"Assets, Current": "-9.43",
"Other Liabilities": "45.8",
"Liabilities, Non-Current": "-5.30",
"Liabilities, Current": "9.15",
"Research and Development": "43.3",
"Expenses": "-2.49",
"Revenues": "57.8",
"Net Income": "56.5",
"Other Expenses": "-12.0",
"Cost of Goods Sold": "-41.0",
"Selling, General and Administrative Expense": "10.8",
"Other Revenues": "57.8",
"Comprehensive Net Income": "56.0",
"Economic Capital Ratio": "47.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001095858_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,666",
"Cost of Goods Sold": "8,158",
"Intangible Assets": "1,153",
"Liabilities, Current": "5,035",
"Liabilities, Non-Current": "1,444",
"Other Assets": "2,388",
"Other Compr. Net Income": "0",
"Other Expenses": "4,762",
"Other Liabilities": "0",
"Other Net Income": "-361",
"Other Revenues": "16,760",
"Property and Equipment": "0",
"Research and Development": "1,452",
"Selling, General and Administrative Expense": "5,324"
},
"output_variables": {
"Assets": "17,207",
"Liabilities": "6,480",
"Expenses": "19,696",
"Revenues": "16,760",
"Stockholders Equity": "10,727",
"Net Income": "-3,297",
"Comprehensive Net Income": "-3,297",
"BaseVar": "30,252",
"ECR before LimitedLiability": "170%",
"Economic Capital Ratio": "282%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.8166572646944728,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001095858.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001095858.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001095858.svg"
},
{
"company_id": "0000855654",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000855654.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000855654.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000855654.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000855654_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000855654_main_keyfigs.svg",
"name": "Immunogen Inc",
"rank": 87,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000855654.svg",
"report_text": "The relative strengths and weaknesses of Immunogen Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immunogen Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 118% points.The greatest weakness of Immunogen Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.
The company's Economic Capital Ratio, given in the ranking table, is 280%, being 46% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000855654_2012_Immunogen_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.46",
"Assets": "73.4",
"Liabilities": "-23.6",
"Stockholders Equity": "69.3",
"ECR before LimitedLiability": "121",
"Intangible Assets": "-10.5",
"Assets, Current": "118",
"Other Liabilities": "-65.6",
"Liabilities, Non-Current": "5.01",
"Liabilities, Current": "30.0",
"Research and Development": "-3.78",
"Expenses": "22.6",
"Revenues": "-14.1",
"Net Income": "10.6",
"Other Expenses": "8.43",
"Cost of Goods Sold": "2.97",
"Selling, General and Administrative Expense": "14.8",
"Other Revenues": "-14.1",
"Comprehensive Net Income": "10.3",
"Other Net Income": "2.72",
"Economic Capital Ratio": "45.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000855654_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "201,525",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,566",
"Liabilities, Non-Current": "3,978",
"Other Assets": "2,707",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "59,128",
"Other Net Income": "1,914",
"Other Revenues": "19,305",
"Property and Equipment": "13,409",
"Research and Development": "63,453",
"Selling, General and Administrative Expense": "16,040"
},
"output_variables": {
"Assets": "217,641",
"Liabilities": "77,672",
"Expenses": "79,493",
"Revenues": "19,305",
"Stockholders Equity": "139,969",
"Net Income": "-58,274",
"Comprehensive Net Income": "-58,274",
"BaseVar": "198,012",
"ECR before LimitedLiability": "167%",
"Economic Capital Ratio": "280%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.79970160063053,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000855654.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000855654.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000855654.svg"
},
{
"company_id": "0000936402",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000936402.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000936402.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000936402_main_keyfigs.svg",
"name": "Shire plc",
"rank": 88,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000936402.svg",
"report_text": "The relative strengths and weaknesses of Shire plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Shire plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 70% points.The greatest weakness of Shire plc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 45% points.
The company's Economic Capital Ratio, given in the ranking table, is 277%, being 43% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000936402_2012_Shire_plc.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-20.3",
"Assets": "-27.8",
"Liabilities": "-59.5",
"Stockholders Equity": "-82.2",
"ECR before LimitedLiability": "-86.0",
"Other Assets": "-6.71",
"Intangible Assets": "2.70",
"Property and Equipment": "-5.41",
"Liabilities, Current": "-1.45",
"Other Liabilities": "-67.9",
"Liabilities, Non-Current": "8.33",
"Cost of Goods Sold": "0.686",
"Expenses": "-1.61",
"Revenues": "-0.0897",
"Net Income": "-1.74",
"Selling, General and Administrative Expense": "-7.24",
"Other Expenses": "8.73",
"Research and Development": "-3.61",
"Other Revenues": "-0.0897",
"Comprehensive Net Income": "-1.23",
"Other Compr. Net Income": "0.508",
"Economic Capital Ratio": "-85.2"
},
"2010": {
"Other Assets": "-11.0",
"Assets": "-19.0",
"Liabilities": "-26.0",
"Stockholders Equity": "-48.2",
"ECR before LimitedLiability": "-19.2",
"Assets, Current": "-28.2",
"Intangible Assets": "27.9",
"Liabilities, Current": "-6.98",
"Other Liabilities": "-39.8",
"Liabilities, Non-Current": "19.2",
"Selling, General and Administrative Expense": "-3.14",
"Expenses": "7.47",
"Revenues": "12.8",
"Net Income": "20.8",
"Research and Development": "3.53",
"Cost of Goods Sold": "5.62",
"Other Expenses": "1.46",
"Other Revenues": "12.8",
"Comprehensive Net Income": "20.2",
"Other Compr. Net Income": "-0.539",
"Economic Capital Ratio": "-25.6"
},
"2011": {
"Other Assets": "-8.11",
"Assets": "5.89",
"Liabilities": "-22.9",
"Stockholders Equity": "-7.06",
"ECR before LimitedLiability": "118",
"Intangible Assets": "66.6",
"Property and Equipment": "9.54",
"Assets, Current": "-32.9",
"Other Liabilities": "5.06",
"Liabilities, Non-Current": "14.1",
"Liabilities, Current": "-44.6",
"Research and Development": "24.9",
"Expenses": "32.3",
"Revenues": "32.1",
"Net Income": "70.0",
"Cost of Goods Sold": "4.03",
"Selling, General and Administrative Expense": "4.24",
"Other Revenues": "32.1",
"Comprehensive Net Income": "69.4",
"Other Net Income": "2.21",
"Economic Capital Ratio": "42.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000936402_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "1,570,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,175,400",
"Liabilities, Current": "1,020,000",
"Liabilities, Non-Current": "290,700",
"Other Assets": "195,100",
"Other Compr. Net Income": "52,300",
"Other Expenses": "545,100",
"Other Liabilities": "1,394,300",
"Other Net Income": "9,700",
"Other Revenues": "3,007,700",
"Property and Equipment": "676,800",
"Research and Development": "638,300",
"Selling, General and Administrative Expense": "1,342,600"
},
"output_variables": {
"Assets": "4,617,500",
"Liabilities": "2,705,000",
"Expenses": "2,526,000",
"Revenues": "3,007,700",
"Stockholders Equity": "1,912,500",
"Net Income": "491,400",
"Comprehensive Net Income": "517,550",
"BaseVar": "6,459,100",
"ECR before LimitedLiability": "128%",
"Economic Capital Ratio": "252%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "1,880,300",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,381,400",
"Liabilities, Current": "1,293,300",
"Liabilities, Non-Current": "182,900",
"Other Assets": "272,500",
"Other Compr. Net Income": "-63,400",
"Other Expenses": "671,900",
"Other Liabilities": "1,460,000",
"Other Net Income": "-23,400",
"Other Revenues": "3,471,100",
"Property and Equipment": "853,400",
"Research and Development": "661,500",
"Selling, General and Administrative Expense": "1,526,300"
},
"output_variables": {
"Assets": "5,387,600",
"Liabilities": "2,936,200",
"Expenses": "2,859,700",
"Revenues": "3,471,100",
"Stockholders Equity": "2,451,400",
"Net Income": "588,000",
"Comprehensive Net Income": "556,300",
"BaseVar": "7,370,700",
"ECR before LimitedLiability": "142%",
"Economic Capital Ratio": "262%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "2,208,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,085,600",
"Liabilities, Current": "2,534,300",
"Liabilities, Non-Current": "0",
"Other Assets": "154,300",
"Other Compr. Net Income": "-25,400",
"Other Expenses": "859,700",
"Other Liabilities": "660,900",
"Other Net Income": "-16,600",
"Other Revenues": "4,263,400",
"Property and Equipment": "932,100",
"Research and Development": "770,700",
"Selling, General and Administrative Expense": "1,751,400"
},
"output_variables": {
"Assets": "6,380,200",
"Liabilities": "3,195,200",
"Expenses": "3,381,800",
"Revenues": "4,263,400",
"Stockholders Equity": "3,185,000",
"Net Income": "865,000",
"Comprehensive Net Income": "852,300",
"BaseVar": "8,631,300",
"ECR before LimitedLiability": "163%",
"Economic Capital Ratio": "277%"
}
}
},
"top_rated": false,
"trend": -68.0,
"value": 2.769168316345424,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000936402.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000936402.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000936402.svg"
},
{
"company_id": "0000884629",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000884629.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000884629.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000884629_main_keyfigs.svg",
"name": "Allergan Finance LLC",
"rank": 89,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000884629.svg",
"report_text": "The relative strengths and weaknesses of Allergan Finance LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Allergan Finance LLC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 71% points.The greatest weakness of Allergan Finance LLC is the variable Other Expenses, reducing the Economic Capital Ratio by 38% points.
The company's Economic Capital Ratio, given in the ranking table, is 277%, being 43% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000884629_2012_Allergan_Finance_LLC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-10.6",
"Assets": "-12.6",
"Liabilities": "-0.571",
"Stockholders Equity": "-22.9",
"ECR before LimitedLiability": "4.54",
"Assets, Current": "-27.1",
"Property and Equipment": "-4.90",
"Intangible Assets": "46.5",
"Liabilities, Current": "18.7",
"Other Liabilities": "10.6",
"Liabilities, Non-Current": "-32.2",
"Selling, General and Administrative Expense": "16.1",
"Expenses": "1.38",
"Revenues": "11.8",
"Net Income": "13.0",
"Research and Development": "10.0",
"Cost of Goods Sold": "5.51",
"Other Expenses": "-29.2",
"Other Revenues": "11.8",
"Comprehensive Net Income": "13.0",
"Economic Capital Ratio": "-1.80"
},
"2011": {
"Other Liabilities": "19.7",
"Liabilities": "-8.84",
"Stockholders Equity": "-4.69",
"ECR before LimitedLiability": "118",
"Liabilities, Non-Current": "-25.0",
"Liabilities, Current": "-4.81",
"Research and Development": "34.8",
"Expenses": "25.8",
"Net Income": "63.1",
"Other Expenses": "-38.1",
"Cost of Goods Sold": "4.28",
"Selling, General and Administrative Expense": "27.6",
"Other Revenues": "33.2",
"Revenues": "33.2",
"Other Assets": "-9.90",
"Property and Equipment": "3.74",
"Assets, Current": "-32.6",
"Intangible Assets": "71.0",
"Comprehensive Net Income": "62.1",
"Other Net Income": "1.45",
"Economic Capital Ratio": "42.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000884629_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,799,400",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,160,100",
"Liabilities, Current": "820,700",
"Liabilities, Non-Current": "1,199,200",
"Other Assets": "225,500",
"Other Compr. Net Income": "0",
"Other Expenses": "2,596,600",
"Other Liabilities": "524,800",
"Other Net Income": "-54,800",
"Other Revenues": "3,566,900",
"Property and Equipment": "642,300",
"Research and Development": "296,100",
"Selling, General and Administrative Expense": "436,100"
},
"output_variables": {
"Assets": "5,827,300",
"Liabilities": "2,544,700",
"Expenses": "3,328,800",
"Revenues": "3,566,900",
"Stockholders Equity": "3,282,600",
"Net Income": "183,300",
"Comprehensive Net Income": "183,300",
"BaseVar": "7,661,250",
"ECR before LimitedLiability": "175%",
"Economic Capital Ratio": "286%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "2,569,700",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,321,900",
"Liabilities, Current": "1,839,500",
"Liabilities, Non-Current": "921,200",
"Other Assets": "93,000",
"Other Compr. Net Income": "-72,200",
"Other Expenses": "3,596,600",
"Other Liabilities": "375,100",
"Other Net Income": "-80,200",
"Other Revenues": "4,584,400",
"Property and Equipment": "713,700",
"Research and Development": "295,400",
"Selling, General and Administrative Expense": "353,100"
},
"output_variables": {
"Assets": "6,698,300",
"Liabilities": "3,135,800",
"Expenses": "4,245,100",
"Revenues": "4,584,400",
"Stockholders Equity": "3,562,500",
"Net Income": "259,100",
"Comprehensive Net Income": "223,000",
"BaseVar": "9,408,000",
"ECR before LimitedLiability": "162%",
"Economic Capital Ratio": "277%"
}
}
},
"top_rated": false,
"trend": -71.0,
"value": 2.766742987767019,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000884629.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000884629.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000884629.svg"
},
{
"company_id": "0001333248",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001333248.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001333248.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001333248_main_keyfigs.svg",
"name": "Cadence Pharmaceuticals INC",
"rank": 90,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001333248.svg",
"report_text": "The relative strengths and weaknesses of Cadence Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cadence Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 87% points.The greatest weakness of Cadence Pharmaceuticals INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 49% points.
The company's Economic Capital Ratio, given in the ranking table, is 275%, being 41% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001333248_2012_Cadence_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.69",
"Assets": "58.7",
"Liabilities": "14.6",
"Stockholders Equity": "87.4",
"ECR before LimitedLiability": "116",
"Intangible Assets": "-1.39",
"Property and Equipment": "1.11",
"Assets, Current": "66.8",
"Other Liabilities": "29.3",
"Liabilities, Non-Current": "-48.6",
"Liabilities, Current": "28.7",
"Research and Development": "26.5",
"Expenses": "0.944",
"Revenues": "-16.8",
"Net Income": "-16.6",
"Cost of Goods Sold": "3.60",
"Selling, General and Administrative Expense": "-27.6",
"Other Revenues": "-16.8",
"Comprehensive Net Income": "-16.8",
"Other Net Income": "-0.701",
"Economic Capital Ratio": "40.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001333248_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "132,929",
"Cost of Goods Sold": "0",
"Intangible Assets": "13,433",
"Liabilities, Current": "16,037",
"Liabilities, Non-Current": "28,813",
"Other Assets": "7,229",
"Other Compr. Net Income": "0",
"Other Expenses": "15,049",
"Other Liabilities": "0",
"Other Net Income": "-4,279",
"Other Revenues": "16,696",
"Property and Equipment": "10,569",
"Research and Development": "8,885",
"Selling, General and Administrative Expense": "81,504"
},
"output_variables": {
"Assets": "164,160",
"Liabilities": "44,850",
"Expenses": "105,438",
"Revenues": "16,696",
"Stockholders Equity": "119,310",
"Net Income": "-93,021",
"Comprehensive Net Income": "-93,021",
"BaseVar": "167,712",
"ECR before LimitedLiability": "160%",
"Economic Capital Ratio": "275%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.7483689855864974,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001333248.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001333248.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001333248.svg"
},
{
"company_id": "0000275053",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000275053.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000275053.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000275053.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000275053_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000275053_main_keyfigs.svg",
"name": "Natures Sunshine Products INC",
"rank": 91,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000275053.svg",
"report_text": "The relative strengths and weaknesses of Natures Sunshine Products INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Natures Sunshine Products INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 132% points.The greatest weakness of Natures Sunshine Products INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 119% points.
The company's Economic Capital Ratio, given in the ranking table, is 273%, being 39% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000275053_2012_Natures_Sunshine_Products_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.34",
"Assets": "-74.4",
"Liabilities": "94.5",
"Stockholders Equity": "-119",
"ECR before LimitedLiability": "114",
"Intangible Assets": "-26.9",
"Assets, Current": "-58.7",
"Other Liabilities": "65.9",
"Liabilities, Non-Current": "-2.90",
"Liabilities, Current": "35.1",
"Research and Development": "82.6",
"Expenses": "-19.6",
"Revenues": "132",
"Net Income": "132",
"Other Expenses": "-55.8",
"Cost of Goods Sold": "-28.1",
"Selling, General and Administrative Expense": "-6.87",
"Other Revenues": "132",
"Comprehensive Net Income": "132",
"Other Net Income": "6.16",
"Economic Capital Ratio": "38.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000275053_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "125,103",
"Cost of Goods Sold": "69,410",
"Intangible Assets": "1,151",
"Liabilities, Current": "67,798",
"Liabilities, Non-Current": "20,575",
"Other Assets": "24,420",
"Other Compr. Net Income": "-2,421",
"Other Expenses": "153,044",
"Other Liabilities": "0",
"Other Net Income": "1,847",
"Other Revenues": "367,813",
"Property and Equipment": "25,137",
"Research and Development": "0",
"Selling, General and Administrative Expense": "129,605"
},
"output_variables": {
"Assets": "175,811",
"Liabilities": "88,373",
"Expenses": "352,059",
"Revenues": "367,813",
"Stockholders Equity": "87,438",
"Net Income": "17,601",
"Comprehensive Net Income": "16,390",
"BaseVar": "494,162",
"ECR before LimitedLiability": "157%",
"Economic Capital Ratio": "273%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.726010082576427,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000275053.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000275053.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000275053.svg"
},
{
"company_id": "0000820096",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000820096.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000820096.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000820096_main_keyfigs.svg",
"name": "Perrigo CO",
"rank": 92,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000820096.svg",
"report_text": "The relative strengths and weaknesses of Perrigo CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Perrigo CO compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 77% points.The greatest weakness of Perrigo CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 86% points.
The company's Economic Capital Ratio, given in the ranking table, is 269%, being 35% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000820096_2012_Perrigo_CO.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "11.1",
"Assets": "-36.5",
"Liabilities": "-39.2",
"Stockholders Equity": "-80.6",
"ECR before LimitedLiability": "-49.4",
"Assets, Current": "-28.2",
"Property and Equipment": "-4.62",
"Intangible Assets": "-16.2",
"Liabilities, Current": "-15.3",
"Other Liabilities": "36.4",
"Liabilities, Non-Current": "-64.6",
"Selling, General and Administrative Expense": "18.7",
"Expenses": "1.76",
"Revenues": "16.0",
"Net Income": "18.6",
"Research and Development": "14.1",
"Cost of Goods Sold": "-38.5",
"Other Expenses": "10.4",
"Other Revenues": "16.0",
"Comprehensive Net Income": "18.6",
"Economic Capital Ratio": "-55.8"
},
"2011": {
"Other Assets": "18.7",
"Assets": "-13.5",
"Liabilities": "-8.49",
"Stockholders Equity": "-27.9",
"ECR before LimitedLiability": "111",
"Intangible Assets": "5.26",
"Property and Equipment": "10.1",
"Assets, Current": "-36.2",
"Other Liabilities": "37.5",
"Liabilities, Non-Current": "-85.5",
"Liabilities, Current": "26.4",
"Research and Development": "40.8",
"Expenses": "23.5",
"Revenues": "47.0",
"Net Income": "77.4",
"Other Expenses": "7.72",
"Cost of Goods Sold": "-46.6",
"Selling, General and Administrative Expense": "26.0",
"Other Revenues": "47.0",
"Comprehensive Net Income": "77.0",
"Economic Capital Ratio": "35.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000820096_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,402,701",
"Cost of Goods Sold": "1,521,917",
"Intangible Assets": "587,000",
"Liabilities, Current": "922,509",
"Liabilities, Non-Current": "1,092,554",
"Other Assets": "670,719",
"Other Compr. Net Income": "0",
"Other Expenses": "150,475",
"Other Liabilities": "0",
"Other Net Income": "530",
"Other Revenues": "2,268,150",
"Property and Equipment": "448,583",
"Research and Development": "102,515",
"Selling, General and Administrative Expense": "269,974"
},
"output_variables": {
"Assets": "3,109,003",
"Liabilities": "2,015,063",
"Expenses": "2,044,881",
"Revenues": "2,268,150",
"Stockholders Equity": "1,093,940",
"Net Income": "223,799",
"Comprehensive Net Income": "223,799",
"BaseVar": "4,718,814",
"ECR before LimitedLiability": "102%",
"Economic Capital Ratio": "232%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,377,293",
"Cost of Goods Sold": "1,810,159",
"Intangible Assets": "567,573",
"Liabilities, Current": "606,035",
"Liabilities, Non-Current": "1,052,199",
"Other Assets": "737,047",
"Other Compr. Net Income": "0",
"Other Expenses": "188,025",
"Other Liabilities": "0",
"Other Net Income": "1,300",
"Other Revenues": "2,755,029",
"Property and Equipment": "507,308",
"Research and Development": "89,250",
"Selling, General and Administrative Expense": "329,698"
},
"output_variables": {
"Assets": "3,189,221",
"Liabilities": "1,658,234",
"Expenses": "2,417,132",
"Revenues": "2,755,029",
"Stockholders Equity": "1,530,987",
"Net Income": "339,197",
"Comprehensive Net Income": "339,197",
"BaseVar": "5,010,458",
"ECR before LimitedLiability": "152%",
"Economic Capital Ratio": "269%"
}
}
},
"top_rated": false,
"trend": -66.0,
"value": 2.690289227940583,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000820096.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000820096.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000820096.svg"
},
{
"company_id": "0001178879",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001178879.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001178879.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178879.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178879_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001178879_main_keyfigs.svg",
"name": "Amicus Therapeutics INC",
"rank": 93,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001178879.svg",
"report_text": "The relative strengths and weaknesses of Amicus Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Amicus Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 80% points.The greatest weakness of Amicus Therapeutics INC is the variable Research and Development, reducing the Economic Capital Ratio by 41% points.
The company's Economic Capital Ratio, given in the ranking table, is 266%, being 32% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001178879_2012_Amicus_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.4",
"Assets": "19.1",
"Liabilities": "37.6",
"Stockholders Equity": "59.6",
"ECR before LimitedLiability": "108",
"Intangible Assets": "-16.5",
"Property and Equipment": "-5.66",
"Assets, Current": "80.2",
"Other Liabilities": "36.1",
"Liabilities, Non-Current": "15.6",
"Liabilities, Current": "-14.5",
"Research and Development": "-40.5",
"Expenses": "-15.5",
"Revenues": "-1.11",
"Net Income": "-13.6",
"Other Expenses": "20.8",
"Cost of Goods Sold": "4.55",
"Selling, General and Administrative Expense": "1.62",
"Other Revenues": "-1.11",
"Comprehensive Net Income": "-13.9",
"Other Net Income": "3.15",
"Economic Capital Ratio": "32.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001178879_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "66,648",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,256",
"Liabilities, Non-Current": "0",
"Other Assets": "709",
"Other Compr. Net Income": "0",
"Other Expenses": "-4,660",
"Other Liabilities": "0",
"Other Net Income": "230",
"Other Revenues": "21,434",
"Property and Equipment": "2,438",
"Research and Development": "50,856",
"Selling, General and Administrative Expense": "19,880"
},
"output_variables": {
"Assets": "69,795",
"Liabilities": "19,256",
"Expenses": "66,076",
"Revenues": "21,434",
"Stockholders Equity": "50,539",
"Net Income": "-44,412",
"Comprehensive Net Income": "-44,412",
"BaseVar": "88,396",
"ECR before LimitedLiability": "148%",
"Economic Capital Ratio": "266%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.6615794985743193,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001178879.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001178879.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001178879.svg"
},
{
"company_id": "0001228627",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001228627.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001228627.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001228627.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001228627_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001228627_main_keyfigs.svg",
"name": "Opus Genetics Inc",
"rank": 94,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001228627.svg",
"report_text": "The relative strengths and weaknesses of Opus Genetics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Opus Genetics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 80% points.The greatest weakness of Opus Genetics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 55% points.
The company's Economic Capital Ratio, given in the ranking table, is 263%, being 29% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001228627_2012_Opus_Genetics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "5.42",
"Liabilities": "67.5",
"Stockholders Equity": "68.2",
"ECR before LimitedLiability": "105",
"Intangible Assets": "-18.9",
"Property and Equipment": "-11.3",
"Assets, Current": "46.9",
"Other Liabilities": "-34.0",
"Liabilities, Non-Current": "17.6",
"Liabilities, Current": "80.1",
"Research and Development": "-55.4",
"Expenses": "-34.8",
"Revenues": "-39.2",
"Net Income": "-31.2",
"Other Expenses": "9.56",
"Cost of Goods Sold": "5.20",
"Selling, General and Administrative Expense": "7.83",
"Other Revenues": "-39.2",
"Comprehensive Net Income": "-31.6",
"Other Net Income": "47.6",
"Economic Capital Ratio": "29.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001228627_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "12,163",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "1,432",
"Other Compr. Net Income": "0",
"Other Expenses": "591",
"Other Liabilities": "2,984",
"Other Net Income": "4,786",
"Other Revenues": "0",
"Property and Equipment": "95",
"Research and Development": "11,992",
"Selling, General and Administrative Expense": "3,548"
},
"output_variables": {
"Assets": "13,690",
"Liabilities": "2,984",
"Expenses": "16,131",
"Revenues": "0",
"Stockholders Equity": "10,706",
"Net Income": "-11,345",
"Comprehensive Net Income": "-11,345",
"BaseVar": "18,795",
"ECR before LimitedLiability": "144%",
"Economic Capital Ratio": "263%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.6339779392641494,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001228627.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001228627.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001228627.svg"
},
{
"company_id": "0000908259",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000908259.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000908259.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000908259.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000908259_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000908259_main_keyfigs.svg",
"name": "Oncotelic Therapeutics Inc",
"rank": 95,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000908259.svg",
"report_text": "The relative strengths and weaknesses of Oncotelic Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oncotelic Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 99% points.The greatest weakness of Oncotelic Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 43% points.
The company's Economic Capital Ratio, given in the ranking table, is 263%, being 29% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000908259_2012_Oncotelic_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.4",
"Assets": "25.0",
"Liabilities": "59.8",
"Stockholders Equity": "90.6",
"ECR before LimitedLiability": "104",
"Intangible Assets": "-13.7",
"Property and Equipment": "-11.0",
"Assets, Current": "99.2",
"Other Liabilities": "37.3",
"Liabilities, Non-Current": "16.2",
"Liabilities, Current": "8.36",
"Research and Development": "-15.5",
"Expenses": "-33.1",
"Revenues": "-36.0",
"Net Income": "-42.5",
"Cost of Goods Sold": "4.76",
"Selling, General and Administrative Expense": "-22.7",
"Other Revenues": "-36.0",
"Comprehensive Net Income": "-42.9",
"Other Net Income": "28.3",
"Economic Capital Ratio": "28.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000908259_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "10,647",
"Cost of Goods Sold": "0",
"Intangible Assets": "289",
"Liabilities, Current": "2,253",
"Liabilities, Non-Current": "0",
"Other Assets": "86",
"Other Compr. Net Income": "0",
"Other Expenses": "1,226",
"Other Liabilities": "6.0",
"Other Net Income": "2,239",
"Other Revenues": "0",
"Property and Equipment": "34",
"Research and Development": "5,291",
"Selling, General and Administrative Expense": "5,375"
},
"output_variables": {
"Assets": "11,056",
"Liabilities": "2,259",
"Expenses": "11,892",
"Revenues": "0",
"Stockholders Equity": "8,797",
"Net Income": "-9,653",
"Comprehensive Net Income": "-9,653",
"BaseVar": "13,723",
"ECR before LimitedLiability": "143%",
"Economic Capital Ratio": "263%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.628078838778511,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000908259.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000908259.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000908259.svg"
},
{
"company_id": "0001114220",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001114220.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001114220.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001114220_main_keyfigs.svg",
"name": "Keryx Biopharmaceuticals INC",
"rank": 96,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001114220.svg",
"report_text": "The relative strengths and weaknesses of Keryx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Keryx Biopharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 102% points.The greatest weakness of Keryx Biopharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 34% points.
The company's Economic Capital Ratio, given in the ranking table, is 262%, being 28% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001114220_2012_Keryx_Biopharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.8",
"Assets": "48.7",
"Liabilities": "17.8",
"Stockholders Equity": "76.9",
"ECR before LimitedLiability": "103",
"Property and Equipment": "-9.42",
"Assets, Current": "102",
"Other Liabilities": "12.2",
"Liabilities, Non-Current": "13.1",
"Liabilities, Current": "-7.70",
"Research and Development": "-34.3",
"Expenses": "-8.74",
"Revenues": "-17.7",
"Net Income": "-22.3",
"Other Expenses": "11.2",
"Cost of Goods Sold": "3.94",
"Selling, General and Administrative Expense": "11.9",
"Other Revenues": "-17.7",
"Comprehensive Net Income": "-22.5",
"Other Net Income": "4.05",
"Economic Capital Ratio": "27.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001114220_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "40,004",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,208",
"Liabilities, Current": "9,767",
"Liabilities, Non-Current": "35",
"Other Assets": "209",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "2,639",
"Other Net Income": "626",
"Other Revenues": "5,000",
"Property and Equipment": "67",
"Research and Development": "27,012",
"Selling, General and Administrative Expense": "6,737"
},
"output_variables": {
"Assets": "43,488",
"Liabilities": "12,441",
"Expenses": "33,749",
"Revenues": "5,000",
"Stockholders Equity": "31,047",
"Net Income": "-28,123",
"Comprehensive Net Income": "-28,123",
"BaseVar": "47,652",
"ECR before LimitedLiability": "141%",
"Economic Capital Ratio": "262%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.6164443805353264,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001114220.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001114220.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001114220.svg"
},
{
"company_id": "0001070494",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001070494.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001070494.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001070494.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001070494_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001070494_main_keyfigs.svg",
"name": "Acadia Pharmaceuticals INC",
"rank": 97,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001070494.svg",
"report_text": "The relative strengths and weaknesses of Acadia Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Acadia Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 120% points.The greatest weakness of Acadia Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 31% points.
The company's Economic Capital Ratio, given in the ranking table, is 259%, being 25% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001070494_2012_Acadia_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.3",
"Assets": "58.6",
"Liabilities": "18.5",
"Stockholders Equity": "87.4",
"ECR before LimitedLiability": "100",
"Intangible Assets": "-14.8",
"Property and Equipment": "-8.88",
"Assets, Current": "120",
"Other Liabilities": "4.81",
"Liabilities, Non-Current": "13.1",
"Research and Development": "-27.1",
"Expenses": "-11.6",
"Revenues": "-22.5",
"Net Income": "-31.0",
"Other Expenses": "11.0",
"Cost of Goods Sold": "3.87",
"Selling, General and Administrative Expense": "1.49",
"Other Revenues": "-22.5",
"Comprehensive Net Income": "-31.3",
"Other Net Income": "2.67",
"Economic Capital Ratio": "24.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001070494_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "31,949",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,165",
"Liabilities, Non-Current": "0",
"Other Assets": "14",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "2,587",
"Other Net Income": "87",
"Other Revenues": "2,067",
"Property and Equipment": "151",
"Research and Development": "17,309",
"Selling, General and Administrative Expense": "7,610"
},
"output_variables": {
"Assets": "32,114",
"Liabilities": "8,752",
"Expenses": "24,919",
"Revenues": "2,067",
"Stockholders Equity": "23,362",
"Net Income": "-22,765",
"Comprehensive Net Income": "-22,765",
"BaseVar": "33,970",
"ECR before LimitedLiability": "138%",
"Economic Capital Ratio": "259%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.5899572583802914,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001070494.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001070494.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001070494.svg"
},
{
"company_id": "0000078003",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000078003.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000078003.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000078003.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000078003_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000078003_main_keyfigs.svg",
"name": "Pfizer INC",
"rank": 98,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000078003.svg",
"report_text": "The relative strengths and weaknesses of Pfizer INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Pfizer INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 98% points.The greatest weakness of Pfizer INC is the variable Liabilities, reducing the Economic Capital Ratio by 62% points.
The company's Economic Capital Ratio, given in the ranking table, is 253%, being 19% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000078003_2012_Pfizer_INC.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-9.58",
"Assets": "20.3",
"Liabilities": "-92.2",
"Stockholders Equity": "-36.6",
"ECR before LimitedLiability": "-90.0",
"Other Assets": "3.10",
"Intangible Assets": "34.8",
"Property and Equipment": "-3.77",
"Liabilities, Current": "-5.50",
"Other Liabilities": "-34.2",
"Liabilities, Non-Current": "-45.5",
"Cost of Goods Sold": "-3.48",
"Expenses": "18.2",
"Revenues": "-21.7",
"Net Income": "-4.66",
"Selling, General and Administrative Expense": "8.03",
"Other Expenses": "10.1",
"Research and Development": "3.33",
"Other Revenues": "-21.7",
"Comprehensive Net Income": "-4.67",
"Economic Capital Ratio": "-89.1"
},
"2010": {
"Other Assets": "-5.24",
"Assets": "11.1",
"Liabilities": "-53.4",
"Stockholders Equity": "-22.7",
"ECR before LimitedLiability": "-25.6",
"Assets, Current": "-21.2",
"Property and Equipment": "-3.96",
"Intangible Assets": "59.2",
"Liabilities, Current": "6.98",
"Other Liabilities": "-19.2",
"Liabilities, Non-Current": "-40.1",
"Selling, General and Administrative Expense": "9.71",
"Expenses": "18.1",
"Revenues": "-5.95",
"Net Income": "12.4",
"Research and Development": "7.77",
"Cost of Goods Sold": "-3.41",
"Other Expenses": "3.83",
"Other Revenues": "-5.95",
"Comprehensive Net Income": "12.4",
"Economic Capital Ratio": "-32.0"
},
"2011": {
"Other Assets": "0.297",
"Assets": "38.2",
"Liabilities": "-62.5",
"ECR before LimitedLiability": "94.4",
"Intangible Assets": "97.9",
"Property and Equipment": "4.16",
"Assets, Current": "-29.6",
"Other Liabilities": "-25.7",
"Liabilities, Non-Current": "-50.7",
"Liabilities, Current": "14.6",
"Research and Development": "26.0",
"Expenses": "41.3",
"Net Income": "51.7",
"Other Expenses": "3.12",
"Cost of Goods Sold": "-4.27",
"Selling, General and Administrative Expense": "15.5",
"Other Revenues": "7.74",
"Revenues": "7.74",
"Comprehensive Net Income": "51.4",
"Other Net Income": "1.46",
"Economic Capital Ratio": "18.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000078003_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "61,670,000",
"Cost of Goods Sold": "8,888,000",
"Intangible Assets": "110,391,000",
"Liabilities, Current": "37,225,000",
"Liabilities, Non-Current": "48,804,000",
"Other Assets": "18,108,000",
"Other Compr. Net Income": "0",
"Other Expenses": "9,771,000",
"Other Liabilities": "36,474,000",
"Other Net Income": "14,000",
"Other Revenues": "50,009,000",
"Property and Equipment": "22,780,000",
"Research and Development": "7,845,000",
"Selling, General and Administrative Expense": "14,875,000"
},
"output_variables": {
"Assets": "212,949,000",
"Liabilities": "122,503,000",
"Expenses": "41,379,000",
"Revenues": "50,009,000",
"Stockholders Equity": "90,446,000",
"Net Income": "8,644,000",
"Comprehensive Net Income": "8,644,000",
"BaseVar": "213,427,000",
"ECR before LimitedLiability": "123%",
"Economic Capital Ratio": "248%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "60,468,000",
"Cost of Goods Sold": "16,279,000",
"Intangible Assets": "101,505,000",
"Liabilities, Current": "28,609,000",
"Liabilities, Non-Current": "44,011,000",
"Other Assets": "13,918,000",
"Other Compr. Net Income": "0",
"Other Expenses": "14,205,000",
"Other Liabilities": "34,129,000",
"Other Net Income": "-9,000",
"Other Revenues": "67,809,000",
"Property and Equipment": "19,123,000",
"Research and Development": "9,413,000",
"Selling, General and Administrative Expense": "19,614,000"
},
"output_variables": {
"Assets": "195,014,000",
"Liabilities": "106,749,000",
"Expenses": "59,511,000",
"Revenues": "67,809,000",
"Stockholders Equity": "88,265,000",
"Net Income": "8,289,000",
"Comprehensive Net Income": "8,289,000",
"BaseVar": "214,546,000",
"ECR before LimitedLiability": "133%",
"Economic Capital Ratio": "255%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "57,728,000",
"Cost of Goods Sold": "15,085,000",
"Intangible Assets": "98,900,000",
"Liabilities, Current": "28,069,000",
"Liabilities, Non-Current": "41,130,000",
"Other Assets": "14,436,000",
"Other Compr. Net Income": "0",
"Other Expenses": "12,542,000",
"Other Liabilities": "36,182,000",
"Other Net Income": "-1,167,000",
"Other Revenues": "67,425,000",
"Property and Equipment": "16,938,000",
"Research and Development": "9,112,000",
"Selling, General and Administrative Expense": "19,468,000"
},
"output_variables": {
"Assets": "188,002,000",
"Liabilities": "105,381,000",
"Expenses": "56,207,000",
"Revenues": "67,425,000",
"Stockholders Equity": "82,621,000",
"Net Income": "10,051,000",
"Comprehensive Net Income": "10,051,000",
"BaseVar": "209,091,000",
"ECR before LimitedLiability": "130%",
"Economic Capital Ratio": "253%"
}
}
},
"top_rated": false,
"trend": -77.0,
"value": 2.529397913633111,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000078003.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000078003.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000078003.svg"
},
{
"company_id": "0001158223",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001158223.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001158223.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001158223_main_keyfigs.svg",
"name": "Affymax INC",
"rank": 99,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001158223.svg",
"report_text": "The relative strengths and weaknesses of Affymax INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Affymax INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 53% points.The greatest weakness of Affymax INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.
The company's Economic Capital Ratio, given in the ranking table, is 252%, being 18% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001158223_2012_Affymax_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.28",
"Assets": "9.34",
"Liabilities": "17.2",
"Stockholders Equity": "27.1",
"ECR before LimitedLiability": "93.8",
"Intangible Assets": "-18.1",
"Property and Equipment": "-7.99",
"Assets, Current": "53.1",
"Other Liabilities": "-19.5",
"Liabilities, Non-Current": "11.6",
"Liabilities, Current": "24.2",
"Research and Development": "-28.1",
"Expenses": "-6.95",
"Revenues": "7.23",
"Net Income": "3.17",
"Other Expenses": "13.2",
"Cost of Goods Sold": "4.68",
"Selling, General and Administrative Expense": "4.51",
"Other Revenues": "7.23",
"Other Net Income": "3.02",
"Economic Capital Ratio": "18.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001158223_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "107,620",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "19,766",
"Liabilities, Non-Current": "1,526",
"Other Assets": "8,362",
"Other Compr. Net Income": "0",
"Other Expenses": "145",
"Other Liabilities": "21,706",
"Other Net Income": "184",
"Other Revenues": "47,720",
"Property and Equipment": "3,013",
"Research and Development": "76,308",
"Selling, General and Administrative Expense": "32,818"
},
"output_variables": {
"Assets": "118,995",
"Liabilities": "42,998",
"Expenses": "109,271",
"Revenues": "47,720",
"Stockholders Equity": "75,997",
"Net Income": "-61,367",
"Comprehensive Net Income": "-61,367",
"BaseVar": "159,584",
"ECR before LimitedLiability": "129%",
"Economic Capital Ratio": "252%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.5230152879275094,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001158223.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001158223.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001158223.svg"
},
{
"company_id": "0000715446",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000715446.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000715446.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000715446.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000715446_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000715446_main_keyfigs.svg",
"name": "Anixa Biosciences Inc",
"rank": 100,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000715446.svg",
"report_text": "The relative strengths and weaknesses of Anixa Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Anixa Biosciences Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 127% points.The greatest weakness of Anixa Biosciences Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 44% points.
The company's Economic Capital Ratio, given in the ranking table, is 252%, being 18% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000715446_2012_Anixa_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "127",
"Assets": "40.4",
"Liabilities": "38.9",
"Stockholders Equity": "87.4",
"ECR before LimitedLiability": "93.2",
"Intangible Assets": "-17.3",
"Property and Equipment": "-11.0",
"Assets, Current": "-32.5",
"Other Liabilities": "34.3",
"Liabilities, Non-Current": "14.7",
"Liabilities, Current": "-10.1",
"Other Revenues": "-20.5",
"Revenues": "-20.5",
"Net Income": "-43.4",
"Research and Development": "-4.24",
"Comprehensive Net Income": "-43.7",
"Cost of Goods Sold": "4.45",
"Selling, General and Administrative Expense": "-6.81",
"Other Expenses": "3.69",
"Other Net Income": "-21.0",
"Economic Capital Ratio": "17.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000715446_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,120",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,105",
"Liabilities, Non-Current": "0",
"Other Assets": "5,510",
"Other Compr. Net Income": "0",
"Other Expenses": "634",
"Other Liabilities": "0",
"Other Net Income": "-1,750",
"Other Revenues": "1,003",
"Property and Equipment": "16",
"Research and Development": "3,125",
"Selling, General and Administrative Expense": "2,873"
},
"output_variables": {
"Assets": "8,646",
"Liabilities": "2,105",
"Expenses": "6,631",
"Revenues": "1,003",
"Stockholders Equity": "6,541",
"Net Income": "-7,378",
"Comprehensive Net Income": "-7,378",
"BaseVar": "10,068",
"ECR before LimitedLiability": "128%",
"Economic Capital Ratio": "252%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.517207623064194,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000715446.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000715446.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000715446.svg"
},
{
"company_id": "0000875320",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000875320.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000875320.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000875320.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000875320_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000875320_main_keyfigs.svg",
"name": "Vertex Pharmaceuticals INC MA",
"rank": 101,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000875320.svg",
"report_text": "The relative strengths and weaknesses of Vertex Pharmaceuticals INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Vertex Pharmaceuticals INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 62% points.The greatest weakness of Vertex Pharmaceuticals INC MA is the variable Other Liabilities, reducing the Economic Capital Ratio by 75% points.
The company's Economic Capital Ratio, given in the ranking table, is 249%, being 15% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000875320_2012_Vertex_Pharmaceuticals_INC_MA.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "24.2",
"Assets": "5.83",
"Liabilities": "-90.6",
"Stockholders Equity": "-66.5",
"ECR before LimitedLiability": "-117",
"Assets, Current": "22.8",
"Property and Equipment": "-19.2",
"Intangible Assets": "-41.0",
"Liabilities, Current": "-24.5",
"Other Liabilities": "-89.3",
"Liabilities, Non-Current": "22.2",
"Selling, General and Administrative Expense": "11.5",
"Expenses": "1.90",
"Revenues": "-36.8",
"Net Income": "-36.8",
"Research and Development": "-25.2",
"Cost of Goods Sold": "5.60",
"Other Expenses": "11.1",
"Other Revenues": "-36.8",
"Comprehensive Net Income": "-36.8",
"Economic Capital Ratio": "-124"
},
"2011": {
"Other Liabilities": "-75.4",
"Liabilities": "-34.2",
"Stockholders Equity": "-24.2",
"ECR before LimitedLiability": "90.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "21.5",
"Research and Development": "7.20",
"Expenses": "28.5",
"Net Income": "62.0",
"Other Expenses": "1.38",
"Cost of Goods Sold": "4.32",
"Selling, General and Administrative Expense": "14.9",
"Other Revenues": "28.7",
"Revenues": "28.7",
"Other Assets": "42.1",
"Property and Equipment": "-2.75",
"Assets, Current": "-13.0",
"Intangible Assets": "-15.3",
"Comprehensive Net Income": "61.6",
"Other Net Income": "1.98",
"Economic Capital Ratio": "15.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000875320_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,057,039",
"Cost of Goods Sold": "0",
"Intangible Assets": "26,102",
"Liabilities, Current": "474,783",
"Liabilities, Non-Current": "0",
"Other Assets": "569,972",
"Other Compr. Net Income": "0",
"Other Expenses": "33,506",
"Other Liabilities": "746,690",
"Other Net Income": "-39,274",
"Other Revenues": "143,370",
"Property and Equipment": "72,333",
"Research and Development": "637,416",
"Selling, General and Administrative Expense": "187,800"
},
"output_variables": {
"Assets": "1,725,446",
"Liabilities": "1,221,473",
"Expenses": "858,722",
"Revenues": "143,370",
"Stockholders Equity": "503,973",
"Net Income": "-754,626",
"Comprehensive Net Income": "-754,626",
"BaseVar": "1,994,142",
"ECR before LimitedLiability": "23%",
"Economic Capital Ratio": "164%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,331,254",
"Cost of Goods Sold": "0",
"Intangible Assets": "30,992",
"Liabilities, Current": "392,348",
"Liabilities, Non-Current": "7,287",
"Other Assets": "708,858",
"Other Compr. Net Income": "0",
"Other Expenses": "246,097",
"Other Liabilities": "839,133",
"Other Net Income": "-14,923",
"Other Revenues": "1,410,626",
"Property and Equipment": "133,176",
"Research and Development": "707,706",
"Selling, General and Administrative Expense": "400,721"
},
"output_variables": {
"Assets": "2,204,280",
"Liabilities": "1,238,768",
"Expenses": "1,354,524",
"Revenues": "1,410,626",
"Stockholders Equity": "965,512",
"Net Income": "41,179",
"Comprehensive Net Income": "41,179",
"BaseVar": "3,111,560",
"ECR before LimitedLiability": "125%",
"Economic Capital Ratio": "249%"
}
}
},
"top_rated": false,
"trend": -72.0,
"value": 2.492159722988863,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000875320.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000875320.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000875320.svg"
},
{
"company_id": "0000059478",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000059478.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000059478.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000059478.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000059478_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000059478_main_keyfigs.svg",
"name": "ELI Lilly Co",
"rank": 102,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000059478.svg",
"report_text": "The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ELI Lilly Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 76% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 81% points.
The company's Economic Capital Ratio, given in the ranking table, is 248%, being 14% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000059478_2012_ELI_Lilly_Co.pdf",
"shrinked_graph_json": {
"2009": {
"Assets, Current": "-13.7",
"Assets": "-42.3",
"Liabilities": "-64.7",
"Stockholders Equity": "-108",
"ECR before LimitedLiability": "-98.7",
"Other Assets": "25.3",
"Intangible Assets": "-54.5",
"Property and Equipment": "15.4",
"Other Liabilities": "18.8",
"Liabilities, Non-Current": "-88.1",
"Cost of Goods Sold": "0.754",
"Expenses": "-4.73",
"Revenues": "6.89",
"Net Income": "1.81",
"Selling, General and Administrative Expense": "-1.40",
"Other Expenses": "0.299",
"Research and Development": "-4.38",
"Other Revenues": "6.89",
"Comprehensive Net Income": "2.32",
"Other Compr. Net Income": "0.508",
"Economic Capital Ratio": "-97.9"
},
"2010": {
"Other Assets": "19.1",
"Assets": "-28.4",
"Liabilities": "-31.4",
"Stockholders Equity": "-66.5",
"ECR before LimitedLiability": "-28.5",
"Assets, Current": "-19.8",
"Property and Equipment": "13.6",
"Intangible Assets": "-33.6",
"Other Liabilities": "35.9",
"Liabilities, Non-Current": "-74.7",
"Selling, General and Administrative Expense": "3.75",
"Expenses": "6.77",
"Revenues": "18.9",
"Net Income": "26.8",
"Research and Development": "1.30",
"Cost of Goods Sold": "5.96",
"Other Expenses": "-4.22",
"Other Revenues": "18.9",
"Comprehensive Net Income": "26.5",
"Other Net Income": "0.704",
"Economic Capital Ratio": "-34.8"
},
"2011": {
"Other Assets": "45.8",
"Assets": "-5.82",
"Liabilities": "-38.2",
"Stockholders Equity": "-35.3",
"ECR before LimitedLiability": "90.0",
"Intangible Assets": "-17.4",
"Property and Equipment": "24.8",
"Assets, Current": "-36.0",
"Other Liabilities": "33.8",
"Liabilities, Non-Current": "-81.0",
"Research and Development": "25.7",
"Expenses": "34.2",
"Revenues": "34.9",
"Net Income": "76.0",
"Other Expenses": "-7.24",
"Cost of Goods Sold": "4.42",
"Selling, General and Administrative Expense": "10.9",
"Other Revenues": "34.9",
"Comprehensive Net Income": "73.5",
"Other Net Income": "2.69",
"Economic Capital Ratio": "14.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000059478_strength_weakness.svg",
"table_records": {
"2009": {
"input_variables": {
"Assets, Current": "12,486,500",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,568,100",
"Liabilities, Non-Current": "11,367,500",
"Other Assets": "6,777,000",
"Other Compr. Net Income": "314,900",
"Other Expenses": "6,288,200",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "21,836,000",
"Property and Equipment": "8,197,400",
"Research and Development": "4,326,500",
"Selling, General and Administrative Expense": "6,892,500"
},
"output_variables": {
"Assets": "27,460,900",
"Liabilities": "17,935,600",
"Expenses": "17,507,200",
"Revenues": "21,836,000",
"Stockholders Equity": "9,525,300",
"Net Income": "4,328,800",
"Comprehensive Net Income": "4,486,250",
"BaseVar": "42,527,300",
"ECR before LimitedLiability": "111%",
"Economic Capital Ratio": "239%"
}
},
"2010": {
"input_variables": {
"Assets, Current": "14,840,000",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,101,400",
"Liabilities, Non-Current": "11,487,200",
"Other Assets": "8,220,700",
"Other Compr. Net Income": "-198,200",
"Other Expenses": "6,068,900",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "23,076,000",
"Property and Equipment": "7,940,700",
"Research and Development": "4,884,200",
"Selling, General and Administrative Expense": "7,053,400"
},
"output_variables": {
"Assets": "31,001,400",
"Liabilities": "18,588,600",
"Expenses": "18,006,500",
"Revenues": "23,076,000",
"Stockholders Equity": "12,412,800",
"Net Income": "5,069,500",
"Comprehensive Net Income": "4,970,400",
"BaseVar": "45,435,350",
"ECR before LimitedLiability": "129%",
"Economic Capital Ratio": "253%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "14,248,200",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,930,900",
"Liabilities, Non-Current": "11,193,300",
"Other Assets": "11,651,300",
"Other Compr. Net Income": "-1,188,500",
"Other Expenses": "7,038,100",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "24,286,500",
"Property and Equipment": "7,760,300",
"Research and Development": "5,020,800",
"Selling, General and Administrative Expense": "7,879,900"
},
"output_variables": {
"Assets": "33,659,800",
"Liabilities": "20,124,200",
"Expenses": "19,938,800",
"Revenues": "24,286,500",
"Stockholders Equity": "13,535,600",
"Net Income": "4,347,700",
"Comprehensive Net Income": "3,753,450",
"BaseVar": "49,598,900",
"ECR before LimitedLiability": "124%",
"Economic Capital Ratio": "248%"
}
}
},
"top_rated": false,
"trend": -80.0,
"value": 2.484840864943311,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000059478.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000059478.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000059478.svg"
},
{
"company_id": "0000748592",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000748592.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000748592.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000748592.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000748592_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000748592_main_keyfigs.svg",
"name": "Ernexa Therapeutics Inc",
"rank": 103,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000748592.svg",
"report_text": "The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 111% points.The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 125% points.
The company's Economic Capital Ratio, given in the ranking table, is 248%, being 14% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000748592_2012_Ernexa_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Assets": "-91.0",
"Liabilities": "108",
"Stockholders Equity": "-125",
"ECR before LimitedLiability": "90.0",
"Intangible Assets": "-12.4",
"Property and Equipment": "39.9",
"Assets, Current": "-97.1",
"Other Liabilities": "46.6",
"Liabilities, Non-Current": "23.6",
"Liabilities, Current": "56.4",
"Research and Development": "96.6",
"Expenses": "-45.6",
"Revenues": "111",
"Net Income": "107",
"Other Expenses": "-31.2",
"Cost of Goods Sold": "9.72",
"Selling, General and Administrative Expense": "-100",
"Other Revenues": "111",
"Comprehensive Net Income": "106",
"Other Net Income": "6.08",
"Economic Capital Ratio": "14.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000748592_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,798",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,081",
"Liabilities, Current": "3,868",
"Liabilities, Non-Current": "323",
"Other Assets": "2,513",
"Other Compr. Net Income": "-223",
"Other Expenses": "6,698",
"Other Liabilities": "1,106",
"Other Net Income": "20",
"Other Revenues": "23,870",
"Property and Equipment": "4,255",
"Research and Development": "0",
"Selling, General and Administrative Expense": "20,448"
},
"output_variables": {
"Assets": "11,647",
"Liabilities": "5,297",
"Expenses": "27,146",
"Revenues": "23,870",
"Stockholders Equity": "6,350",
"Net Income": "-3,256",
"Comprehensive Net Income": "-3,368",
"BaseVar": "34,102",
"ECR before LimitedLiability": "124%",
"Economic Capital Ratio": "248%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.4845746608642836,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000748592.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000748592.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000748592.svg"
},
{
"company_id": "0001069530",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001069530.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001069530.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001069530.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001069530_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001069530_main_keyfigs.svg",
"name": "Filana Therapeutics INC",
"rank": 104,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001069530.svg",
"report_text": "The relative strengths and weaknesses of Filana Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Filana Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 109% points.The greatest weakness of Filana Therapeutics INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 105% points.
The company's Economic Capital Ratio, given in the ranking table, is 248%, being 14% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001069530_2012_Filana_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.41",
"Assets": "77.8",
"Liabilities": "-80.3",
"Stockholders Equity": "19.1",
"ECR before LimitedLiability": "89.2",
"Intangible Assets": "-11.6",
"Property and Equipment": "-7.30",
"Assets, Current": "109",
"Other Liabilities": "-105",
"Liabilities, Non-Current": "9.34",
"Liabilities, Current": "9.09",
"Research and Development": "17.1",
"Expenses": "44.5",
"Revenues": "-9.95",
"Net Income": "35.2",
"Other Expenses": "8.02",
"Cost of Goods Sold": "2.82",
"Selling, General and Administrative Expense": "14.7",
"Other Revenues": "-9.95",
"Comprehensive Net Income": "34.9",
"Economic Capital Ratio": "13.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001069530_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "98,489",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,272",
"Liabilities, Non-Current": "0",
"Other Assets": "352",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "41,298",
"Other Net Income": "0",
"Other Revenues": "12,385",
"Property and Equipment": "122",
"Research and Development": "8,300",
"Selling, General and Administrative Expense": "6,698"
},
"output_variables": {
"Assets": "98,963",
"Liabilities": "54,570",
"Expenses": "14,998",
"Revenues": "12,385",
"Stockholders Equity": "44,393",
"Net Income": "-2,613",
"Comprehensive Net Income": "-2,613",
"BaseVar": "90,458",
"ECR before LimitedLiability": "123%",
"Economic Capital Ratio": "248%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.477142328802321,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001069530.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001069530.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001069530.svg"
},
{
"company_id": "0000912183",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000912183.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000912183.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000912183_main_keyfigs.svg",
"name": "Cubist Pharmaceuticals INC",
"rank": 105,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000912183.svg",
"report_text": "The relative strengths and weaknesses of Cubist Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cubist Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 51% points.The greatest weakness of Cubist Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 98% points.
The company's Economic Capital Ratio, given in the ranking table, is 245%, being 11% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000912183_2012_Cubist_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Liabilities, Current": "21.2",
"Liabilities": "-40.6",
"Stockholders Equity": "-27.6",
"ECR before LimitedLiability": "-18.9",
"Other Liabilities": "-97.6",
"Liabilities, Non-Current": "23.3",
"Selling, General and Administrative Expense": "17.0",
"Expenses": "16.3",
"Net Income": "15.3",
"Research and Development": "2.55",
"Cost of Goods Sold": "-4.56",
"Other Expenses": "1.42",
"Other Revenues": "0.833",
"Revenues": "0.833",
"Other Assets": "7.83",
"Assets, Current": "34.7",
"Property and Equipment": "-10.1",
"Intangible Assets": "-21.9",
"Comprehensive Net Income": "15.3",
"Other Net Income": "-1.79",
"Economic Capital Ratio": "-25.3"
},
"2011": {
"Other Assets": "20.6",
"Assets": "29.7",
"Liabilities": "-60.0",
"Stockholders Equity": "-8.63",
"ECR before LimitedLiability": "86.8",
"Intangible Assets": "8.37",
"Property and Equipment": "3.62",
"Assets, Current": "-4.42",
"Other Liabilities": "-97.6",
"Liabilities, Non-Current": "7.66",
"Liabilities, Current": "21.7",
"Research and Development": "23.1",
"Expenses": "39.0",
"Revenues": "10.2",
"Net Income": "51.3",
"Other Expenses": "1.33",
"Cost of Goods Sold": "-5.20",
"Selling, General and Administrative Expense": "19.0",
"Other Revenues": "10.2",
"Comprehensive Net Income": "51.0",
"Economic Capital Ratio": "11.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000912183_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,016,243",
"Cost of Goods Sold": "140,765",
"Intangible Assets": "75,304",
"Liabilities, Current": "150,644",
"Liabilities, Non-Current": "6,370",
"Other Assets": "241,176",
"Other Compr. Net Income": "0",
"Other Expenses": "150,383",
"Other Liabilities": "594,720",
"Other Net Income": "-35,290",
"Other Revenues": "636,458",
"Property and Equipment": "82,434",
"Research and Development": "157,854",
"Selling, General and Administrative Expense": "57,841"
},
"output_variables": {
"Assets": "1,415,157",
"Liabilities": "751,734",
"Expenses": "506,843",
"Revenues": "636,458",
"Stockholders Equity": "663,423",
"Net Income": "94,325",
"Comprehensive Net Income": "94,325",
"BaseVar": "1,672,741",
"ECR before LimitedLiability": "142%",
"Economic Capital Ratio": "262%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,043,274",
"Cost of Goods Sold": "172,864",
"Intangible Assets": "297,113",
"Liabilities, Current": "252,385",
"Liabilities, Non-Current": "30,039",
"Other Assets": "378,643",
"Other Compr. Net Income": "0",
"Other Expenses": "172,582",
"Other Liabilities": "805,174",
"Other Net Income": "-27,742",
"Other Revenues": "753,972",
"Property and Equipment": "168,425",
"Research and Development": "184,533",
"Selling, General and Administrative Expense": "163,228"
},
"output_variables": {
"Assets": "1,887,455",
"Liabilities": "1,087,598",
"Expenses": "693,207",
"Revenues": "753,972",
"Stockholders Equity": "799,857",
"Net Income": "33,023",
"Comprehensive Net Income": "33,023",
"BaseVar": "2,224,987",
"ECR before LimitedLiability": "119%",
"Economic Capital Ratio": "245%"
}
}
},
"top_rated": false,
"trend": -86.0,
"value": 2.4527513086045385,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000912183.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000912183.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000912183.svg"
},
{
"company_id": "0000896747",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000896747.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000896747.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000896747.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000896747_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000896747_main_keyfigs.svg",
"name": "American BIO Medica CORP",
"rank": 106,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000896747.svg",
"report_text": "The relative strengths and weaknesses of American BIO Medica CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of American BIO Medica CORP compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 96% points.The greatest weakness of American BIO Medica CORP is the variable Stockholders Equity, reducing the Economic Capital Ratio by 106% points.
The company's Economic Capital Ratio, given in the ranking table, is 237%, being 2.7% points above the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000896747_2012_American_BIO_Medica_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-22.2",
"Assets": "-74.5",
"Liabilities": "48.4",
"Stockholders Equity": "-106",
"ECR before LimitedLiability": "78.2",
"Intangible Assets": "-29.9",
"Property and Equipment": "16.3",
"Assets, Current": "-53.7",
"Other Liabilities": "51.0",
"Liabilities, Non-Current": "-10.7",
"Liabilities, Current": "7.68",
"Research and Development": "70.6",
"Expenses": "-13.2",
"Revenues": "96.2",
"Net Income": "95.8",
"Other Expenses": "-96.4",
"Cost of Goods Sold": "7.77",
"Selling, General and Administrative Expense": "22.8",
"Other Revenues": "96.2",
"Comprehensive Net Income": "95.8",
"Other Net Income": "4.88",
"Economic Capital Ratio": "2.66"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000896747_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,276",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,391",
"Liabilities, Non-Current": "751",
"Other Assets": "56",
"Other Compr. Net Income": "0",
"Other Expenses": "7,381",
"Other Liabilities": "124",
"Other Net Income": "9.0",
"Other Revenues": "9,272",
"Property and Equipment": "1,304",
"Research and Development": "223",
"Selling, General and Administrative Expense": "2,022"
},
"output_variables": {
"Assets": "5,636",
"Liabilities": "3,266",
"Expenses": "9,626",
"Revenues": "9,272",
"Stockholders Equity": "2,370",
"Net Income": "-345",
"Comprehensive Net Income": "-345",
"BaseVar": "13,904",
"ECR before LimitedLiability": "108%",
"Economic Capital Ratio": "237%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.3673508209700573,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000896747.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000896747.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000896747.svg"
},
{
"company_id": "0001513856",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001513856.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001513856.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001513856_main_keyfigs.svg",
"name": "Neurotrope Inc",
"rank": 107,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001513856.svg",
"report_text": "The relative strengths and weaknesses of Neurotrope Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Neurotrope Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 100% points.The greatest weakness of Neurotrope Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 125% points.
The company's Economic Capital Ratio, given in the ranking table, is 233%, being 1.3% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001513856_2012_Neurotrope_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.9",
"Assets": "86.1",
"Liabilities": "-47.3",
"Stockholders Equity": "43.9",
"ECR before LimitedLiability": "74.3",
"Intangible Assets": "-14.1",
"Property and Equipment": "-9.14",
"Assets, Current": "100",
"Other Liabilities": "-125",
"Liabilities, Non-Current": "10.4",
"Liabilities, Current": "48.7",
"Research and Development": "30.1",
"Expenses": "17.2",
"Revenues": "-24.9",
"Net Income": "-6.90",
"Other Expenses": "-36.4",
"Cost of Goods Sold": "3.27",
"Selling, General and Administrative Expense": "23.7",
"Other Revenues": "-24.9",
"Comprehensive Net Income": "-7.15",
"Other Net Income": "2.00",
"Economic Capital Ratio": "-1.26"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001513856_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8.0",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "3.5",
"Other Liabilities": "3.6",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0.10"
},
"output_variables": {
"Assets": "8.0",
"Liabilities": "3.6",
"Expenses": "3.6",
"Revenues": "0",
"Stockholders Equity": "4.4",
"Net Income": "-3.6",
"Comprehensive Net Income": "-3.6",
"BaseVar": "7.6",
"ECR before LimitedLiability": "103%",
"Economic Capital Ratio": "233%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.328143432032089,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001513856.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001513856.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001513856.svg"
},
{
"company_id": "0001411906",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001411906.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001411906.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001411906.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001411906_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001411906_main_keyfigs.svg",
"name": "Ampio Pharmaceuticals Inc",
"rank": 108,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001411906.svg",
"report_text": "The relative strengths and weaknesses of Ampio Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ampio Pharmaceuticals Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 95% points.The greatest weakness of Ampio Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 118% points.
The company's Economic Capital Ratio, given in the ranking table, is 232%, being 2.5% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001411906_2012_Ampio_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "91.4",
"Assets": "30.7",
"Liabilities": "90.8",
"Stockholders Equity": "95.1",
"ECR before LimitedLiability": "73.1",
"Intangible Assets": "-19.3",
"Property and Equipment": "-14.9",
"Assets, Current": "-8.70",
"Other Liabilities": "34.4",
"Liabilities, Non-Current": "18.3",
"Liabilities, Current": "60.8",
"Research and Development": "-18.7",
"Expenses": "-27.3",
"Revenues": "-43.2",
"Net Income": "-118",
"Other Expenses": "14.3",
"Cost of Goods Sold": "5.83",
"Selling, General and Administrative Expense": "-27.8",
"Other Revenues": "-43.2",
"Comprehensive Net Income": "-118",
"Other Net Income": "-55.3",
"Economic Capital Ratio": "-2.47"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001411906_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "11,405",
"Cost of Goods Sold": "0",
"Intangible Assets": "466",
"Liabilities, Current": "1,292",
"Liabilities, Non-Current": "0",
"Other Assets": "7,535",
"Other Compr. Net Income": "0",
"Other Expenses": "313",
"Other Liabilities": "431",
"Other Net Income": "-8,473",
"Other Revenues": "0",
"Property and Equipment": "76",
"Research and Development": "9,460",
"Selling, General and Administrative Expense": "9,679"
},
"output_variables": {
"Assets": "19,483",
"Liabilities": "1,723",
"Expenses": "19,452",
"Revenues": "0",
"Stockholders Equity": "17,760",
"Net Income": "-27,926",
"Comprehensive Net Income": "-27,926",
"BaseVar": "24,565",
"ECR before LimitedLiability": "102%",
"Economic Capital Ratio": "232%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.316054319962544,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001411906.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001411906.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001411906.svg"
},
{
"company_id": "0001168220",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001168220.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001168220.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001168220_main_keyfigs.svg",
"name": "Altrazeal Life Sciences Inc",
"rank": 109,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001168220.svg",
"report_text": "The relative strengths and weaknesses of Altrazeal Life Sciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Altrazeal Life Sciences Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 103% points.The greatest weakness of Altrazeal Life Sciences Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 48% points.
The company's Economic Capital Ratio, given in the ranking table, is 228%, being 6.1% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001168220_2012_Altrazeal_Life_Sciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.3",
"Assets": "61.4",
"Liabilities": "-26.6",
"Stockholders Equity": "41.2",
"ECR before LimitedLiability": "69.5",
"Intangible Assets": "103",
"Property and Equipment": "19.2",
"Assets, Current": "-48.5",
"Other Liabilities": "28.0",
"Liabilities, Non-Current": "-27.0",
"Liabilities, Current": "-29.2",
"Research and Development": "19.0",
"Expenses": "3.82",
"Revenues": "-21.6",
"Net Income": "-15.7",
"Other Expenses": "-10.5",
"Cost of Goods Sold": "3.81",
"Selling, General and Administrative Expense": "-7.79",
"Other Revenues": "-21.6",
"Comprehensive Net Income": "-15.9",
"Economic Capital Ratio": "-6.10"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001168220_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,349",
"Cost of Goods Sold": "0",
"Intangible Assets": "4,622",
"Liabilities, Current": "2,054",
"Liabilities, Non-Current": "907",
"Other Assets": "18",
"Other Compr. Net Income": "0",
"Other Expenses": "1,343",
"Other Liabilities": "0",
"Other Net Income": "11",
"Other Revenues": "485",
"Property and Equipment": "1,072",
"Research and Development": "947",
"Selling, General and Administrative Expense": "2,277"
},
"output_variables": {
"Assets": "7,062",
"Liabilities": "2,961",
"Expenses": "4,566",
"Revenues": "485",
"Stockholders Equity": "4,101",
"Net Income": "-4,070",
"Comprehensive Net Income": "-4,070",
"BaseVar": "7,543",
"ECR before LimitedLiability": "97%",
"Economic Capital Ratio": "228%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.279722424279658,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001168220.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001168220.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001168220.svg"
},
{
"company_id": "0001274644",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001274644.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001274644.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001274644_main_keyfigs.svg",
"name": "Ocera Therapeutics Inc",
"rank": 110,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001274644.svg",
"report_text": "The relative strengths and weaknesses of Ocera Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ocera Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points.The greatest weakness of Ocera Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 41% points.
The company's Economic Capital Ratio, given in the ranking table, is 227%, being 7.1% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001274644_2012_Ocera_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-14.1",
"Assets": "32.5",
"Liabilities": "-23.0",
"Stockholders Equity": "17.7",
"ECR before LimitedLiability": "68.5",
"Intangible Assets": "-18.2",
"Property and Equipment": "-7.43",
"Assets, Current": "86.6",
"Other Liabilities": "-41.3",
"Liabilities, Non-Current": "13.2",
"Liabilities, Current": "3.66",
"Research and Development": "-23.4",
"Expenses": "4.49",
"Revenues": "-8.06",
"Comprehensive Net Income": "-1.15",
"Other Expenses": "8.01",
"Cost of Goods Sold": "4.22",
"Selling, General and Administrative Expense": "16.9",
"Other Revenues": "-8.06",
"Other Net Income": "2.88",
"Economic Capital Ratio": "-7.07"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001274644_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "43,540",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,332",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1,589",
"Other Liabilities": "10,897",
"Other Net Income": "126",
"Other Revenues": "10,167",
"Property and Equipment": "1,171",
"Research and Development": "24,884",
"Selling, General and Administrative Expense": "6,028"
},
"output_variables": {
"Assets": "44,711",
"Liabilities": "20,229",
"Expenses": "32,501",
"Revenues": "10,167",
"Stockholders Equity": "24,482",
"Net Income": "-22,208",
"Comprehensive Net Income": "-22,208",
"BaseVar": "53,867",
"ECR before LimitedLiability": "96%",
"Economic Capital Ratio": "227%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.270015946020469,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001274644.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001274644.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001274644.svg"
},
{
"company_id": "0001036968",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001036968.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001036968.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001036968_main_keyfigs.svg",
"name": "Diadexus Inc",
"rank": 111,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001036968.svg",
"report_text": "The relative strengths and weaknesses of Diadexus Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Diadexus Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 38% points.The greatest weakness of Diadexus Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 59% points.
The company's Economic Capital Ratio, given in the ranking table, is 222%, being 12% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001036968_2012_Diadexus_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.78",
"Assets": "-21.3",
"Liabilities": "-12.2",
"Stockholders Equity": "-37.9",
"ECR before LimitedLiability": "63.2",
"Intangible Assets": "-23.0",
"Property and Equipment": "-6.04",
"Assets, Current": "15.4",
"Other Liabilities": "-58.7",
"Liabilities, Non-Current": "13.4",
"Liabilities, Current": "28.8",
"Research and Development": "25.8",
"Expenses": "3.87",
"Revenues": "29.8",
"Net Income": "38.0",
"Other Expenses": "-24.1",
"Cost of Goods Sold": "5.36",
"Other Revenues": "29.8",
"Comprehensive Net Income": "37.5",
"Other Net Income": "3.59",
"Economic Capital Ratio": "-12.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001036968_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "21,180",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,546",
"Liabilities, Non-Current": "284",
"Other Assets": "1,825",
"Other Compr. Net Income": "0",
"Other Expenses": "9,260",
"Other Liabilities": "8,385",
"Other Net Income": "75",
"Other Revenues": "16,384",
"Property and Equipment": "1,350",
"Research and Development": "5,138",
"Selling, General and Administrative Expense": "9,544"
},
"output_variables": {
"Assets": "24,355",
"Liabilities": "13,215",
"Expenses": "23,942",
"Revenues": "16,384",
"Stockholders Equity": "11,140",
"Net Income": "-7,483",
"Comprehensive Net Income": "-7,483",
"BaseVar": "38,986",
"ECR before LimitedLiability": "89%",
"Economic Capital Ratio": "222%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.217475440058231,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001036968.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001036968.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001036968.svg"
},
{
"company_id": "0001178670",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001178670.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001178670.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001178670.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001178670_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001178670_main_keyfigs.svg",
"name": "Alnylam Pharmaceuticals INC",
"rank": 112,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001178670.svg",
"report_text": "The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 81% points.The greatest weakness of Alnylam Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 61% points.
The company's Economic Capital Ratio, given in the ranking table, is 222%, being 12% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001178670_2012_Alnylam_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "40.2",
"Assets": "11.2",
"Liabilities": "-65.6",
"Stockholders Equity": "-34.9",
"ECR before LimitedLiability": "-54.1",
"Assets, Current": "32.7",
"Property and Equipment": "-12.8",
"Intangible Assets": "-31.2",
"Liabilities, Current": "-23.2",
"Other Liabilities": "-65.8",
"Liabilities, Non-Current": "22.3",
"Selling, General and Administrative Expense": "10.9",
"Expenses": "13.0",
"Revenues": "-15.7",
"Net Income": "-2.44",
"Research and Development": "-13.8",
"Cost of Goods Sold": "4.85",
"Other Expenses": "11.4",
"Other Revenues": "-15.7",
"Comprehensive Net Income": "-2.43",
"Economic Capital Ratio": "-60.4"
},
"2011": {
"Other Assets": "80.6",
"Assets": "35.0",
"Liabilities": "-61.5",
"Stockholders Equity": "-10.2",
"ECR before LimitedLiability": "63.2",
"Intangible Assets": "-16.9",
"Property and Equipment": "-2.46",
"Assets, Current": "-7.33",
"Other Liabilities": "-52.7",
"Liabilities, Non-Current": "11.2",
"Liabilities, Current": "-19.5",
"Expenses": "28.0",
"Revenues": "-29.0",
"Net Income": "29.2",
"Other Expenses": "10.9",
"Cost of Goods Sold": "3.84",
"Selling, General and Administrative Expense": "14.9",
"Other Revenues": "-29.0",
"Comprehensive Net Income": "28.8",
"Other Net Income": "32.9",
"Economic Capital Ratio": "-12.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001178670_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "254,139",
"Cost of Goods Sold": "0",
"Intangible Assets": "448",
"Liabilities, Current": "102,046",
"Liabilities, Non-Current": "143",
"Other Assets": "120,389",
"Other Compr. Net Income": "-2.0",
"Other Expenses": "514",
"Other Liabilities": "132,843",
"Other Net Income": "1,069",
"Other Revenues": "100,041",
"Property and Equipment": "18,289",
"Research and Development": "106,384",
"Selling, General and Administrative Expense": "37,727"
},
"output_variables": {
"Assets": "393,265",
"Liabilities": "235,032",
"Expenses": "144,625",
"Revenues": "100,041",
"Stockholders Equity": "158,233",
"Net Income": "-43,515",
"Comprehensive Net Income": "-43,516",
"BaseVar": "437,017",
"ECR before LimitedLiability": "96%",
"Economic Capital Ratio": "227%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "152,028",
"Cost of Goods Sold": "0",
"Intangible Assets": "275",
"Liabilities, Current": "80,990",
"Liabilities, Non-Current": "716",
"Other Assets": "114,971",
"Other Compr. Net Income": "-879",
"Other Expenses": "0",
"Other Liabilities": "82,214",
"Other Net Income": "79,926",
"Other Revenues": "0",
"Property and Equipment": "14,643",
"Research and Development": "99,295",
"Selling, General and Administrative Expense": "38,280"
},
"output_variables": {
"Assets": "281,917",
"Liabilities": "163,920",
"Expenses": "137,575",
"Revenues": "0",
"Stockholders Equity": "117,997",
"Net Income": "-57,649",
"Comprehensive Net Income": "-58,088",
"BaseVar": "332,108",
"ECR before LimitedLiability": "89%",
"Economic Capital Ratio": "222%"
}
}
},
"top_rated": false,
"trend": -85.0,
"value": 2.216588081794219,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001178670.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001178670.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001178670.svg"
},
{
"company_id": "0001124524",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001124524.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001124524.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001124524.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001124524_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001124524_main_keyfigs.svg",
"name": "Cryoport Inc",
"rank": 113,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001124524.svg",
"report_text": "The relative strengths and weaknesses of Cryoport Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cryoport Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 79% points.The greatest weakness of Cryoport Inc is the variable Liabilities, reducing the Economic Capital Ratio by 40% points.
The company's Economic Capital Ratio, given in the ranking table, is 218%, being 16% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001124524_2012_Cryoport_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.9",
"Assets": "67.2",
"Liabilities": "-40.3",
"Stockholders Equity": "31.6",
"ECR before LimitedLiability": "59.3",
"Intangible Assets": "-11.5",
"Assets, Current": "78.7",
"Other Liabilities": "-21.6",
"Liabilities, Non-Current": "11.5",
"Liabilities, Current": "-30.1",
"Research and Development": "29.7",
"Expenses": "13.7",
"Revenues": "-23.9",
"Net Income": "-14.3",
"Other Expenses": "10.7",
"Cost of Goods Sold": "-9.39",
"Selling, General and Administrative Expense": "-15.7",
"Other Revenues": "-23.9",
"Comprehensive Net Income": "-14.6",
"Other Net Income": "-3.33",
"Economic Capital Ratio": "-16.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001124524_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,998",
"Cost of Goods Sold": "1,303",
"Intangible Assets": "355",
"Liabilities, Current": "3,238",
"Liabilities, Non-Current": "0",
"Other Assets": "9.4",
"Other Compr. Net Income": "0",
"Other Expenses": "1.6",
"Other Liabilities": "1,845",
"Other Net Income": "-554",
"Other Revenues": "476",
"Property and Equipment": "670",
"Research and Development": "449",
"Selling, General and Administrative Expense": "4,320"
},
"output_variables": {
"Assets": "11,031",
"Liabilities": "5,083",
"Expenses": "6,074",
"Revenues": "476",
"Stockholders Equity": "5,948",
"Net Income": "-6,152",
"Comprehensive Net Income": "-6,152",
"BaseVar": "11,609",
"ECR before LimitedLiability": "85%",
"Economic Capital Ratio": "218%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1778614873821867,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001124524.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001124524.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001124524.svg"
},
{
"company_id": "0000069499",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000069499.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000069499.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000069499_main_keyfigs.svg",
"name": "Mylan INC",
"rank": 114,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000069499.svg",
"report_text": "The relative strengths and weaknesses of Mylan INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mylan INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 76% points.The greatest weakness of Mylan INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 103% points.
The company's Economic Capital Ratio, given in the ranking table, is 217%, being 18% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000069499_2012_Mylan_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-11.4",
"Assets": "-15.4",
"Liabilities": "-69.6",
"Stockholders Equity": "-68.4",
"ECR before LimitedLiability": "-63.3",
"Assets, Current": "-36.0",
"Property and Equipment": "-7.28",
"Intangible Assets": "60.2",
"Liabilities, Current": "11.8",
"Other Liabilities": "20.8",
"Liabilities, Non-Current": "-111",
"Selling, General and Administrative Expense": "14.2",
"Expenses": "13.9",
"Revenues": "-1.25",
"Net Income": "12.9",
"Research and Development": "12.6",
"Cost of Goods Sold": "-21.1",
"Other Expenses": "9.13",
"Other Revenues": "-1.25",
"Comprehensive Net Income": "13.0",
"Economic Capital Ratio": "-69.7"
},
"2011": {
"Other Assets": "-6.75",
"Assets": "7.71",
"Liabilities": "-74.9",
"Stockholders Equity": "-46.0",
"ECR before LimitedLiability": "58.0",
"Intangible Assets": "76.5",
"Property and Equipment": "6.36",
"Assets, Current": "-47.7",
"Other Liabilities": "15.6",
"Liabilities, Non-Current": "-103",
"Liabilities, Current": "6.93",
"Research and Development": "36.0",
"Expenses": "39.0",
"Revenues": "18.9",
"Net Income": "62.9",
"Other Expenses": "7.61",
"Cost of Goods Sold": "-24.8",
"Selling, General and Administrative Expense": "21.5",
"Other Revenues": "18.9",
"Comprehensive Net Income": "62.5",
"Economic Capital Ratio": "-17.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000069499_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "3,559,443",
"Cost of Goods Sold": "3,233,125",
"Intangible Assets": "6,100,484",
"Liabilities, Current": "1,809,612",
"Liabilities, Non-Current": "5,633,697",
"Other Assets": "667,535",
"Other Compr. Net Income": "0",
"Other Expenses": "468,922",
"Other Liabilities": "478,094",
"Other Net Income": "-34,178",
"Other Revenues": "5,450,522",
"Property and Equipment": "1,209,342",
"Research and Development": "282,146",
"Selling, General and Administrative Expense": "1,086,609"
},
"output_variables": {
"Assets": "11,536,804",
"Liabilities": "7,921,403",
"Expenses": "5,070,802",
"Revenues": "5,450,522",
"Stockholders Equity": "3,615,401",
"Net Income": "345,542",
"Comprehensive Net Income": "345,542",
"BaseVar": "15,006,854",
"ECR before LimitedLiability": "85%",
"Economic Capital Ratio": "218%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "3,568,844",
"Cost of Goods Sold": "3,566,461",
"Intangible Assets": "6,148,682",
"Liabilities, Current": "2,563,156",
"Liabilities, Non-Current": "4,845,180",
"Other Assets": "582,583",
"Other Compr. Net Income": "0",
"Other Expenses": "500,333",
"Other Liabilities": "685,025",
"Other Net Income": "-14,869",
"Other Revenues": "6,129,825",
"Property and Equipment": "1,298,034",
"Research and Development": "294,728",
"Selling, General and Administrative Expense": "1,214,631"
},
"output_variables": {
"Assets": "11,598,143",
"Liabilities": "8,093,361",
"Expenses": "5,576,153",
"Revenues": "6,129,825",
"Stockholders Equity": "3,504,782",
"Net Income": "538,803",
"Comprehensive Net Income": "538,803",
"BaseVar": "15,706,176",
"ECR before LimitedLiability": "83%",
"Economic Capital Ratio": "217%"
}
}
},
"top_rated": false,
"trend": -86.0,
"value": 2.165449218146279,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000069499.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000069499.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000069499.svg"
},
{
"company_id": "0000820081",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000820081.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000820081.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000820081_main_keyfigs.svg",
"name": "Cambrex CORP",
"rank": 115,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000820081.svg",
"report_text": "The relative strengths and weaknesses of Cambrex CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cambrex CORP compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 73% points.The greatest weakness of Cambrex CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 70% points.
The company's Economic Capital Ratio, given in the ranking table, is 214%, being 20% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000820081_2012_Cambrex_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.64",
"Assets": "-19.9",
"Liabilities": "-54.0",
"Stockholders Equity": "-64.3",
"ECR before LimitedLiability": "55.9",
"Intangible Assets": "-3.40",
"Property and Equipment": "73.3",
"Assets, Current": "-50.3",
"Other Liabilities": "-15.3",
"Liabilities, Non-Current": "-70.3",
"Liabilities, Current": "28.6",
"Research and Development": "42.7",
"Expenses": "30.5",
"Revenues": "37.1",
"Net Income": "72.9",
"Other Expenses": "-39.0",
"Cost of Goods Sold": "4.95",
"Selling, General and Administrative Expense": "26.2",
"Other Revenues": "37.1",
"Comprehensive Net Income": "72.4",
"Economic Capital Ratio": "-19.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000820081_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "136,609",
"Cost of Goods Sold": "0",
"Intangible Assets": "40,992",
"Liabilities, Current": "59,133",
"Liabilities, Non-Current": "107,938",
"Other Assets": "18,515",
"Other Compr. Net Income": "0",
"Other Expenses": "190,144",
"Other Liabilities": "68,332",
"Other Net Income": "-4,277",
"Other Revenues": "255,653",
"Property and Equipment": "139,628",
"Research and Development": "11,037",
"Selling, General and Administrative Expense": "39,227"
},
"output_variables": {
"Assets": "335,744",
"Liabilities": "235,403",
"Expenses": "240,408",
"Revenues": "255,653",
"Stockholders Equity": "100,341",
"Net Income": "10,968",
"Comprehensive Net Income": "10,968",
"BaseVar": "535,742",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "214%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1437072559165418,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000820081.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000820081.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000820081.svg"
},
{
"company_id": "0001041024",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001041024.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001041024.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001041024.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001041024_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001041024_main_keyfigs.svg",
"name": "Rockwell Medical INC",
"rank": 116,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001041024.svg",
"report_text": "The relative strengths and weaknesses of Rockwell Medical INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Rockwell Medical INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 75% points.The greatest weakness of Rockwell Medical INC is the variable Other Expenses, reducing the Economic Capital Ratio by 113% points.
The company's Economic Capital Ratio, given in the ranking table, is 214%, being 20% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001041024_2012_Rockwell_Medical_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-20.7",
"Assets": "-95.5",
"Liabilities": "74.1",
"Stockholders Equity": "-100",
"ECR before LimitedLiability": "55.8",
"Intangible Assets": "-30.9",
"Property and Equipment": "-14.1",
"Assets, Current": "-66.4",
"Other Liabilities": "65.4",
"Liabilities, Non-Current": "28.6",
"Liabilities, Current": "13.9",
"Research and Development": "20.0",
"Expenses": "-59.9",
"Revenues": "75.4",
"Net Income": "47.0",
"Other Expenses": "-113",
"Cost of Goods Sold": "9.63",
"Selling, General and Administrative Expense": "38.3",
"Other Revenues": "75.4",
"Comprehensive Net Income": "46.2",
"Economic Capital Ratio": "-19.8"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001041024_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,897",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,755",
"Liabilities, Current": "13,692",
"Liabilities, Non-Current": "0",
"Other Assets": "1,998",
"Other Compr. Net Income": "0",
"Other Expenses": "43,325",
"Other Liabilities": "0",
"Other Net Income": "242",
"Other Revenues": "48,966",
"Property and Equipment": "2,290",
"Research and Development": "17,805",
"Selling, General and Administrative Expense": "9,522"
},
"output_variables": {
"Assets": "31,940",
"Liabilities": "13,692",
"Expenses": "70,653",
"Revenues": "48,966",
"Stockholders Equity": "18,247",
"Net Income": "-21,445",
"Comprehensive Net Income": "-21,445",
"BaseVar": "82,747",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "214%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.143039331065918,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001041024.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001041024.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001041024.svg"
},
{
"company_id": "0000885590",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000885590.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000885590.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000885590.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000885590_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000885590_main_keyfigs.svg",
"name": "Bausch Health Companies Inc",
"rank": 117,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000885590.svg",
"report_text": "The relative strengths and weaknesses of Bausch Health Companies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Bausch Health Companies Inc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 116% points.The greatest weakness of Bausch Health Companies Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 138% points.
The company's Economic Capital Ratio, given in the ranking table, is 214%, being 20% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000885590_2012_Bausch_Health_Companies_Inc.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-10.9",
"Assets": "47.4",
"Liabilities": "-75.2",
"Stockholders Equity": "-0.525",
"ECR before LimitedLiability": "-31.0",
"Assets, Current": "-35.4",
"Property and Equipment": "-10.8",
"Intangible Assets": "126",
"Liabilities, Current": "20.2",
"Other Liabilities": "-16.8",
"Liabilities, Non-Current": "-80.4",
"Selling, General and Administrative Expense": "13.6",
"Expenses": "27.4",
"Revenues": "-21.1",
"Net Income": "4.87",
"Research and Development": "8.81",
"Cost of Goods Sold": "3.77",
"Other Expenses": "0.605",
"Other Revenues": "-21.1",
"Comprehensive Net Income": "4.88",
"Economic Capital Ratio": "-37.3"
},
"2011": {
"Other Assets": "-10.0",
"Assets": "61.3",
"Liabilities": "-106",
"Stockholders Equity": "-21.1",
"ECR before LimitedLiability": "55.4",
"Intangible Assets": "116",
"Property and Equipment": "-4.46",
"Assets, Current": "-52.9",
"Other Liabilities": "-7.26",
"Liabilities, Non-Current": "-138",
"Liabilities, Current": "29.2",
"Research and Development": "28.8",
"Expenses": "50.2",
"Revenues": "-6.82",
"Net Income": "44.7",
"Other Expenses": "-3.51",
"Cost of Goods Sold": "3.20",
"Selling, General and Administrative Expense": "20.1",
"Other Revenues": "-6.82",
"Comprehensive Net Income": "44.4",
"Economic Capital Ratio": "-20.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000885590_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,020,166",
"Cost of Goods Sold": "0",
"Intangible Assets": "9,374,156",
"Liabilities, Current": "692,456",
"Liabilities, Non-Current": "3,608,699",
"Other Assets": "119,043",
"Other Compr. Net Income": "0",
"Other Expenses": "919,231",
"Other Liabilities": "1,582,866",
"Other Net Income": "-36,097",
"Other Revenues": "1,181,237",
"Property and Equipment": "281,752",
"Research and Development": "157,556",
"Selling, General and Administrative Expense": "276,546"
},
"output_variables": {
"Assets": "10,795,117",
"Liabilities": "5,884,021",
"Expenses": "1,353,333",
"Revenues": "1,181,237",
"Stockholders Equity": "4,911,096",
"Net Income": "-208,193",
"Comprehensive Net Income": "-208,193",
"BaseVar": "9,624,902",
"ECR before LimitedLiability": "126%",
"Economic Capital Ratio": "250%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,357,506",
"Cost of Goods Sold": "0",
"Intangible Assets": "11,256,584",
"Liabilities, Current": "924,272",
"Liabilities, Non-Current": "6,616,439",
"Other Assets": "113,381",
"Other Compr. Net Income": "0",
"Other Expenses": "1,682,299",
"Other Liabilities": "1,593,986",
"Other Net Income": "16,567",
"Other Revenues": "2,463,450",
"Property and Equipment": "414,242",
"Research and Development": "65,687",
"Selling, General and Administrative Expense": "572,472"
},
"output_variables": {
"Assets": "13,141,713",
"Liabilities": "9,134,697",
"Expenses": "2,320,458",
"Revenues": "2,463,450",
"Stockholders Equity": "4,007,016",
"Net Income": "159,559",
"Comprehensive Net Income": "159,559",
"BaseVar": "13,538,442",
"ECR before LimitedLiability": "80%",
"Economic Capital Ratio": "214%"
}
}
},
"top_rated": false,
"trend": -93.0,
"value": 2.1389065513353622,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000885590.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000885590.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000885590.svg"
},
{
"company_id": "0000070793",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000070793.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000070793.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000070793_main_keyfigs.svg",
"name": "NBTY INC",
"rank": 118,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000070793.svg",
"report_text": "The relative strengths and weaknesses of NBTY INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of NBTY INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 77% points.The greatest weakness of NBTY INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 212%, being 22% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000070793_2012_NBTY_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.4",
"Assets": "-1.37",
"Liabilities": "-68.4",
"Stockholders Equity": "-52.0",
"ECR before LimitedLiability": "53.9",
"Intangible Assets": "77.3",
"Property and Equipment": "2.51",
"Assets, Current": "-57.7",
"Other Liabilities": "-4.69",
"Liabilities, Non-Current": "-121",
"Liabilities, Current": "44.6",
"Research and Development": "41.4",
"Expenses": "38.4",
"Revenues": "22.6",
"Net Income": "62.3",
"Other Expenses": "-23.1",
"Cost of Goods Sold": "4.45",
"Selling, General and Administrative Expense": "17.2",
"Other Revenues": "22.6",
"Comprehensive Net Income": "61.9",
"Economic Capital Ratio": "-21.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000070793_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,292,251",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,217,352",
"Liabilities, Current": "392,553",
"Liabilities, Non-Current": "2,417,230",
"Other Assets": "106,680",
"Other Compr. Net Income": "0",
"Other Expenses": "1,890,870",
"Other Liabilities": "748,878",
"Other Net Income": "-194,057",
"Other Revenues": "2,958,491",
"Property and Equipment": "479,273",
"Research and Development": "0",
"Selling, General and Administrative Expense": "843,645"
},
"output_variables": {
"Assets": "5,095,556",
"Liabilities": "3,558,661",
"Expenses": "2,734,515",
"Revenues": "2,958,491",
"Stockholders Equity": "1,536,895",
"Net Income": "29,919",
"Comprehensive Net Income": "29,919",
"BaseVar": "7,270,640",
"ECR before LimitedLiability": "78%",
"Economic Capital Ratio": "212%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.1244684235553315,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000070793.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000070793.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000070793.svg"
},
{
"company_id": "0000872589",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000872589.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000872589.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000872589.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000872589_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000872589_main_keyfigs.svg",
"name": "Regeneron Pharmaceuticals INC",
"rank": 119,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000872589.svg",
"report_text": "The relative strengths and weaknesses of Regeneron Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Regeneron Pharmaceuticals INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 47% points.The greatest weakness of Regeneron Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 212%, being 22% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000872589_2012_Regeneron_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "44.3",
"Assets": "-5.23",
"Liabilities": "-31.6",
"Stockholders Equity": "-30.1",
"ECR before LimitedLiability": "-30.3",
"Assets, Current": "-26.5",
"Property and Equipment": "32.3",
"Intangible Assets": "-30.7",
"Liabilities, Current": "25.0",
"Other Liabilities": "-91.4",
"Liabilities, Non-Current": "23.9",
"Selling, General and Administrative Expense": "16.6",
"Expenses": "3.55",
"Revenues": "-3.58",
"Net Income": "-0.0762",
"Research and Development": "-29.1",
"Cost of Goods Sold": "5.29",
"Other Expenses": "12.4",
"Other Revenues": "-3.58",
"Comprehensive Net Income": "-0.0618",
"Economic Capital Ratio": "-36.7"
},
"2011": {
"Other Assets": "30.5",
"Assets": "25.9",
"Liabilities": "-69.5",
"Stockholders Equity": "-26.0",
"ECR before LimitedLiability": "53.4",
"Intangible Assets": "-18.4",
"Property and Equipment": "46.6",
"Assets, Current": "-19.6",
"Other Liabilities": "-121",
"Liabilities, Non-Current": "10.9",
"Liabilities, Current": "29.4",
"Research and Development": "-5.45",
"Expenses": "31.7",
"Revenues": "2.79",
"Net Income": "35.9",
"Other Expenses": "11.2",
"Cost of Goods Sold": "4.02",
"Selling, General and Administrative Expense": "21.4",
"Other Revenues": "2.79",
"Comprehensive Net Income": "35.5",
"Economic Capital Ratio": "-22.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000872589_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "357,622",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "109,056",
"Liabilities, Non-Current": "7,350",
"Other Assets": "384,360",
"Other Compr. Net Income": "0",
"Other Expenses": "2,093",
"Other Liabilities": "445,211",
"Other Net Income": "-6,996",
"Other Revenues": "459,074",
"Property and Equipment": "347,450",
"Research and Development": "489,252",
"Selling, General and Administrative Expense": "65,201"
},
"output_variables": {
"Assets": "1,089,432",
"Liabilities": "561,617",
"Expenses": "556,546",
"Revenues": "459,074",
"Stockholders Equity": "527,815",
"Net Income": "-104,468",
"Comprehensive Net Income": "-104,468",
"BaseVar": "1,336,832",
"ECR before LimitedLiability": "127%",
"Economic Capital Ratio": "251%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "652,875",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "148,271",
"Liabilities, Non-Current": "6,443",
"Other Assets": "302,753",
"Other Compr. Net Income": "0",
"Other Expenses": "3,084",
"Other Liabilities": "683,137",
"Other Net Income": "-17,733",
"Other Revenues": "445,824",
"Property and Equipment": "367,955",
"Research and Development": "529,506",
"Selling, General and Administrative Expense": "117,261"
},
"output_variables": {
"Assets": "1,323,583",
"Liabilities": "837,851",
"Expenses": "649,851",
"Revenues": "445,824",
"Stockholders Equity": "485,732",
"Net Income": "-221,760",
"Comprehensive Net Income": "-221,760",
"BaseVar": "1,637,421",
"ECR before LimitedLiability": "77%",
"Economic Capital Ratio": "212%"
}
}
},
"top_rated": false,
"trend": -96.0,
"value": 2.118979371413351,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000872589.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000872589.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000872589.svg"
},
{
"company_id": "0001411158",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001411158.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001411158.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001411158_main_keyfigs.svg",
"name": "Anacor Pharmaceuticals Inc",
"rank": 120,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001411158.svg",
"report_text": "The relative strengths and weaknesses of Anacor Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Anacor Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points.The greatest weakness of Anacor Pharmaceuticals Inc is the variable Research and Development, reducing the Economic Capital Ratio by 66% points.
The company's Economic Capital Ratio, given in the ranking table, is 208%, being 26% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001411158_2012_Anacor_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-16.7",
"Assets": "-9.43",
"Liabilities": "25.5",
"Stockholders Equity": "10.7",
"ECR before LimitedLiability": "49.2",
"Intangible Assets": "-25.8",
"Property and Equipment": "-10.9",
"Assets, Current": "63.4",
"Other Liabilities": "39.9",
"Liabilities, Non-Current": "17.2",
"Liabilities, Current": "-33.9",
"Research and Development": "-66.1",
"Expenses": "-32.5",
"Revenues": "-42.7",
"Net Income": "-30.4",
"Other Expenses": "13.3",
"Selling, General and Administrative Expense": "20.2",
"Other Revenues": "-42.7",
"Comprehensive Net Income": "-30.8",
"Other Net Income": "51.0",
"Economic Capital Ratio": "-26.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001411158_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "53,045",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "21,025",
"Liabilities, Non-Current": "0",
"Other Assets": "1,001",
"Other Compr. Net Income": "0",
"Other Expenses": "1,396",
"Other Liabilities": "0",
"Other Net Income": "20,101",
"Other Revenues": "0",
"Property and Equipment": "1,743",
"Research and Development": "56,097",
"Selling, General and Administrative Expense": "10,552"
},
"output_variables": {
"Assets": "55,789",
"Liabilities": "21,025",
"Expenses": "68,045",
"Revenues": "0",
"Stockholders Equity": "34,764",
"Net Income": "-47,944",
"Comprehensive Net Income": "-47,944",
"BaseVar": "82,480",
"ECR before LimitedLiability": "72%",
"Economic Capital Ratio": "208%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.0773151927796696,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001411158.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001411158.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001411158.svg"
},
{
"company_id": "0000874015",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000874015.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000874015.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000874015.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000874015_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000874015_main_keyfigs.svg",
"name": "Ionis Pharmaceuticals INC",
"rank": 121,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000874015.svg",
"report_text": "The relative strengths and weaknesses of Ionis Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ionis Pharmaceuticals INC compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 47% points.The greatest weakness of Ionis Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 114% points.
The company's Economic Capital Ratio, given in the ranking table, is 208%, being 26% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000874015_2012_Ionis_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-6.94",
"Assets": "23.7",
"Liabilities": "-62.7",
"Stockholders Equity": "-18.0",
"ECR before LimitedLiability": "-42.9",
"Assets, Current": "97.4",
"Property and Equipment": "-8.26",
"Intangible Assets": "-28.1",
"Liabilities, Current": "-8.38",
"Other Liabilities": "-78.8",
"Liabilities, Non-Current": "21.3",
"Selling, General and Administrative Expense": "17.0",
"Expenses": "15.3",
"Revenues": "-18.2",
"Net Income": "-3.10",
"Research and Development": "-14.0",
"Cost of Goods Sold": "4.48",
"Other Expenses": "8.21",
"Other Revenues": "-18.2",
"Comprehensive Net Income": "-3.09",
"Economic Capital Ratio": "-49.2"
},
"2011": {
"Other Assets": "-3.18",
"Assets": "47.2",
"Liabilities": "-84.1",
"Stockholders Equity": "-19.4",
"ECR before LimitedLiability": "49.1",
"Intangible Assets": "-17.1",
"Property and Equipment": "28.8",
"Assets, Current": "42.0",
"Other Liabilities": "-114",
"Liabilities, Non-Current": "11.0",
"Liabilities, Current": "12.6",
"Expenses": "35.3",
"Revenues": "-7.73",
"Net Income": "29.9",
"Other Expenses": "6.78",
"Cost of Goods Sold": "3.65",
"Selling, General and Administrative Expense": "25.3",
"Other Revenues": "-7.73",
"Comprehensive Net Income": "29.6",
"Other Net Income": "2.87",
"Economic Capital Ratio": "-26.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000874015_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "483,137",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "105,890",
"Liabilities, Non-Current": "0",
"Other Assets": "31,637",
"Other Compr. Net Income": "0",
"Other Expenses": "13,324",
"Other Liabilities": "200,045",
"Other Net Income": "429",
"Other Revenues": "108,473",
"Property and Equipment": "35,703",
"Research and Development": "145,160",
"Selling, General and Administrative Expense": "11,669"
},
"output_variables": {
"Assets": "550,477",
"Liabilities": "305,935",
"Expenses": "170,153",
"Revenues": "108,473",
"Stockholders Equity": "244,542",
"Net Income": "-61,251",
"Comprehensive Net Income": "-61,251",
"BaseVar": "567,734",
"ECR before LimitedLiability": "110%",
"Economic Capital Ratio": "238%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "360,139",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "76,112",
"Liabilities, Non-Current": "0",
"Other Assets": "28,140",
"Other Compr. Net Income": "0",
"Other Expenses": "16,743",
"Other Liabilities": "237,348",
"Other Net Income": "3,042",
"Other Revenues": "99,086",
"Property and Equipment": "96,615",
"Research and Development": "157,397",
"Selling, General and Administrative Expense": "12,789"
},
"output_variables": {
"Assets": "484,894",
"Liabilities": "313,460",
"Expenses": "186,929",
"Revenues": "99,086",
"Stockholders Equity": "171,434",
"Net Income": "-84,801",
"Comprehensive Net Income": "-84,801",
"BaseVar": "543,706",
"ECR before LimitedLiability": "72%",
"Economic Capital Ratio": "208%"
}
}
},
"top_rated": false,
"trend": -96.0,
"value": 2.076383050347933,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000874015.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000874015.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000874015.svg"
},
{
"company_id": "0001023024",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001023024.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001023024.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001023024.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001023024_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001023024_main_keyfigs.svg",
"name": "ANI Pharmaceuticals INC",
"rank": 122,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001023024.svg",
"report_text": "The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points.The greatest weakness of ANI Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 58% points.
The company's Economic Capital Ratio, given in the ranking table, is 206%, being 28% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001023024_2012_ANI_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.16",
"Assets": "59.4",
"Liabilities": "-14.2",
"Stockholders Equity": "46.5",
"ECR before LimitedLiability": "47.9",
"Intangible Assets": "-20.0",
"Property and Equipment": "-10.3",
"Assets, Current": "70.0",
"Other Liabilities": "-57.7",
"Liabilities, Non-Current": "12.9",
"Liabilities, Current": "26.8",
"Research and Development": "-45.1",
"Expenses": "-14.5",
"Revenues": "-31.7",
"Net Income": "-42.7",
"Other Expenses": "10.6",
"Cost of Goods Sold": "4.32",
"Selling, General and Administrative Expense": "19.0",
"Other Revenues": "-31.7",
"Comprehensive Net Income": "-43.0",
"Economic Capital Ratio": "-27.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001023024_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "58,026",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,228",
"Liabilities, Non-Current": "0",
"Other Assets": "3,492",
"Other Compr. Net Income": "0",
"Other Expenses": "880",
"Other Liabilities": "17,337",
"Other Net Income": "-15",
"Other Revenues": "450",
"Property and Equipment": "861",
"Research and Development": "44,182",
"Selling, General and Administrative Expense": "6,981"
},
"output_variables": {
"Assets": "62,380",
"Liabilities": "24,564",
"Expenses": "52,044",
"Revenues": "450",
"Stockholders Equity": "37,815",
"Net Income": "-51,609",
"Comprehensive Net Income": "-51,609",
"BaseVar": "69,727",
"ECR before LimitedLiability": "71%",
"Economic Capital Ratio": "206%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.064016218334781,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001023024.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001023024.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001023024.svg"
},
{
"company_id": "0000906709",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000906709.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000906709.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000906709.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000906709_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000906709_main_keyfigs.svg",
"name": "Nektar Therapeutics",
"rank": 123,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000906709.svg",
"report_text": "The relative strengths and weaknesses of Nektar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nektar Therapeutics compared to the market average is the variable Assets, increasing the Economic Capital Ratio by 55% points.The greatest weakness of Nektar Therapeutics is the variable Liabilities, reducing the Economic Capital Ratio by 97% points.
The company's Economic Capital Ratio, given in the ranking table, is 196%, being 38% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000906709_2012_Nektar_Therapeutics.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "52.3",
"Assets": "54.8",
"Liabilities": "-96.8",
"Stockholders Equity": "-20.8",
"ECR before LimitedLiability": "37.3",
"Intangible Assets": "6.32",
"Property and Equipment": "14.6",
"Assets, Current": "-13.0",
"Other Liabilities": "-29.6",
"Liabilities, Non-Current": "7.32",
"Liabilities, Current": "-71.3",
"Research and Development": "9.41",
"Expenses": "38.9",
"Revenues": "-15.2",
"Net Income": "22.7",
"Other Expenses": "6.02",
"Cost of Goods Sold": "3.53",
"Selling, General and Administrative Expense": "18.6",
"Other Revenues": "-15.2",
"Comprehensive Net Income": "22.4",
"Economic Capital Ratio": "-38.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000906709_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "276,706",
"Cost of Goods Sold": "0",
"Intangible Assets": "76,501",
"Liabilities, Current": "275,532",
"Liabilities, Non-Current": "7,159",
"Other Assets": "174,767",
"Other Compr. Net Income": "0",
"Other Expenses": "22,909",
"Other Liabilities": "126,048",
"Other Net Income": "-9,023",
"Other Revenues": "71,480",
"Property and Equipment": "78,576",
"Research and Development": "126,766",
"Selling, General and Administrative Expense": "46,760"
},
"output_variables": {
"Assets": "606,550",
"Liabilities": "408,739",
"Expenses": "196,435",
"Revenues": "71,480",
"Stockholders Equity": "197,811",
"Net Income": "-133,978",
"Comprehensive Net Income": "-133,978",
"BaseVar": "646,114",
"ECR before LimitedLiability": "59%",
"Economic Capital Ratio": "196%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.9578589860023876,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000906709.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000906709.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000906709.svg"
},
{
"company_id": "0001019695",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001019695.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001019695.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001019695_main_keyfigs.svg",
"name": "Arqule INC",
"rank": 124,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001019695.svg",
"report_text": "The relative strengths and weaknesses of Arqule INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arqule INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 50% points.The greatest weakness of Arqule INC is the variable Liabilities, reducing the Economic Capital Ratio by 90% points.
The company's Economic Capital Ratio, given in the ranking table, is 191%, being 43% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001019695_2012_Arqule_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "50.1",
"Assets": "13.0",
"Liabilities": "-89.7",
"Stockholders Equity": "-55.0",
"ECR before LimitedLiability": "32.3",
"Intangible Assets": "-20.8",
"Property and Equipment": "-9.15",
"Assets, Current": "-7.23",
"Other Liabilities": "-54.4",
"Liabilities, Non-Current": "12.3",
"Liabilities, Current": "-44.9",
"Expenses": "36.7",
"Revenues": "-32.1",
"Net Income": "48.0",
"Other Expenses": "12.1",
"Cost of Goods Sold": "4.27",
"Selling, General and Administrative Expense": "20.7",
"Other Revenues": "-32.1",
"Comprehensive Net Income": "47.7",
"Other Net Income": "46.5",
"Economic Capital Ratio": "-43.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001019695_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "72,188",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "48,889",
"Liabilities, Non-Current": "0",
"Other Assets": "41,924",
"Other Compr. Net Income": "0",
"Other Expenses": "25",
"Other Liabilities": "38,433",
"Other Net Income": "47,647",
"Other Revenues": "0",
"Property and Equipment": "2,939",
"Research and Development": "45,011",
"Selling, General and Administrative Expense": "13,373"
},
"output_variables": {
"Assets": "117,051",
"Liabilities": "87,322",
"Expenses": "58,409",
"Revenues": "0",
"Stockholders Equity": "29,729",
"Net Income": "-10,762",
"Comprehensive Net Income": "-10,762",
"BaseVar": "155,214",
"ECR before LimitedLiability": "53%",
"Economic Capital Ratio": "191%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.908166534770167,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001019695.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001019695.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001019695.svg"
},
{
"company_id": "0001365216",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001365216.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001365216.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001365216_main_keyfigs.svg",
"name": "Sucampo Pharmaceuticals Inc",
"rank": 125,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001365216.svg",
"report_text": "The relative strengths and weaknesses of Sucampo Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sucampo Pharmaceuticals Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 44% points.The greatest weakness of Sucampo Pharmaceuticals Inc is the variable Liabilities, reducing the Economic Capital Ratio by 96% points.
The company's Economic Capital Ratio, given in the ranking table, is 187%, being 47% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001365216_2012_Sucampo_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "26.4",
"Assets": "19.8",
"Liabilities": "-95.9",
"Stockholders Equity": "-53.8",
"ECR before LimitedLiability": "28.7",
"Intangible Assets": "-11.5",
"Property and Equipment": "-11.5",
"Assets, Current": "20.3",
"Other Liabilities": "-86.8",
"Liabilities, Non-Current": "7.88",
"Liabilities, Current": "-15.7",
"Research and Development": "15.2",
"Expenses": "41.5",
"Revenues": "2.67",
"Net Income": "44.2",
"Other Expenses": "16.5",
"Cost of Goods Sold": "4.15",
"Selling, General and Administrative Expense": "4.23",
"Other Revenues": "2.67",
"Comprehensive Net Income": "44.3",
"Economic Capital Ratio": "-46.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001365216_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "114,916",
"Cost of Goods Sold": "0",
"Intangible Assets": "8,364",
"Liabilities, Current": "47,081",
"Liabilities, Non-Current": "2,603",
"Other Assets": "32,620",
"Other Compr. Net Income": "1,280",
"Other Expenses": "-6,925",
"Other Liabilities": "69,291",
"Other Net Income": "-4,225",
"Other Revenues": "54,761",
"Property and Equipment": "1,669",
"Research and Development": "33,497",
"Selling, General and Administrative Expense": "41,270"
},
"output_variables": {
"Assets": "157,569",
"Liabilities": "118,975",
"Expenses": "67,842",
"Revenues": "54,761",
"Stockholders Equity": "38,594",
"Net Income": "-17,306",
"Comprehensive Net Income": "-16,666",
"BaseVar": "202,326",
"ECR before LimitedLiability": "49%",
"Economic Capital Ratio": "187%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.8718062224348895,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001365216.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001365216.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001365216.svg"
},
{
"company_id": "0000886163",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000886163.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000886163.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000886163.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000886163_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000886163_main_keyfigs.svg",
"name": "Ligand Pharmaceuticals INC",
"rank": 126,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000886163.svg",
"report_text": "The relative strengths and weaknesses of Ligand Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ligand Pharmaceuticals INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 50% points.The greatest weakness of Ligand Pharmaceuticals INC is the variable Liabilities, reducing the Economic Capital Ratio by 136% points.
The company's Economic Capital Ratio, given in the ranking table, is 181%, being 53% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000886163_2012_Ligand_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "13.3",
"Assets": "39.6",
"Liabilities": "-136",
"Stockholders Equity": "-60.4",
"ECR before LimitedLiability": "22.1",
"Intangible Assets": "50.3",
"Property and Equipment": "-11.0",
"Assets, Current": "-46.3",
"Other Liabilities": "-103",
"Liabilities, Non-Current": "9.20",
"Liabilities, Current": "-35.7",
"Research and Development": "23.5",
"Expenses": "40.0",
"Revenues": "-3.73",
"Net Income": "39.9",
"Other Expenses": "14.9",
"Cost of Goods Sold": "3.52",
"Selling, General and Administrative Expense": "14.5",
"Other Revenues": "-3.73",
"Comprehensive Net Income": "39.9",
"Economic Capital Ratio": "-53.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000886163_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "32,230",
"Cost of Goods Sold": "0",
"Intangible Assets": "72,331",
"Liabilities, Current": "43,643",
"Liabilities, Non-Current": "388",
"Other Assets": "17,334",
"Other Compr. Net Income": "0",
"Other Expenses": "-5,956",
"Other Liabilities": "61,329",
"Other Net Income": "-549",
"Other Revenues": "30,037",
"Property and Equipment": "455",
"Research and Development": "10,291",
"Selling, General and Administrative Expense": "14,977"
},
"output_variables": {
"Assets": "122,350",
"Liabilities": "105,360",
"Expenses": "19,312",
"Revenues": "30,037",
"Stockholders Equity": "16,990",
"Net Income": "10,176",
"Comprehensive Net Income": "10,176",
"BaseVar": "138,804",
"ECR before LimitedLiability": "41%",
"Economic Capital Ratio": "181%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.8058897084108607,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000886163.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000886163.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000886163.svg"
},
{
"company_id": "0001390478",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001390478.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001390478.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001390478.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001390478_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001390478_main_keyfigs.svg",
"name": "Sellas Life Sciences Group Inc",
"rank": 127,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001390478.svg",
"report_text": "The relative strengths and weaknesses of Sellas Life Sciences Group Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sellas Life Sciences Group Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 42% points.The greatest weakness of Sellas Life Sciences Group Inc is the variable Liabilities, reducing the Economic Capital Ratio by 73% points.
The company's Economic Capital Ratio, given in the ranking table, is 180%, being 54% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001390478_2012_Sellas_Life_Sciences_Group_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "42.3",
"Assets": "15.0",
"Liabilities": "-72.5",
"Stockholders Equity": "-43.6",
"ECR before LimitedLiability": "21.4",
"Intangible Assets": "16.7",
"Property and Equipment": "-12.5",
"Assets, Current": "-47.1",
"Other Liabilities": "-52.5",
"Liabilities, Non-Current": "12.8",
"Liabilities, Current": "-31.7",
"Expenses": "19.1",
"Revenues": "-34.3",
"Net Income": "18.5",
"Other Expenses": "13.0",
"Cost of Goods Sold": "4.58",
"Selling, General and Administrative Expense": "1.49",
"Other Revenues": "-34.3",
"Comprehensive Net Income": "18.1",
"Other Net Income": "37.1",
"Economic Capital Ratio": "-54.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001390478_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "11,810",
"Cost of Goods Sold": "0",
"Intangible Assets": "5,898",
"Liabilities, Current": "11,202",
"Liabilities, Non-Current": "0",
"Other Assets": "12,867",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "9,654",
"Other Net Income": "9,302",
"Other Revenues": "0",
"Property and Equipment": "393",
"Research and Development": "11,538",
"Selling, General and Administrative Expense": "9,249"
},
"output_variables": {
"Assets": "30,968",
"Liabilities": "20,856",
"Expenses": "20,787",
"Revenues": "0",
"Stockholders Equity": "10,112",
"Net Income": "-11,485",
"Comprehensive Net Income": "-11,485",
"BaseVar": "40,956",
"ECR before LimitedLiability": "41%",
"Economic Capital Ratio": "180%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.7993611288325044,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001390478.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001390478.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001390478.svg"
},
{
"company_id": "0001347178",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001347178.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001347178.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001347178.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001347178_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001347178_main_keyfigs.svg",
"name": "Vanda Pharmaceuticals Inc",
"rank": 128,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001347178.svg",
"report_text": "The relative strengths and weaknesses of Vanda Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Vanda Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 38% points.The greatest weakness of Vanda Pharmaceuticals Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 152% points.
The company's Economic Capital Ratio, given in the ranking table, is 178%, being 57% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001347178_2012_Vanda_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "7.36",
"Assets": "36.7",
"Liabilities": "-128",
"Stockholders Equity": "-52.0",
"ECR before LimitedLiability": "19.0",
"Intangible Assets": "-10.5",
"Property and Equipment": "-10.9",
"Assets, Current": "38.1",
"Other Liabilities": "-152",
"Liabilities, Non-Current": "9.95",
"Liabilities, Current": "7.24",
"Research and Development": "15.6",
"Expenses": "36.7",
"Revenues": "-10.6",
"Net Income": "36.5",
"Other Expenses": "9.51",
"Cost of Goods Sold": "3.55",
"Selling, General and Administrative Expense": "20.6",
"Other Revenues": "-10.6",
"Comprehensive Net Income": "36.5",
"Economic Capital Ratio": "-56.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001347178_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "153,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "8,027",
"Liabilities, Current": "31,619",
"Liabilities, Non-Current": "0",
"Other Assets": "20,126",
"Other Compr. Net Income": "0",
"Other Expenses": "1,051",
"Other Liabilities": "117,525",
"Other Net Income": "461",
"Other Revenues": "31,270",
"Property and Equipment": "964",
"Research and Development": "28,996",
"Selling, General and Administrative Expense": "11,486"
},
"output_variables": {
"Assets": "182,618",
"Liabilities": "149,144",
"Expenses": "41,533",
"Revenues": "31,270",
"Stockholders Equity": "33,474",
"Net Income": "-9,802",
"Comprehensive Net Income": "-9,802",
"BaseVar": "202,513",
"ECR before LimitedLiability": "38%",
"Economic Capital Ratio": "178%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.7750271842452219,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001347178.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001347178.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001347178.svg"
},
{
"company_id": "0001368148",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001368148.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001368148.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001368148.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001368148_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001368148_main_keyfigs.svg",
"name": "Athersys INC NEW",
"rank": 129,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001368148.svg",
"report_text": "The relative strengths and weaknesses of Athersys INC NEW are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Athersys INC NEW compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 36% points.The greatest weakness of Athersys INC NEW is the variable Research and Development, reducing the Economic Capital Ratio by 77% points.
The company's Economic Capital Ratio, given in the ranking table, is 177%, being 57% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001368148_2012_Athersys_INC_NEW.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-26.9",
"Assets": "-56.6",
"Liabilities": "28.4",
"Stockholders Equity": "-49.9",
"ECR before LimitedLiability": "18.2",
"Intangible Assets": "-34.8",
"Property and Equipment": "-5.35",
"Other Liabilities": "35.8",
"Liabilities, Non-Current": "20.1",
"Liabilities, Current": "-41.6",
"Research and Development": "-77.4",
"Expenses": "-43.2",
"Revenues": "25.7",
"Net Income": "-15.9",
"Other Expenses": "18.6",
"Cost of Goods Sold": "7.30",
"Selling, General and Administrative Expense": "15.3",
"Other Revenues": "25.7",
"Comprehensive Net Income": "-16.4",
"Other Net Income": "4.71",
"Economic Capital Ratio": "-57.3"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001368148_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "14,406",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,420",
"Liabilities, Non-Current": "0",
"Other Assets": "28",
"Other Compr. Net Income": "0",
"Other Expenses": "278",
"Other Liabilities": "0",
"Other Net Income": "34",
"Other Revenues": "10,344",
"Property and Equipment": "1,267",
"Research and Development": "18,930",
"Selling, General and Administrative Expense": "4,916"
},
"output_variables": {
"Assets": "15,701",
"Liabilities": "7,420",
"Expenses": "24,124",
"Revenues": "10,344",
"Stockholders Equity": "8,281",
"Net Income": "-13,746",
"Comprehensive Net Income": "-13,746",
"BaseVar": "28,812",
"ECR before LimitedLiability": "37%",
"Economic Capital Ratio": "177%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.7674268693656408,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001368148.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001368148.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001368148.svg"
},
{
"company_id": "0001522724",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001522724.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001522724.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001522724_main_keyfigs.svg",
"name": "Global Green INC",
"rank": 130,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001522724.svg",
"report_text": "The relative strengths and weaknesses of Global Green INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Global Green INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 32% points.The greatest weakness of Global Green INC is the variable Other Expenses, reducing the Economic Capital Ratio by 194% points.
The company's Economic Capital Ratio, given in the ranking table, is 165%, being 69% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001522724_2012_Global_Green_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Liabilities": "-10.1",
"Liabilities": "29.4",
"Stockholders Equity": "31.7",
"ECR before LimitedLiability": "6.96",
"Liabilities, Non-Current": "20.0",
"Liabilities, Current": "28.4",
"Research and Development": "26.6",
"Expenses": "-111",
"Net Income": "-149",
"Other Expenses": "-194",
"Cost of Goods Sold": "7.44",
"Selling, General and Administrative Expense": "25.0",
"Other Revenues": "-54.2",
"Revenues": "-54.2",
"Other Assets": "-28.6",
"Property and Equipment": "-24.3",
"Assets, Current": "31.7",
"Intangible Assets": "-21.5",
"Comprehensive Net Income": "-150",
"Other Net Income": "4.53",
"Economic Capital Ratio": "-68.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001522724_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "107",
"Cost of Goods Sold": "0",
"Intangible Assets": "6.5",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "185",
"Other Liabilities": "18",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "6.7"
},
"output_variables": {
"Assets": "113",
"Liabilities": "18",
"Expenses": "192",
"Revenues": "0",
"Stockholders Equity": "96",
"Net Income": "-192",
"Comprehensive Net Income": "-192",
"BaseVar": "161",
"ECR before LimitedLiability": "25%",
"Economic Capital Ratio": "165%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.6546056249009011,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001522724.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001522724.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001522724.svg"
},
{
"company_id": "0001338042",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001338042.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001338042.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001338042_main_keyfigs.svg",
"name": "Aegerion Pharmaceuticals Inc",
"rank": 131,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001338042.svg",
"report_text": "The relative strengths and weaknesses of Aegerion Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Aegerion Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 23% points.The greatest weakness of Aegerion Pharmaceuticals Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 129% points.
The company's Economic Capital Ratio, given in the ranking table, is 154%, being 80% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001338042_2012_Aegerion_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-25.5",
"Assets": "-9.07",
"Liabilities": "15.6",
"Stockholders Equity": "15.5",
"Intangible Assets": "-37.1",
"Property and Equipment": "-22.6",
"Assets, Current": "23.3",
"Other Liabilities": "4.31",
"ECR before LimitedLiability": "-4.91",
"Liabilities, Non-Current": "12.6",
"Liabilities, Current": "13.8",
"Research and Development": "-79.6",
"Expenses": "-95.2",
"Revenues": "-53.2",
"Net Income": "-129",
"Cost of Goods Sold": "7.26",
"Selling, General and Administrative Expense": "-26.6",
"Other Revenues": "-53.2",
"Comprehensive Net Income": "-129",
"Other Net Income": "12.2",
"Economic Capital Ratio": "-80.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001338042_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "74,077",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,400",
"Liabilities, Non-Current": "0",
"Other Assets": "965",
"Other Compr. Net Income": "0",
"Other Expenses": "9,596",
"Other Liabilities": "8,966",
"Other Net Income": "3,686",
"Other Revenues": "0",
"Property and Equipment": "526",
"Research and Development": "73,558",
"Selling, General and Administrative Expense": "39,254"
},
"output_variables": {
"Assets": "75,568",
"Liabilities": "18,367",
"Expenses": "122,408",
"Revenues": "0",
"Stockholders Equity": "57,201",
"Net Income": "-118,722",
"Comprehensive Net Income": "-118,722",
"BaseVar": "110,014",
"ECR before LimitedLiability": "13%",
"Economic Capital Ratio": "154%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.5359039311383784,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001338042.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001338042.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001338042.svg"
},
{
"company_id": "0000704562",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000704562.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000704562.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000704562.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000704562_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000704562_main_keyfigs.svg",
"name": "Avid Bioservices Inc",
"rank": 132,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000704562.svg",
"report_text": "The relative strengths and weaknesses of Avid Bioservices Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Avid Bioservices Inc compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 13% points.The greatest weakness of Avid Bioservices Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 62% points.
The company's Economic Capital Ratio, given in the ranking table, is 153%, being 81% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000704562_2012_Avid_Bioservices_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.9",
"Assets": "-40.8",
"Liabilities": "2.86",
"Stockholders Equity": "-44.0",
"Intangible Assets": "-35.3",
"Property and Equipment": "-7.87",
"Assets, Current": "11.7",
"Other Liabilities": "12.6",
"Liabilities, Non-Current": "11.7",
"Liabilities, Current": "-62.5",
"Research and Development": "-46.4",
"Expenses": "-41.7",
"Net Income": "-37.8",
"Other Net Income": "4.17",
"Other Expenses": "-9.72",
"Cost of Goods Sold": "6.85",
"Selling, General and Administrative Expense": "8.40",
"ECR before LimitedLiability": "-5.80",
"Comprehensive Net Income": "-38.2",
"Other Compr. Net Income": "-0.526",
"Economic Capital Ratio": "-81.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000704562_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "30,815",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "17,679",
"Liabilities, Non-Current": "0",
"Other Assets": "1,742",
"Other Compr. Net Income": "0",
"Other Expenses": "7,812",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "14,544",
"Property and Equipment": "2,209",
"Research and Development": "29,462",
"Selling, General and Administrative Expense": "11,421"
},
"output_variables": {
"Assets": "34,766",
"Liabilities": "17,679",
"Expenses": "48,695",
"Revenues": "14,544",
"Stockholders Equity": "17,087",
"Net Income": "-34,151",
"Comprehensive Net Income": "-34,151",
"BaseVar": "57,842",
"ECR before LimitedLiability": "12%",
"Economic Capital Ratio": "153%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.5270671923663808,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000704562.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000704562.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000704562.svg"
},
{
"company_id": "0001473579",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001473579.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001473579.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001473579_main_keyfigs.svg",
"name": "Nanomix Corp",
"rank": 133,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001473579.svg",
"report_text": "The relative strengths and weaknesses of Nanomix Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nanomix Corp compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 79% points.The greatest weakness of Nanomix Corp is the variable Liabilities, reducing the Economic Capital Ratio by 76% points.
The company's Economic Capital Ratio, given in the ranking table, is 151%, being 83% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001473579_2012_Nanomix_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-18.8",
"Assets": "12.0",
"Liabilities": "-76.0",
"Stockholders Equity": "-24.3",
"ECR before LimitedLiability": "-7.06",
"Intangible Assets": "79.1",
"Property and Equipment": "-15.8",
"Assets, Current": "-68.8",
"Other Liabilities": "-32.7",
"Liabilities, Non-Current": "10.4",
"Liabilities, Current": "-53.6",
"Research and Development": "10.5",
"Expenses": "3.34",
"Revenues": "-33.5",
"Net Income": "-27.9",
"Other Expenses": "-11.1",
"Cost of Goods Sold": "4.49",
"Selling, General and Administrative Expense": "-9.11",
"Other Revenues": "-33.5",
"Comprehensive Net Income": "-28.2",
"Economic Capital Ratio": "-82.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001473579_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "255",
"Cost of Goods Sold": "0",
"Intangible Assets": "895",
"Liabilities, Current": "467",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "229",
"Other Liabilities": "258",
"Other Net Income": "0",
"Other Revenues": "4.1",
"Property and Equipment": "0",
"Research and Development": "194",
"Selling, General and Administrative Expense": "408"
},
"output_variables": {
"Assets": "1,150",
"Liabilities": "725",
"Expenses": "831",
"Revenues": "4.1",
"Stockholders Equity": "425",
"Net Income": "-827",
"Comprehensive Net Income": "-827",
"BaseVar": "1,355",
"ECR before LimitedLiability": "11%",
"Economic Capital Ratio": "151%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.5144853006151402,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001473579.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001473579.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001473579.svg"
},
{
"company_id": "0001323854",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001323854.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001323854.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001323854_main_keyfigs.svg",
"name": "Warner Chilcott plc",
"rank": 134,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001323854.svg",
"report_text": "The relative strengths and weaknesses of Warner Chilcott plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Warner Chilcott plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 32% points.The greatest weakness of Warner Chilcott plc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 186% points.
The company's Economic Capital Ratio, given in the ranking table, is 147%, being 87% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001323854_2012_Warner_Chilcott_plc.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-23.0",
"Assets": "-50.1",
"Liabilities": "-125",
"Stockholders Equity": "-142",
"Assets, Current": "-72.5",
"Property and Equipment": "-26.0",
"Intangible Assets": "14.2",
"Liabilities, Current": "0.459",
"Other Liabilities": "1.20",
"Liabilities, Non-Current": "-177",
"Selling, General and Administrative Expense": "0.459",
"Expenses": "0.733",
"Revenues": "-3.96",
"Net Income": "0.618",
"Research and Development": "0.630",
"Cost of Goods Sold": "-2.12",
"Other Expenses": "-3.40",
"Other Revenues": "-3.96",
"ECR before LimitedLiability": "-140",
"Comprehensive Net Income": "0.615",
"Economic Capital Ratio": "-146"
},
"2011": {
"Other Assets": "-15.2",
"Assets": "-14.8",
"Liabilities": "-128",
"Stockholders Equity": "-110",
"Intangible Assets": "31.9",
"Property and Equipment": "-8.76",
"Assets, Current": "-77.7",
"Other Liabilities": "6.74",
"Liabilities, Non-Current": "-186",
"Liabilities, Current": "6.35",
"Research and Development": "7.62",
"Expenses": "8.74",
"Revenues": "6.41",
"Net Income": "10.2",
"Other Expenses": "-2.89",
"Selling, General and Administrative Expense": "6.44",
"Other Revenues": "6.41",
"ECR before LimitedLiability": "-11.2",
"Comprehensive Net Income": "10.1",
"Other Net Income": "-3.78",
"Economic Capital Ratio": "-86.7"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001323854_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,177,040",
"Cost of Goods Sold": "492,801",
"Intangible Assets": "4,045,291",
"Liabilities, Current": "1,123,442",
"Liabilities, Non-Current": "4,523,854",
"Other Assets": "193,949",
"Other Compr. Net Income": "-11,738",
"Other Expenses": "1,073,852",
"Other Liabilities": "70,335",
"Other Net Income": "0",
"Other Revenues": "2,974,482",
"Property and Equipment": "235,709",
"Research and Development": "146,506",
"Selling, General and Administrative Expense": "1,090,351"
},
"output_variables": {
"Assets": "5,651,989",
"Liabilities": "5,717,631",
"Expenses": "2,803,510",
"Revenues": "2,974,482",
"Stockholders Equity": "-65,642",
"Net Income": "170,972",
"Comprehensive Net Income": "165,103",
"BaseVar": "8,579,675",
"ECR before LimitedLiability": "0.39%",
"Economic Capital Ratio": "141%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "1,231,930",
"Cost of Goods Sold": "356,144",
"Intangible Assets": "3,448,871",
"Liabilities, Current": "1,101,173",
"Liabilities, Non-Current": "3,801,610",
"Other Assets": "134,521",
"Other Compr. Net Income": "-10,043",
"Other Expenses": "829,172",
"Other Liabilities": "58,115",
"Other Net Income": "-339,923",
"Other Revenues": "2,728,106",
"Property and Equipment": "214,707",
"Research and Development": "107,796",
"Selling, General and Administrative Expense": "923,925"
},
"output_variables": {
"Assets": "5,030,029",
"Liabilities": "4,960,898",
"Expenses": "2,217,037",
"Revenues": "2,728,106",
"Stockholders Equity": "69,131",
"Net Income": "171,146",
"Comprehensive Net Income": "166,124",
"BaseVar": "7,643,018",
"ECR before LimitedLiability": "6.3%",
"Economic Capital Ratio": "147%"
}
}
},
"top_rated": false,
"trend": -104.0,
"value": 1.4734436961556252,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001323854.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001323854.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001323854.svg"
},
{
"company_id": "0000791908",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000791908.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000791908.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000791908.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000791908_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000791908_main_keyfigs.svg",
"name": "XOMA Royalty Corp",
"rank": 135,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000791908.svg",
"report_text": "The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of XOMA Royalty Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 1.7% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 116% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 93% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000791908_2012_XOMA_Royalty_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-21.1",
"Assets": "-64.7",
"Liabilities": "-54.6",
"Stockholders Equity": "-116",
"Intangible Assets": "-35.8",
"Property and Equipment": "0.221",
"Assets, Current": "-30.0",
"Other Liabilities": "0.341",
"Liabilities, Non-Current": "-98.5",
"Liabilities, Current": "0.395",
"Other Revenues": "0.994",
"Revenues": "0.994",
"Net Income": "1.73",
"ECR before LimitedLiability": "-17.5",
"Research and Development": "-35.9",
"Other Compr. Net Income": "-0.490",
"Comprehensive Net Income": "1.68",
"Selling, General and Administrative Expense": "0.282",
"Other Expenses": "0.265",
"Other Net Income": "0.0983",
"Economic Capital Ratio": "-93.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000791908_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "62,695",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "21,010",
"Liabilities, Non-Current": "34,476",
"Other Assets": "2,632",
"Other Compr. Net Income": "0",
"Other Expenses": "2,477",
"Other Liabilities": "7,539",
"Other Net Income": "3,689",
"Other Revenues": "58,196",
"Property and Equipment": "12,709",
"Research and Development": "68,137",
"Selling, General and Administrative Expense": "24,014"
},
"output_variables": {
"Assets": "78,036",
"Liabilities": "63,025",
"Expenses": "94,628",
"Revenues": "58,196",
"Stockholders Equity": "15,011",
"Net Income": "-32,743",
"Comprehensive Net Income": "-32,743",
"BaseVar": "148,787",
"ECR before LimitedLiability": "-0.027%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.4104739506635673,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000791908.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000791908.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000791908.svg"
},
{
"company_id": "0001113148",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001113148.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001113148.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001113148.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001113148_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001113148_main_keyfigs.svg",
"name": "Infinity Pharmaceuticals INC",
"rank": 136,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001113148.svg",
"report_text": "The relative strengths and weaknesses of Infinity Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Infinity Pharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 8.3% points.The greatest weakness of Infinity Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 120% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 93% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001113148_2012_Infinity_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-18.1",
"Assets": "-51.1",
"Liabilities": "-71.5",
"Stockholders Equity": "-115",
"Intangible Assets": "-28.9",
"Property and Equipment": "-9.40",
"Assets, Current": "0.245",
"Other Liabilities": "-120",
"Liabilities, Non-Current": "0.427",
"Liabilities, Current": "0.849",
"Research and Development": "-31.7",
"Expenses": "0.309",
"Revenues": "-41.3",
"Net Income": "2.81",
"Other Expenses": "0.557",
"Selling, General and Administrative Expense": "1.13",
"Other Revenues": "-41.3",
"ECR before LimitedLiability": "-17.5",
"Comprehensive Net Income": "2.76",
"Other Net Income": "8.33",
"Economic Capital Ratio": "-93.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001113148_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "117,980",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "28,986",
"Liabilities, Non-Current": "371",
"Other Assets": "1,928",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "79,700",
"Other Net Income": "91,259",
"Other Revenues": "0",
"Property and Equipment": "4,582",
"Research and Development": "108,582",
"Selling, General and Administrative Expense": "22,719"
},
"output_variables": {
"Assets": "124,490",
"Liabilities": "109,057",
"Expenses": "131,301",
"Revenues": "0",
"Stockholders Equity": "15,433",
"Net Income": "-40,042",
"Comprehensive Net Income": "-40,042",
"BaseVar": "228,053",
"ECR before LimitedLiability": "-5.5%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.41013535580928,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001113148.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001113148.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001113148.svg"
},
{
"company_id": "0001063104",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001063104.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001063104.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001063104_main_keyfigs.svg",
"name": "Proteo INC",
"rank": 137,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001063104.svg",
"report_text": "The relative strengths and weaknesses of Proteo INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Proteo INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 9.2% points.The greatest weakness of Proteo INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 132% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 93% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001063104_2012_Proteo_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-14.5",
"Assets": "1.71",
"Liabilities": "-90.1",
"Stockholders Equity": "-47.3",
"Intangible Assets": "-20.4",
"Property and Equipment": "0.200",
"Assets, Current": "9.20",
"Other Liabilities": "1.10",
"Liabilities, Non-Current": "-132",
"Liabilities, Current": "0.0865",
"Research and Development": "2.31",
"Expenses": "0.330",
"Revenues": "-29.3",
"Net Income": "-11.6",
"Other Expenses": "-27.5",
"Cost of Goods Sold": "0.0811",
"Other Revenues": "-29.3",
"ECR before LimitedLiability": "-17.5",
"Comprehensive Net Income": "-9.76",
"Other Net Income": "0.121",
"Economic Capital Ratio": "-93.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001063104_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,067",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "248",
"Liabilities, Non-Current": "622",
"Other Assets": "0",
"Other Compr. Net Income": "46",
"Other Expenses": "482",
"Other Liabilities": "0",
"Other Net Income": "35",
"Other Revenues": "0",
"Property and Equipment": "123",
"Research and Development": "0",
"Selling, General and Administrative Expense": "332"
},
"output_variables": {
"Assets": "1,190",
"Liabilities": "870",
"Expenses": "814",
"Revenues": "0",
"Stockholders Equity": "320",
"Net Income": "-779",
"Comprehensive Net Income": "-756",
"BaseVar": "1,477",
"ECR before LimitedLiability": "-5.7%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.410113569593654,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001063104.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001063104.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001063104.svg"
},
{
"company_id": "0001011835",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001011835.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001011835.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001011835_main_keyfigs.svg",
"name": "Medivation INC",
"rank": 138,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001011835.svg",
"report_text": "The relative strengths and weaknesses of Medivation INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Medivation INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 7.3% points.The greatest weakness of Medivation INC is the variable Liabilities, reducing the Economic Capital Ratio by 116% points.
The company's Economic Capital Ratio, given in the ranking table, is 141%, being 94% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001011835_2012_Medivation_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.426",
"Assets": "-0.224",
"Liabilities": "-116",
"Stockholders Equity": "-92.0",
"ECR before LimitedLiability": "-17.9",
"Intangible Assets": "-7.61",
"Property and Equipment": "-0.464",
"Assets, Current": "7.31",
"Other Liabilities": "-62.3",
"Liabilities, Non-Current": "0.605",
"Liabilities, Current": "-36.6",
"Expenses": "3.09",
"Revenues": "-16.0",
"Net Income": "3.20",
"Other Expenses": "0.984",
"Cost of Goods Sold": "0.237",
"Selling, General and Administrative Expense": "1.13",
"Other Revenues": "-16.0",
"Comprehensive Net Income": "3.15",
"Other Net Income": "3.25",
"Economic Capital Ratio": "-93.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001011835_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "168,189",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "89,634",
"Liabilities, Non-Current": "653",
"Other Assets": "6,208",
"Other Compr. Net Income": "0",
"Other Expenses": "-4,331",
"Other Liabilities": "83,509",
"Other Net Income": "60,147",
"Other Revenues": "0",
"Property and Equipment": "720",
"Research and Development": "73,432",
"Selling, General and Administrative Expense": "29,887"
},
"output_variables": {
"Assets": "175,117",
"Liabilities": "173,796",
"Expenses": "98,988",
"Revenues": "0",
"Stockholders Equity": "1,321",
"Net Income": "-38,841",
"Comprehensive Net Income": "-38,841",
"BaseVar": "254,024",
"ECR before LimitedLiability": "-21%",
"Economic Capital Ratio": "141%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.4056875295338336,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001011835.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001011835.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001011835.svg"
},
{
"company_id": "0001133416",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001133416.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001133416.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001133416.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001133416_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001133416_main_keyfigs.svg",
"name": "Galectin Therapeutics INC",
"rank": 139,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001133416.svg",
"report_text": "The relative strengths and weaknesses of Galectin Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Galectin Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 18% points.The greatest weakness of Galectin Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 111% points.
The company's Economic Capital Ratio, given in the ranking table, is 140%, being 94% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001133416_2012_Galectin_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.02",
"Assets": "-0.862",
"Liabilities": "3.84",
"Stockholders Equity": "2.33",
"ECR before LimitedLiability": "-18.5",
"Intangible Assets": "-11.4",
"Property and Equipment": "-1.01",
"Assets, Current": "18.2",
"Other Liabilities": "3.99",
"Liabilities, Non-Current": "1.41",
"Liabilities, Current": "-0.890",
"Research and Development": "-0.851",
"Expenses": "-59.8",
"Revenues": "-26.1",
"Net Income": "-110",
"Other Expenses": "1.78",
"Cost of Goods Sold": "0.533",
"Selling, General and Administrative Expense": "-67.6",
"Other Revenues": "-26.1",
"Comprehensive Net Income": "-111",
"Economic Capital Ratio": "-94.0"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001133416_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,501",
"Cost of Goods Sold": "0",
"Intangible Assets": "36",
"Liabilities, Current": "2,215",
"Liabilities, Non-Current": "0",
"Other Assets": "69",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-506",
"Other Revenues": "0",
"Property and Equipment": "6.0",
"Research and Development": "3,552",
"Selling, General and Administrative Expense": "6,857"
},
"output_variables": {
"Assets": "6,612",
"Liabilities": "2,215",
"Expenses": "10,409",
"Revenues": "0",
"Stockholders Equity": "4,397",
"Net Income": "-10,915",
"Comprehensive Net Income": "-10,915",
"BaseVar": "9,871",
"ECR before LimitedLiability": "-30%",
"Economic Capital Ratio": "140%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.400271235430558,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001133416.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001133416.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001133416.svg"
},
{
"company_id": "0001420030",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001420030.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001420030.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001420030_main_keyfigs.svg",
"name": "Targeted Medical Pharma Inc",
"rank": 140,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001420030.svg",
"report_text": "The relative strengths and weaknesses of Targeted Medical Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Targeted Medical Pharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 9.6% points.The greatest weakness of Targeted Medical Pharma Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 126% points.
The company's Economic Capital Ratio, given in the ranking table, is 139%, being 95% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001420030_2012_Targeted_Medical_Pharma_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "8.22",
"Assets": "-62.4",
"Liabilities": "-24.0",
"Stockholders Equity": "-126",
"Intangible Assets": "2.12",
"Property and Equipment": "-1.37",
"Assets, Current": "-84.5",
"Other Liabilities": "1.89",
"Liabilities, Non-Current": "1.81",
"Liabilities, Current": "-70.5",
"Other Revenues": "6.38",
"Revenues": "6.38",
"Net Income": "6.10",
"ECR before LimitedLiability": "-19.5",
"Research and Development": "9.65",
"Comprehensive Net Income": "5.99",
"Cost of Goods Sold": "-1.68",
"Selling, General and Administrative Expense": "-38.8",
"Other Expenses": "7.06",
"Other Net Income": "-0.502",
"Economic Capital Ratio": "-95.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001420030_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,900",
"Cost of Goods Sold": "2,757",
"Intangible Assets": "2,388",
"Liabilities, Current": "7,585",
"Liabilities, Non-Current": "0",
"Other Assets": "3,089",
"Other Compr. Net Income": "-3.2",
"Other Expenses": "-2,472",
"Other Liabilities": "989",
"Other Net Income": "-868",
"Other Revenues": "8,810",
"Property and Equipment": "412",
"Research and Development": "163",
"Selling, General and Administrative Expense": "11,670"
},
"output_variables": {
"Assets": "8,788",
"Liabilities": "8,574",
"Expenses": "12,119",
"Revenues": "8,810",
"Stockholders Equity": "214",
"Net Income": "-4,177",
"Comprehensive Net Income": "-4,179",
"BaseVar": "19,581",
"ECR before LimitedLiability": "-43%",
"Economic Capital Ratio": "139%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3899998220691845,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001420030.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001420030.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001420030.svg"
},
{
"company_id": "0001107421",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001107421.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001107421.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001107421.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001107421_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001107421_main_keyfigs.svg",
"name": "Alaunos Therapeutics Inc",
"rank": 141,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001107421.svg",
"report_text": "The relative strengths and weaknesses of Alaunos Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Alaunos Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Alaunos Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 105% points.
The company's Economic Capital Ratio, given in the ranking table, is 139%, being 95% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001107421_2012_Alaunos_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.02",
"Assets": "-7.27",
"Liabilities": "6.32",
"ECR before LimitedLiability": "-19.6",
"Intangible Assets": "-5.50",
"Property and Equipment": "-1.83",
"Assets, Current": "12.3",
"Other Liabilities": "3.91",
"Liabilities, Non-Current": "-2.09",
"Liabilities, Current": "6.56",
"Research and Development": "-63.7",
"Expenses": "-70.6",
"Net Income": "-104",
"Other Expenses": "2.61",
"Cost of Goods Sold": "0.810",
"Selling, General and Administrative Expense": "-2.08",
"Other Revenues": "-18.3",
"Revenues": "-18.3",
"Comprehensive Net Income": "-105",
"Other Net Income": "2.05",
"Economic Capital Ratio": "-95.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001107421_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "106,105",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "13,363",
"Liabilities, Non-Current": "19,425",
"Other Assets": "862",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "3,713",
"Other Net Income": "9,435",
"Other Revenues": "667",
"Property and Equipment": "1,141",
"Research and Development": "128,899",
"Selling, General and Administrative Expense": "68,795"
},
"output_variables": {
"Assets": "108,108",
"Liabilities": "36,501",
"Expenses": "197,694",
"Revenues": "667",
"Stockholders Equity": "71,607",
"Net Income": "-187,592",
"Comprehensive Net Income": "-187,592",
"BaseVar": "176,202",
"ECR before LimitedLiability": "-44%",
"Economic Capital Ratio": "139%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3892344547255369,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001107421.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001107421.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001107421.svg"
},
{
"company_id": "0001285819",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001285819.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001285819.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001285819.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001285819_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001285819_main_keyfigs.svg",
"name": "Omeros CORP",
"rank": 142,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001285819.svg",
"report_text": "The relative strengths and weaknesses of Omeros CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Omeros CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 9.6% points.The greatest weakness of Omeros CORP is the variable Liabilities, Current, reducing the Economic Capital Ratio by 72% points.
The company's Economic Capital Ratio, given in the ranking table, is 138%, being 96% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001285819_2012_Omeros_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.03",
"Assets": "-2.24",
"Liabilities": "-9.44",
"Stockholders Equity": "-36.3",
"ECR before LimitedLiability": "-20.1",
"Intangible Assets": "-2.46",
"Property and Equipment": "-1.49",
"Assets, Current": "9.64",
"Other Liabilities": "4.11",
"Liabilities, Non-Current": "1.59",
"Liabilities, Current": "-72.4",
"Research and Development": "-5.65",
"Expenses": "-2.20",
"Revenues": "-2.08",
"Net Income": "-3.33",
"Other Expenses": "0.964",
"Selling, General and Administrative Expense": "0.919",
"Other Revenues": "-2.08",
"Comprehensive Net Income": "-3.78",
"Other Net Income": "0.781",
"Economic Capital Ratio": "-95.6"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001285819_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "25,948",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18,985",
"Liabilities, Non-Current": "0",
"Other Assets": "295",
"Other Compr. Net Income": "0",
"Other Expenses": "1,884",
"Other Liabilities": "0",
"Other Net Income": "748",
"Other Revenues": "4,524",
"Property and Equipment": "739",
"Research and Development": "23,718",
"Selling, General and Administrative Expense": "8,216"
},
"output_variables": {
"Assets": "26,982",
"Liabilities": "18,985",
"Expenses": "33,818",
"Revenues": "4,524",
"Stockholders Equity": "7,997",
"Net Income": "-28,546",
"Comprehensive Net Income": "-28,546",
"BaseVar": "42,528",
"ECR before LimitedLiability": "-48%",
"Economic Capital Ratio": "138%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3843406332527546,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001285819.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001285819.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001285819.svg"
},
{
"company_id": "0000849636",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000849636.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000849636.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000849636_main_keyfigs.svg",
"name": "Respirerx Pharmaceuticals Inc",
"rank": 143,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000849636.svg",
"report_text": "The relative strengths and weaknesses of Respirerx Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Respirerx Pharmaceuticals Inc compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 25% points.The greatest weakness of Respirerx Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 151% points.
The company's Economic Capital Ratio, given in the ranking table, is 138%, being 96% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000849636_2012_Respirerx_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.44",
"Assets": "-135",
"Liabilities": "12.5",
"Stockholders Equity": "-151",
"Intangible Assets": "-21.8",
"Property and Equipment": "-2.87",
"Assets, Current": "-74.7",
"Other Liabilities": "9.80",
"ECR before LimitedLiability": "-20.6",
"Liabilities, Non-Current": "3.75",
"Liabilities, Current": "-1.27",
"Research and Development": "-2.90",
"Expenses": "-62.3",
"Revenues": "24.8",
"Net Income": "0.594",
"Other Expenses": "5.23",
"Cost of Goods Sold": "1.58",
"Selling, General and Administrative Expense": "-68.6",
"Other Revenues": "24.8",
"Other Net Income": "0.989",
"Economic Capital Ratio": "-96.1"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000849636_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,745",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,145",
"Liabilities, Non-Current": "0",
"Other Assets": "8.9",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "6.9",
"Other Revenues": "3,115",
"Property and Equipment": "67",
"Research and Development": "2,188",
"Selling, General and Administrative Expense": "3,189"
},
"output_variables": {
"Assets": "1,821",
"Liabilities": "1,145",
"Expenses": "5,376",
"Revenues": "3,115",
"Stockholders Equity": "676",
"Net Income": "-2,255",
"Comprehensive Net Income": "-2,255",
"BaseVar": "5,732",
"ECR before LimitedLiability": "-53%",
"Economic Capital Ratio": "138%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3794827212966498,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000849636.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000849636.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000849636.svg"
},
{
"company_id": "0001017491",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001017491.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001017491.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001017491.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001017491_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001017491_main_keyfigs.svg",
"name": "Seelos Therapeutics INC",
"rank": 144,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001017491.svg",
"report_text": "The relative strengths and weaknesses of Seelos Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Seelos Therapeutics INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 9.4% points.The greatest weakness of Seelos Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 40% points.
The company's Economic Capital Ratio, given in the ranking table, is 138%, being 96% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001017491_2012_Seelos_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.32",
"Assets": "-3.09",
"Liabilities": "-3.18",
"Stockholders Equity": "-40.1",
"ECR before LimitedLiability": "-20.7",
"Intangible Assets": "3.40",
"Property and Equipment": "9.40",
"Assets, Current": "-26.7",
"Other Liabilities": "1.21",
"Liabilities, Non-Current": "1.74",
"Liabilities, Current": "-30.1",
"Research and Development": "1.72",
"Expenses": "-2.76",
"Revenues": "-1.90",
"Net Income": "-3.18",
"Other Expenses": "-1.78",
"Cost of Goods Sold": "0.761",
"Selling, General and Administrative Expense": "-2.82",
"Other Revenues": "-1.90",
"Comprehensive Net Income": "-3.19",
"Economic Capital Ratio": "-96.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001017491_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "8,191",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,760",
"Liabilities, Current": "10,021",
"Liabilities, Non-Current": "28",
"Other Assets": "280",
"Other Compr. Net Income": "0",
"Other Expenses": "4,997",
"Other Liabilities": "1,749",
"Other Net Income": "63",
"Other Revenues": "4,101",
"Property and Equipment": "4,384",
"Research and Development": "5,821",
"Selling, General and Administrative Expense": "11,463"
},
"output_variables": {
"Assets": "16,616",
"Liabilities": "11,797",
"Expenses": "22,281",
"Revenues": "4,101",
"Stockholders Equity": "4,818",
"Net Income": "-18,117",
"Comprehensive Net Income": "-18,117",
"BaseVar": "27,429",
"ECR before LimitedLiability": "-54%",
"Economic Capital Ratio": "138%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3784351749169963,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001017491.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001017491.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001017491.svg"
},
{
"company_id": "0001367083",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001367083.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001367083.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001367083.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001367083_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001367083_main_keyfigs.svg",
"name": "Sonoma Pharmaceuticals Inc",
"rank": 145,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001367083.svg",
"report_text": "The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 9.6% points.The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 138%, being 96% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001367083_2012_Sonoma_Pharmaceuticals_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.02",
"Assets": "-86.7",
"Stockholders Equity": "-121",
"Other Liabilities": "3.43",
"Intangible Assets": "-3.45",
"Property and Equipment": "-1.33",
"Assets, Current": "-26.1",
"Research and Development": "8.76",
"Expenses": "-3.21",
"Revenues": "9.56",
"Net Income": "1.45",
"Other Expenses": "2.37",
"Cost of Goods Sold": "-2.92",
"Selling, General and Administrative Expense": "-31.4",
"Other Revenues": "9.56",
"ECR before LimitedLiability": "-20.7",
"Liabilities, Non-Current": "-2.01",
"Liabilities, Current": "-1.15",
"Comprehensive Net Income": "1.43",
"Other Net Income": "0.899",
"Economic Capital Ratio": "-96.2"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001367083_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,809",
"Cost of Goods Sold": "3,613",
"Intangible Assets": "0",
"Liabilities, Current": "4,415",
"Liabilities, Non-Current": "1,638",
"Other Assets": "53",
"Other Compr. Net Income": "87",
"Other Expenses": "581",
"Other Liabilities": "910",
"Other Net Income": "138",
"Other Revenues": "9,754",
"Property and Equipment": "802",
"Research and Development": "2,046",
"Selling, General and Administrative Expense": "11,600"
},
"output_variables": {
"Assets": "8,664",
"Liabilities": "6,963",
"Expenses": "17,840",
"Revenues": "9,754",
"Stockholders Equity": "1,701",
"Net Income": "-7,948",
"Comprehensive Net Income": "-7,904",
"BaseVar": "21,723",
"ECR before LimitedLiability": "-54%",
"Economic Capital Ratio": "138%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3783003296305227,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001367083.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001367083.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001367083.svg"
},
{
"company_id": "0000832489",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000832489.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000832489.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000832489.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000832489_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000832489_main_keyfigs.svg",
"name": "Geovax Labs Inc",
"rank": 146,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000832489.svg",
"report_text": "The relative strengths and weaknesses of Geovax Labs Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Geovax Labs Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 109% points.The greatest weakness of Geovax Labs Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 238% points.
The company's Economic Capital Ratio, given in the ranking table, is 137%, being 97% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000832489_2012_Geovax_Labs_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-19.9",
"Assets": "-183",
"Liabilities": "31.3",
"Stockholders Equity": "-238",
"Intangible Assets": "-36.3",
"Property and Equipment": "-3.89",
"Assets, Current": "-144",
"Other Liabilities": "15.8",
"ECR before LimitedLiability": "-21.8",
"Liabilities, Non-Current": "6.30",
"Liabilities, Current": "9.56",
"Research and Development": "-100",
"Expenses": "-120",
"Revenues": "-77.1",
"Net Income": "9.25",
"Other Expenses": "9.47",
"Selling, General and Administrative Expense": "-35.6",
"Other Revenues": "-77.1",
"Comprehensive Net Income": "8.93",
"Other Net Income": "109",
"Economic Capital Ratio": "-97.4"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000832489_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,418",
"Cost of Goods Sold": "0",
"Intangible Assets": "40",
"Liabilities, Current": "942",
"Liabilities, Non-Current": "0",
"Other Assets": "11",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "4,902",
"Other Revenues": "0",
"Property and Equipment": "176",
"Research and Development": "4,276",
"Selling, General and Administrative Expense": "2,973"
},
"output_variables": {
"Assets": "1,645",
"Liabilities": "942",
"Expenses": "7,249",
"Revenues": "0",
"Stockholders Equity": "704",
"Net Income": "-2,347",
"Comprehensive Net Income": "-2,347",
"BaseVar": "7,369",
"ECR before LimitedLiability": "-63%",
"Economic Capital Ratio": "137%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.366587932052362,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000832489.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000832489.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000832489.svg"
},
{
"company_id": "0000897448",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000897448.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000897448.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000897448.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000897448_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000897448_main_keyfigs.svg",
"name": "Amarin CORP PLC UK",
"rank": 147,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000897448.svg",
"report_text": "The relative strengths and weaknesses of Amarin CORP PLC UK are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Amarin CORP PLC UK compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 19% points.The greatest weakness of Amarin CORP PLC UK is the variable Other Liabilities, reducing the Economic Capital Ratio by 171% points.
The company's Economic Capital Ratio, given in the ranking table, is 137%, being 98% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000897448_2012_Amarin_CORP_PLC_UK.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.01",
"Assets": "3.41",
"Liabilities": "-99.2",
"Stockholders Equity": "-56.6",
"ECR before LimitedLiability": "-21.9",
"Intangible Assets": "-2.95",
"Property and Equipment": "-1.99",
"Assets, Current": "18.6",
"Other Liabilities": "-171",
"Liabilities, Non-Current": "1.29",
"Liabilities, Current": "4.81",
"Research and Development": "2.96",
"Expenses": "8.12",
"Revenues": "-3.34",
"Comprehensive Net Income": "-0.313",
"Other Expenses": "1.39",
"Cost of Goods Sold": "0.573",
"Selling, General and Administrative Expense": "1.89",
"Other Revenues": "-3.34",
"Other Net Income": "-1.84",
"Economic Capital Ratio": "-97.5"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000897448_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "118,972",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,452",
"Liabilities, Non-Current": "0",
"Other Assets": "6,975",
"Other Compr. Net Income": "0",
"Other Expenses": "2,517",
"Other Liabilities": "123,889",
"Other Net Income": "-22,448",
"Other Revenues": "0",
"Property and Equipment": "432",
"Research and Development": "21,602",
"Selling, General and Administrative Expense": "22,559"
},
"output_variables": {
"Assets": "126,379",
"Liabilities": "132,341",
"Expenses": "46,678",
"Revenues": "0",
"Stockholders Equity": "-5,962",
"Net Income": "-69,126",
"Comprehensive Net Income": "-69,126",
"BaseVar": "163,923",
"ECR before LimitedLiability": "-63%",
"Economic Capital Ratio": "137%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.365722838695821,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000897448.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000897448.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000897448.svg"
},
{
"company_id": "0001103021",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001103021.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001103021.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001103021.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001103021_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001103021_main_keyfigs.svg",
"name": "Biodelivery Sciences International INC",
"rank": 148,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001103021.svg",
"report_text": "The relative strengths and weaknesses of Biodelivery Sciences International INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biodelivery Sciences International INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 15% points.The greatest weakness of Biodelivery Sciences International INC is the variable Liabilities, Current, reducing the Economic Capital Ratio by 54% points.
The company's Economic Capital Ratio, given in the ranking table, is 136%, being 98% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001103021_2012_Biodelivery_Sciences_International_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-3.00",
"Assets": "-4.58",
"Liabilities": "-10.0",
"Stockholders Equity": "-54.0",
"ECR before LimitedLiability": "-22.4",
"Intangible Assets": "14.7",
"Property and Equipment": "1.95",
"Assets, Current": "-22.9",
"Other Liabilities": "2.59",
"Liabilities, Non-Current": "1.98",
"Liabilities, Current": "-54.2",
"Research and Development": "-4.34",
"Expenses": "-2.64",
"Revenues": "-3.52",
"Net Income": "-3.60",
"Other Expenses": "2.61",
"Selling, General and Administrative Expense": "1.34",
"Other Revenues": "-3.52",
"Comprehensive Net Income": "-3.63",
"Other Net Income": "3.39",
"Economic Capital Ratio": "-97.9"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001103021_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "11,081",
"Cost of Goods Sold": "1,757",
"Intangible Assets": "8,865",
"Liabilities, Current": "17,878",
"Liabilities, Non-Current": "0",
"Other Assets": "411",
"Other Compr. Net Income": "0",
"Other Expenses": "81",
"Other Liabilities": "1,647",
"Other Net Income": "3,663",
"Other Revenues": "3,263",
"Property and Equipment": "3,288",
"Research and Development": "20,805",
"Selling, General and Administrative Expense": "7,608"
},
"output_variables": {
"Assets": "23,645",
"Liabilities": "19,525",
"Expenses": "30,251",
"Revenues": "3,263",
"Stockholders Equity": "4,120",
"Net Income": "-23,325",
"Comprehensive Net Income": "-23,325",
"BaseVar": "40,173",
"ECR before LimitedLiability": "-66%",
"Economic Capital Ratio": "136%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3615228781846613,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001103021.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001103021.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001103021.svg"
},
{
"company_id": "0001262104",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001262104.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001262104.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001262104.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001262104_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001262104_main_keyfigs.svg",
"name": "Lite Strategy Inc",
"rank": 149,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001262104.svg",
"report_text": "The relative strengths and weaknesses of Lite Strategy Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lite Strategy Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 19% points.The greatest weakness of Lite Strategy Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 44% points.
The company's Economic Capital Ratio, given in the ranking table, is 133%, being 101% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001262104_2012_Lite_Strategy_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.15",
"Assets": "-5.85",
"Liabilities": "-2.83",
"Stockholders Equity": "-7.27",
"ECR before LimitedLiability": "-25.9",
"Intangible Assets": "-6.24",
"Property and Equipment": "-4.12",
"Assets, Current": "19.1",
"Other Liabilities": "6.20",
"Liabilities, Non-Current": "2.57",
"Liabilities, Current": "-8.22",
"Research and Development": "-1.37",
"Expenses": "-7.96",
"Revenues": "-6.91",
"Net Income": "-43.8",
"Other Expenses": "3.68",
"Cost of Goods Sold": "1.24",
"Selling, General and Administrative Expense": "-8.41",
"Other Revenues": "-6.91",
"Comprehensive Net Income": "-44.2",
"Economic Capital Ratio": "-101"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001262104_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4,130",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,374",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "1.0",
"Other Liabilities": "0",
"Other Net Income": "-329",
"Other Revenues": "0",
"Property and Equipment": "38",
"Research and Development": "2,115",
"Selling, General and Administrative Expense": "4,336"
},
"output_variables": {
"Assets": "4,168",
"Liabilities": "2,374",
"Expenses": "6,452",
"Revenues": "0",
"Stockholders Equity": "1,794",
"Net Income": "-6,781",
"Comprehensive Net Income": "-6,781",
"BaseVar": "6,662",
"ECR before LimitedLiability": "-88%",
"Economic Capital Ratio": "133%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.3262227165644076,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001262104.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001262104.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001262104.svg"
},
{
"company_id": "0001429260",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001429260.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001429260.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001429260.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001429260_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001429260_main_keyfigs.svg",
"name": "Fortress Biotech Inc",
"rank": 150,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001429260.svg",
"report_text": "The relative strengths and weaknesses of Fortress Biotech Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Fortress Biotech Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 50% points.The greatest weakness of Fortress Biotech Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 218% points.
The company's Economic Capital Ratio, given in the ranking table, is 129%, being 106% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001429260_2012_Fortress_Biotech_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.95",
"Assets": "-13.2",
"Liabilities": "22.6",
"Stockholders Equity": "8.74",
"ECR before LimitedLiability": "-29.9",
"Intangible Assets": "-10.5",
"Property and Equipment": "-7.91",
"Assets, Current": "12.2",
"Other Liabilities": "8.21",
"Liabilities, Non-Current": "4.31",
"Liabilities, Current": "11.5",
"Research and Development": "24.3",
"Expenses": "50.3",
"Revenues": "-11.1",
"Net Income": "-158",
"Cost of Goods Sold": "2.25",
"Selling, General and Administrative Expense": "20.0",
"Other Revenues": "-11.1",
"Comprehensive Net Income": "-158",
"Other Net Income": "-218",
"Economic Capital Ratio": "-106"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001429260_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "23,375",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,493",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "4,689",
"Other Liabilities": "750",
"Other Net Income": "-52,618",
"Other Revenues": "733",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "23,375",
"Liabilities": "4,243",
"Expenses": "4,689",
"Revenues": "733",
"Stockholders Equity": "19,132",
"Net Income": "-56,574",
"Comprehensive Net Income": "-56,574",
"BaseVar": "42,829",
"ECR before LimitedLiability": "-108%",
"Economic Capital Ratio": "129%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.2855761554567249,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001429260.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001429260.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001429260.svg"
},
{
"company_id": "0001016504",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001016504.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001016504.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001016504.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001016504_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001016504_main_keyfigs.svg",
"name": "Integrated Biopharma INC",
"rank": 151,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001016504.svg",
"report_text": "The relative strengths and weaknesses of Integrated Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Integrated Biopharma INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 45% points.The greatest weakness of Integrated Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 226% points.
The company's Economic Capital Ratio, given in the ranking table, is 128%, being 106% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001016504_2012_Integrated_Biopharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.53",
"Assets": "-128",
"Liabilities": "-5.77",
"Stockholders Equity": "-226",
"ECR before LimitedLiability": "-30.2",
"Intangible Assets": "-9.61",
"Property and Equipment": "-4.97",
"Assets, Current": "-86.3",
"Other Liabilities": "11.1",
"Liabilities, Non-Current": "4.73",
"Liabilities, Current": "-41.9",
"Research and Development": "27.1",
"Expenses": "-3.85",
"Revenues": "44.9",
"Net Income": "37.1",
"Other Expenses": "-46.6",
"Cost of Goods Sold": "2.49",
"Selling, General and Administrative Expense": "4.77",
"Other Revenues": "44.9",
"Comprehensive Net Income": "36.8",
"Economic Capital Ratio": "-106"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001016504_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "10,635",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,294",
"Liabilities, Current": "21,329",
"Liabilities, Non-Current": "0",
"Other Assets": "54",
"Other Compr. Net Income": "0",
"Other Expenses": "30,503",
"Other Liabilities": "16",
"Other Net Income": "-1,919",
"Other Revenues": "40,665",
"Property and Equipment": "1,667",
"Research and Development": "0",
"Selling, General and Administrative Expense": "10,524"
},
"output_variables": {
"Assets": "13,650",
"Liabilities": "21,345",
"Expenses": "41,027",
"Revenues": "40,665",
"Stockholders Equity": "-7,695",
"Net Income": "-2,281",
"Comprehensive Net Income": "-2,281",
"BaseVar": "59,303",
"ECR before LimitedLiability": "-109%",
"Economic Capital Ratio": "128%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.2827919827925351,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001016504.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001016504.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001016504.svg"
},
{
"company_id": "0000890821",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000890821.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000890821.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000890821.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000890821_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000890821_main_keyfigs.svg",
"name": "Enveric Biosciences Inc",
"rank": 152,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000890821.svg",
"report_text": "The relative strengths and weaknesses of Enveric Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Enveric Biosciences Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 32% points.The greatest weakness of Enveric Biosciences Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 49% points.
The company's Economic Capital Ratio, given in the ranking table, is 127%, being 107% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000890821_2012_Enveric_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-6.66",
"Assets": "-8.86",
"Liabilities": "-11.0",
"Stockholders Equity": "-14.4",
"ECR before LimitedLiability": "-31.9",
"Intangible Assets": "-8.30",
"Property and Equipment": "-5.72",
"Assets, Current": "18.1",
"Other Liabilities": "6.16",
"Liabilities, Non-Current": "2.61",
"Liabilities, Current": "-19.9",
"Research and Development": "13.9",
"Expenses": "31.8",
"Revenues": "-8.95",
"Net Income": "-13.8",
"Other Expenses": "1.56",
"Selling, General and Administrative Expense": "11.5",
"Other Revenues": "-8.95",
"Comprehensive Net Income": "-13.8",
"Other Net Income": "-48.9",
"Economic Capital Ratio": "-107"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000890821_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "22",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "18",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "2.0",
"Other Liabilities": "0",
"Other Net Income": "-31",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "22",
"Liabilities": "18",
"Expenses": "2.0",
"Revenues": "0",
"Stockholders Equity": "4.6",
"Net Income": "-33",
"Comprehensive Net Income": "-33",
"BaseVar": "37",
"ECR before LimitedLiability": "-116%",
"Economic Capital Ratio": "127%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.2659429572495473,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000890821.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000890821.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000890821.svg"
},
{
"company_id": "0001160308",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001160308.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001160308.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001160308.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001160308_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001160308_main_keyfigs.svg",
"name": "Savara Inc",
"rank": 153,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001160308.svg",
"report_text": "The relative strengths and weaknesses of Savara Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Savara Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 32% points.The greatest weakness of Savara Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 194% points.
The company's Economic Capital Ratio, given in the ranking table, is 120%, being 114% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001160308_2012_Savara_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.19",
"Assets": "-45.5",
"Liabilities": "31.6",
"Stockholders Equity": "13.5",
"ECR before LimitedLiability": "-38.7",
"Intangible Assets": "-14.3",
"Property and Equipment": "-12.2",
"Assets, Current": "-16.7",
"Other Liabilities": "9.95",
"Liabilities, Non-Current": "5.60",
"Liabilities, Current": "21.4",
"Research and Development": "-21.0",
"Expenses": "-148",
"Revenues": "-17.9",
"Net Income": "-194",
"Other Expenses": "-17.8",
"Selling, General and Administrative Expense": "-18.2",
"Other Revenues": "-17.9",
"Comprehensive Net Income": "-194",
"Other Net Income": "6.29",
"Economic Capital Ratio": "-114"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001160308_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,792",
"Cost of Goods Sold": "0",
"Intangible Assets": "3,007",
"Liabilities, Current": "2,469",
"Liabilities, Non-Current": "0",
"Other Assets": "6,593",
"Other Compr. Net Income": "0",
"Other Expenses": "40,462",
"Other Liabilities": "2,609",
"Other Net Income": "4,893",
"Other Revenues": "2,094",
"Property and Equipment": "464",
"Research and Development": "77,969",
"Selling, General and Administrative Expense": "60,147"
},
"output_variables": {
"Assets": "61,856",
"Liabilities": "5,078",
"Expenses": "178,579",
"Revenues": "2,094",
"Stockholders Equity": "56,779",
"Net Income": "-171,592",
"Comprehensive Net Income": "-171,592",
"BaseVar": "126,250",
"ECR before LimitedLiability": "-143%",
"Economic Capital Ratio": "120%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.1979747893838215,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001160308.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001160308.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001160308.svg"
},
{
"company_id": "0001427925",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001427925.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001427925.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001427925.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001427925_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001427925_main_keyfigs.svg",
"name": "Talphera INC",
"rank": 154,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001427925.svg",
"report_text": "The relative strengths and weaknesses of Talphera INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Talphera INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 8.3% points.The greatest weakness of Talphera INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 43% points.
The company's Economic Capital Ratio, given in the ranking table, is 116%, being 118% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001427925_2012_Talphera_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.3",
"Assets": "-23.5",
"Liabilities": "1.92",
"Stockholders Equity": "-21.1",
"ECR before LimitedLiability": "-42.9",
"Intangible Assets": "-14.9",
"Property and Equipment": "-5.43",
"Assets, Current": "-3.46",
"Other Liabilities": "8.30",
"Liabilities, Non-Current": "-16.2",
"Liabilities, Current": "8.17",
"Research and Development": "-25.1",
"Expenses": "-24.5",
"Revenues": "-15.5",
"Net Income": "-42.6",
"Other Expenses": "1.55",
"Cost of Goods Sold": "2.33",
"Other Revenues": "-15.5",
"Comprehensive Net Income": "-43.2",
"Other Net Income": "4.70",
"Economic Capital Ratio": "-118"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001427925_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "38,146",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,845",
"Liabilities, Non-Current": "15,275",
"Other Assets": "383",
"Other Compr. Net Income": "0",
"Other Expenses": "5,439",
"Other Liabilities": "247",
"Other Net Income": "3,490",
"Other Revenues": "0",
"Property and Equipment": "2,306",
"Research and Development": "67,421",
"Selling, General and Administrative Expense": "19,294"
},
"output_variables": {
"Assets": "40,835",
"Liabilities": "23,367",
"Expenses": "92,154",
"Revenues": "0",
"Stockholders Equity": "17,468",
"Net Income": "-88,664",
"Comprehensive Net Income": "-88,664",
"BaseVar": "79,923",
"ECR before LimitedLiability": "-158%",
"Economic Capital Ratio": "116%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.1563655718651245,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001427925.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001427925.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001427925.svg"
},
{
"company_id": "0000802724",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000802724.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000802724.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000802724_main_keyfigs.svg",
"name": "Insite Vision INC",
"rank": 155,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000802724.svg",
"report_text": "The relative strengths and weaknesses of Insite Vision INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Insite Vision INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Insite Vision INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 124% points.
The company's Economic Capital Ratio, given in the ranking table, is 113%, being 121% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000802724_2012_Insite_Vision_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.99",
"Assets": "-21.8",
"Liabilities": "-80.2",
"Stockholders Equity": "-124",
"ECR before LimitedLiability": "-45.2",
"Intangible Assets": "-10.1",
"Property and Equipment": "-6.14",
"Assets, Current": "-9.94",
"Other Liabilities": "-89.2",
"Liabilities, Non-Current": "2.18",
"Liabilities, Current": "-1.30",
"Research and Development": "7.91",
"Expenses": "13.0",
"Revenues": "-1.15",
"Net Income": "14.1",
"Other Expenses": "-3.39",
"Cost of Goods Sold": "1.37",
"Selling, General and Administrative Expense": "6.99",
"Other Revenues": "-1.15",
"Comprehensive Net Income": "14.0",
"Other Net Income": "2.19",
"Economic Capital Ratio": "-121"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000802724_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "28,971",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "14,668",
"Liabilities, Non-Current": "0",
"Other Assets": "3,085",
"Other Compr. Net Income": "0",
"Other Expenses": "12,084",
"Other Liabilities": "52,272",
"Other Net Income": "2,201",
"Other Revenues": "15,923",
"Property and Equipment": "345",
"Research and Development": "7,337",
"Selling, General and Administrative Expense": "5,645"
},
"output_variables": {
"Assets": "32,401",
"Liabilities": "66,940",
"Expenses": "25,066",
"Revenues": "15,923",
"Stockholders Equity": "-34,539",
"Net Income": "-6,942",
"Comprehensive Net Income": "-6,942",
"BaseVar": "71,266",
"ECR before LimitedLiability": "-166%",
"Economic Capital Ratio": "113%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.1327307754967613,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000802724.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000802724.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000802724.svg"
},
{
"company_id": "0001133818",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001133818.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001133818.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001133818.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001133818_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001133818_main_keyfigs.svg",
"name": "BIO PATH Holdings INC",
"rank": 156,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001133818.svg",
"report_text": "The relative strengths and weaknesses of BIO PATH Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of BIO PATH Holdings INC compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 102% points.The greatest weakness of BIO PATH Holdings INC is the variable Other Expenses, reducing the Economic Capital Ratio by 288% points.
The company's Economic Capital Ratio, given in the ranking table, is 109%, being 125% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001133818_2012_BIO_PATH_Holdings_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-19.4",
"Assets": "-45.0",
"Liabilities": "29.1",
"Stockholders Equity": "8.12",
"ECR before LimitedLiability": "-49.7",
"Intangible Assets": "102",
"Property and Equipment": "-16.9",
"Assets, Current": "-86.7",
"Other Liabilities": "12.4",
"Liabilities, Non-Current": "5.61",
"Liabilities, Current": "17.8",
"Research and Development": "36.3",
"Expenses": "-144",
"Revenues": "-24.6",
"Net Income": "-194",
"Other Expenses": "-288",
"Selling, General and Administrative Expense": "30.6",
"Other Revenues": "-24.6",
"Comprehensive Net Income": "-195",
"Other Net Income": "8.20",
"Economic Capital Ratio": "-125"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001133818_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,154",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,077",
"Liabilities, Current": "316",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "9,866",
"Other Liabilities": "0",
"Other Net Income": "318",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "3,231",
"Liabilities": "316",
"Expenses": "9,866",
"Revenues": "0",
"Stockholders Equity": "2,915",
"Net Income": "-9,549",
"Comprehensive Net Income": "-9,549",
"BaseVar": "6,866",
"ECR before LimitedLiability": "-180%",
"Economic Capital Ratio": "109%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.0881374738016698,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001133818.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001133818.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001133818.svg"
},
{
"company_id": "0001279704",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001279704.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001279704.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001279704_main_keyfigs.svg",
"name": "Cellectar Biosciences Inc",
"rank": 157,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001279704.svg",
"report_text": "The relative strengths and weaknesses of Cellectar Biosciences Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cellectar Biosciences Inc compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 39% points.The greatest weakness of Cellectar Biosciences Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 199% points.
The company's Economic Capital Ratio, given in the ranking table, is 107%, being 127% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001279704_2012_Cellectar_Biosciences_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-19.1",
"Assets": "-33.9",
"Liabilities": "27.4",
"Stockholders Equity": "11.9",
"ECR before LimitedLiability": "-51.5",
"Intangible Assets": "-4.00",
"Property and Equipment": "39.1",
"Assets, Current": "-34.0",
"Other Liabilities": "11.8",
"Liabilities, Non-Current": "1.62",
"Liabilities, Current": "19.1",
"Research and Development": "-96.9",
"Expenses": "-135",
"Revenues": "-24.6",
"Net Income": "-198",
"Other Expenses": "6.27",
"Cost of Goods Sold": "3.78",
"Selling, General and Administrative Expense": "-21.6",
"Other Revenues": "-24.6",
"Comprehensive Net Income": "-199",
"Economic Capital Ratio": "-127"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001279704_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,816",
"Cost of Goods Sold": "0",
"Intangible Assets": "1,675",
"Liabilities, Current": "504",
"Liabilities, Non-Current": "578",
"Other Assets": "27",
"Other Compr. Net Income": "0",
"Other Expenses": "799",
"Other Liabilities": "0",
"Other Net Income": "-214",
"Other Revenues": "0",
"Property and Equipment": "3,045",
"Research and Development": "20,805",
"Selling, General and Administrative Expense": "9,663"
},
"output_variables": {
"Assets": "10,563",
"Liabilities": "1,082",
"Expenses": "31,267",
"Revenues": "0",
"Stockholders Equity": "9,481",
"Net Income": "-31,480",
"Comprehensive Net Income": "-31,480",
"BaseVar": "21,563",
"ECR before LimitedLiability": "-186%",
"Economic Capital Ratio": "107%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.0704742517537158,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001279704.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001279704.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001279704.svg"
},
{
"company_id": "0001347613",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001347613.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001347613.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001347613_main_keyfigs.svg",
"name": "Synergy Pharmaceuticals LLC",
"rank": 158,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001347613.svg",
"report_text": "The relative strengths and weaknesses of Synergy Pharmaceuticals LLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Synergy Pharmaceuticals LLC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 20% points.The greatest weakness of Synergy Pharmaceuticals LLC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 88% points.
The company's Economic Capital Ratio, given in the ranking table, is 104%, being 130% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001347613_2012_Synergy_Pharmaceuticals_LLC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.58",
"Assets": "-52.3",
"Liabilities": "16.9",
"Stockholders Equity": "-27.7",
"ECR before LimitedLiability": "-54.1",
"Intangible Assets": "-23.7",
"Property and Equipment": "-16.6",
"Assets, Current": "-28.2",
"Liabilities, Non-Current": "4.90",
"Liabilities, Current": "13.1",
"Research and Development": "-7.98",
"Expenses": "-61.9",
"Revenues": "-24.2",
"Net Income": "-87.5",
"Other Expenses": "-67.4",
"Cost of Goods Sold": "3.59",
"Selling, General and Administrative Expense": "6.69",
"Other Revenues": "-24.2",
"Comprehensive Net Income": "-88.2",
"Other Net Income": "19.7",
"Economic Capital Ratio": "-130"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001347613_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "14,308",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,747",
"Liabilities, Non-Current": "0",
"Other Assets": "1,555",
"Other Compr. Net Income": "0",
"Other Expenses": "28,157",
"Other Liabilities": "3,325",
"Other Net Income": "5,697",
"Other Revenues": "0",
"Property and Equipment": "5.8",
"Research and Development": "13,419",
"Selling, General and Administrative Expense": "6,746"
},
"output_variables": {
"Assets": "15,870",
"Liabilities": "6,072",
"Expenses": "48,321",
"Revenues": "0",
"Stockholders Equity": "9,797",
"Net Income": "-42,624",
"Comprehensive Net Income": "-42,624",
"BaseVar": "37,980",
"ECR before LimitedLiability": "-194%",
"Economic Capital Ratio": "104%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.0443075216412314,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001347613.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001347613.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001347613.svg"
},
{
"company_id": "0001100412",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001100412.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001100412.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001100412_main_keyfigs.svg",
"name": "Array Biopharma INC",
"rank": 159,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001100412.svg",
"report_text": "The relative strengths and weaknesses of Array Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Array Biopharma INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Array Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 139% points.
The company's Economic Capital Ratio, given in the ranking table, is 95%, being 139% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001100412_2012_Array_Biopharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.58",
"Assets": "-40.6",
"Liabilities": "-43.7",
"Stockholders Equity": "-139",
"ECR before LimitedLiability": "-63.6",
"Intangible Assets": "-14.8",
"Property and Equipment": "0.921",
"Assets, Current": "-30.6",
"Other Liabilities": "5.06",
"Liabilities, Non-Current": "-43.9",
"Liabilities, Current": "-5.60",
"Research and Development": "1.89",
"Expenses": "7.89",
"Revenues": "1.62",
"Net Income": "10.6",
"Cost of Goods Sold": "-4.50",
"Selling, General and Administrative Expense": "9.82",
"Other Revenues": "1.62",
"Comprehensive Net Income": "9.88",
"Other Net Income": "1.09",
"Economic Capital Ratio": "-139"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001100412_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "70,562",
"Cost of Goods Sold": "28,916",
"Intangible Assets": "0",
"Liabilities, Current": "69,808",
"Liabilities, Non-Current": "150,424",
"Other Assets": "3,114",
"Other Compr. Net Income": "-5,525",
"Other Expenses": "19,550",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "71,901",
"Property and Equipment": "15,698",
"Research and Development": "63,498",
"Selling, General and Administrative Expense": "16,261"
},
"output_variables": {
"Assets": "89,374",
"Liabilities": "220,232",
"Expenses": "128,225",
"Revenues": "71,901",
"Stockholders Equity": "-130,858",
"Net Income": "-56,324",
"Comprehensive Net Income": "-59,086",
"BaseVar": "257,628",
"ECR before LimitedLiability": "-222%",
"Economic Capital Ratio": "95%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.9493850061808804,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001100412.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001100412.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001100412.svg"
},
{
"company_id": "0001377053",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001377053.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001377053.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001377053_main_keyfigs.svg",
"name": "Atheronova Inc",
"rank": 160,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001377053.svg",
"report_text": "The relative strengths and weaknesses of Atheronova Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Atheronova Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 58% points.The greatest weakness of Atheronova Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 292% points.
The company's Economic Capital Ratio, given in the ranking table, is 84%, being 150% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001377053_2012_Atheronova_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-17.5",
"Assets": "-99.3",
"Liabilities": "-54.5",
"Stockholders Equity": "-292",
"ECR before LimitedLiability": "-74.0",
"Intangible Assets": "-22.4",
"Property and Equipment": "-14.7",
"Assets, Current": "-56.1",
"Other Liabilities": "6.11",
"Liabilities, Non-Current": "2.74",
"Liabilities, Current": "-184",
"Research and Development": "19.0",
"Expenses": "21.6",
"Revenues": "-20.3",
"Net Income": "57.7",
"Other Expenses": "1.76",
"Cost of Goods Sold": "2.61",
"Other Revenues": "-20.3",
"Comprehensive Net Income": "57.6",
"Other Net Income": "56.8",
"Economic Capital Ratio": "-150"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001377053_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "629",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,421",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "579",
"Other Liabilities": "0",
"Other Net Income": "6,829",
"Other Revenues": "0",
"Property and Equipment": "4.0",
"Research and Development": "382",
"Selling, General and Administrative Expense": "2,179"
},
"output_variables": {
"Assets": "633",
"Liabilities": "6,421",
"Expenses": "3,139",
"Revenues": "0",
"Stockholders Equity": "-5,788",
"Net Income": "3,690",
"Comprehensive Net Income": "3,690",
"BaseVar": "8,511",
"ECR before LimitedLiability": "-253%",
"Economic Capital Ratio": "84%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.8448068261388474,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001377053.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001377053.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001377053.svg"
},
{
"company_id": "0001335103",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001335103.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001335103.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001335103_main_keyfigs.svg",
"name": "Protea Biosciences Group Inc",
"rank": 161,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001335103.svg",
"report_text": "The relative strengths and weaknesses of Protea Biosciences Group Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Protea Biosciences Group Inc compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 54% points.The greatest weakness of Protea Biosciences Group Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 65% points.
The company's Economic Capital Ratio, given in the ranking table, is 76%, being 158% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001335103_2012_Protea_Biosciences_Group_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.7",
"Assets": "-54.7",
"Liabilities": "-19.9",
"Stockholders Equity": "-65.2",
"ECR before LimitedLiability": "-82.8",
"Intangible Assets": "-20.7",
"Property and Equipment": "53.8",
"Assets, Current": "-59.0",
"Other Liabilities": "4.53",
"Liabilities, Current": "-35.7",
"Research and Development": "-16.0",
"Expenses": "-20.6",
"Revenues": "-13.8",
"Net Income": "-36.3",
"Other Expenses": "6.24",
"Cost of Goods Sold": "2.23",
"Selling, General and Administrative Expense": "-13.3",
"Other Revenues": "-13.8",
"Comprehensive Net Income": "-36.4",
"Other Net Income": "-2.76",
"Economic Capital Ratio": "-158"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001335103_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,432",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "7,083",
"Liabilities, Non-Current": "0",
"Other Assets": "18",
"Other Compr. Net Income": "19",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-722",
"Other Revenues": "713",
"Property and Equipment": "3,319",
"Research and Development": "6,243",
"Selling, General and Administrative Expense": "5,246"
},
"output_variables": {
"Assets": "4,769",
"Liabilities": "7,083",
"Expenses": "11,489",
"Revenues": "713",
"Stockholders Equity": "-2,314",
"Net Income": "-11,497",
"Comprehensive Net Income": "-11,488",
"BaseVar": "12,397",
"ECR before LimitedLiability": "-279%",
"Economic Capital Ratio": "76%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.7566648834923976,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001335103.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001335103.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001335103.svg"
},
{
"company_id": "0001375200",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001375200.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001375200.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001375200_main_keyfigs.svg",
"name": "Nupathe INC",
"rank": 162,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001375200.svg",
"report_text": "The relative strengths and weaknesses of Nupathe INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Nupathe INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Nupathe INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 66% points.
The company's Economic Capital Ratio, given in the ranking table, is 75%, being 159% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001375200_2012_Nupathe_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "11.6",
"Assets": "-61.6",
"Liabilities": "4.99",
"Stockholders Equity": "-46.7",
"ECR before LimitedLiability": "-83.3",
"Intangible Assets": "-28.8",
"Property and Equipment": "-18.2",
"Assets, Current": "-48.5",
"Other Liabilities": "6.24",
"Liabilities, Non-Current": "-3.06",
"Research and Development": "-51.9",
"Expenses": "-60.1",
"Revenues": "-25.8",
"Net Income": "-65.8",
"Other Expenses": "-8.41",
"Cost of Goods Sold": "3.23",
"Selling, General and Administrative Expense": "-9.14",
"Other Revenues": "-25.8",
"Comprehensive Net Income": "-65.8",
"Other Net Income": "3.75",
"Economic Capital Ratio": "-159"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001375200_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "23,392",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "12,397",
"Liabilities, Non-Current": "5,481",
"Other Assets": "7,244",
"Other Compr. Net Income": "0",
"Other Expenses": "12,625",
"Other Liabilities": "0",
"Other Net Income": "1,296",
"Other Revenues": "0",
"Property and Equipment": "213",
"Research and Development": "61,258",
"Selling, General and Administrative Expense": "24,015"
},
"output_variables": {
"Assets": "30,849",
"Liabilities": "17,878",
"Expenses": "97,898",
"Revenues": "0",
"Stockholders Equity": "12,971",
"Net Income": "-96,602",
"Comprehensive Net Income": "-96,602",
"BaseVar": "73,960",
"ECR before LimitedLiability": "-280%",
"Economic Capital Ratio": "75%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.7518255053919009,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001375200.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001375200.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001375200.svg"
},
{
"company_id": "0001421204",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001421204.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001421204.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001421204_main_keyfigs.svg",
"name": "Rebus Holdings Inc",
"rank": 163,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001421204.svg",
"report_text": "The relative strengths and weaknesses of Rebus Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Rebus Holdings Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 9.1% points.The greatest weakness of Rebus Holdings Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 101% points.
The company's Economic Capital Ratio, given in the ranking table, is 61%, being 173% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001421204_2012_Rebus_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-26.1",
"Assets": "-75.9",
"Liabilities": "6.13",
"Stockholders Equity": "-44.9",
"ECR before LimitedLiability": "-97.7",
"Intangible Assets": "-30.1",
"Property and Equipment": "-21.8",
"Assets, Current": "-39.1",
"Liabilities, Non-Current": "2.13",
"Liabilities, Current": "5.88",
"Research and Development": "-55.7",
"Expenses": "-73.2",
"Revenues": "-28.6",
"Net Income": "-101",
"Other Expenses": "9.08",
"Cost of Goods Sold": "3.38",
"Selling, General and Administrative Expense": "-38.5",
"Other Revenues": "-28.6",
"Comprehensive Net Income": "-101",
"Other Net Income": "-5.01",
"Economic Capital Ratio": "-173"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001421204_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,530",
"Cost of Goods Sold": "0",
"Intangible Assets": "152",
"Liabilities, Current": "904",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "30",
"Other Liabilities": "1,734",
"Other Net Income": "-926",
"Other Revenues": "0",
"Property and Equipment": "8.8",
"Research and Development": "11,058",
"Selling, General and Administrative Expense": "8,150"
},
"output_variables": {
"Assets": "5,691",
"Liabilities": "2,638",
"Expenses": "19,237",
"Revenues": "0",
"Stockholders Equity": "3,053",
"Net Income": "-20,163",
"Comprehensive Net Income": "-20,163",
"BaseVar": "14,246",
"ECR before LimitedLiability": "-324%",
"Economic Capital Ratio": "61%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.6079239229161559,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001421204.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001421204.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001421204.svg"
},
{
"company_id": "0000318306",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000318306.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000318306.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000318306.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000318306_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000318306_main_keyfigs.svg",
"name": "Abeona Therapeutics INC",
"rank": 164,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000318306.svg",
"report_text": "The relative strengths and weaknesses of Abeona Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Abeona Therapeutics INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Abeona Therapeutics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 188% points.
The company's Economic Capital Ratio, given in the ranking table, is 61%, being 173% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000318306_2012_Abeona_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.7",
"Assets": "-71.2",
"Liabilities": "-52.6",
"Stockholders Equity": "-188",
"ECR before LimitedLiability": "-97.9",
"Intangible Assets": "-14.1",
"Property and Equipment": "-10.6",
"Assets, Current": "-55.0",
"Other Liabilities": "-14.9",
"Liabilities, Non-Current": "1.07",
"Liabilities, Current": "-18.1",
"Research and Development": "4.18",
"Expenses": "8.89",
"Revenues": "-8.79",
"Net Income": "14.2",
"Cost of Goods Sold": "1.66",
"Selling, General and Administrative Expense": "2.23",
"Other Revenues": "-8.79",
"Comprehensive Net Income": "14.1",
"Other Net Income": "13.6",
"Economic Capital Ratio": "-173"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000318306_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,313",
"Cost of Goods Sold": "0",
"Intangible Assets": "362",
"Liabilities, Current": "12,190",
"Liabilities, Non-Current": "0",
"Other Assets": "59",
"Other Compr. Net Income": "0",
"Other Expenses": "1,466",
"Other Liabilities": "9,201",
"Other Net Income": "5,361",
"Other Revenues": "1,848",
"Property and Equipment": "51",
"Research and Development": "4,200",
"Selling, General and Administrative Expense": "4,075"
},
"output_variables": {
"Assets": "3,785",
"Liabilities": "21,391",
"Expenses": "9,741",
"Revenues": "1,848",
"Stockholders Equity": "-17,606",
"Net Income": "-2,532",
"Comprehensive Net Income": "-2,532",
"BaseVar": "21,063",
"ECR before LimitedLiability": "-325%",
"Economic Capital Ratio": "61%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.60582740946726,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000318306.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000318306.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000318306.svg"
},
{
"company_id": "0001175680",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001175680.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001175680.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001175680.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001175680_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001175680_main_keyfigs.svg",
"name": "Cytodyn Inc",
"rank": 165,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001175680.svg",
"report_text": "The relative strengths and weaknesses of Cytodyn Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cytodyn Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 8.8% points.The greatest weakness of Cytodyn Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 118% points.
The company's Economic Capital Ratio, given in the ranking table, is 60%, being 174% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001175680_2012_Cytodyn_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.8",
"Assets": "-54.5",
"Liabilities": "-46.6",
"Stockholders Equity": "-118",
"ECR before LimitedLiability": "-98.0",
"Intangible Assets": "-14.8",
"Property and Equipment": "-9.24",
"Assets, Current": "-29.2",
"Other Liabilities": "2.04",
"Liabilities, Non-Current": "0.907",
"Liabilities, Current": "-64.8",
"Research and Development": "8.79",
"Expenses": "2.30",
"Revenues": "-11.5",
"Net Income": "-8.16",
"Other Expenses": "-1.02",
"Cost of Goods Sold": "1.40",
"Selling, General and Administrative Expense": "-7.33",
"Other Revenues": "-11.5",
"Comprehensive Net Income": "-8.27",
"Economic Capital Ratio": "-174"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001175680_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,974",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "6,995",
"Liabilities, Non-Current": "0",
"Other Assets": "16",
"Other Compr. Net Income": "0",
"Other Expenses": "713",
"Other Liabilities": "6.9",
"Other Net Income": "0",
"Other Revenues": "0",
"Property and Equipment": "5.4",
"Research and Development": "481",
"Selling, General and Administrative Expense": "2,526"
},
"output_variables": {
"Assets": "1,995",
"Liabilities": "7,002",
"Expenses": "3,720",
"Revenues": "0",
"Stockholders Equity": "-5,008",
"Net Income": "-3,720",
"Comprehensive Net Income": "-3,720",
"BaseVar": "6,358",
"ECR before LimitedLiability": "-325%",
"Economic Capital Ratio": "60%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.604730918786628,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001175680.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001175680.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001175680.svg"
},
{
"company_id": "0001208261",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001208261.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001208261.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001208261_main_keyfigs.svg",
"name": "Immune Pharmaceuticals INC",
"rank": 166,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001208261.svg",
"report_text": "The relative strengths and weaknesses of Immune Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Immune Pharmaceuticals INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 3.0% points.The greatest weakness of Immune Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 117% points.
The company's Economic Capital Ratio, given in the ranking table, is 59%, being 175% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001208261_2012_Immune_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.50",
"Assets": "-59.7",
"Liabilities": "-39.6",
"Stockholders Equity": "-117",
"ECR before LimitedLiability": "-99.0",
"Intangible Assets": "-16.2",
"Property and Equipment": "-9.41",
"Assets, Current": "-38.0",
"Other Liabilities": "-15.4",
"Liabilities, Current": "-10.8",
"Research and Development": "-1.66",
"Expenses": "1.80",
"Revenues": "-10.7",
"Net Income": "-11.0",
"Other Expenses": "2.95",
"Cost of Goods Sold": "1.53",
"Selling, General and Administrative Expense": "-1.06",
"Other Revenues": "-10.7",
"Comprehensive Net Income": "-10.9",
"Other Net Income": "-2.18",
"Economic Capital Ratio": "-175"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001208261_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,737",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "12,237",
"Liabilities, Non-Current": "365",
"Other Assets": "664",
"Other Compr. Net Income": "299",
"Other Expenses": "696",
"Other Liabilities": "12,065",
"Other Net Income": "-1,599",
"Other Revenues": "944",
"Property and Equipment": "120",
"Research and Development": "7,853",
"Selling, General and Administrative Expense": "6,452"
},
"output_variables": {
"Assets": "7,521",
"Liabilities": "24,667",
"Expenses": "15,001",
"Revenues": "944",
"Stockholders Equity": "-17,146",
"Net Income": "-15,656",
"Comprehensive Net Income": "-15,506",
"BaseVar": "25,016",
"ECR before LimitedLiability": "-329%",
"Economic Capital Ratio": "59%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.5945832770174474,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001208261.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001208261.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001208261.svg"
},
{
"company_id": "0000822411",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000822411.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000822411.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000822411_main_keyfigs.svg",
"name": "EOM Pharmaceutical Holdings Inc",
"rank": 167,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000822411.svg",
"report_text": "The relative strengths and weaknesses of EOM Pharmaceutical Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of EOM Pharmaceutical Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.7% points.The greatest weakness of EOM Pharmaceutical Holdings Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 165% points.
The company's Economic Capital Ratio, given in the ranking table, is 58%, being 176% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000822411_2012_EOM_Pharmaceutical_Holdings_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-24.3",
"Assets": "-82.6",
"Liabilities": "9.74",
"Stockholders Equity": "-34.4",
"ECR before LimitedLiability": "-100",
"Intangible Assets": "-40.9",
"Property and Equipment": "-25.3",
"Assets, Current": "-57.7",
"Other Liabilities": "5.04",
"Liabilities, Current": "5.08",
"Research and Development": "-39.2",
"Expenses": "-103",
"Revenues": "-33.3",
"Net Income": "-164",
"Other Expenses": "-49.2",
"Cost of Goods Sold": "4.11",
"Selling, General and Administrative Expense": "-33.6",
"Other Revenues": "-33.3",
"Comprehensive Net Income": "-165",
"Other Net Income": "8.83",
"Economic Capital Ratio": "-176"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000822411_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,744",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,761",
"Liabilities, Non-Current": "0",
"Other Assets": "330",
"Other Compr. Net Income": "0",
"Other Expenses": "8,294",
"Other Liabilities": "0",
"Other Net Income": "953",
"Other Revenues": "300",
"Property and Equipment": "76",
"Research and Development": "10,549",
"Selling, General and Administrative Expense": "8,991"
},
"output_variables": {
"Assets": "7,151",
"Liabilities": "1,761",
"Expenses": "27,834",
"Revenues": "300",
"Stockholders Equity": "5,389",
"Net Income": "-26,581",
"Comprehensive Net Income": "-26,581",
"BaseVar": "19,000",
"ECR before LimitedLiability": "-333%",
"Economic Capital Ratio": "58%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.5813394503335062,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000822411.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000822411.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000822411.svg"
},
{
"company_id": "0000811779",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000811779.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000811779.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000811779_main_keyfigs.svg",
"name": "Multicell Technologies Inc",
"rank": 168,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000811779.svg",
"report_text": "The relative strengths and weaknesses of Multicell Technologies Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Multicell Technologies Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Multicell Technologies Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 128% points.
The company's Economic Capital Ratio, given in the ranking table, is 50%, being 184% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000811779_2012_Multicell_Technologies_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-14.3",
"Assets": "-76.1",
"Liabilities": "-21.8",
"Stockholders Equity": "-128",
"ECR before LimitedLiability": "-109",
"Intangible Assets": "-19.0",
"Property and Equipment": "-12.0",
"Assets, Current": "-49.8",
"Liabilities, Non-Current": "-5.67",
"Liabilities, Current": "-12.9",
"Research and Development": "13.7",
"Expenses": "-8.62",
"Revenues": "-13.3",
"Net Income": "-14.2",
"Other Expenses": "-6.59",
"Cost of Goods Sold": "1.68",
"Selling, General and Administrative Expense": "-20.2",
"Other Revenues": "-13.3",
"Comprehensive Net Income": "-14.3",
"Other Net Income": "7.19",
"Economic Capital Ratio": "-184"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000811779_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "719",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,706",
"Liabilities, Non-Current": "769",
"Other Assets": "1.7",
"Other Compr. Net Income": "0",
"Other Expenses": "622",
"Other Liabilities": "0",
"Other Net Income": "360",
"Other Revenues": "49",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "1,739"
},
"output_variables": {
"Assets": "721",
"Liabilities": "2,474",
"Expenses": "2,361",
"Revenues": "49",
"Stockholders Equity": "-1,754",
"Net Income": "-1,952",
"Comprehensive Net Income": "-1,952",
"BaseVar": "2,983",
"ECR before LimitedLiability": "-361%",
"Economic Capital Ratio": "50%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.49583941994732195,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000811779.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000811779.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000811779.svg"
},
{
"company_id": "0001261734",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001261734.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001261734.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001261734_main_keyfigs.svg",
"name": "Aeolus Pharmaceuticals INC",
"rank": 169,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001261734.svg",
"report_text": "The relative strengths and weaknesses of Aeolus Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Aeolus Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 18% points.The greatest weakness of Aeolus Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 214% points.
The company's Economic Capital Ratio, given in the ranking table, is 49%, being 185% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001261734_2012_Aeolus_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-12.4",
"Assets": "-81.3",
"Liabilities": "-47.6",
"Stockholders Equity": "-214",
"ECR before LimitedLiability": "-109",
"Intangible Assets": "-16.7",
"Property and Equipment": "-10.5",
"Assets, Current": "-63.4",
"Other Liabilities": "-76.8",
"Liabilities, Current": "1.44",
"Research and Development": "2.69",
"Expenses": "11.2",
"Revenues": "-12.4",
"Net Income": "17.5",
"Other Expenses": "4.13",
"Cost of Goods Sold": "1.47",
"Selling, General and Administrative Expense": "3.46",
"Other Revenues": "-12.4",
"Comprehensive Net Income": "17.4",
"Other Net Income": "17.3",
"Economic Capital Ratio": "-185"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001261734_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,258",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,144",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "0",
"Other Expenses": "-21",
"Other Liabilities": "23,405",
"Other Net Income": "9,043",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "5,055",
"Selling, General and Administrative Expense": "3,668"
},
"output_variables": {
"Assets": "2,290",
"Liabilities": "25,549",
"Expenses": "8,702",
"Revenues": "0",
"Stockholders Equity": "-23,259",
"Net Income": "341",
"Comprehensive Net Income": "341",
"BaseVar": "22,792",
"ECR before LimitedLiability": "-362%",
"Economic Capital Ratio": "49%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.4949059920191147,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001261734.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001261734.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001261734.svg"
},
{
"company_id": "0000704384",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000704384.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000704384.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000704384_main_keyfigs.svg",
"name": "Biovest International INC",
"rank": 170,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000704384.svg",
"report_text": "The relative strengths and weaknesses of Biovest International INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Biovest International INC compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 8.2% points.The greatest weakness of Biovest International INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 158% points.
The company's Economic Capital Ratio, given in the ranking table, is 40%, being 194% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000704384_2012_Biovest_International_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.69",
"Assets": "-77.2",
"Liabilities": "-19.1",
"Stockholders Equity": "-158",
"ECR before LimitedLiability": "-119",
"Intangible Assets": "-2.92",
"Property and Equipment": "-5.37",
"Assets, Current": "-67.3",
"Liabilities, Non-Current": "-23.9",
"Liabilities, Current": "0.480",
"Research and Development": "8.17",
"Expenses": "7.64",
"Revenues": "-5.38",
"Net Income": "-2.13",
"Other Expenses": "0.874",
"Cost of Goods Sold": "1.22",
"Selling, General and Administrative Expense": "-2.77",
"Other Revenues": "-5.38",
"Comprehensive Net Income": "-2.23",
"Other Net Income": "-5.26",
"Economic Capital Ratio": "-194"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000704384_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,604",
"Cost of Goods Sold": "0",
"Intangible Assets": "2,362",
"Liabilities, Current": "3,845",
"Liabilities, Non-Current": "30,849",
"Other Assets": "681",
"Other Compr. Net Income": "0",
"Other Expenses": "2,211",
"Other Liabilities": "3,270",
"Other Net Income": "-4,983",
"Other Revenues": "3,881",
"Property and Equipment": "771",
"Research and Development": "1,799",
"Selling, General and Administrative Expense": "10,172"
},
"output_variables": {
"Assets": "5,418",
"Liabilities": "37,964",
"Expenses": "14,182",
"Revenues": "3,881",
"Stockholders Equity": "-32,546",
"Net Income": "-15,284",
"Comprehensive Net Income": "-15,284",
"BaseVar": "33,214",
"ECR before LimitedLiability": "-398%",
"Economic Capital Ratio": "40%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.39832287376531816,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000704384.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000704384.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000704384.svg"
},
{
"company_id": "0001409565",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001409565.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001409565.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001409565_main_keyfigs.svg",
"name": "Puramed Bioscience Inc",
"rank": 171,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001409565.svg",
"report_text": "The relative strengths and weaknesses of Puramed Bioscience Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Puramed Bioscience Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Puramed Bioscience Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 100% points.
The company's Economic Capital Ratio, given in the ranking table, is 40%, being 195% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001409565_2012_Puramed_Bioscience_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-4.46",
"Assets": "-80.2",
"Liabilities": "-6.71",
"Stockholders Equity": "-100",
"ECR before LimitedLiability": "-119",
"Property and Equipment": "-11.0",
"Assets, Current": "-71.5",
"Other Liabilities": "-0.402",
"Liabilities, Non-Current": "0.350",
"Liabilities, Current": "-6.65",
"Research and Development": "11.1",
"Expenses": "-5.55",
"Revenues": "-13.7",
"Net Income": "-37.0",
"Other Expenses": "-34.1",
"Cost of Goods Sold": "1.61",
"Selling, General and Administrative Expense": "8.69",
"Other Revenues": "-13.7",
"Comprehensive Net Income": "-37.2",
"Other Net Income": "-14.2",
"Economic Capital Ratio": "-195"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001409565_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "192",
"Cost of Goods Sold": "0",
"Intangible Assets": "134",
"Liabilities, Current": "856",
"Liabilities, Non-Current": "0",
"Other Assets": "69",
"Other Compr. Net Income": "0",
"Other Expenses": "957",
"Other Liabilities": "192",
"Other Net Income": "-402",
"Other Revenues": "8.6",
"Property and Equipment": "8.8",
"Research and Development": "59",
"Selling, General and Administrative Expense": "80"
},
"output_variables": {
"Assets": "404",
"Liabilities": "1,048",
"Expenses": "1,096",
"Revenues": "8.6",
"Stockholders Equity": "-644",
"Net Income": "-1,489",
"Comprehensive Net Income": "-1,489",
"BaseVar": "1,479",
"ECR before LimitedLiability": "-399%",
"Economic Capital Ratio": "40%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.39553752131081665,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001409565.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001409565.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001409565.svg"
},
{
"company_id": "0000025743",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000025743.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000025743.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000025743.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000025743_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000025743_main_keyfigs.svg",
"name": "Therapeuticsmd Inc",
"rank": 172,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000025743.svg",
"report_text": "The relative strengths and weaknesses of Therapeuticsmd Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Therapeuticsmd Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 17% points.The greatest weakness of Therapeuticsmd Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 130% points.
The company's Economic Capital Ratio, given in the ranking table, is 39%, being 195% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000025743_2012_Therapeuticsmd_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-16.3",
"Assets": "-100",
"Liabilities": "-2.43",
"Stockholders Equity": "-130",
"ECR before LimitedLiability": "-119",
"Intangible Assets": "-29.9",
"Property and Equipment": "-15.4",
"Assets, Current": "-85.6",
"Other Liabilities": "1.12",
"Liabilities, Current": "-6.55",
"Research and Development": "17.3",
"Expenses": "-39.8",
"Revenues": "3.33",
"Net Income": "-33.1",
"Other Expenses": "-4.17",
"Cost of Goods Sold": "2.42",
"Selling, General and Administrative Expense": "-65.3",
"Other Revenues": "3.33",
"Comprehensive Net Income": "-33.4",
"Other Net Income": "1.49",
"Economic Capital Ratio": "-195"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000025743_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,237",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,151",
"Liabilities, Non-Current": "0",
"Other Assets": "131",
"Other Compr. Net Income": "0",
"Other Expenses": "1,002",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "2,088",
"Property and Equipment": "70",
"Research and Development": "107",
"Selling, General and Administrative Expense": "6,406"
},
"output_variables": {
"Assets": "1,439",
"Liabilities": "3,151",
"Expenses": "7,515",
"Revenues": "2,088",
"Stockholders Equity": "-1,712",
"Net Income": "-5,427",
"Comprehensive Net Income": "-5,427",
"BaseVar": "7,096",
"ECR before LimitedLiability": "-399%",
"Economic Capital Ratio": "39%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.39430424716056967,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000025743.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000025743.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000025743.svg"
},
{
"company_id": "0000887247",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000887247.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000887247.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000887247.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000887247_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000887247_main_keyfigs.svg",
"name": "DMK Pharmaceuticals Corp",
"rank": 173,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000887247.svg",
"report_text": "The relative strengths and weaknesses of DMK Pharmaceuticals Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of DMK Pharmaceuticals Corp compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 5.0% points.The greatest weakness of DMK Pharmaceuticals Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 98% points.
The company's Economic Capital Ratio, given in the ranking table, is 36%, being 198% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000887247_2012_DMK_Pharmaceuticals_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.48",
"Assets": "-87.5",
"Liabilities": "-2.06",
"Stockholders Equity": "-98.1",
"ECR before LimitedLiability": "-122",
"Intangible Assets": "-23.1",
"Property and Equipment": "-14.4",
"Assets, Current": "-58.4",
"Other Liabilities": "0.562",
"Liabilities, Current": "-4.25",
"Research and Development": "-13.3",
"Expenses": "-29.1",
"Revenues": "-16.4",
"Net Income": "-58.4",
"Other Expenses": "4.97",
"Cost of Goods Sold": "1.82",
"Selling, General and Administrative Expense": "-22.5",
"Other Revenues": "-16.4",
"Comprehensive Net Income": "-58.6",
"Other Net Income": "-6.49",
"Economic Capital Ratio": "-198"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000887247_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,534",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,113",
"Liabilities, Non-Current": "0",
"Other Assets": "200",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-739",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "2,876",
"Selling, General and Administrative Expense": "3,365"
},
"output_variables": {
"Assets": "1,734",
"Liabilities": "3,113",
"Expenses": "6,241",
"Revenues": "0",
"Stockholders Equity": "-1,380",
"Net Income": "-6,980",
"Comprehensive Net Income": "-6,980",
"BaseVar": "5,913",
"ECR before LimitedLiability": "-412%",
"Economic Capital Ratio": "36%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.36246863947855607,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000887247.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000887247.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000887247.svg"
},
{
"company_id": "0000849146",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000849146.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000849146.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000849146.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000849146_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000849146_main_keyfigs.svg",
"name": "Lifevantage Corp",
"rank": 174,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000849146.svg",
"report_text": "The relative strengths and weaknesses of Lifevantage Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Lifevantage Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 19% points.The greatest weakness of Lifevantage Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 200% points.
The company's Economic Capital Ratio, given in the ranking table, is 34%, being 200% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000849146_2012_Lifevantage_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-26.7",
"Assets": "-129",
"Liabilities": "-0.578",
"Stockholders Equity": "-200",
"ECR before LimitedLiability": "-124",
"Intangible Assets": "-26.6",
"Property and Equipment": "-21.2",
"Assets, Current": "-102",
"Other Liabilities": "-1.35",
"Liabilities, Non-Current": "0.250",
"Research and Development": "18.8",
"Expenses": "16.6",
"Revenues": "14.5",
"Net Income": "-17.7",
"Other Expenses": "-15.4",
"Cost of Goods Sold": "-3.28",
"Selling, General and Administrative Expense": "11.6",
"Other Revenues": "14.5",
"Comprehensive Net Income": "-18.0",
"Other Net Income": "-71.3",
"Economic Capital Ratio": "-200"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000849146_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "10,275",
"Cost of Goods Sold": "5,917",
"Intangible Assets": "1,963",
"Liabilities, Current": "13,380",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "-28",
"Other Expenses": "21,367",
"Other Liabilities": "19,926",
"Other Net Income": "-54,402",
"Other Revenues": "38,919",
"Property and Equipment": "228",
"Research and Development": "509",
"Selling, General and Administrative Expense": "7,516"
},
"output_variables": {
"Assets": "12,499",
"Liabilities": "33,307",
"Expenses": "35,309",
"Revenues": "38,919",
"Stockholders Equity": "-20,808",
"Net Income": "-50,792",
"Comprehensive Net Income": "-50,806",
"BaseVar": "87,232",
"ECR before LimitedLiability": "-420%",
"Economic Capital Ratio": "34%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.34418087602785047,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000849146.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000849146.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000849146.svg"
},
{
"company_id": "0001053691",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001053691.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001053691.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001053691_main_keyfigs.svg",
"name": "Cervomed Inc",
"rank": 175,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001053691.svg",
"report_text": "The relative strengths and weaknesses of Cervomed Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cervomed Inc compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 32% points.The greatest weakness of Cervomed Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 107% points.
The company's Economic Capital Ratio, given in the ranking table, is 32%, being 202% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001053691_2012_Cervomed_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "31.6",
"Assets": "-104",
"Stockholders Equity": "-91.6",
"Other Liabilities": "0.141",
"ECR before LimitedLiability": "-127",
"Intangible Assets": "-31.5",
"Property and Equipment": "-17.4",
"Assets, Current": "-107",
"Research and Development": "16.6",
"Expenses": "-72.4",
"Revenues": "-18.0",
"Net Income": "-87.0",
"Other Expenses": "-54.5",
"Cost of Goods Sold": "-12.5",
"Selling, General and Administrative Expense": "-26.3",
"Other Revenues": "-18.0",
"Liabilities, Current": "-0.252",
"Comprehensive Net Income": "-87.3",
"Other Net Income": "4.70",
"Other Compr. Net Income": "-0.185",
"Economic Capital Ratio": "-202"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001053691_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "186",
"Cost of Goods Sold": "2,309",
"Intangible Assets": "0",
"Liabilities, Current": "3,786",
"Liabilities, Non-Current": "0",
"Other Assets": "3,409",
"Other Compr. Net Income": "0",
"Other Expenses": "7,992",
"Other Liabilities": "0",
"Other Net Income": "592",
"Other Revenues": "570",
"Property and Equipment": "78",
"Research and Development": "0",
"Selling, General and Administrative Expense": "6,699"
},
"output_variables": {
"Assets": "3,674",
"Liabilities": "3,786",
"Expenses": "17,000",
"Revenues": "570",
"Stockholders Equity": "-113",
"Net Income": "-15,837",
"Comprehensive Net Income": "-15,837",
"BaseVar": "12,811",
"ECR before LimitedLiability": "-431%",
"Economic Capital Ratio": "32%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.318716859642668,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001053691.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001053691.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001053691.svg"
},
{
"company_id": "0001226616",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001226616.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001226616.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001226616.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001226616_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001226616_main_keyfigs.svg",
"name": "Medicinova INC",
"rank": 176,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001226616.svg",
"report_text": "The relative strengths and weaknesses of Medicinova INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Medicinova INC compared to the market average is the variable Other Compr. Net Income, increasing the Economic Capital Ratio by 29% points.The greatest weakness of Medicinova INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 555% points.
The company's Economic Capital Ratio, given in the ranking table, is 29%, being 205% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001226616_2012_Medicinova_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-69.5",
"Assets": "-323",
"Liabilities": "-1.19",
"Stockholders Equity": "-555",
"ECR before LimitedLiability": "-129",
"Intangible Assets": "-77.7",
"Property and Equipment": "-78.2",
"Assets, Current": "-294",
"Liabilities, Current": "-0.978",
"Research and Development": "-112",
"Expenses": "-147",
"Revenues": "-80.2",
"Net Income": "-328",
"Other Expenses": "17.2",
"Cost of Goods Sold": "7.59",
"Selling, General and Administrative Expense": "-58.8",
"Other Revenues": "-80.2",
"Comprehensive Net Income": "-28.5",
"Other Net Income": "3.89",
"Other Compr. Net Income": "29.0",
"Economic Capital Ratio": "-205"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001226616_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "15,708",
"Cost of Goods Sold": "1,258",
"Intangible Assets": "9,600",
"Liabilities, Current": "3,697",
"Liabilities, Non-Current": "0",
"Other Assets": "5,450",
"Other Compr. Net Income": "236,174",
"Other Expenses": "4,030",
"Other Liabilities": "3,592",
"Other Net Income": "-1,735",
"Other Revenues": "20,679",
"Property and Equipment": "29",
"Research and Development": "162,042",
"Selling, General and Administrative Expense": "105,523"
},
"output_variables": {
"Assets": "30,787",
"Liabilities": "7,290",
"Expenses": "272,853",
"Revenues": "20,679",
"Stockholders Equity": "23,498",
"Net Income": "-253,909",
"Comprehensive Net Income": "-135,822",
"BaseVar": "284,759",
"ECR before LimitedLiability": "-444%",
"Economic Capital Ratio": "29%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.29064794390539456,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001226616.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001226616.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001226616.svg"
},
{
"company_id": "0001415684",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001415684.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001415684.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001415684.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001415684_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001415684_main_keyfigs.svg",
"name": "Musclepharm Corp",
"rank": 177,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001415684.svg",
"report_text": "The relative strengths and weaknesses of Musclepharm Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Musclepharm Corp compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 16% points.The greatest weakness of Musclepharm Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 222% points.
The company's Economic Capital Ratio, given in the ranking table, is 29%, being 206% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001415684_2012_Musclepharm_Corp.pdf",
"shrinked_graph_json": {
"2010": {
"Other Assets": "-5.35",
"Assets": "-164",
"Liabilities": "-1.89",
"Stockholders Equity": "-136",
"ECR before LimitedLiability": "-276",
"Assets, Current": "-113",
"Property and Equipment": "-28.0",
"Intangible Assets": "-64.2",
"Liabilities, Current": "2.17",
"Other Liabilities": "-2.42",
"Selling, General and Administrative Expense": "-98.8",
"Expenses": "-82.2",
"Revenues": "-4.59",
"Net Income": "-115",
"Research and Development": "2.20",
"Cost of Goods Sold": "-3.65",
"Other Expenses": "1.99",
"Other Revenues": "-4.59",
"Comprehensive Net Income": "-115",
"Other Net Income": "-1.98",
"Economic Capital Ratio": "-283"
},
"2011": {
"Other Assets": "-24.3",
"Assets": "-133",
"Liabilities": "0.516",
"Stockholders Equity": "-222",
"ECR before LimitedLiability": "-130",
"Intangible Assets": "-34.0",
"Property and Equipment": "-12.9",
"Assets, Current": "-108",
"Other Liabilities": "-0.333",
"Liabilities, Current": "1.59",
"Research and Development": "16.4",
"Expenses": "-19.0",
"Revenues": "13.9",
"Net Income": "-10.7",
"Other Expenses": "6.37",
"Cost of Goods Sold": "-29.4",
"Selling, General and Administrative Expense": "-27.0",
"Other Revenues": "13.9",
"Comprehensive Net Income": "-10.9",
"Other Net Income": "-12.4",
"Economic Capital Ratio": "-206"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001415684_strength_weakness.svg",
"table_records": {
"2010": {
"input_variables": {
"Assets, Current": "1,406",
"Cost of Goods Sold": "2,804",
"Intangible Assets": "0",
"Liabilities, Current": "4,216",
"Liabilities, Non-Current": "250",
"Other Assets": "1,176",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-1,318",
"Other Revenues": "4,047",
"Property and Equipment": "139",
"Research and Development": "0",
"Selling, General and Administrative Expense": "19,495"
},
"output_variables": {
"Assets": "2,721",
"Liabilities": "4,466",
"Expenses": "22,299",
"Revenues": "4,047",
"Stockholders Equity": "-1,745",
"Net Income": "-19,569",
"Comprehensive Net Income": "-19,569",
"BaseVar": "17,425",
"ECR before LimitedLiability": "-650%",
"Economic Capital Ratio": "4.8%"
}
},
"2011": {
"input_variables": {
"Assets, Current": "4,017",
"Cost of Goods Sold": "14,471",
"Intangible Assets": "0",
"Liabilities, Current": "17,710",
"Liabilities, Non-Current": "307",
"Other Assets": "122",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "-7,061",
"Other Revenues": "20,838",
"Property and Equipment": "908",
"Research and Development": "0",
"Selling, General and Administrative Expense": "22,588"
},
"output_variables": {
"Assets": "5,046",
"Liabilities": "18,017",
"Expenses": "37,058",
"Revenues": "20,838",
"Stockholders Equity": "-12,971",
"Net Income": "-23,281",
"Comprehensive Net Income": "-23,281",
"BaseVar": "44,011",
"ECR before LimitedLiability": "-447%",
"Economic Capital Ratio": "29%"
}
}
},
"top_rated": false,
"trend": -146.0,
"value": 0.2850046821537664,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001415684.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001415684.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001415684.svg"
},
{
"company_id": "0001140098",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001140098.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001140098.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001140098_main_keyfigs.svg",
"name": "Ocata Therapeutics Inc",
"rank": 178,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001140098.svg",
"report_text": "The relative strengths and weaknesses of Ocata Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Ocata Therapeutics Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 11% points.The greatest weakness of Ocata Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 113% points.
The company's Economic Capital Ratio, given in the ranking table, is 27%, being 207% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001140098_2012_Ocata_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.30",
"Assets": "-88.4",
"Liabilities": "3.17",
"Stockholders Equity": "-113",
"ECR before LimitedLiability": "-131",
"Intangible Assets": "-16.9",
"Property and Equipment": "-9.93",
"Assets, Current": "-61.0",
"Other Liabilities": "7.53",
"Liabilities, Current": "-0.537",
"Research and Development": "5.28",
"Expenses": "11.3",
"Revenues": "-10.7",
"Net Income": "-28.7",
"Other Expenses": "3.23",
"Cost of Goods Sold": "1.04",
"Selling, General and Administrative Expense": "3.30",
"Other Revenues": "-10.7",
"Comprehensive Net Income": "-28.8",
"Other Net Income": "-35.1",
"Economic Capital Ratio": "-207"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001140098_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "13,407",
"Cost of Goods Sold": "344",
"Intangible Assets": "0",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "1,624",
"Other Compr. Net Income": "0",
"Other Expenses": "226",
"Other Liabilities": "59,880",
"Other Net Income": "-51,685",
"Other Revenues": "506",
"Property and Equipment": "155",
"Research and Development": "10,022",
"Selling, General and Administrative Expense": "11,025"
},
"output_variables": {
"Assets": "15,185",
"Liabilities": "59,880",
"Expenses": "21,617",
"Revenues": "506",
"Stockholders Equity": "-44,695",
"Net Income": "-72,795",
"Comprehensive Net Income": "-72,795",
"BaseVar": "74,437",
"ECR before LimitedLiability": "-454%",
"Economic Capital Ratio": "27%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.2720587657793502,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001140098.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001140098.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001140098.svg"
},
{
"company_id": "0001360214",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001360214.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001360214.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001360214.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001360214_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001360214_main_keyfigs.svg",
"name": "Harrow INC",
"rank": 179,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001360214.svg",
"report_text": "The relative strengths and weaknesses of Harrow INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Harrow INC compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 14% points.The greatest weakness of Harrow INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 146% points.
The company's Economic Capital Ratio, given in the ranking table, is 26%, being 208% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001360214_2012_Harrow_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-8.93",
"Assets": "-80.9",
"Liabilities": "9.11",
"Stockholders Equity": "-146",
"ECR before LimitedLiability": "-133",
"Intangible Assets": "-12.0",
"Property and Equipment": "-7.38",
"Assets, Current": "-55.5",
"Other Liabilities": "-0.296",
"Liabilities, Current": "13.5",
"Research and Development": "7.01",
"Expenses": "13.6",
"Revenues": "-7.68",
"Net Income": "-7.17",
"Other Expenses": "2.15",
"Cost of Goods Sold": "0.875",
"Selling, General and Administrative Expense": "6.02",
"Other Revenues": "-7.68",
"Comprehensive Net Income": "-7.26",
"Other Net Income": "-21.2",
"Economic Capital Ratio": "-208"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001360214_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "161",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,861",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "15",
"Other Liabilities": "0",
"Other Net Income": "-939",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "161",
"Liabilities": "1,861",
"Expenses": "15",
"Revenues": "0",
"Stockholders Equity": "-1,700",
"Net Income": "-954",
"Comprehensive Net Income": "-954",
"BaseVar": "1,488",
"ECR before LimitedLiability": "-461%",
"Economic Capital Ratio": "26%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.2577354269879411,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001360214.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001360214.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001360214.svg"
},
{
"company_id": "0001174940",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001174940.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001174940.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001174940.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001174940_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001174940_main_keyfigs.svg",
"name": "Oragenics INC",
"rank": 180,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001174940.svg",
"report_text": "The relative strengths and weaknesses of Oragenics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Oragenics INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 12% points.The greatest weakness of Oragenics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 145% points.
The company's Economic Capital Ratio, given in the ranking table, is 23%, being 211% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001174940_2012_Oragenics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-11.6",
"Assets": "-97.6",
"Liabilities": "8.08",
"Stockholders Equity": "-145",
"ECR before LimitedLiability": "-136",
"Intangible Assets": "-15.7",
"Property and Equipment": "-7.06",
"Assets, Current": "-72.1",
"Other Liabilities": "-0.583",
"Liabilities, Current": "12.5",
"Research and Development": "1.68",
"Expenses": "-7.27",
"Revenues": "-4.24",
"Net Income": "-12.9",
"Other Expenses": "0.762",
"Cost of Goods Sold": "1.08",
"Selling, General and Administrative Expense": "-11.9",
"Other Revenues": "-4.24",
"Comprehensive Net Income": "-13.0",
"Other Net Income": "-0.418",
"Economic Capital Ratio": "-211"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001174940_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "1,118",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "9,446",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "714",
"Other Liabilities": "0",
"Other Net Income": "-333",
"Other Revenues": "1,444",
"Property and Equipment": "149",
"Research and Development": "2,449",
"Selling, General and Administrative Expense": "5,628"
},
"output_variables": {
"Assets": "1,267",
"Liabilities": "9,446",
"Expenses": "8,791",
"Revenues": "1,444",
"Stockholders Equity": "-8,179",
"Net Income": "-7,679",
"Comprehensive Net Income": "-7,679",
"BaseVar": "10,640",
"ECR before LimitedLiability": "-476%",
"Economic Capital Ratio": "23%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.22982588643489357,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001174940.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001174940.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001174940.svg"
},
{
"company_id": "0001195116",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001195116.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001195116.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001195116_main_keyfigs.svg",
"name": "Arno Therapeutics Inc",
"rank": 181,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001195116.svg",
"report_text": "The relative strengths and weaknesses of Arno Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arno Therapeutics Inc compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 4.3% points.The greatest weakness of Arno Therapeutics Inc is the variable Assets, reducing the Economic Capital Ratio by 114% points.
The company's Economic Capital Ratio, given in the ranking table, is 17%, being 217% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001195116_2012_Arno_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-20.5",
"Assets": "-114",
"Liabilities": "-1.42",
"Stockholders Equity": "-74.3",
"ECR before LimitedLiability": "-141",
"Intangible Assets": "-28.4",
"Property and Equipment": "-16.3",
"Assets, Current": "-69.3",
"Other Liabilities": "1.45",
"Liabilities, Non-Current": "-0.742",
"Liabilities, Current": "-1.83",
"Research and Development": "-93.8",
"Expenses": "-85.9",
"Revenues": "-17.7",
"Net Income": "-111",
"Other Expenses": "4.29",
"Cost of Goods Sold": "1.63",
"Selling, General and Administrative Expense": "-3.21",
"Other Revenues": "-17.7",
"Comprehensive Net Income": "-112",
"Economic Capital Ratio": "-217"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001195116_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,975",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,963",
"Liabilities, Non-Current": "0",
"Other Assets": "10",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "3,705",
"Other Net Income": "-161",
"Other Revenues": "0",
"Property and Equipment": "39",
"Research and Development": "28,308",
"Selling, General and Administrative Expense": "7,044"
},
"output_variables": {
"Assets": "7,024",
"Liabilities": "5,669",
"Expenses": "35,352",
"Revenues": "0",
"Stockholders Equity": "1,356",
"Net Income": "-35,513",
"Comprehensive Net Income": "-35,513",
"BaseVar": "24,103",
"ECR before LimitedLiability": "-513%",
"Economic Capital Ratio": "17%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.17180752276368183,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001195116.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001195116.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001195116.svg"
},
{
"company_id": "0001094038",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001094038.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001094038.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001094038_main_keyfigs.svg",
"name": "Marker Therapeutics Inc",
"rank": 182,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001094038.svg",
"report_text": "The relative strengths and weaknesses of Marker Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Marker Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 15% points.The greatest weakness of Marker Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 125% points.
The company's Economic Capital Ratio, given in the ranking table, is 16%, being 218% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001094038_2012_Marker_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.47",
"Assets": "-93.2",
"Liabilities": "12.1",
"Stockholders Equity": "-125",
"ECR before LimitedLiability": "-143",
"Intangible Assets": "-11.9",
"Property and Equipment": "-7.11",
"Assets, Current": "-65.6",
"Other Liabilities": "-0.883",
"Liabilities, Current": "14.9",
"Research and Development": "5.71",
"Expenses": "-6.84",
"Revenues": "-6.95",
"Net Income": "-14.5",
"Other Expenses": "-29.0",
"Cost of Goods Sold": "0.748",
"Selling, General and Administrative Expense": "4.95",
"Other Revenues": "-6.95",
"Comprehensive Net Income": "-14.6",
"Other Net Income": "0.750",
"Economic Capital Ratio": "-218"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001094038_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "308",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "3,801",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "0",
"Other Expenses": "3,316",
"Other Liabilities": "0",
"Other Net Income": "46",
"Other Revenues": "0",
"Property and Equipment": "0",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "340",
"Liabilities": "3,801",
"Expenses": "3,316",
"Revenues": "0",
"Stockholders Equity": "-3,460",
"Net Income": "-3,270",
"Comprehensive Net Income": "-3,270",
"BaseVar": "3,752",
"ECR before LimitedLiability": "-522%",
"Economic Capital Ratio": "16%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.15908672808072216,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001094038.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001094038.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001094038.svg"
},
{
"company_id": "0001385818",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001385818.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001385818.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001385818.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001385818_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001385818_main_keyfigs.svg",
"name": "AYTU Biopharma INC",
"rank": 183,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001385818.svg",
"report_text": "The relative strengths and weaknesses of AYTU Biopharma INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of AYTU Biopharma INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 13% points.The greatest weakness of AYTU Biopharma INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 114% points.
The company's Economic Capital Ratio, given in the ranking table, is 15%, being 219% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001385818_2012_AYTU_Biopharma_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-13.1",
"Assets": "-105",
"Liabilities": "4.44",
"Stockholders Equity": "-114",
"ECR before LimitedLiability": "-143",
"Intangible Assets": "-18.1",
"Property and Equipment": "12.5",
"Assets, Current": "-99.1",
"Other Liabilities": "-1.31",
"Liabilities, Non-Current": "-0.578",
"Liabilities, Current": "8.00",
"Research and Development": "7.50",
"Expenses": "-32.0",
"Revenues": "-10.7",
"Net Income": "-53.5",
"Other Expenses": "-16.7",
"Cost of Goods Sold": "1.06",
"Selling, General and Administrative Expense": "-28.5",
"Other Revenues": "-10.7",
"Comprehensive Net Income": "-53.7",
"Economic Capital Ratio": "-219"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001385818_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "4.2",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "58",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "49",
"Other Liabilities": "0",
"Other Net Income": "-3.2",
"Other Revenues": "0",
"Property and Equipment": "19",
"Research and Development": "0",
"Selling, General and Administrative Expense": "85"
},
"output_variables": {
"Assets": "23",
"Liabilities": "58",
"Expenses": "134",
"Revenues": "0",
"Stockholders Equity": "-36",
"Net Income": "-137",
"Comprehensive Net Income": "-137",
"BaseVar": "109",
"ECR before LimitedLiability": "-528%",
"Economic Capital Ratio": "15%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.1521182449935387,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001385818.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001385818.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001385818.svg"
},
{
"company_id": "0000072170",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000072170.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000072170.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000072170_main_keyfigs.svg",
"name": "Inergetics INC",
"rank": 184,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000072170.svg",
"report_text": "The relative strengths and weaknesses of Inergetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Inergetics INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.5% points.The greatest weakness of Inergetics INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 130% points.
The company's Economic Capital Ratio, given in the ranking table, is 11%, being 223% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000072170_2012_Inergetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-7.72",
"Assets": "-99.7",
"Liabilities": "9.48",
"Stockholders Equity": "-130",
"ECR before LimitedLiability": "-148",
"Intangible Assets": "-10.6",
"Property and Equipment": "-6.32",
"Assets, Current": "-69.3",
"Other Liabilities": "2.28",
"Liabilities, Current": "7.54",
"Research and Development": "4.35",
"Expenses": "-2.24",
"Revenues": "-5.21",
"Net Income": "-16.2",
"Other Expenses": "1.39",
"Cost of Goods Sold": "0.604",
"Selling, General and Administrative Expense": "-13.4",
"Other Revenues": "-5.21",
"Comprehensive Net Income": "-16.3",
"Other Net Income": "-5.24",
"Economic Capital Ratio": "-223"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000072170_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "394",
"Cost of Goods Sold": "0",
"Intangible Assets": "5.5",
"Liabilities, Current": "3,734",
"Liabilities, Non-Current": "30",
"Other Assets": "2.3",
"Other Compr. Net Income": "0",
"Other Expenses": "79",
"Other Liabilities": "1,426",
"Other Net Income": "-1,397",
"Other Revenues": "137",
"Property and Equipment": "0",
"Research and Development": "38",
"Selling, General and Administrative Expense": "4,094"
},
"output_variables": {
"Assets": "402",
"Liabilities": "5,189",
"Expenses": "4,211",
"Revenues": "137",
"Stockholders Equity": "-4,787",
"Net Income": "-5,471",
"Comprehensive Net Income": "-5,471",
"BaseVar": "5,668",
"ECR before LimitedLiability": "-569%",
"Economic Capital Ratio": "11%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.10583402648824737,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000072170.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000072170.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000072170.svg"
},
{
"company_id": "0001346973",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001346973.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001346973.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001346973_main_keyfigs.svg",
"name": "Praxsyn Corp",
"rank": 185,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001346973.svg",
"report_text": "The relative strengths and weaknesses of Praxsyn Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Praxsyn Corp compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 6.4% points.The greatest weakness of Praxsyn Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 132% points.
The company's Economic Capital Ratio, given in the ranking table, is 9.2%, being 225% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001346973_2012_Praxsyn_Corp.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-9.60",
"Assets": "-119",
"Liabilities": "6.43",
"Stockholders Equity": "-132",
"ECR before LimitedLiability": "-149",
"Intangible Assets": "-14.8",
"Property and Equipment": "-5.30",
"Assets, Current": "-93.3",
"Other Liabilities": "6.24",
"Liabilities, Non-Current": "-0.664",
"Liabilities, Current": "0.860",
"Other Revenues": "-1.53",
"Revenues": "-1.53",
"Net Income": "-20.0",
"Research and Development": "5.00",
"Comprehensive Net Income": "-20.1",
"Cost of Goods Sold": "-5.54",
"Selling, General and Administrative Expense": "-5.80",
"Other Expenses": "1.96",
"Other Net Income": "-15.9",
"Economic Capital Ratio": "-225"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001346973_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "526",
"Cost of Goods Sold": "1,821",
"Intangible Assets": "0",
"Liabilities, Current": "1,911",
"Liabilities, Non-Current": "0",
"Other Assets": "40",
"Other Compr. Net Income": "0",
"Other Expenses": "1.7",
"Other Liabilities": "3,274",
"Other Net Income": "-3,696",
"Other Revenues": "1,584",
"Property and Equipment": "155",
"Research and Development": "0",
"Selling, General and Administrative Expense": "3,579"
},
"output_variables": {
"Assets": "721",
"Liabilities": "5,185",
"Expenses": "5,402",
"Revenues": "1,584",
"Stockholders Equity": "-4,464",
"Net Income": "-7,514",
"Comprehensive Net Income": "-7,514",
"BaseVar": "8,294",
"ECR before LimitedLiability": "-584%",
"Economic Capital Ratio": "9.2%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.09206409896681747,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001346973.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001346973.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001346973.svg"
},
{
"company_id": "0001088856",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001088856.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001088856.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001088856.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001088856_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001088856_main_keyfigs.svg",
"name": "Corcept Therapeutics INC",
"rank": 186,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001088856.svg",
"report_text": "The relative strengths and weaknesses of Corcept Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Corcept Therapeutics INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 3.1% points.The greatest weakness of Corcept Therapeutics INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 219% points.
The company's Economic Capital Ratio, given in the ranking table, is 8.6%, being 225% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001088856_2012_Corcept_Therapeutics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-25.9",
"Assets": "-132",
"Liabilities": "-7.45",
"Stockholders Equity": "-27.3",
"ECR before LimitedLiability": "-150",
"Intangible Assets": "-37.2",
"Property and Equipment": "-20.5",
"Assets, Current": "-91.2",
"Other Liabilities": "-3.05",
"Liabilities, Non-Current": "-1.37",
"Liabilities, Current": "-4.62",
"Research and Development": "-127",
"Expenses": "-132",
"Revenues": "-14.4",
"Net Income": "-217",
"Other Expenses": "3.13",
"Cost of Goods Sold": "1.43",
"Selling, General and Administrative Expense": "-16.8",
"Other Revenues": "-14.4",
"Comprehensive Net Income": "-219",
"Economic Capital Ratio": "-225"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001088856_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "39,775",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "5,026",
"Liabilities, Non-Current": "0",
"Other Assets": "32",
"Other Compr. Net Income": "0",
"Other Expenses": "1,655",
"Other Liabilities": "0",
"Other Net Income": "0",
"Other Revenues": "7,839",
"Property and Equipment": "26",
"Research and Development": "154,161",
"Selling, General and Administrative Expense": "60,581"
},
"output_variables": {
"Assets": "39,833",
"Liabilities": "5,026",
"Expenses": "216,397",
"Revenues": "7,839",
"Stockholders Equity": "34,807",
"Net Income": "-208,558",
"Comprehensive Net Income": "-208,558",
"BaseVar": "134,548",
"ECR before LimitedLiability": "-592%",
"Economic Capital Ratio": "8.6%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.08582883811097029,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001088856.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001088856.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001088856.svg"
},
{
"company_id": "0001369568",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001369568.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001369568.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001369568.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001369568_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001369568_main_keyfigs.svg",
"name": "Catalyst Pharmaceuticals INC",
"rank": 187,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001369568.svg",
"report_text": "The relative strengths and weaknesses of Catalyst Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Catalyst Pharmaceuticals INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 1.5% points.The greatest weakness of Catalyst Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 136% points.
The company's Economic Capital Ratio, given in the ranking table, is 3.3%, being 231% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001369568_2012_Catalyst_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-15.1",
"Assets": "-135",
"Liabilities": "-5.35",
"Stockholders Equity": "-41.5",
"ECR before LimitedLiability": "-155",
"Intangible Assets": "-23.3",
"Property and Equipment": "-11.5",
"Assets, Current": "-92.0",
"Other Liabilities": "-2.36",
"Liabilities, Non-Current": "0.705",
"Liabilities, Current": "-3.89",
"Research and Development": "-79.4",
"Expenses": "-117",
"Revenues": "-10.3",
"Net Income": "-135",
"Other Expenses": "1.47",
"Selling, General and Administrative Expense": "-16.2",
"Other Revenues": "-10.3",
"Comprehensive Net Income": "-136",
"Other Net Income": "1.41",
"Economic Capital Ratio": "-231"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001369568_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "6,228",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "834",
"Liabilities, Non-Current": "1,645",
"Other Assets": "8.9",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "9.5",
"Other Net Income": "1,647",
"Other Revenues": "0",
"Property and Equipment": "12",
"Research and Development": "25,644",
"Selling, General and Administrative Expense": "14,106"
},
"output_variables": {
"Assets": "6,249",
"Liabilities": "2,489",
"Expenses": "39,749",
"Revenues": "0",
"Stockholders Equity": "3,761",
"Net Income": "-38,103",
"Comprehensive Net Income": "-38,103",
"BaseVar": "25,067",
"ECR before LimitedLiability": "-684%",
"Economic Capital Ratio": "3.3%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.03323420572478343,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001369568.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001369568.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001369568.svg"
},
{
"company_id": "0000899460",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000899460.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000899460.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000899460.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000899460_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000899460_main_keyfigs.svg",
"name": "Mannkind CORP",
"rank": 188,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000899460.svg",
"report_text": "The relative strengths and weaknesses of Mannkind CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Mannkind CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 1.9% points.The greatest weakness of Mannkind CORP is the variable Assets, reducing the Economic Capital Ratio by 121% points.
The company's Economic Capital Ratio, given in the ranking table, is 1.9%, being 232% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000899460_2012_Mannkind_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-5.86",
"Assets": "-121",
"Liabilities": "0.751",
"Stockholders Equity": "-95.9",
"ECR before LimitedLiability": "-157",
"Intangible Assets": "-9.14",
"Property and Equipment": "1.79",
"Assets, Current": "-110",
"Other Liabilities": "1.85",
"Liabilities, Non-Current": "-0.495",
"Liabilities, Current": "-2.31",
"Research and Development": "-24.3",
"Expenses": "-31.5",
"Revenues": "-3.44",
"Net Income": "-51.9",
"Other Expenses": "-0.771",
"Selling, General and Administrative Expense": "-0.392",
"Other Revenues": "-3.44",
"Comprehensive Net Income": "-52.2",
"Other Net Income": "0.352",
"Economic Capital Ratio": "-232"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000899460_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "5,821",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "25,360",
"Liabilities, Non-Current": "0",
"Other Assets": "703",
"Other Compr. Net Income": "0",
"Other Expenses": "228,308",
"Other Liabilities": "487,845",
"Other Net Income": "35,913",
"Other Revenues": "3,131",
"Property and Equipment": "193,029",
"Research and Development": "1,366,051",
"Selling, General and Administrative Expense": "380,231"
},
"output_variables": {
"Assets": "199,553",
"Liabilities": "513,205",
"Expenses": "1,974,590",
"Revenues": "3,131",
"Stockholders Equity": "-313,652",
"Net Income": "-1,935,546",
"Comprehensive Net Income": "-1,935,546",
"BaseVar": "1,363,196",
"ECR before LimitedLiability": "-735%",
"Economic Capital Ratio": "1.9%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.01873024149637947,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000899460.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000899460.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000899460.svg"
},
{
"company_id": "0000315545",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000315545.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000315545.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000315545_main_keyfigs.svg",
"name": "Provectus Biopharmaceuticals INC",
"rank": 189,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000315545.svg",
"report_text": "The relative strengths and weaknesses of Provectus Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Provectus Biopharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 0.028% points.The greatest weakness of Provectus Biopharmaceuticals INC is the variable Assets, reducing the Economic Capital Ratio by 138% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.043%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000315545_2012_Provectus_Biopharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-2.53",
"Assets": "-138",
"Stockholders Equity": "-8.29",
"ECR before LimitedLiability": "-158",
"Intangible Assets": "-0.0147",
"Property and Equipment": "-1.56",
"Assets, Current": "-118",
"Other Liabilities": "-0.109",
"Liabilities": "-2.23",
"Liabilities, Non-Current": "-0.0914",
"Liabilities, Current": "-1.17",
"Research and Development": "-1.20",
"Expenses": "-106",
"Net Income": "-138",
"Other Expenses": "-0.156",
"Selling, General and Administrative Expense": "-18.8",
"Other Revenues": "-0.689",
"Revenues": "-0.689",
"Comprehensive Net Income": "-138",
"Other Net Income": "0.0278",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000315545_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,706",
"Cost of Goods Sold": "15",
"Intangible Assets": "5,597",
"Liabilities, Current": "263",
"Liabilities, Non-Current": "0",
"Other Assets": "27",
"Other Compr. Net Income": "0",
"Other Expenses": "14,216",
"Other Liabilities": "3,067",
"Other Net Income": "4,025",
"Other Revenues": "40",
"Property and Equipment": "20",
"Research and Development": "38,093",
"Selling, General and Administrative Expense": "57,525"
},
"output_variables": {
"Assets": "13,350",
"Liabilities": "3,330",
"Expenses": "109,850",
"Revenues": "40",
"Stockholders Equity": "10,020",
"Net Income": "-105,785",
"Comprehensive Net Income": "-105,785",
"BaseVar": "65,298",
"ECR before LimitedLiability": "-1,006%",
"Economic Capital Ratio": "0.043%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.00042638261853890407,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000315545.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000315545.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000315545.svg"
},
{
"company_id": "0001061983",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001061983.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001061983.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001061983.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001061983_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001061983_main_keyfigs.svg",
"name": "Cytokinetics INC",
"rank": 190,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001061983.svg",
"report_text": "The relative strengths and weaknesses of Cytokinetics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cytokinetics INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 0.018% points.The greatest weakness of Cytokinetics INC is the variable Assets, reducing the Economic Capital Ratio by 271% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.018%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001061983_2012_Cytokinetics_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-10.9",
"Assets": "-271",
"Stockholders Equity": "-118",
"ECR before LimitedLiability": "-158",
"Intangible Assets": "-25.1",
"Property and Equipment": "-5.43",
"Assets, Current": "-178",
"Other Liabilities": "-0.729",
"Liabilities": "-5.94",
"Liabilities, Non-Current": "-0.140",
"Liabilities, Current": "-2.51",
"Research and Development": "-234",
"Expenses": "-223",
"Net Income": "-90.8",
"Other Expenses": "0.0161",
"Selling, General and Administrative Expense": "-0.181",
"Other Revenues": "0.0179",
"Revenues": "0.0179",
"Comprehensive Net Income": "-92.0",
"Other Net Income": "0.0153",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001061983_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "51,140",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "4,592",
"Liabilities, Non-Current": "0",
"Other Assets": "323",
"Other Compr. Net Income": "0",
"Other Expenses": "3,616",
"Other Liabilities": "3.0",
"Other Net Income": "21,454",
"Other Revenues": "170,076",
"Property and Equipment": "1,310",
"Research and Development": "452,472",
"Selling, General and Administrative Expense": "143,952"
},
"output_variables": {
"Assets": "52,773",
"Liabilities": "4,595",
"Expenses": "600,040",
"Revenues": "170,076",
"Stockholders Equity": "48,178",
"Net Income": "-408,510",
"Comprehensive Net Income": "-408,510",
"BaseVar": "424,469",
"ECR before LimitedLiability": "-1,058%",
"Economic Capital Ratio": "0.018%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.000182037935675464,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001061983.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001061983.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001061983.svg"
},
{
"company_id": "0000879407",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000879407.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000879407.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000879407.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000879407_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000879407_main_keyfigs.svg",
"name": "Arrowhead Pharmaceuticals INC",
"rank": 191,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000879407.svg",
"report_text": "The relative strengths and weaknesses of Arrowhead Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Arrowhead Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 0.0072% points.The greatest weakness of Arrowhead Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 138% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.012%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000879407_2012_Arrowhead_Pharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "0",
"Assets": "-138",
"Stockholders Equity": "-4.39",
"ECR before LimitedLiability": "-158",
"Intangible Assets": "-3.66",
"Property and Equipment": "-0.832",
"Assets, Current": "-113",
"Other Liabilities": "-0.180",
"Liabilities": "-1.70",
"Liabilities, Non-Current": "-0.0251",
"Liabilities, Current": "-0.521",
"Research and Development": "-0.222",
"Expenses": "-10.6",
"Net Income": "-138",
"Other Expenses": "-0.800",
"Selling, General and Administrative Expense": "-0.0268",
"Other Revenues": "-0.153",
"Revenues": "-0.153",
"Comprehensive Net Income": "-138",
"Other Net Income": "-1.94",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000879407_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "9,861",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "2,582",
"Liabilities, Non-Current": "742",
"Other Assets": "6,002",
"Other Compr. Net Income": "0",
"Other Expenses": "34,099",
"Other Liabilities": "0",
"Other Net Income": "-35,415",
"Other Revenues": "3,992",
"Property and Equipment": "25",
"Research and Development": "40,429",
"Selling, General and Administrative Expense": "25,591"
},
"output_variables": {
"Assets": "15,889",
"Liabilities": "3,324",
"Expenses": "100,119",
"Revenues": "3,992",
"Stockholders Equity": "12,564",
"Net Income": "-131,542",
"Comprehensive Net Income": "-131,542",
"BaseVar": "79,370",
"ECR before LimitedLiability": "-1,084%",
"Economic Capital Ratio": "0.012%"
}
}
},
"top_rated": false,
"trend": null,
"value": 0.00011624601370597877,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000879407.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000879407.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000879407.svg"
},
{
"company_id": "0001355790",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001355790.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001355790.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001355790.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001355790_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001355790_main_keyfigs.svg",
"name": "International Stem Cell CORP",
"rank": 192,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001355790.svg",
"report_text": "The relative strengths and weaknesses of International Stem Cell CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest weakness of International Stem Cell CORP is the variable Assets, reducing the Economic Capital Ratio by 149% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.0038%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001355790_2012_International_Stem_Cell_CORP.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-1.40",
"Assets": "-149",
"Stockholders Equity": "-17.4",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-0.729",
"Property and Equipment": "-0.0336",
"Assets, Current": "-132",
"Other Liabilities": "-0.0190",
"Liabilities": "-1.51",
"Liabilities, Non-Current": "-0.0225",
"Liabilities, Current": "-0.722",
"Research and Development": "-0.0950",
"Expenses": "-65.7",
"Net Income": "-105",
"Cost of Goods Sold": "0",
"Selling, General and Administrative Expense": "-10.6",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-105",
"Other Net Income": "0",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001355790_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "3,019",
"Cost of Goods Sold": "3,334",
"Intangible Assets": "1,282",
"Liabilities, Current": "0",
"Liabilities, Non-Current": "0",
"Other Assets": "16",
"Other Compr. Net Income": "0",
"Other Expenses": "3,881",
"Other Liabilities": "2,114",
"Other Net Income": "-3,490",
"Other Revenues": "7,766",
"Property and Equipment": "1,420",
"Research and Development": "18,294",
"Selling, General and Administrative Expense": "31,684"
},
"output_variables": {
"Assets": "5,737",
"Liabilities": "2,114",
"Expenses": "57,193",
"Revenues": "7,766",
"Stockholders Equity": "3,623",
"Net Income": "-52,917",
"Comprehensive Net Income": "-52,917",
"BaseVar": "38,150",
"ECR before LimitedLiability": "-1,147%",
"Economic Capital Ratio": "0.0038%"
}
}
},
"top_rated": false,
"trend": null,
"value": 3.800285753059427e-05,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001355790.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001355790.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001355790.svg"
},
{
"company_id": "0000707511",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0000707511.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0000707511.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000707511_main_keyfigs.svg",
"name": "Regenerx Biopharmaceuticals INC",
"rank": 193,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0000707511.svg",
"report_text": "The relative strengths and weaknesses of Regenerx Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Regenerx Biopharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 0.0029% points.The greatest weakness of Regenerx Biopharmaceuticals INC is the variable Assets, reducing the Economic Capital Ratio by 146% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.0029%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0000707511_2012_Regenerx_Biopharmaceuticals_INC.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.701",
"Assets": "-146",
"Stockholders Equity": "-79.2",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-2.21",
"Property and Equipment": "-0.339",
"Assets, Current": "-123",
"Other Liabilities": "-0.0859",
"Liabilities": "-0.309",
"Liabilities, Non-Current": "-0.0146",
"Liabilities, Current": "0",
"Research and Development": "-12.2",
"Expenses": "-28.3",
"Net Income": "-18.5",
"Other Expenses": "0",
"Selling, General and Administrative Expense": "-0.0957",
"Other Revenues": "-0.104",
"Revenues": "-0.104",
"Comprehensive Net Income": "-18.8",
"Other Net Income": "0",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0000707511_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "355",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "811",
"Liabilities, Non-Current": "0",
"Other Assets": "12",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "0",
"Other Net Income": "1,516",
"Other Revenues": "0",
"Property and Equipment": "17",
"Research and Development": "5,067",
"Selling, General and Administrative Expense": "2,456"
},
"output_variables": {
"Assets": "384",
"Liabilities": "811",
"Expenses": "7,523",
"Revenues": "0",
"Stockholders Equity": "-427",
"Net Income": "-6,007",
"Comprehensive Net Income": "-6,007",
"BaseVar": "5,117",
"ECR before LimitedLiability": "-1,162%",
"Economic Capital Ratio": "0.0029%"
}
}
},
"top_rated": false,
"trend": null,
"value": 2.8766633114057093e-05,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0000707511.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0000707511.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0000707511.svg"
},
{
"company_id": "0001183765",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001183765.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001183765.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0000000000.png",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0000000000_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001183765_main_keyfigs.svg",
"name": "Molecular Templates Inc",
"rank": 194,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001183765.svg",
"report_text": "The relative strengths and weaknesses of Molecular Templates Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Molecular Templates Inc compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 0.0012% points.The greatest weakness of Molecular Templates Inc is the variable Assets, reducing the Economic Capital Ratio by 138% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.0015%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001183765_2012_Molecular_Templates_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "-0.298",
"Assets": "-138",
"Stockholders Equity": "-14.2",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-1.41",
"Property and Equipment": "-0.198",
"Assets, Current": "-99.2",
"Other Liabilities": "0",
"Liabilities": "-0.437",
"Liabilities, Non-Current": "0",
"Liabilities, Current": "-0.140",
"Research and Development": "-33.7",
"Expenses": "-45.8",
"Net Income": "-73.1",
"Other Expenses": "0",
"Selling, General and Administrative Expense": "-0.0195",
"Other Revenues": "-0.0350",
"Revenues": "-0.0350",
"Comprehensive Net Income": "-73.8",
"Other Net Income": "0",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001183765_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "20,544",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "8,591",
"Liabilities, Non-Current": "0",
"Other Assets": "1,349",
"Other Compr. Net Income": "0",
"Other Expenses": "0",
"Other Liabilities": "9,362",
"Other Net Income": "15,557",
"Other Revenues": "5,089",
"Property and Equipment": "543",
"Research and Development": "203,035",
"Selling, General and Administrative Expense": "69,207"
},
"output_variables": {
"Assets": "22,436",
"Liabilities": "17,953",
"Expenses": "272,242",
"Revenues": "5,089",
"Stockholders Equity": "4,483",
"Net Income": "-251,596",
"Comprehensive Net Income": "-251,596",
"BaseVar": "166,638",
"ECR before LimitedLiability": "-1,197%",
"Economic Capital Ratio": "0.0015%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.4701697400917601e-05,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001183765.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001183765.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001183765.svg"
},
{
"company_id": "0001069308",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001069308.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001069308.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001069308.svg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001069308_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001069308_main_keyfigs.svg",
"name": "Acer Therapeutics Inc",
"rank": 195,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001069308.svg",
"report_text": "The relative strengths and weaknesses of Acer Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Acer Therapeutics Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 0.00000000042% points.The greatest weakness of Acer Therapeutics Inc is the variable Other Net Income, reducing the Economic Capital Ratio by 245% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.00000000042%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001069308_2012_Acer_Therapeutics_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "0",
"Assets": "-132",
"Stockholders Equity": "0",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "-0.0228",
"Property and Equipment": "0",
"Assets, Current": "-74.1",
"Other Liabilities": "0",
"Liabilities": "-0.111",
"Liabilities, Non-Current": "0",
"Liabilities, Current": "0",
"Research and Development": "0",
"Expenses": "0",
"Net Income": "-120",
"Other Expenses": "0",
"Selling, General and Administrative Expense": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-121",
"Other Net Income": "-245",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001069308_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "7,234",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,068",
"Liabilities, Non-Current": "0",
"Other Assets": "0",
"Other Compr. Net Income": "0",
"Other Expenses": "9,057",
"Other Liabilities": "0",
"Other Net Income": "-91,624",
"Other Revenues": "0",
"Property and Equipment": "1,029",
"Research and Development": "0",
"Selling, General and Administrative Expense": "0"
},
"output_variables": {
"Assets": "8,263",
"Liabilities": "1,068",
"Expenses": "9,057",
"Revenues": "0",
"Stockholders Equity": "7,195",
"Net Income": "-100,681",
"Comprehensive Net Income": "-100,681",
"BaseVar": "55,006",
"ECR before LimitedLiability": "-1,822%",
"Economic Capital Ratio": "0.00000000042%"
}
}
},
"top_rated": false,
"trend": null,
"value": 4.155877886201298e-12,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001069308.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001069308.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001069308.svg"
},
{
"company_id": "0001410098",
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution_0001410098.svg",
"graph_url": "https://www.realrate-archive.com/us_pharma/2011/graphs/IME_0001410098.svg",
"logo_url": "https://www.realrate-archive.com/us_pharma/logos/0001410098.jpg",
"logo_url_256x256": "https://www.realrate-archive.com/us_pharma/logos/0001410098_256x256.png",
"main_keyfigs_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001410098_main_keyfigs.svg",
"name": "Cormedix Inc",
"rank": 196,
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_0001410098.svg",
"report_text": "The relative strengths and weaknesses of Cormedix Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.
The greatest strength of Cormedix Inc compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 0.00000000000011% points.The greatest weakness of Cormedix Inc is the variable Assets, reducing the Economic Capital Ratio by 131% points.
The company's Economic Capital Ratio, given in the ranking table, is 0.00000000000013%, being 234% points below the market average of 234%.",
"report_url": "https://www.realrate-archive.com/us_pharma/2011/report/0001410098_2012_Cormedix_Inc.pdf",
"shrinked_graph_json": {
"2011": {
"Other Assets": "0",
"Assets": "-131",
"Stockholders Equity": "0",
"ECR before LimitedLiability": "-159",
"Intangible Assets": "0",
"Property and Equipment": "0",
"Assets, Current": "-67.7",
"Other Liabilities": "0",
"Liabilities": "-0.0147",
"Liabilities, Non-Current": "0",
"Liabilities, Current": "0",
"Research and Development": "0",
"Expenses": "-6.49",
"Net Income": "-49.2",
"Other Expenses": "0",
"Cost of Goods Sold": "0",
"Selling, General and Administrative Expense": "0",
"Other Revenues": "0",
"Revenues": "0",
"Comprehensive Net Income": "-50.1",
"Economic Capital Ratio": "-234"
}
},
"strength_weakness_over_time_plot": "https://www.realrate-archive.com/us_pharma/2011/plot_over_time/0001410098_strength_weakness.svg",
"table_records": {
"2011": {
"input_variables": {
"Assets, Current": "2,531",
"Cost of Goods Sold": "0",
"Intangible Assets": "0",
"Liabilities, Current": "1,305",
"Liabilities, Non-Current": "0",
"Other Assets": "13",
"Other Compr. Net Income": "0",
"Other Expenses": "10,418",
"Other Liabilities": "14",
"Other Net Income": "124",
"Other Revenues": "421",
"Property and Equipment": "12",
"Research and Development": "22,156",
"Selling, General and Administrative Expense": "10,919"
},
"output_variables": {
"Assets": "2,556",
"Liabilities": "1,319",
"Expenses": "43,493",
"Revenues": "421",
"Stockholders Equity": "1,237",
"Net Income": "-42,948",
"Comprehensive Net Income": "-42,948",
"BaseVar": "23,957",
"ECR before LimitedLiability": "-2,077%",
"Economic Capital Ratio": "0.00000000000014%"
}
}
},
"top_rated": false,
"trend": null,
"value": 1.4370974804428526e-15,
"company_index": "https://www.realrate-archive.com/us_pharma/2011/industry_indexes/0001410098.svg",
"analysing_equity": "https://www.realrate-archive.com/us_pharma/2011/analytics/equity/0001410098.svg",
"analysing_profit_loss": "https://www.realrate-archive.com/us_pharma/2011/analytics/profit_loss/0001410098.svg"
}
],
"feature_distribution_plot": "https://www.realrate-archive.com/us_pharma/2011/feature_distribution/feature_distribution.svg",
"final_var_label": "Economic Capital Ratio",
"industry_box": [
[
"Revenues",
"301 B"
],
[
"Assets",
"610 B"
],
[
"Expenses",
"262 B"
],
[
"Stockholders Equity",
"352 B"
]
],
"industry_id": "us_pharma",
"industry_label": "Pharmaceutical",
"num_companies": 196,
"num_top_companies": 49,
"ecr_records": {
"2009": {
"0000850693": {
"rank": 1,
"ecr": "414"
},
"0000310158": {
"rank": 2,
"ecr": "402"
},
"0000038074": {
"rank": 3,
"ecr": "397"
},
"0001274057": {
"rank": 4,
"ecr": "388"
},
"0000001800": {
"rank": 5,
"ecr": "355"
},
"0000936402": {
"rank": 6,
"ecr": "252"
},
"0000078003": {
"rank": 7,
"ecr": "248"
},
"0000059478": {
"rank": 8,
"ecr": "239"
}
},
"2010": {
"0000899866": {
"rank": 1,
"ecr": "395"
},
"0000038074": {
"rank": 2,
"ecr": "394"
},
"0001274057": {
"rank": 3,
"ecr": "389"
},
"0000310158": {
"rank": 4,
"ecr": "386"
},
"0001100962": {
"rank": 5,
"ecr": "376"
},
"0000850693": {
"rank": 6,
"ecr": "369"
},
"0001113481": {
"rank": 7,
"ecr": "368"
},
"0000859368": {
"rank": 8,
"ecr": "352"
},
"0000001800": {
"rank": 9,
"ecr": "337"
},
"0000881464": {
"rank": 10,
"ecr": "328"
},
"0001130591": {
"rank": 11,
"ecr": "326"
},
"0001107332": {
"rank": 12,
"ecr": "326"
},
"0001182129": {
"rank": 13,
"ecr": "316"
},
"0000792977": {
"rank": 14,
"ecr": "311"
},
"0001082554": {
"rank": 15,
"ecr": "308"
},
"0001048477": {
"rank": 16,
"ecr": "300"
},
"0000200406": {
"rank": 17,
"ecr": "287"
},
"0000884629": {
"rank": 18,
"ecr": "286"
},
"0000912183": {
"rank": 19,
"ecr": "262"
},
"0000936402": {
"rank": 20,
"ecr": "262"
},
"0000078003": {
"rank": 21,
"ecr": "255"
},
"0000059478": {
"rank": 22,
"ecr": "253"
},
"0000872589": {
"rank": 23,
"ecr": "251"
},
"0000885590": {
"rank": 24,
"ecr": "250"
},
"0000874015": {
"rank": 25,
"ecr": "238"
},
"0000820096": {
"rank": 26,
"ecr": "232"
},
"0001178670": {
"rank": 27,
"ecr": "227"
},
"0000069499": {
"rank": 28,
"ecr": "218"
},
"0000875320": {
"rank": 29,
"ecr": "164"
},
"0001323854": {
"rank": 30,
"ecr": "141"
},
"0001415684": {
"rank": 31,
"ecr": "4.8"
}
},
"2011": {
"0000786947": {
"rank": 1,
"ecr": "501"
},
"0000875622": {
"rank": 2,
"ecr": "483"
},
"0000847464": {
"rank": 3,
"ecr": "472"
},
"0000926844": {
"rank": 4,
"ecr": "445"
},
"0001052284": {
"rank": 5,
"ecr": "441"
},
"0001059790": {
"rank": 6,
"ecr": "436"
},
"0001362718": {
"rank": 7,
"ecr": "434"
},
"0000887497": {
"rank": 8,
"ecr": "429"
},
"0001178711": {
"rank": 9,
"ecr": "428"
},
"0001401667": {
"rank": 10,
"ecr": "427"
},
"0001173784": {
"rank": 11,
"ecr": "427"
},
"0000863894": {
"rank": 12,
"ecr": "424"
},
"0000835887": {
"rank": 13,
"ecr": "423"
},
"0000850693": {
"rank": 14,
"ecr": "416"
},
"0001232524": {
"rank": 15,
"ecr": "415"
},
"0001325879": {
"rank": 16,
"ecr": "412"
},
"0001092662": {
"rank": 17,
"ecr": "411"
},
"0001443242": {
"rank": 18,
"ecr": "406"
},
"0001459450": {
"rank": 19,
"ecr": "403"
},
"0001087294": {
"rank": 20,
"ecr": "399"
},
"0001520512": {
"rank": 21,
"ecr": "396"
},
"0000891288": {
"rank": 22,
"ecr": "394"
},
"0001005201": {
"rank": 23,
"ecr": "393"
},
"0001034842": {
"rank": 24,
"ecr": "392"
},
"0000310158": {
"rank": 25,
"ecr": "389"
},
"0001416083": {
"rank": 26,
"ecr": "388"
},
"0001100962": {
"rank": 27,
"ecr": "386"
},
"0001354071": {
"rank": 28,
"ecr": "384"
},
"0001274057": {
"rank": 29,
"ecr": "384"
},
"0000881524": {
"rank": 30,
"ecr": "383"
},
"0001087432": {
"rank": 31,
"ecr": "380"
},
"0001520262": {
"rank": 32,
"ecr": "379"
},
"0000038074": {
"rank": 33,
"ecr": "377"
},
"0001107332": {
"rank": 34,
"ecr": "376"
},
"0000934473": {
"rank": 35,
"ecr": "371"
},
"0001322505": {
"rank": 36,
"ecr": "371"
},
"0001375247": {
"rank": 37,
"ecr": "370"
},
"0000944809": {
"rank": 38,
"ecr": "365"
},
"0001260990": {
"rank": 39,
"ecr": "365"
},
"0000919722": {
"rank": 40,
"ecr": "362"
},
"0001096294": {
"rank": 41,
"ecr": "360"
},
"0000949699": {
"rank": 42,
"ecr": "358"
},
"0001003642": {
"rank": 43,
"ecr": "355"
},
"0001130591": {
"rank": 44,
"ecr": "355"
},
"0001379006": {
"rank": 45,
"ecr": "353"
},
"0001235007": {
"rank": 46,
"ecr": "352"
},
"0001367644": {
"rank": 47,
"ecr": "351"
},
"0000001800": {
"rank": 48,
"ecr": "348"
},
"0000881464": {
"rank": 49,
"ecr": "347"
},
"0001145404": {
"rank": 50,
"ecr": "344"
},
"0000812796": {
"rank": 51,
"ecr": "340"
},
"0000886744": {
"rank": 52,
"ecr": "340"
},
"0000831547": {
"rank": 53,
"ecr": "332"
},
"0000057725": {
"rank": 54,
"ecr": "331"
},
"0000352998": {
"rank": 55,
"ecr": "330"
},
"0001080709": {
"rank": 56,
"ecr": "326"
},
"0001070336": {
"rank": 57,
"ecr": "325"
},
"0001098880": {
"rank": 58,
"ecr": "324"
},
"0001428522": {
"rank": 59,
"ecr": "323"
},
"0001159019": {
"rank": 60,
"ecr": "321"
},
"0001029142": {
"rank": 61,
"ecr": "321"
},
"0001061027": {
"rank": 62,
"ecr": "320"
},
"0001130166": {
"rank": 63,
"ecr": "318"
},
"0001082554": {
"rank": 64,
"ecr": "317"
},
"0001413754": {
"rank": 65,
"ecr": "316"
},
"0001124105": {
"rank": 66,
"ecr": "314"
},
"0001182129": {
"rank": 67,
"ecr": "314"
},
"0001356857": {
"rank": 68,
"ecr": "309"
},
"0001326190": {
"rank": 69,
"ecr": "306"
},
"0001135906": {
"rank": 70,
"ecr": "306"
},
"0000859368": {
"rank": 71,
"ecr": "303"
},
"0001484478": {
"rank": 72,
"ecr": "299"
},
"0000768710": {
"rank": 73,
"ecr": "298"
},
"0001062822": {
"rank": 74,
"ecr": "295"
},
"0001366541": {
"rank": 75,
"ecr": "294"
},
"0001267602": {
"rank": 76,
"ecr": "293"
},
"0000816284": {
"rank": 77,
"ecr": "292"
},
"0000200406": {
"rank": 78,
"ecr": "291"
},
"0001001316": {
"rank": 79,
"ecr": "290"
},
"0000792977": {
"rank": 80,
"ecr": "288"
},
"0001048477": {
"rank": 81,
"ecr": "287"
},
"0001369786": {
"rank": 82,
"ecr": "287"
},
"0001348362": {
"rank": 83,
"ecr": "285"
},
"0000749647": {
"rank": 84,
"ecr": "284"
},
"0000003116": {
"rank": 85,
"ecr": "283"
},
"0001095858": {
"rank": 86,
"ecr": "282"
},
"0000855654": {
"rank": 87,
"ecr": "280"
},
"0000936402": {
"rank": 88,
"ecr": "277"
},
"0000884629": {
"rank": 89,
"ecr": "277"
},
"0001333248": {
"rank": 90,
"ecr": "275"
},
"0000275053": {
"rank": 91,
"ecr": "273"
},
"0000820096": {
"rank": 92,
"ecr": "269"
},
"0001178879": {
"rank": 93,
"ecr": "266"
},
"0001228627": {
"rank": 94,
"ecr": "263"
},
"0000908259": {
"rank": 95,
"ecr": "263"
},
"0001114220": {
"rank": 96,
"ecr": "262"
},
"0001070494": {
"rank": 97,
"ecr": "259"
},
"0000078003": {
"rank": 98,
"ecr": "253"
},
"0001158223": {
"rank": 99,
"ecr": "252"
},
"0000715446": {
"rank": 100,
"ecr": "252"
},
"0000875320": {
"rank": 101,
"ecr": "249"
},
"0000059478": {
"rank": 102,
"ecr": "248"
},
"0000748592": {
"rank": 103,
"ecr": "248"
},
"0001069530": {
"rank": 104,
"ecr": "248"
},
"0000912183": {
"rank": 105,
"ecr": "245"
},
"0000896747": {
"rank": 106,
"ecr": "237"
},
"0001513856": {
"rank": 107,
"ecr": "233"
},
"0001411906": {
"rank": 108,
"ecr": "232"
},
"0001168220": {
"rank": 109,
"ecr": "228"
},
"0001274644": {
"rank": 110,
"ecr": "227"
},
"0001036968": {
"rank": 111,
"ecr": "222"
},
"0001178670": {
"rank": 112,
"ecr": "222"
},
"0001124524": {
"rank": 113,
"ecr": "218"
},
"0000069499": {
"rank": 114,
"ecr": "217"
},
"0000820081": {
"rank": 115,
"ecr": "214"
},
"0001041024": {
"rank": 116,
"ecr": "214"
},
"0000885590": {
"rank": 117,
"ecr": "214"
},
"0000070793": {
"rank": 118,
"ecr": "212"
},
"0000872589": {
"rank": 119,
"ecr": "212"
},
"0001411158": {
"rank": 120,
"ecr": "208"
},
"0000874015": {
"rank": 121,
"ecr": "208"
},
"0001023024": {
"rank": 122,
"ecr": "206"
},
"0000906709": {
"rank": 123,
"ecr": "196"
},
"0001019695": {
"rank": 124,
"ecr": "191"
},
"0001365216": {
"rank": 125,
"ecr": "187"
},
"0000886163": {
"rank": 126,
"ecr": "181"
},
"0001390478": {
"rank": 127,
"ecr": "180"
},
"0001347178": {
"rank": 128,
"ecr": "178"
},
"0001368148": {
"rank": 129,
"ecr": "177"
},
"0001522724": {
"rank": 130,
"ecr": "165"
},
"0001338042": {
"rank": 131,
"ecr": "154"
},
"0000704562": {
"rank": 132,
"ecr": "153"
},
"0001473579": {
"rank": 133,
"ecr": "151"
},
"0001323854": {
"rank": 134,
"ecr": "147"
},
"0000791908": {
"rank": 135,
"ecr": "141"
},
"0001113148": {
"rank": 136,
"ecr": "141"
},
"0001063104": {
"rank": 137,
"ecr": "141"
},
"0001011835": {
"rank": 138,
"ecr": "141"
},
"0001133416": {
"rank": 139,
"ecr": "140"
},
"0001420030": {
"rank": 140,
"ecr": "139"
},
"0001107421": {
"rank": 141,
"ecr": "139"
},
"0001285819": {
"rank": 142,
"ecr": "138"
},
"0000849636": {
"rank": 143,
"ecr": "138"
},
"0001017491": {
"rank": 144,
"ecr": "138"
},
"0001367083": {
"rank": 145,
"ecr": "138"
},
"0000832489": {
"rank": 146,
"ecr": "137"
},
"0000897448": {
"rank": 147,
"ecr": "137"
},
"0001103021": {
"rank": 148,
"ecr": "136"
},
"0001262104": {
"rank": 149,
"ecr": "133"
},
"0001429260": {
"rank": 150,
"ecr": "129"
},
"0001016504": {
"rank": 151,
"ecr": "128"
},
"0000890821": {
"rank": 152,
"ecr": "127"
},
"0001160308": {
"rank": 153,
"ecr": "120"
},
"0001427925": {
"rank": 154,
"ecr": "116"
},
"0000802724": {
"rank": 155,
"ecr": "113"
},
"0001133818": {
"rank": 156,
"ecr": "109"
},
"0001279704": {
"rank": 157,
"ecr": "107"
},
"0001347613": {
"rank": 158,
"ecr": "104"
},
"0001100412": {
"rank": 159,
"ecr": "95"
},
"0001377053": {
"rank": 160,
"ecr": "84"
},
"0001335103": {
"rank": 161,
"ecr": "76"
},
"0001375200": {
"rank": 162,
"ecr": "75"
},
"0001421204": {
"rank": 163,
"ecr": "61"
},
"0000318306": {
"rank": 164,
"ecr": "61"
},
"0001175680": {
"rank": 165,
"ecr": "60"
},
"0001208261": {
"rank": 166,
"ecr": "59"
},
"0000822411": {
"rank": 167,
"ecr": "58"
},
"0000811779": {
"rank": 168,
"ecr": "50"
},
"0001261734": {
"rank": 169,
"ecr": "49"
},
"0000704384": {
"rank": 170,
"ecr": "40"
},
"0001409565": {
"rank": 171,
"ecr": "40"
},
"0000025743": {
"rank": 172,
"ecr": "39"
},
"0000887247": {
"rank": 173,
"ecr": "36"
},
"0000849146": {
"rank": 174,
"ecr": "34"
},
"0001053691": {
"rank": 175,
"ecr": "32"
},
"0001226616": {
"rank": 176,
"ecr": "29"
},
"0001415684": {
"rank": 177,
"ecr": "29"
},
"0001140098": {
"rank": 178,
"ecr": "27"
},
"0001360214": {
"rank": 179,
"ecr": "26"
},
"0001174940": {
"rank": 180,
"ecr": "23"
},
"0001195116": {
"rank": 181,
"ecr": "17"
},
"0001094038": {
"rank": 182,
"ecr": "16"
},
"0001385818": {
"rank": 183,
"ecr": "15"
},
"0000072170": {
"rank": 184,
"ecr": "11"
},
"0001346973": {
"rank": 185,
"ecr": "9.2"
},
"0001088856": {
"rank": 186,
"ecr": "8.6"
},
"0001369568": {
"rank": 187,
"ecr": "3.3"
},
"0000899460": {
"rank": 188,
"ecr": "1.9"
},
"0000315545": {
"rank": 189,
"ecr": "0.043"
},
"0001061983": {
"rank": 190,
"ecr": "0.018"
},
"0000879407": {
"rank": 191,
"ecr": "0.012"
},
"0001355790": {
"rank": 192,
"ecr": "0.0038"
},
"0000707511": {
"rank": 193,
"ecr": "0.0029"
},
"0001183765": {
"rank": 194,
"ecr": "0.0015"
},
"0001069308": {
"rank": 195,
"ecr": "0.00000000042"
},
"0001410098": {
"rank": 196,
"ecr": "0.00000000000014"
}
}
},
"rating_box": [
[
"Top rated",
"49 of 196"
],
[
"Best, worst rating",
"501 %, < 0.001 %"
],
[
"New companies",
"167"
]
],
"regression_plot": "https://www.realrate-archive.com/us_pharma/2011/backtesting_correlation/regression_2011.svg",
"scentences": [
"Allergan INC climbed -8 positions from 6 to 14 due to its excellent Stockholders Equity.",
"Musclepharm Corp lost 146 positions from 31 to 177 due to its bad Stockholders Equity.",
"Acura Pharmaceuticals INC entered the 2012 ranking at rank 1, making it the best newcomer."
],
"url_segment": "2012-us-pharma",
"year": 2012,
"feature_importance": "https://www.realrate-archive.com/us_pharma/2011/feature_importance/feature_importance.svg",
"obs_ecr": {
"0000001800": {
"2011": {
"obs_EconomicCapitalRatio": 1.713107979288017
},
"2012": {
"obs_EconomicCapitalRatio": 1.9818897856107043
},
"2013": {
"obs_EconomicCapitalRatio": 1.769123933983911
},
"2014": {
"obs_EconomicCapitalRatio": 2.1310058713021722
},
"2015": {
"obs_EconomicCapitalRatio": 2.183359905306885
},
"2016": {
"obs_EconomicCapitalRatio": 1.5961090407785672
},
"2017": {
"obs_EconomicCapitalRatio": 2.000468071061702
},
"2018": {
"obs_EconomicCapitalRatio": 2.810827504766453
},
"2019": {
"obs_EconomicCapitalRatio": 3.481865615110975
},
"2020": {
"obs_EconomicCapitalRatio": 4.107812733572192
},
"2021": {
"obs_EconomicCapitalRatio": 5.136856213515629
},
"2022": {
"obs_EconomicCapitalRatio": 3.9093024416771485
},
"2023": {
"obs_EconomicCapitalRatio": 4.126727193145108
},
"2024": {
"obs_EconomicCapitalRatio": 4.006765354897495
},
"2025": {
"obs_EconomicCapitalRatio": 4.169990837258094
}
},
"0000059478": {
"2011": {
"obs_EconomicCapitalRatio": 1.3011542204549682
},
"2012": {
"obs_EconomicCapitalRatio": 1.6073698634051163
},
"2013": {
"obs_EconomicCapitalRatio": 1.7086734027999013
},
"2014": {
"obs_EconomicCapitalRatio": 2.168132783245762
},
"2015": {
"obs_EconomicCapitalRatio": 2.828430576978719
},
"2016": {
"obs_EconomicCapitalRatio": 2.1987283790775205
},
"2017": {
"obs_EconomicCapitalRatio": 2.123950765224203
},
"2018": {
"obs_EconomicCapitalRatio": 2.731455167628783
},
"2019": {
"obs_EconomicCapitalRatio": 3.077422071844895
},
"2020": {
"obs_EconomicCapitalRatio": 3.4529271354729705
},
"2021": {
"obs_EconomicCapitalRatio": 5.70344420672454
},
"2022": {
"obs_EconomicCapitalRatio": 7.6589144018063715
},
"2023": {
"obs_EconomicCapitalRatio": 9.17322017661815
},
"2024": {
"obs_EconomicCapitalRatio": 10.183951826657761
},
"2025": {
"obs_EconomicCapitalRatio": 10.21482121245407
}
},
"0000078003": {
"2011": {
"obs_EconomicCapitalRatio": 0.6204658798489293
},
"2012": {
"obs_EconomicCapitalRatio": 0.7275629998959219
},
"2013": {
"obs_EconomicCapitalRatio": 0.8708003565331511
},
"2014": {
"obs_EconomicCapitalRatio": 0.9027716576964234
},
"2015": {
"obs_EconomicCapitalRatio": 0.9342018064245718
},
"2016": {
"obs_EconomicCapitalRatio": 0.907660993640416
},
"2019": {
"obs_EconomicCapitalRatio": 1.1640232368871106
},
"2020": {
"obs_EconomicCapitalRatio": 1.2783936545298629
},
"2021": {
"obs_EconomicCapitalRatio": 1.8276579049294321
},
"2022": {
"obs_EconomicCapitalRatio": 1.570764514575865
},
"2023": {
"obs_EconomicCapitalRatio": 0.7485848149955884
},
"2024": {
"obs_EconomicCapitalRatio": 0.8004626854205364
},
"2025": {
"obs_EconomicCapitalRatio": 0.8358387669038688
}
},
"0000310158": {
"2011": {
"obs_EconomicCapitalRatio": 1.1838108948285708
},
"2012": {
"obs_EconomicCapitalRatio": 1.3266057959183948
},
"2013": {
"obs_EconomicCapitalRatio": 1.5875598350732738
},
"2014": {
"obs_EconomicCapitalRatio": 1.9668047289520008
},
"2015": {
"obs_EconomicCapitalRatio": 1.765264109808397
},
"2016": {
"obs_EconomicCapitalRatio": 2.179324674206441
},
"2017": {
"obs_EconomicCapitalRatio": 2.2179160781193725
},
"2018": {
"obs_EconomicCapitalRatio": 2.918914539340223
},
"2019": {
"obs_EconomicCapitalRatio": 3.5493653686617934
},
"2020": {
"obs_EconomicCapitalRatio": 2.861832807217268
},
"2021": {
"obs_EconomicCapitalRatio": 2.598974464066237
},
"2022": {
"obs_EconomicCapitalRatio": 3.7956011713029745
},
"2024": {
"obs_EconomicCapitalRatio": 3.2845310383661435
},
"2025": {
"obs_EconomicCapitalRatio": 3.1141288688122706
}
},
"0000200406": {
"2011": {
"obs_EconomicCapitalRatio": 1.585118624542793
},
"2012": {
"obs_EconomicCapitalRatio": 1.504690567647153
},
"2013": {
"obs_EconomicCapitalRatio": 1.9242798191550312
},
"2014": {
"obs_EconomicCapitalRatio": 2.2278890509924185
},
"2016": {
"obs_EconomicCapitalRatio": 2.4777357391297277
},
"2017": {
"obs_EconomicCapitalRatio": 2.3520652022077133
},
"2018": {
"obs_EconomicCapitalRatio": 2.2634671786176646
},
"2019": {
"obs_EconomicCapitalRatio": 2.5042625665138107
},
"2021": {
"obs_EconomicCapitalRatio": 2.7314212375357267
},
"2022": {
"obs_EconomicCapitalRatio": 2.878621220487235
},
"2023": {
"obs_EconomicCapitalRatio": 2.6197519723699583
},
"2024": {
"obs_EconomicCapitalRatio": 2.3191305413843795
},
"2025": {
"obs_EconomicCapitalRatio": 3.119823423001993
}
},
"0000872589": {
"2011": {
"obs_EconomicCapitalRatio": 4.582076910345481
},
"2012": {
"obs_EconomicCapitalRatio": 0.24585036111793895
},
"2013": {
"obs_EconomicCapitalRatio": 0.2815811600194353
},
"2014": {
"obs_EconomicCapitalRatio": 0.3100470608736094
},
"2015": {
"obs_EconomicCapitalRatio": 0.27182465887451096
},
"2016": {
"obs_EconomicCapitalRatio": 0.14892623314075953
},
"2017": {
"obs_EconomicCapitalRatio": 0.12780427752058388
},
"2018": {
"obs_EconomicCapitalRatio": 0.09353815222614291
},
"2019": {
"obs_EconomicCapitalRatio": 0.07405318854905384
},
"2020": {
"obs_EconomicCapitalRatio": 0.07704699466107758
},
"2021": {
"obs_EconomicCapitalRatio": 0.0708054489047348
},
"2022": {
"obs_EconomicCapitalRatio": 0.0728389877336521
},
"2023": {
"obs_EconomicCapitalRatio": 0.0762989818667771
},
"2024": {
"obs_EconomicCapitalRatio": 0.05570410882668733
},
"2025": {
"obs_EconomicCapitalRatio": 0.056457061472648826
}
},
"0000874015": {
"2011": {
"obs_EconomicCapitalRatio": 1.7488613998301505
},
"2012": {
"obs_EconomicCapitalRatio": 2.270155255658294
},
"2013": {
"obs_EconomicCapitalRatio": 7.062785583504883
},
"2014": {
"obs_EconomicCapitalRatio": 8.820019473688006
},
"2015": {
"obs_EconomicCapitalRatio": 8.300195128294876
},
"2016": {
"obs_EconomicCapitalRatio": 7.244631215797163
},
"2017": {
"obs_EconomicCapitalRatio": 5.7055360292456125
},
"2018": {
"obs_EconomicCapitalRatio": 3.4034656712267033
},
"2019": {
"obs_EconomicCapitalRatio": 3.6247798271585627
},
"2020": {
"obs_EconomicCapitalRatio": 4.057757935086542
},
"2021": {
"obs_EconomicCapitalRatio": 2.0111035177647114
},
"2022": {
"obs_EconomicCapitalRatio": 2.405605379604031
},
"2023": {
"obs_EconomicCapitalRatio": 2.5857751168273673
},
"2025": {
"obs_EconomicCapitalRatio": 3.8706342956245274
}
},
"0000875320": {
"2011": {
"obs_EconomicCapitalRatio": 4.011950728873362
},
"2012": {
"obs_EconomicCapitalRatio": 4.271057005011649
},
"2013": {
"obs_EconomicCapitalRatio": 10.465959059153883
},
"2014": {
"obs_EconomicCapitalRatio": 15.896010008565815
},
"2015": {
"obs_EconomicCapitalRatio": 15.592867642583915
},
"2016": {
"obs_EconomicCapitalRatio": 8.296574202463598
},
"2017": {
"obs_EconomicCapitalRatio": 14.958650129119075
},
"2018": {
"obs_EconomicCapitalRatio": 10.253923586592718
},
"2019": {
"obs_EconomicCapitalRatio": 10.706680332118959
},
"2020": {
"obs_EconomicCapitalRatio": 8.238943652191004
},
"2021": {
"obs_EconomicCapitalRatio": 6.737638276287789
},
"2022": {
"obs_EconomicCapitalRatio": 6.652462385791637
},
"2023": {
"obs_EconomicCapitalRatio": 7.506270617948925
},
"2024": {
"obs_EconomicCapitalRatio": 7.310208963840968
},
"2025": {
"obs_EconomicCapitalRatio": 7.120028571708822
}
},
"0000885590": {
"2011": {
"obs_EconomicCapitalRatio": 1.2666859338583747
},
"2012": {
"obs_EconomicCapitalRatio": 1.133546210262225
},
"2013": {
"obs_EconomicCapitalRatio": 1.4857321204621172
},
"2014": {
"obs_EconomicCapitalRatio": 2.022848068353309
},
"2015": {
"obs_EconomicCapitalRatio": 0.8112057344714052
},
"2017": {
"obs_EconomicCapitalRatio": 0.2138501706421959
},
"2018": {
"obs_EconomicCapitalRatio": 0.21104827651258354
},
"2019": {
"obs_EconomicCapitalRatio": 0.31527749153545165
},
"2020": {
"obs_EconomicCapitalRatio": 0.23248358716778134
},
"2021": {
"obs_EconomicCapitalRatio": 0.339482039945958
},
"2022": {
"obs_EconomicCapitalRatio": 0.09104758594800844
},
"2023": {
"obs_EconomicCapitalRatio": 0.09992833157007878
},
"2024": {
"obs_EconomicCapitalRatio": 0.10434237028585064
},
"2025": {
"obs_EconomicCapitalRatio": 0.09893661457111663
}
},
"0001048477": {
"2011": {
"obs_EconomicCapitalRatio": 4.191088034178572
},
"2012": {
"obs_EconomicCapitalRatio": 5.537160403950625
},
"2013": {
"obs_EconomicCapitalRatio": 6.234147377653601
},
"2014": {
"obs_EconomicCapitalRatio": 7.769566635963881
},
"2015": {
"obs_EconomicCapitalRatio": 6.696971026740999
},
"2016": {
"obs_EconomicCapitalRatio": 5.5154730752925385
},
"2017": {
"obs_EconomicCapitalRatio": 4.9407181151439135
},
"2018": {
"obs_EconomicCapitalRatio": 5.116817632896571
},
"2019": {
"obs_EconomicCapitalRatio": 4.872335389121422
},
"2020": {
"obs_EconomicCapitalRatio": 4.209123471121257
},
"2021": {
"obs_EconomicCapitalRatio": 4.250038133443851
},
"2022": {
"obs_EconomicCapitalRatio": 4.766788663625819
},
"2023": {
"obs_EconomicCapitalRatio": 4.161003152678966
},
"2024": {
"obs_EconomicCapitalRatio": 3.023712826972472
},
"2025": {
"obs_EconomicCapitalRatio": 2.5199974939053984
}
},
"0001082554": {
"2011": {
"obs_EconomicCapitalRatio": 2.5911979399197222
},
"2012": {
"obs_EconomicCapitalRatio": 2.465978801573956
},
"2013": {
"obs_EconomicCapitalRatio": 3.924599868968605
},
"2014": {
"obs_EconomicCapitalRatio": 4.970769469753602
},
"2015": {
"obs_EconomicCapitalRatio": 5.218004291411121
},
"2016": {
"obs_EconomicCapitalRatio": 4.35971495180887
},
"2017": {
"obs_EconomicCapitalRatio": 3.262507002920337
},
"2018": {
"obs_EconomicCapitalRatio": 2.2953600704628623
},
"2019": {
"obs_EconomicCapitalRatio": 1.5558122744235194
},
"2020": {
"obs_EconomicCapitalRatio": 2.270010361107863
},
"2021": {
"obs_EconomicCapitalRatio": 3.0205299234286707
},
"2022": {
"obs_EconomicCapitalRatio": 3.437755821443613
},
"2023": {
"obs_EconomicCapitalRatio": 2.471650006778008
},
"2024": {
"obs_EconomicCapitalRatio": 3.880904249672765
},
"2025": {
"obs_EconomicCapitalRatio": 5.057179921650618
}
},
"0001178670": {
"2011": {
"obs_EconomicCapitalRatio": 1.5487006572365678
},
"2012": {
"obs_EconomicCapitalRatio": 4.348978489565005
},
"2013": {
"obs_EconomicCapitalRatio": 14.4117591901869
},
"2014": {
"obs_EconomicCapitalRatio": 12.210984605617043
},
"2015": {
"obs_EconomicCapitalRatio": 10.225771894885957
},
"2016": {
"obs_EconomicCapitalRatio": 4.357512767955176
},
"2017": {
"obs_EconomicCapitalRatio": 10.37169962203894
},
"2018": {
"obs_EconomicCapitalRatio": 7.48962729612636
},
"2019": {
"obs_EconomicCapitalRatio": 7.779988241681978
},
"2020": {
"obs_EconomicCapitalRatio": 5.528023267295534
},
"2021": {
"obs_EconomicCapitalRatio": 6.399472454496644
},
"2022": {
"obs_EconomicCapitalRatio": 8.062817835829533
},
"2023": {
"obs_EconomicCapitalRatio": 6.027810663540046
},
"2024": {
"obs_EconomicCapitalRatio": 7.376380265814746
},
"2025": {
"obs_EconomicCapitalRatio": 11.523330894989943
}
},
"0000025743": {
"2011": {
"obs_EconomicCapitalRatio": 60.20949105963872
},
"2012": {
"obs_EconomicCapitalRatio": 44.69064821898129
},
"2013": {
"obs_EconomicCapitalRatio": 21.201251272186344
},
"2014": {
"obs_EconomicCapitalRatio": 19.322141949843708
},
"2015": {
"obs_EconomicCapitalRatio": 44.10663573129477
},
"2016": {
"obs_EconomicCapitalRatio": 14.66973471892876
},
"2017": {
"obs_EconomicCapitalRatio": 16.58982671505257
},
"2018": {
"obs_EconomicCapitalRatio": 5.458000746358346
},
"2019": {
"obs_EconomicCapitalRatio": 2.484721409784232
},
"2020": {
"obs_EconomicCapitalRatio": 1.3438452828795873
},
"2021": {
"obs_EconomicCapitalRatio": 0.7957005830337637
},
"2022": {
"obs_EconomicCapitalRatio": 0.7475072146889215
},
"2023": {
"obs_EconomicCapitalRatio": 0.8688035841356281
}
},
"0000275053": {
"2011": {
"obs_EconomicCapitalRatio": 1.2531988908057246
},
"2012": {
"obs_EconomicCapitalRatio": 1.1558901920083584
},
"2013": {
"obs_EconomicCapitalRatio": 1.4698845321423835
},
"2014": {
"obs_EconomicCapitalRatio": 1.8506510041043027
},
"2015": {
"obs_EconomicCapitalRatio": 1.3828122477889726
},
"2016": {
"obs_EconomicCapitalRatio": 1.8800614803325786
},
"2017": {
"obs_EconomicCapitalRatio": 1.5906624242068597
},
"2018": {
"obs_EconomicCapitalRatio": 1.0639683885140225
},
"2019": {
"obs_EconomicCapitalRatio": 1.1261240844321403
},
"2020": {
"obs_EconomicCapitalRatio": 1.614631166398386
},
"2021": {
"obs_EconomicCapitalRatio": 2.041252601886645
},
"2022": {
"obs_EconomicCapitalRatio": 1.0248487934144268
},
"2023": {
"obs_EconomicCapitalRatio": 1.9759150347492755
},
"2024": {
"obs_EconomicCapitalRatio": 1.733962234691023
},
"2025": {
"obs_EconomicCapitalRatio": 2.1266911651471774
}
},
"0000315545": {
"2011": {
"obs_EconomicCapitalRatio": 9.728230006085877
},
"2012": {
"obs_EconomicCapitalRatio": 15.887423730276764
},
"2016": {
"obs_EconomicCapitalRatio": 1.0066834133413627
},
"2021": {
"obs_EconomicCapitalRatio": 3.8900064558665526
},
"2022": {
"obs_EconomicCapitalRatio": 8.87714792904606
},
"2023": {
"obs_EconomicCapitalRatio": 7.797781413794207
},
"2024": {
"obs_EconomicCapitalRatio": 12.847856868898074
},
"2025": {
"obs_EconomicCapitalRatio": 6.551754447968051
}
},
"0000318306": {
"2011": {
"obs_EconomicCapitalRatio": 3.1752133102955193
},
"2015": {
"obs_EconomicCapitalRatio": 2.5013091166697334
},
"2016": {
"obs_EconomicCapitalRatio": 3.069615158757255
},
"2017": {
"obs_EconomicCapitalRatio": 7.910921427809256
},
"2018": {
"obs_EconomicCapitalRatio": 3.0094651589500496
},
"2019": {
"obs_EconomicCapitalRatio": 1.3725865674867888
},
"2020": {
"obs_EconomicCapitalRatio": 1.5776662593509971
},
"2021": {
"obs_EconomicCapitalRatio": 0.605095364063935
},
"2022": {
"obs_EconomicCapitalRatio": 0.878496970737568
},
"2023": {
"obs_EconomicCapitalRatio": 2.1538587998309753
},
"2024": {
"obs_EconomicCapitalRatio": 2.8283640249010116
},
"2025": {
"obs_EconomicCapitalRatio": 2.046279329648632
}
},
"0000715446": {
"2012": {
"obs_EconomicCapitalRatio": 8.892991148763185
},
"2014": {
"obs_EconomicCapitalRatio": 3.6906327637788694
},
"2015": {
"obs_EconomicCapitalRatio": 3.876288621898964
},
"2017": {
"obs_EconomicCapitalRatio": 7.917082397538187
},
"2018": {
"obs_EconomicCapitalRatio": 18.202537277953734
},
"2019": {
"obs_EconomicCapitalRatio": 15.15218182490549
},
"2020": {
"obs_EconomicCapitalRatio": 12.697740921912375
},
"2021": {
"obs_EconomicCapitalRatio": 4.776368566800651
},
"2022": {
"obs_EconomicCapitalRatio": 7.387227293212897
},
"2023": {
"obs_EconomicCapitalRatio": 8.690130111527727
},
"2024": {
"obs_EconomicCapitalRatio": 6.821617650312289
},
"2025": {
"obs_EconomicCapitalRatio": 11.76766152312355
}
},
"0000748592": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.6925555190903209
},
"2023": {
"obs_EconomicCapitalRatio": 0.22247029122106401
},
"2024": {
"obs_EconomicCapitalRatio": 3.3355484422032364
},
"2025": {
"obs_EconomicCapitalRatio": 2.100490419769073
}
},
"0000749647": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 1.2119887459957592
},
"2018": {
"obs_EconomicCapitalRatio": 0.7571314740855524
},
"2019": {
"obs_EconomicCapitalRatio": 1.1777291102712146
},
"2020": {
"obs_EconomicCapitalRatio": 0.9468259412544934
},
"2022": {
"obs_EconomicCapitalRatio": 0.3413380313211731
},
"2023": {
"obs_EconomicCapitalRatio": 0.46505525070218745
},
"2024": {
"obs_EconomicCapitalRatio": 1.5915148096808187
},
"2025": {
"obs_EconomicCapitalRatio": 1.2902447483616575
}
},
"0000791908": {
"2011": {
"obs_EconomicCapitalRatio": 0.5583856749916702
},
"2012": {
"obs_EconomicCapitalRatio": 2.1709958491689902
},
"2013": {
"obs_EconomicCapitalRatio": 4.620702296336393
},
"2014": {
"obs_EconomicCapitalRatio": 4.499100115951777
},
"2015": {
"obs_EconomicCapitalRatio": 2.1564470760800925
},
"2016": {
"obs_EconomicCapitalRatio": 0.6280492703738663
},
"2017": {
"obs_EconomicCapitalRatio": 6.4554819522962195
},
"2018": {
"obs_EconomicCapitalRatio": 1.9052029000318187
},
"2019": {
"obs_EconomicCapitalRatio": 3.265630189155313
},
"2020": {
"obs_EconomicCapitalRatio": 5.954049697671537
},
"2021": {
"obs_EconomicCapitalRatio": 2.601758183620559
},
"2022": {
"obs_EconomicCapitalRatio": 2.5787179787158876
},
"2023": {
"obs_EconomicCapitalRatio": 1.1152712280926076
}
},
"0000812796": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 1.3457726017492695
},
"2017": {
"obs_EconomicCapitalRatio": 2.662725746021708
},
"2018": {
"obs_EconomicCapitalRatio": 1.0112986820465009
},
"2019": {
"obs_EconomicCapitalRatio": 3.9109096857646555
},
"2020": {
"obs_EconomicCapitalRatio": 2.1465813648935557
},
"2021": {
"obs_EconomicCapitalRatio": 1.4351857012915932
},
"2022": {
"obs_EconomicCapitalRatio": 1.6716849128061206
},
"2023": {
"obs_EconomicCapitalRatio": 0.7417373755183468
},
"2024": {
"obs_EconomicCapitalRatio": 1.0535798266037453
}
},
"0000832489": {
"2020": {
"obs_EconomicCapitalRatio": 2.533577843676224
},
"2022": {
"obs_EconomicCapitalRatio": 0.9397960609714056
},
"2023": {
"obs_EconomicCapitalRatio": 1.6326053628418118
},
"2024": {
"obs_EconomicCapitalRatio": 3.8621601278642066
},
"2025": {
"obs_EconomicCapitalRatio": 1.1837070965076288
}
},
"0000849146": {
"2011": {
"obs_EconomicCapitalRatio": 5.133799114691684
},
"2012": {
"obs_EconomicCapitalRatio": 7.0759325639561705
},
"2013": {
"obs_EconomicCapitalRatio": 3.8064085468765803
},
"2014": {
"obs_EconomicCapitalRatio": 2.169949711761878
},
"2015": {
"obs_EconomicCapitalRatio": 2.73458678948633
},
"2016": {
"obs_EconomicCapitalRatio": 2.270039911669275
},
"2017": {
"obs_EconomicCapitalRatio": 1.5925782016539693
},
"2018": {
"obs_EconomicCapitalRatio": 3.884682222330364
},
"2019": {
"obs_EconomicCapitalRatio": 4.525643174601984
},
"2020": {
"obs_EconomicCapitalRatio": 2.824684450107507
},
"2021": {
"obs_EconomicCapitalRatio": 1.2348824711451079
},
"2022": {
"obs_EconomicCapitalRatio": 0.7537315251607775
},
"2023": {
"obs_EconomicCapitalRatio": 1.5398212604493489
},
"2024": {
"obs_EconomicCapitalRatio": 4.544921489881177
}
},
"0000863894": {
"2011": {
"obs_EconomicCapitalRatio": 10.700068515838652
},
"2015": {
"obs_EconomicCapitalRatio": 2.006174387707465
},
"2016": {
"obs_EconomicCapitalRatio": 1.4325559018195881
},
"2017": {
"obs_EconomicCapitalRatio": 2.1228772969992913
},
"2018": {
"obs_EconomicCapitalRatio": 2.4982538018636133
},
"2019": {
"obs_EconomicCapitalRatio": 5.21705955273325
},
"2020": {
"obs_EconomicCapitalRatio": 16.967671288010344
},
"2021": {
"obs_EconomicCapitalRatio": 4.876334264454306
},
"2022": {
"obs_EconomicCapitalRatio": 4.237261674743829
},
"2023": {
"obs_EconomicCapitalRatio": 1.6059750284116059
},
"2024": {
"obs_EconomicCapitalRatio": 2.149766238076027
},
"2025": {
"obs_EconomicCapitalRatio": 1.7665972830796772
}
},
"0000879407": {
"2011": {
"obs_EconomicCapitalRatio": 4.558164646367193
},
"2012": {
"obs_EconomicCapitalRatio": 2.7337420538024295
},
"2013": {
"obs_EconomicCapitalRatio": 16.935793379415518
},
"2014": {
"obs_EconomicCapitalRatio": 3.5359828982433434
},
"2015": {
"obs_EconomicCapitalRatio": 4.70934763569825
},
"2016": {
"obs_EconomicCapitalRatio": 1.3333215592276315
},
"2017": {
"obs_EconomicCapitalRatio": 4.183361895725003
},
"2018": {
"obs_EconomicCapitalRatio": 17.57601912062697
},
"2019": {
"obs_EconomicCapitalRatio": 27.19874135672785
},
"2020": {
"obs_EconomicCapitalRatio": 28.20740718699276
},
"2021": {
"obs_EconomicCapitalRatio": 14.158611567248395
},
"2022": {
"obs_EconomicCapitalRatio": 8.308844151619333
},
"2023": {
"obs_EconomicCapitalRatio": 5.212086989973918
},
"2024": {
"obs_EconomicCapitalRatio": 2.325391915553657
},
"2025": {
"obs_EconomicCapitalRatio": 8.216237250704822
}
},
"0000886163": {
"2011": {
"obs_EconomicCapitalRatio": 2.0528169474592
},
"2012": {
"obs_EconomicCapitalRatio": 4.688551600471962
},
"2016": {
"obs_EconomicCapitalRatio": 5.191668762826494
},
"2017": {
"obs_EconomicCapitalRatio": 6.247336815338922
},
"2018": {
"obs_EconomicCapitalRatio": 2.9187542937303745
},
"2019": {
"obs_EconomicCapitalRatio": 1.6909103782381305
},
"2020": {
"obs_EconomicCapitalRatio": 1.6235498567426718
},
"2021": {
"obs_EconomicCapitalRatio": 2.9450386595365905
},
"2022": {
"obs_EconomicCapitalRatio": 2.3986179476784764
},
"2025": {
"obs_EconomicCapitalRatio": 3.675901913739014
}
},
"0000886744": {
"2011": {
"obs_EconomicCapitalRatio": 2.1521859391249407
},
"2012": {
"obs_EconomicCapitalRatio": 3.557226129775963
},
"2013": {
"obs_EconomicCapitalRatio": 16.540241022155513
},
"2014": {
"obs_EconomicCapitalRatio": 4.731529553667248
},
"2015": {
"obs_EconomicCapitalRatio": 9.876524947988056
},
"2016": {
"obs_EconomicCapitalRatio": 4.793318515735717
},
"2017": {
"obs_EconomicCapitalRatio": 5.111053783735203
},
"2018": {
"obs_EconomicCapitalRatio": 1.9713747376326156
},
"2019": {
"obs_EconomicCapitalRatio": 2.9500565017262677
},
"2020": {
"obs_EconomicCapitalRatio": 3.0435783432248256
},
"2021": {
"obs_EconomicCapitalRatio": 2.6099809060401853
},
"2022": {
"obs_EconomicCapitalRatio": 5.278895972838991
},
"2025": {
"obs_EconomicCapitalRatio": 1.876268265003127
}
},
"0000890821": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0000897448": {
"2011": {
"obs_EconomicCapitalRatio": 7.060017923283657
}
},
"0000899460": {
"2011": {
"obs_EconomicCapitalRatio": 0.987680321189219
},
"2012": {
"obs_EconomicCapitalRatio": 1.7592520406979646
},
"2013": {
"obs_EconomicCapitalRatio": 6.741934446075487
},
"2014": {
"obs_EconomicCapitalRatio": 5.074493209423393
},
"2015": {
"obs_EconomicCapitalRatio": 2.0503086064890024
},
"2016": {
"obs_EconomicCapitalRatio": 1.6718936044598256
},
"2017": {
"obs_EconomicCapitalRatio": 1.4830988576198576
},
"2018": {
"obs_EconomicCapitalRatio": 0.9114209531413758
},
"2019": {
"obs_EconomicCapitalRatio": 1.4635164586620224
},
"2020": {
"obs_EconomicCapitalRatio": 3.966029438015374
},
"2021": {
"obs_EconomicCapitalRatio": 2.5902381462411137
},
"2022": {
"obs_EconomicCapitalRatio": 3.198017637267306
}
},
"0000906709": {
"2011": {
"obs_EconomicCapitalRatio": 1.2198840615029938
},
"2012": {
"obs_EconomicCapitalRatio": 1.7021961631875409
},
"2013": {
"obs_EconomicCapitalRatio": 2.7465545409505356
},
"2014": {
"obs_EconomicCapitalRatio": 4.680730778508984
},
"2015": {
"obs_EconomicCapitalRatio": 4.5531019930727235
},
"2016": {
"obs_EconomicCapitalRatio": 3.6584647178446996
},
"2017": {
"obs_EconomicCapitalRatio": 19.71925223631124
},
"2018": {
"obs_EconomicCapitalRatio": 4.447823678924978
},
"2019": {
"obs_EconomicCapitalRatio": 2.9932544199314077
},
"2020": {
"obs_EconomicCapitalRatio": 3.349493049250769
},
"2021": {
"obs_EconomicCapitalRatio": 3.5440957945153957
},
"2022": {
"obs_EconomicCapitalRatio": 0.8167920134851411
}
},
"0000908259": {
"2011": {
"obs_EconomicCapitalRatio": 2.2928948216517826
},
"2012": {
"obs_EconomicCapitalRatio": 29.962434305066648
},
"2013": {
"obs_EconomicCapitalRatio": 1.8595490030165929
},
"2014": {
"obs_EconomicCapitalRatio": 2.0938306536143934
},
"2018": {
"obs_EconomicCapitalRatio": 3.38121902646468
},
"2019": {
"obs_EconomicCapitalRatio": 0.9813033712527973
},
"2021": {
"obs_EconomicCapitalRatio": 3.0536485439404255
},
"2022": {
"obs_EconomicCapitalRatio": 0.7373792125771812
},
"2023": {
"obs_EconomicCapitalRatio": 0.6595581698615146
},
"2024": {
"obs_EconomicCapitalRatio": 0.5326676859160112
},
"2025": {
"obs_EconomicCapitalRatio": 0.15128398062521595
}
},
"0000944809": {
"2011": {
"obs_EconomicCapitalRatio": 10.212715569467793
},
"2012": {
"obs_EconomicCapitalRatio": 7.462920051834949
},
"2013": {
"obs_EconomicCapitalRatio": 3.7615161019547734
},
"2014": {
"obs_EconomicCapitalRatio": 4.924906406362779
},
"2015": {
"obs_EconomicCapitalRatio": 3.049230320818117
},
"2016": {
"obs_EconomicCapitalRatio": 3.790950737489276
},
"2017": {
"obs_EconomicCapitalRatio": 1.6797136409187279
},
"2018": {
"obs_EconomicCapitalRatio": 1.000574746336909
},
"2019": {
"obs_EconomicCapitalRatio": 0.6714096811879043
},
"2020": {
"obs_EconomicCapitalRatio": 1.7371110357496995
},
"2021": {
"obs_EconomicCapitalRatio": 2.095893547803228
},
"2022": {
"obs_EconomicCapitalRatio": 0.6548492146984649
},
"2023": {
"obs_EconomicCapitalRatio": 0.9273707539895665
},
"2024": {
"obs_EconomicCapitalRatio": 0.6813640563694751
}
},
"0001001316": {
"2011": {
"obs_EconomicCapitalRatio": 0.02094069371323602
},
"2014": {
"obs_EconomicCapitalRatio": 15.082869869678678
},
"2016": {
"obs_EconomicCapitalRatio": 7.018209109082157
},
"2017": {
"obs_EconomicCapitalRatio": 9.289800999999851
},
"2018": {
"obs_EconomicCapitalRatio": 4.428644142234769
},
"2019": {
"obs_EconomicCapitalRatio": 7.527390932886038
},
"2020": {
"obs_EconomicCapitalRatio": 19.08396570545782
},
"2021": {
"obs_EconomicCapitalRatio": 10.30790574467113
}
},
"0001016504": {
"2011": {
"obs_EconomicCapitalRatio": 0.035945261091117155
},
"2012": {
"obs_EconomicCapitalRatio": 0.18525507371166935
},
"2013": {
"obs_EconomicCapitalRatio": 0.22557068088200882
},
"2014": {
"obs_EconomicCapitalRatio": 0.11401012787599316
},
"2015": {
"obs_EconomicCapitalRatio": 0.1231491667258505
},
"2016": {
"obs_EconomicCapitalRatio": 0.2446976706070115
},
"2017": {
"obs_EconomicCapitalRatio": 0.20948385072936013
},
"2018": {
"obs_EconomicCapitalRatio": 0.2563069722468672
},
"2019": {
"obs_EconomicCapitalRatio": 0.37656625156663687
},
"2020": {
"obs_EconomicCapitalRatio": 1.1464993618718018
},
"2021": {
"obs_EconomicCapitalRatio": 1.697303158889242
},
"2022": {
"obs_EconomicCapitalRatio": 0.7974054290207178
},
"2023": {
"obs_EconomicCapitalRatio": 0.47029170963407396
},
"2024": {
"obs_EconomicCapitalRatio": 0.580653182102171
}
},
"0001023024": {
"2025": {
"obs_EconomicCapitalRatio": 1.5697482097453828
}
},
"0001034842": {
"2011": {
"obs_EconomicCapitalRatio": 4.184973940587285
},
"2018": {
"obs_EconomicCapitalRatio": 4.53448892985124
},
"2019": {
"obs_EconomicCapitalRatio": 3.4290834421731513
},
"2020": {
"obs_EconomicCapitalRatio": 8.246867354558892
},
"2021": {
"obs_EconomicCapitalRatio": 4.014400705411107
},
"2022": {
"obs_EconomicCapitalRatio": 1.531292181419975
},
"2023": {
"obs_EconomicCapitalRatio": 1.782837907433584
},
"2024": {
"obs_EconomicCapitalRatio": 1.8533923185575185
}
},
"0001041024": {
"2011": {
"obs_EconomicCapitalRatio": 6.864401419926169
},
"2012": {
"obs_EconomicCapitalRatio": 7.665477298235786
},
"2013": {
"obs_EconomicCapitalRatio": 16.200961448783545
},
"2014": {
"obs_EconomicCapitalRatio": 6.823227479640062
},
"2015": {
"obs_EconomicCapitalRatio": 10.781551495937341
},
"2016": {
"obs_EconomicCapitalRatio": 7.080561630250149
},
"2017": {
"obs_EconomicCapitalRatio": 9.204121624289595
},
"2018": {
"obs_EconomicCapitalRatio": 3.7248376391274483
},
"2019": {
"obs_EconomicCapitalRatio": 4.411810117408765
},
"2020": {
"obs_EconomicCapitalRatio": 1.534718360025618
},
"2021": {
"obs_EconomicCapitalRatio": 0.7865871894137169
},
"2022": {
"obs_EconomicCapitalRatio": 0.2909490633684185
},
"2023": {
"obs_EconomicCapitalRatio": 1.2794707220084427
},
"2024": {
"obs_EconomicCapitalRatio": 1.5814864872422232
}
},
"0001061983": {
"2011": {
"obs_EconomicCapitalRatio": 2.499653747304144
},
"2012": {
"obs_EconomicCapitalRatio": 2.265925122836351
},
"2013": {
"obs_EconomicCapitalRatio": 3.4818397980547005
},
"2014": {
"obs_EconomicCapitalRatio": 2.398166528838458
},
"2015": {
"obs_EconomicCapitalRatio": 5.132953958619455
},
"2016": {
"obs_EconomicCapitalRatio": 4.003531368306603
},
"2017": {
"obs_EconomicCapitalRatio": 1.886835990998462
},
"2018": {
"obs_EconomicCapitalRatio": 1.7279073639824796
},
"2019": {
"obs_EconomicCapitalRatio": 2.0578846433493947
},
"2020": {
"obs_EconomicCapitalRatio": 3.0945606278198854
},
"2021": {
"obs_EconomicCapitalRatio": 5.258808656390064
},
"2022": {
"obs_EconomicCapitalRatio": 4.01908917413911
}
},
"0001062822": {
"2011": {
"obs_EconomicCapitalRatio": 1.3677650735673388
},
"2012": {
"obs_EconomicCapitalRatio": 4.183731183292958
},
"2013": {
"obs_EconomicCapitalRatio": 4.9070900906027735
},
"2014": {
"obs_EconomicCapitalRatio": 1.4003761344938945
},
"2015": {
"obs_EconomicCapitalRatio": 2.704397422234801
},
"2017": {
"obs_EconomicCapitalRatio": 2.617264752541097
},
"2018": {
"obs_EconomicCapitalRatio": 2.3298433436614046
},
"2019": {
"obs_EconomicCapitalRatio": 1.2634354219312478
},
"2020": {
"obs_EconomicCapitalRatio": 3.9708097565733844
},
"2021": {
"obs_EconomicCapitalRatio": 7.685335401596773
},
"2022": {
"obs_EconomicCapitalRatio": 2.688334739503511
},
"2023": {
"obs_EconomicCapitalRatio": 1.727707860094187
},
"2024": {
"obs_EconomicCapitalRatio": 1.1785439552715242
},
"2025": {
"obs_EconomicCapitalRatio": 3.254076663809848
}
},
"0001069530": {
"2011": {
"obs_EconomicCapitalRatio": 1.6920367721878569
},
"2012": {
"obs_EconomicCapitalRatio": 2.353113921576425
},
"2013": {
"obs_EconomicCapitalRatio": 8.035629301696703
},
"2014": {
"obs_EconomicCapitalRatio": 4.453386467914091
},
"2015": {
"obs_EconomicCapitalRatio": 4.863351449111631
},
"2016": {
"obs_EconomicCapitalRatio": 2.8915258260504832
},
"2017": {
"obs_EconomicCapitalRatio": 4.636648807456758
},
"2018": {
"obs_EconomicCapitalRatio": 1.4092308454695395
},
"2019": {
"obs_EconomicCapitalRatio": 5.275240949415371
},
"2020": {
"obs_EconomicCapitalRatio": 3.988044196645427
},
"2021": {
"obs_EconomicCapitalRatio": 12.502340699582172
},
"2022": {
"obs_EconomicCapitalRatio": 10.744987341161343
},
"2023": {
"obs_EconomicCapitalRatio": 12.416401043316418
},
"2024": {
"obs_EconomicCapitalRatio": 1.3663714024841915
},
"2025": {
"obs_EconomicCapitalRatio": 1.3036319444534121
}
},
"0001070494": {
"2011": {
"obs_EconomicCapitalRatio": 2.932953680881476
},
"2012": {
"obs_EconomicCapitalRatio": 4.5529405778863055
},
"2013": {
"obs_EconomicCapitalRatio": 23.302183453643206
},
"2014": {
"obs_EconomicCapitalRatio": 18.54984696092805
},
"2015": {
"obs_EconomicCapitalRatio": 28.934092219944826
},
"2016": {
"obs_EconomicCapitalRatio": 11.449655133128285
},
"2017": {
"obs_EconomicCapitalRatio": 16.67808614739591
},
"2018": {
"obs_EconomicCapitalRatio": 6.5373853496850005
},
"2019": {
"obs_EconomicCapitalRatio": 15.725238773169458
},
"2020": {
"obs_EconomicCapitalRatio": 18.655998772273424
},
"2021": {
"obs_EconomicCapitalRatio": 9.02784999201308
},
"2022": {
"obs_EconomicCapitalRatio": 6.442054975572726
}
},
"0001087294": {
"2011": {
"obs_EconomicCapitalRatio": 2.133325711370675
},
"2012": {
"obs_EconomicCapitalRatio": 1.4741118648312574
},
"2013": {
"obs_EconomicCapitalRatio": 1.9420121698610198
},
"2014": {
"obs_EconomicCapitalRatio": 1.8405724060005366
},
"2016": {
"obs_EconomicCapitalRatio": 1.5541808322415878
},
"2017": {
"obs_EconomicCapitalRatio": 1.889112943592727
},
"2018": {
"obs_EconomicCapitalRatio": 1.1292501763391123
},
"2019": {
"obs_EconomicCapitalRatio": 0.9859121896587316
},
"2021": {
"obs_EconomicCapitalRatio": 1.0973775649988797
},
"2022": {
"obs_EconomicCapitalRatio": 0.4333168488598409
},
"2023": {
"obs_EconomicCapitalRatio": 0.3715399695981037
},
"2024": {
"obs_EconomicCapitalRatio": 0.5087599565594081
},
"2025": {
"obs_EconomicCapitalRatio": 0.963869140200575
}
},
"0001088856": {
"2011": {
"obs_EconomicCapitalRatio": 12.880945590095282
},
"2012": {
"obs_EconomicCapitalRatio": 2.840563583246527
},
"2013": {
"obs_EconomicCapitalRatio": 7.846638973918242
},
"2014": {
"obs_EconomicCapitalRatio": 12.810210834279417
},
"2015": {
"obs_EconomicCapitalRatio": 14.759813082944229
},
"2016": {
"obs_EconomicCapitalRatio": 18.296036223725203
},
"2017": {
"obs_EconomicCapitalRatio": 16.029930900609163
},
"2018": {
"obs_EconomicCapitalRatio": 8.65608179405391
},
"2019": {
"obs_EconomicCapitalRatio": 6.358701486657653
},
"2020": {
"obs_EconomicCapitalRatio": 9.972013421558033
},
"2021": {
"obs_EconomicCapitalRatio": 9.64819974668179
},
"2022": {
"obs_EconomicCapitalRatio": 6.602885091667568
},
"2023": {
"obs_EconomicCapitalRatio": 8.970790437540055
},
"2024": {
"obs_EconomicCapitalRatio": 10.835124023970803
},
"2025": {
"obs_EconomicCapitalRatio": 16.849652464590477
}
},
"0001094038": {
"2017": {
"obs_EconomicCapitalRatio": 12.248591009591806
},
"2022": {
"obs_EconomicCapitalRatio": 0.9337214180332358
},
"2023": {
"obs_EconomicCapitalRatio": 3.7356145408172226
}
},
"0001107421": {
"2011": {
"obs_EconomicCapitalRatio": 4.3489446663070765
},
"2012": {
"obs_EconomicCapitalRatio": 5.827030060175055
},
"2018": {
"obs_EconomicCapitalRatio": 5.6631567818400965
},
"2020": {
"obs_EconomicCapitalRatio": 7.575407591507219
},
"2021": {
"obs_EconomicCapitalRatio": 4.171108524583441
},
"2022": {
"obs_EconomicCapitalRatio": 2.883405722314086
}
},
"0001124105": {
"2011": {
"obs_EconomicCapitalRatio": 0.20196174709409623
},
"2012": {
"obs_EconomicCapitalRatio": 0.2876341525006027
},
"2013": {
"obs_EconomicCapitalRatio": 0.33472830653949776
},
"2015": {
"obs_EconomicCapitalRatio": 0.07621137264136414
},
"2016": {
"obs_EconomicCapitalRatio": 0.039853488863282854
},
"2017": {
"obs_EconomicCapitalRatio": 0.3820750886265207
},
"2018": {
"obs_EconomicCapitalRatio": 0.2297698596314896
},
"2019": {
"obs_EconomicCapitalRatio": 0.2159376702997681
},
"2020": {
"obs_EconomicCapitalRatio": 0.41223677548471455
},
"2021": {
"obs_EconomicCapitalRatio": 0.143358984955954
},
"2022": {
"obs_EconomicCapitalRatio": 0.43278504174366134
}
},
"0001124524": {
"2011": {
"obs_EconomicCapitalRatio": 2.4648333091878083
},
"2012": {
"obs_EconomicCapitalRatio": 1.8593608580180503
},
"2013": {
"obs_EconomicCapitalRatio": 7.3656864720939925
},
"2014": {
"obs_EconomicCapitalRatio": 8.359677065323194
},
"2015": {
"obs_EconomicCapitalRatio": 5.583052291948538
},
"2017": {
"obs_EconomicCapitalRatio": 19.729762301247288
},
"2018": {
"obs_EconomicCapitalRatio": 7.676546478299643
},
"2020": {
"obs_EconomicCapitalRatio": 5.19008689022509
},
"2021": {
"obs_EconomicCapitalRatio": 3.4190316765012354
},
"2022": {
"obs_EconomicCapitalRatio": 1.09260354339657
},
"2023": {
"obs_EconomicCapitalRatio": 1.0997798689853466
}
},
"0001130166": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001133416": {
"2011": {
"obs_EconomicCapitalRatio": 16.88270157281871
},
"2012": {
"obs_EconomicCapitalRatio": 5.842248119350461
},
"2013": {
"obs_EconomicCapitalRatio": 22.267375550627374
},
"2018": {
"obs_EconomicCapitalRatio": 27.945147556095687
},
"2019": {
"obs_EconomicCapitalRatio": 6.382354795772914
},
"2020": {
"obs_EconomicCapitalRatio": 7.956581110405078
},
"2021": {
"obs_EconomicCapitalRatio": 3.287870628790478
},
"2022": {
"obs_EconomicCapitalRatio": 1.8599439115005227
},
"2023": {
"obs_EconomicCapitalRatio": 1.7657258004588605
},
"2025": {
"obs_EconomicCapitalRatio": 3.119665476127909
}
},
"0001133818": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 1.8441117010428738
},
"2019": {
"obs_EconomicCapitalRatio": 1.9003845840591052
},
"2020": {
"obs_EconomicCapitalRatio": 1.8771993245543837
},
"2021": {
"obs_EconomicCapitalRatio": 2.175547460076075
},
"2022": {
"obs_EconomicCapitalRatio": 1.254415758667267
},
"2023": {
"obs_EconomicCapitalRatio": 1.9355732103322663
}
},
"0001160308": {
"2017": {
"obs_EconomicCapitalRatio": 4.745640338481788
},
"2018": {
"obs_EconomicCapitalRatio": 2.608425955539138
},
"2019": {
"obs_EconomicCapitalRatio": 0.8425161535078196
},
"2020": {
"obs_EconomicCapitalRatio": 1.0736826396507102
},
"2021": {
"obs_EconomicCapitalRatio": 1.3531258013583032
},
"2022": {
"obs_EconomicCapitalRatio": 1.9983725428604209
}
},
"0001174940": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 6.639869177624493
},
"2022": {
"obs_EconomicCapitalRatio": 3.4580165138523955
},
"2023": {
"obs_EconomicCapitalRatio": 4.027329150416326
},
"2024": {
"obs_EconomicCapitalRatio": 2.8724066451160235
},
"2025": {
"obs_EconomicCapitalRatio": 0.5801836078992786
}
},
"0001175680": {
"2012": {
"obs_EconomicCapitalRatio": 11.990129245785083
},
"2013": {
"obs_EconomicCapitalRatio": 12.895495155433496
},
"2018": {
"obs_EconomicCapitalRatio": 12.37742571335845
},
"2019": {
"obs_EconomicCapitalRatio": 10.798161833204716
},
"2020": {
"obs_EconomicCapitalRatio": 60.212585469417306
},
"2021": {
"obs_EconomicCapitalRatio": 4.985942038812679
},
"2022": {
"obs_EconomicCapitalRatio": 2.6172100457911642
},
"2023": {
"obs_EconomicCapitalRatio": 3.114671171984183
}
},
"0001226616": {
"2011": {
"obs_EconomicCapitalRatio": 1.537941564786132
},
"2012": {
"obs_EconomicCapitalRatio": 2.3546405810486153
},
"2013": {
"obs_EconomicCapitalRatio": 2.8607221186039924
},
"2014": {
"obs_EconomicCapitalRatio": 4.577912758120495
},
"2015": {
"obs_EconomicCapitalRatio": 4.904665514441517
},
"2016": {
"obs_EconomicCapitalRatio": 10.416358307263954
},
"2017": {
"obs_EconomicCapitalRatio": 10.052119682955091
},
"2018": {
"obs_EconomicCapitalRatio": 8.212750684667608
},
"2019": {
"obs_EconomicCapitalRatio": 7.170880167965075
},
"2020": {
"obs_EconomicCapitalRatio": 6.36238702776273
},
"2021": {
"obs_EconomicCapitalRatio": 2.9543530255773915
},
"2022": {
"obs_EconomicCapitalRatio": 2.575833676860721
}
},
"0001228627": {
"2011": {
"obs_EconomicCapitalRatio": 4.8858943708985025
},
"2012": {
"obs_EconomicCapitalRatio": 2.6145991303811
},
"2013": {
"obs_EconomicCapitalRatio": 5.051688102935165
},
"2014": {
"obs_EconomicCapitalRatio": 6.044271975481872
},
"2015": {
"obs_EconomicCapitalRatio": 4.276801962477386
},
"2016": {
"obs_EconomicCapitalRatio": 2.731363504841381
},
"2017": {
"obs_EconomicCapitalRatio": 3.285683833578194
},
"2018": {
"obs_EconomicCapitalRatio": 3.49693809277238
},
"2019": {
"obs_EconomicCapitalRatio": 0.9733713874489118
},
"2021": {
"obs_EconomicCapitalRatio": 4.329166205231533
},
"2022": {
"obs_EconomicCapitalRatio": 2.1231238489802973
},
"2023": {
"obs_EconomicCapitalRatio": 2.1080021065509533
}
},
"0001232524": {
"2011": {
"obs_EconomicCapitalRatio": 10.532355239038857
},
"2013": {
"obs_EconomicCapitalRatio": 5.889833169313314
},
"2014": {
"obs_EconomicCapitalRatio": 5.64349843494089
},
"2015": {
"obs_EconomicCapitalRatio": 4.871215974868773
},
"2016": {
"obs_EconomicCapitalRatio": 2.5562075124184336
},
"2017": {
"obs_EconomicCapitalRatio": 2.9738332853576335
},
"2018": {
"obs_EconomicCapitalRatio": 2.6756193268421327
},
"2019": {
"obs_EconomicCapitalRatio": 2.9055945060951887
},
"2020": {
"obs_EconomicCapitalRatio": 2.4278244366726334
},
"2021": {
"obs_EconomicCapitalRatio": 1.1999951953961885
},
"2022": {
"obs_EconomicCapitalRatio": 1.6900419826766677
},
"2023": {
"obs_EconomicCapitalRatio": 1.1819590371878657
},
"2024": {
"obs_EconomicCapitalRatio": 1.1400872089425345
},
"2025": {
"obs_EconomicCapitalRatio": 1.4846995550060347
}
},
"0001262104": {
"2011": {
"obs_EconomicCapitalRatio": 2.976131474060693
},
"2012": {
"obs_EconomicCapitalRatio": 29.84004095620544
},
"2013": {
"obs_EconomicCapitalRatio": 7.194268741361899
},
"2016": {
"obs_EconomicCapitalRatio": 1.5454523453078879
},
"2017": {
"obs_EconomicCapitalRatio": 1.9367829777284602
},
"2018": {
"obs_EconomicCapitalRatio": 1.450311890880624
},
"2019": {
"obs_EconomicCapitalRatio": 1.9689337997298595
},
"2020": {
"obs_EconomicCapitalRatio": 1.4548882386917967
},
"2021": {
"obs_EconomicCapitalRatio": 1.4860588196065856
},
"2022": {
"obs_EconomicCapitalRatio": 0.17066667598512655
}
},
"0001279704": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.7802934836126804
},
"2019": {
"obs_EconomicCapitalRatio": 2.409518801482663
},
"2020": {
"obs_EconomicCapitalRatio": 1.6673740926374905
},
"2021": {
"obs_EconomicCapitalRatio": 1.8215826030676574
},
"2022": {
"obs_EconomicCapitalRatio": 1.0140222570705515
}
},
"0001285819": {
"2011": {
"obs_EconomicCapitalRatio": 3.9008953991679225
},
"2012": {
"obs_EconomicCapitalRatio": 8.856529930836997
},
"2013": {
"obs_EconomicCapitalRatio": 23.416633068756767
},
"2014": {
"obs_EconomicCapitalRatio": 52.38187959476351
},
"2015": {
"obs_EconomicCapitalRatio": 17.417008725890156
},
"2016": {
"obs_EconomicCapitalRatio": 10.493546623850774
},
"2017": {
"obs_EconomicCapitalRatio": 13.17928717267996
},
"2018": {
"obs_EconomicCapitalRatio": 8.556002006090099
},
"2019": {
"obs_EconomicCapitalRatio": 7.515377707617327
},
"2020": {
"obs_EconomicCapitalRatio": 8.340041355471396
},
"2021": {
"obs_EconomicCapitalRatio": 1.9397706515990498
},
"2022": {
"obs_EconomicCapitalRatio": 0.383787450562039
},
"2023": {
"obs_EconomicCapitalRatio": 0.9380626426710665
},
"2024": {
"obs_EconomicCapitalRatio": 3.267956572971576
},
"2025": {
"obs_EconomicCapitalRatio": 4.383705131472446
}
},
"0001326190": {
"2017": {
"obs_EconomicCapitalRatio": 0.6508211474874072
},
"2018": {
"obs_EconomicCapitalRatio": 0.5494527370680612
},
"2019": {
"obs_EconomicCapitalRatio": 0.8698678361974307
},
"2020": {
"obs_EconomicCapitalRatio": 2.992421119800507
},
"2021": {
"obs_EconomicCapitalRatio": 3.0562409786664384
},
"2022": {
"obs_EconomicCapitalRatio": 6.357729243605622
},
"2023": {
"obs_EconomicCapitalRatio": 4.155348811357878
}
},
"0001347178": {
"2011": {
"obs_EconomicCapitalRatio": 0.7547629174581635
},
"2012": {
"obs_EconomicCapitalRatio": 0.8349347296948693
},
"2013": {
"obs_EconomicCapitalRatio": 3.200328803096651
},
"2014": {
"obs_EconomicCapitalRatio": 5.1801032398517055
},
"2015": {
"obs_EconomicCapitalRatio": 2.784492138224985
},
"2016": {
"obs_EconomicCapitalRatio": 4.859040274237193
},
"2017": {
"obs_EconomicCapitalRatio": 4.847027555030574
},
"2018": {
"obs_EconomicCapitalRatio": 6.838860800683274
},
"2019": {
"obs_EconomicCapitalRatio": 3.2008903413809926
},
"2020": {
"obs_EconomicCapitalRatio": 2.368962168982374
},
"2021": {
"obs_EconomicCapitalRatio": 2.7331520944826213
},
"2022": {
"obs_EconomicCapitalRatio": 1.0969963189923904
},
"2023": {
"obs_EconomicCapitalRatio": 0.6082415452655552
},
"2024": {
"obs_EconomicCapitalRatio": 0.7203169054780709
},
"2025": {
"obs_EconomicCapitalRatio": 1.2660125487260627
}
},
"0001348362": {
"2021": {
"obs_EconomicCapitalRatio": 3.688977745827279
},
"2022": {
"obs_EconomicCapitalRatio": 3.6289445963532447
},
"2023": {
"obs_EconomicCapitalRatio": 7.572181575460779
},
"2024": {
"obs_EconomicCapitalRatio": 7.638141696833459
},
"2025": {
"obs_EconomicCapitalRatio": 4.640465465175871
}
},
"0001355790": {
"2011": {
"obs_EconomicCapitalRatio": 9.179995649598776
},
"2012": {
"obs_EconomicCapitalRatio": 4.978283029972212
},
"2013": {
"obs_EconomicCapitalRatio": 4.670844633739837
},
"2014": {
"obs_EconomicCapitalRatio": 2.3489847354135502
},
"2015": {
"obs_EconomicCapitalRatio": 1.3378663555234789
},
"2016": {
"obs_EconomicCapitalRatio": 0.7698728160811572
},
"2017": {
"obs_EconomicCapitalRatio": 1.1388606479717176
},
"2018": {
"obs_EconomicCapitalRatio": 1.5664269146568608
},
"2019": {
"obs_EconomicCapitalRatio": 0.630516760385617
},
"2020": {
"obs_EconomicCapitalRatio": 0.6396888771805517
},
"2021": {
"obs_EconomicCapitalRatio": 0.6840686118043124
},
"2022": {
"obs_EconomicCapitalRatio": 0.267067323314091
}
},
"0001360214": {
"2012": {
"obs_EconomicCapitalRatio": 11.271163127854932
},
"2014": {
"obs_EconomicCapitalRatio": 11.638297387028627
},
"2015": {
"obs_EconomicCapitalRatio": 4.6241476669712975
},
"2016": {
"obs_EconomicCapitalRatio": 1.3484853410256559
},
"2017": {
"obs_EconomicCapitalRatio": 1.4895887864053496
},
"2018": {
"obs_EconomicCapitalRatio": 3.139266496743132
},
"2019": {
"obs_EconomicCapitalRatio": 4.022032566775388
},
"2021": {
"obs_EconomicCapitalRatio": 2.5406885482118433
},
"2022": {
"obs_EconomicCapitalRatio": 2.6086812218171045
},
"2023": {
"obs_EconomicCapitalRatio": 1.3459592890349485
},
"2024": {
"obs_EconomicCapitalRatio": 3.4220324055830136
},
"2025": {
"obs_EconomicCapitalRatio": 4.8861055897922885
}
},
"0001367083": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 1.994470946458264
},
"2014": {
"obs_EconomicCapitalRatio": 0.7868720336054744
},
"2015": {
"obs_EconomicCapitalRatio": 1.891607107582308
},
"2016": {
"obs_EconomicCapitalRatio": 2.6568269721745104
},
"2017": {
"obs_EconomicCapitalRatio": 1.5709904421686274
},
"2018": {
"obs_EconomicCapitalRatio": 0.42252706083525265
},
"2019": {
"obs_EconomicCapitalRatio": 0.6068179714239148
},
"2020": {
"obs_EconomicCapitalRatio": 1.4163627569047794
},
"2021": {
"obs_EconomicCapitalRatio": 1.2007561835223088
},
"2022": {
"obs_EconomicCapitalRatio": 0.24080595316110787
},
"2023": {
"obs_EconomicCapitalRatio": 0.17877829794683045
},
"2024": {
"obs_EconomicCapitalRatio": 0.30807278696085183
},
"2025": {
"obs_EconomicCapitalRatio": 0.5338305819074114
}
},
"0001367644": {
"2011": {
"obs_EconomicCapitalRatio": 1.7976370649598783
},
"2012": {
"obs_EconomicCapitalRatio": 1.6553627727050257
},
"2013": {
"obs_EconomicCapitalRatio": 2.2274553933987518
},
"2014": {
"obs_EconomicCapitalRatio": 1.5230589567105508
},
"2015": {
"obs_EconomicCapitalRatio": 2.1371256774520164
},
"2016": {
"obs_EconomicCapitalRatio": 2.0215611137578677
},
"2017": {
"obs_EconomicCapitalRatio": 3.1513393230994735
},
"2019": {
"obs_EconomicCapitalRatio": 1.5667597014802146
},
"2020": {
"obs_EconomicCapitalRatio": 2.302469812906637
},
"2021": {
"obs_EconomicCapitalRatio": 1.1285330392970574
},
"2022": {
"obs_EconomicCapitalRatio": 0.22635234499274465
},
"2023": {
"obs_EconomicCapitalRatio": 0.08309536561881938
},
"2024": {
"obs_EconomicCapitalRatio": 0.39093964867994657
},
"2025": {
"obs_EconomicCapitalRatio": 0.6154566792280605
}
},
"0001369568": {
"2011": {
"obs_EconomicCapitalRatio": 6.3889201791876715
},
"2012": {
"obs_EconomicCapitalRatio": 1.6500315683457198
},
"2013": {
"obs_EconomicCapitalRatio": 7.24899447590868
},
"2014": {
"obs_EconomicCapitalRatio": 7.717318407302692
},
"2015": {
"obs_EconomicCapitalRatio": 6.397961577879862
},
"2016": {
"obs_EconomicCapitalRatio": 4.096110143541204
},
"2017": {
"obs_EconomicCapitalRatio": 7.592382758094557
},
"2018": {
"obs_EconomicCapitalRatio": 5.934355974386351
},
"2019": {
"obs_EconomicCapitalRatio": 5.80155007335537
},
"2020": {
"obs_EconomicCapitalRatio": 3.295770377836332
},
"2021": {
"obs_EconomicCapitalRatio": 5.317984424463229
},
"2022": {
"obs_EconomicCapitalRatio": 8.584912933619535
},
"2023": {
"obs_EconomicCapitalRatio": 6.301951486531034
}
},
"0001379006": {
"2012": {
"obs_EconomicCapitalRatio": 8.82692233269271
},
"2014": {
"obs_EconomicCapitalRatio": 5.005091122551198
},
"2015": {
"obs_EconomicCapitalRatio": 2.279453044698694
},
"2016": {
"obs_EconomicCapitalRatio": 2.6540924954040306
},
"2017": {
"obs_EconomicCapitalRatio": 3.610151360278
},
"2018": {
"obs_EconomicCapitalRatio": 1.999905258053884
},
"2019": {
"obs_EconomicCapitalRatio": 1.2415729695877673
},
"2020": {
"obs_EconomicCapitalRatio": 2.8594669245643027
},
"2021": {
"obs_EconomicCapitalRatio": 2.974100414432412
},
"2022": {
"obs_EconomicCapitalRatio": 1.1703385171652987
}
},
"0001385818": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.47539841134977767
},
"2019": {
"obs_EconomicCapitalRatio": 0.6184507895794792
},
"2020": {
"obs_EconomicCapitalRatio": 7.419178312245873
},
"2021": {
"obs_EconomicCapitalRatio": 0.21444895471445116
},
"2022": {
"obs_EconomicCapitalRatio": 0.10542865791319143
},
"2023": {
"obs_EconomicCapitalRatio": 0.13920572699943723
},
"2024": {
"obs_EconomicCapitalRatio": 0.08701631303291904
}
},
"0001390478": {
"2011": {
"obs_EconomicCapitalRatio": 0.0
},
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 13.057185525906862
},
"2017": {
"obs_EconomicCapitalRatio": 0.5909151161860207
},
"2018": {
"obs_EconomicCapitalRatio": 1.957224034983383
},
"2019": {
"obs_EconomicCapitalRatio": 1.4332895378611077
},
"2021": {
"obs_EconomicCapitalRatio": 5.6975438796109055
},
"2022": {
"obs_EconomicCapitalRatio": 2.5238461075906766
},
"2023": {
"obs_EconomicCapitalRatio": 3.471029264381213
},
"2024": {
"obs_EconomicCapitalRatio": 4.405008459786115
}
},
"0001401667": {
"2012": {
"obs_EconomicCapitalRatio": 6.208129575901305
},
"2013": {
"obs_EconomicCapitalRatio": 47.28546182478878
},
"2016": {
"obs_EconomicCapitalRatio": 8.166416840300958
},
"2017": {
"obs_EconomicCapitalRatio": 26.524215277890093
},
"2018": {
"obs_EconomicCapitalRatio": 3.3687600343432424
},
"2019": {
"obs_EconomicCapitalRatio": 1.515901568624176
},
"2020": {
"obs_EconomicCapitalRatio": 1.793524192155767
},
"2022": {
"obs_EconomicCapitalRatio": 0.9862356814586613
},
"2023": {
"obs_EconomicCapitalRatio": 0.9476593306311685
},
"2024": {
"obs_EconomicCapitalRatio": 0.8715847856281287
},
"2025": {
"obs_EconomicCapitalRatio": 1.9772070498623269
}
},
"0001410098": {
"2011": {
"obs_EconomicCapitalRatio": 1.707348625435781
},
"2012": {
"obs_EconomicCapitalRatio": 5.495184693083727
},
"2013": {
"obs_EconomicCapitalRatio": 3.5549801222373585
},
"2014": {
"obs_EconomicCapitalRatio": 10.54156882709548
},
"2015": {
"obs_EconomicCapitalRatio": 3.5823663057939346
},
"2016": {
"obs_EconomicCapitalRatio": 5.255700805598911
},
"2017": {
"obs_EconomicCapitalRatio": 3.8414521129507024
},
"2018": {
"obs_EconomicCapitalRatio": 8.20786823667722
},
"2022": {
"obs_EconomicCapitalRatio": 4.731337422878887
}
},
"0001427925": {
"2011": {
"obs_EconomicCapitalRatio": 1.3034921695309352
},
"2012": {
"obs_EconomicCapitalRatio": 1.8794397350645533
},
"2013": {
"obs_EconomicCapitalRatio": 6.190613990895643
},
"2014": {
"obs_EconomicCapitalRatio": 4.632558275150405
},
"2015": {
"obs_EconomicCapitalRatio": 1.6283040693257576
},
"2020": {
"obs_EconomicCapitalRatio": 1.2009877482213018
},
"2021": {
"obs_EconomicCapitalRatio": 0.6909657662137705
},
"2022": {
"obs_EconomicCapitalRatio": 0.43682041596359344
},
"2023": {
"obs_EconomicCapitalRatio": 0.98467364218298
},
"2024": {
"obs_EconomicCapitalRatio": 0.7297125653194421
},
"2025": {
"obs_EconomicCapitalRatio": 2.4292445713278736
}
},
"0001429260": {
"2011": {
"obs_EconomicCapitalRatio": 3.253092521290889
},
"2015": {
"obs_EconomicCapitalRatio": 1.6662457324617772
},
"2016": {
"obs_EconomicCapitalRatio": 0.8588979539480799
},
"2018": {
"obs_EconomicCapitalRatio": 0.35840342417624116
},
"2019": {
"obs_EconomicCapitalRatio": 0.9183721904509325
}
},
"0001520262": {
"2011": {
"obs_EconomicCapitalRatio": 8.732023309477322
},
"2012": {
"obs_EconomicCapitalRatio": 2.517461855559167
},
"2021": {
"obs_EconomicCapitalRatio": 2.592124046221965
},
"2022": {
"obs_EconomicCapitalRatio": 2.9128639481286616
}
},
"0000034956": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.3540114054548826
},
"2019": {
"obs_EconomicCapitalRatio": 2.8899991460190257
},
"2020": {
"obs_EconomicCapitalRatio": 4.897165306601755
},
"2022": {
"obs_EconomicCapitalRatio": 3.2820129462831895
}
},
"0001010086": {
"2012": {
"obs_EconomicCapitalRatio": 0.9648025582518476
},
"2013": {
"obs_EconomicCapitalRatio": 0.6122333166847467
},
"2014": {
"obs_EconomicCapitalRatio": 0.17171419351669243
},
"2015": {
"obs_EconomicCapitalRatio": 0.0432894554129469
},
"2016": {
"obs_EconomicCapitalRatio": 0.3312190917217559
},
"2017": {
"obs_EconomicCapitalRatio": 0.8228692095294068
},
"2018": {
"obs_EconomicCapitalRatio": 2.367189708200457
},
"2019": {
"obs_EconomicCapitalRatio": 1.6709424646890423
},
"2020": {
"obs_EconomicCapitalRatio": 4.320985928424905
},
"2021": {
"obs_EconomicCapitalRatio": 2.8752768361840704
},
"2022": {
"obs_EconomicCapitalRatio": 3.4587745773706
},
"2023": {
"obs_EconomicCapitalRatio": 1.9068535975232734
},
"2024": {
"obs_EconomicCapitalRatio": 2.5027926004205803
},
"2025": {
"obs_EconomicCapitalRatio": 3.3031185345796064
}
},
"0001053369": {
"2012": {
"obs_EconomicCapitalRatio": 1.6726245064737015
},
"2013": {
"obs_EconomicCapitalRatio": 3.942127979494112
},
"2014": {
"obs_EconomicCapitalRatio": 2.3327765420151856
},
"2015": {
"obs_EconomicCapitalRatio": 10.622213853856026
},
"2019": {
"obs_EconomicCapitalRatio": 4.007498141213826
},
"2021": {
"obs_EconomicCapitalRatio": 1.6749061695400072
},
"2022": {
"obs_EconomicCapitalRatio": 1.3496143238340297
},
"2023": {
"obs_EconomicCapitalRatio": 5.373588498873877
},
"2024": {
"obs_EconomicCapitalRatio": 10.709577886668663
},
"2025": {
"obs_EconomicCapitalRatio": 7.561446798527235
}
},
"0001072379": {
"2012": {
"obs_EconomicCapitalRatio": 4.228018601326807
},
"2013": {
"obs_EconomicCapitalRatio": 7.2865613000880245
},
"2014": {
"obs_EconomicCapitalRatio": 4.52993998077677
},
"2015": {
"obs_EconomicCapitalRatio": 4.527295199401648
},
"2016": {
"obs_EconomicCapitalRatio": 0.6543832260773149
},
"2017": {
"obs_EconomicCapitalRatio": 1.0230629448163566
},
"2018": {
"obs_EconomicCapitalRatio": 2.3408783084374467
},
"2019": {
"obs_EconomicCapitalRatio": 4.249206486316114
},
"2020": {
"obs_EconomicCapitalRatio": 5.050165155650398
},
"2022": {
"obs_EconomicCapitalRatio": 10.296921656988848
},
"2023": {
"obs_EconomicCapitalRatio": 16.389711808491185
}
},
"0001106644": {
"2012": {
"obs_EconomicCapitalRatio": 0.10529819253310034
},
"2017": {
"obs_EconomicCapitalRatio": 0.20418745392206505
},
"2018": {
"obs_EconomicCapitalRatio": 0.30945320350833017
},
"2019": {
"obs_EconomicCapitalRatio": 0.5937127287741156
},
"2020": {
"obs_EconomicCapitalRatio": 1.145776768270793
},
"2021": {
"obs_EconomicCapitalRatio": 1.0364130811908552
},
"2022": {
"obs_EconomicCapitalRatio": 0.39625593318918223
},
"2023": {
"obs_EconomicCapitalRatio": 0.29740034984607266
}
},
"0001335105": {
"2012": {
"obs_EconomicCapitalRatio": 49.54886091585484
},
"2013": {
"obs_EconomicCapitalRatio": 73.73107600728025
},
"2014": {
"obs_EconomicCapitalRatio": 184.6777060447673
},
"2015": {
"obs_EconomicCapitalRatio": 227.5628680751955
},
"2016": {
"obs_EconomicCapitalRatio": 123.34925799596552
},
"2017": {
"obs_EconomicCapitalRatio": 59.98915919863948
},
"2018": {
"obs_EconomicCapitalRatio": 143.21102280858813
},
"2019": {
"obs_EconomicCapitalRatio": 193.5388975202505
},
"2020": {
"obs_EconomicCapitalRatio": 85.08478882834855
},
"2021": {
"obs_EconomicCapitalRatio": 6.317707417866715
},
"2022": {
"obs_EconomicCapitalRatio": 2.82344689908857
},
"2023": {
"obs_EconomicCapitalRatio": 2.1556305622560687
},
"2024": {
"obs_EconomicCapitalRatio": 6.146495357589595
},
"2025": {
"obs_EconomicCapitalRatio": 3.1498425897523785
}
},
"0001356576": {
"2012": {
"obs_EconomicCapitalRatio": 2.695540367680527
},
"2013": {
"obs_EconomicCapitalRatio": 2.6819507906417344
},
"2014": {
"obs_EconomicCapitalRatio": 3.6192991362911293
},
"2015": {
"obs_EconomicCapitalRatio": 5.316418467284552
},
"2016": {
"obs_EconomicCapitalRatio": 5.88475069658678
},
"2017": {
"obs_EconomicCapitalRatio": 6.845847663884459
},
"2018": {
"obs_EconomicCapitalRatio": 2.2751603686509516
},
"2019": {
"obs_EconomicCapitalRatio": 1.4335697423386706
},
"2020": {
"obs_EconomicCapitalRatio": 1.166670190388528
},
"2021": {
"obs_EconomicCapitalRatio": 1.2466838685294064
},
"2022": {
"obs_EconomicCapitalRatio": 1.5813024649466632
},
"2024": {
"obs_EconomicCapitalRatio": 2.335857420368807
},
"2025": {
"obs_EconomicCapitalRatio": 3.1951230806398243
}
},
"0001388320": {
"2012": {
"obs_EconomicCapitalRatio": 3.1758383030536113
},
"2013": {
"obs_EconomicCapitalRatio": 20.019256940326006
},
"2014": {
"obs_EconomicCapitalRatio": 21.102887995768853
},
"2015": {
"obs_EconomicCapitalRatio": 6.972635870887473
},
"2016": {
"obs_EconomicCapitalRatio": 3.96230988267313
},
"2017": {
"obs_EconomicCapitalRatio": 4.591006599702462
},
"2018": {
"obs_EconomicCapitalRatio": 4.370547084943421
},
"2019": {
"obs_EconomicCapitalRatio": 3.906735389662115
},
"2020": {
"obs_EconomicCapitalRatio": 4.214246383862464
},
"2021": {
"obs_EconomicCapitalRatio": 3.2352607848056922
},
"2022": {
"obs_EconomicCapitalRatio": 3.2565770272742274
},
"2023": {
"obs_EconomicCapitalRatio": 2.1343787594410806
}
},
"0001389545": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 5.799501346685527
},
"2023": {
"obs_EconomicCapitalRatio": 0.14129171741239246
},
"2024": {
"obs_EconomicCapitalRatio": 0.5000556342652639
},
"2025": {
"obs_EconomicCapitalRatio": 29.918924920830538
}
},
"0001396814": {
"2012": {
"obs_EconomicCapitalRatio": 6.812999715393255
},
"2013": {
"obs_EconomicCapitalRatio": 12.636013346815789
},
"2018": {
"obs_EconomicCapitalRatio": 3.3327445733519814
},
"2019": {
"obs_EconomicCapitalRatio": 2.9220177647014838
},
"2020": {
"obs_EconomicCapitalRatio": 2.6584057140847492
},
"2021": {
"obs_EconomicCapitalRatio": 1.5788473346705905
}
},
"0001420720": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.34077731721950805
},
"2019": {
"obs_EconomicCapitalRatio": 0.26100959550370434
},
"2020": {
"obs_EconomicCapitalRatio": 3.164789801549658
},
"2021": {
"obs_EconomicCapitalRatio": 1.4815209121315438
},
"2022": {
"obs_EconomicCapitalRatio": 0.057123507229856735
}
},
"0001445815": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.08307183763266385
},
"2018": {
"obs_EconomicCapitalRatio": 311.14325814608617
},
"2019": {
"obs_EconomicCapitalRatio": 39.30893470756033
},
"2020": {
"obs_EconomicCapitalRatio": 17.983410572796405
},
"2022": {
"obs_EconomicCapitalRatio": 24.0879966140076
},
"2024": {
"obs_EconomicCapitalRatio": 7.4472678808704975
},
"2025": {
"obs_EconomicCapitalRatio": 3.879519452350511
}
},
"0001530746": {
"2012": {
"obs_EconomicCapitalRatio": 48.743731158522266
},
"2015": {
"obs_EconomicCapitalRatio": 2.874689942555272
},
"2020": {
"obs_EconomicCapitalRatio": 5.888234447141673
},
"2021": {
"obs_EconomicCapitalRatio": 0.22244353315329501
}
},
"0001533040": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.6486316593055985
},
"2023": {
"obs_EconomicCapitalRatio": 0.3373636555128727
},
"2024": {
"obs_EconomicCapitalRatio": 0.6281623329011384
},
"2025": {
"obs_EconomicCapitalRatio": 0.9997190225657764
}
},
"0001538495": {
"2014": {
"obs_EconomicCapitalRatio": 90.5824484998404
},
"2018": {
"obs_EconomicCapitalRatio": 97.152601082712
},
"2019": {
"obs_EconomicCapitalRatio": 8.080338857180678
},
"2023": {
"obs_EconomicCapitalRatio": 8.712763067559049
},
"2024": {
"obs_EconomicCapitalRatio": 13.4928062961499
},
"2025": {
"obs_EconomicCapitalRatio": 7.536035522691852
}
},
"0001544227": {
"2012": {
"obs_EconomicCapitalRatio": 0.0
},
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 5.756485829560471
}
},
"0000818033": {
"2013": {
"obs_EconomicCapitalRatio": 3.2901186557493314
},
"2014": {
"obs_EconomicCapitalRatio": 6.2947477925451345
},
"2016": {
"obs_EconomicCapitalRatio": 6.69787657841924
},
"2017": {
"obs_EconomicCapitalRatio": 5.773831569020795
},
"2018": {
"obs_EconomicCapitalRatio": 6.710899739303245
},
"2019": {
"obs_EconomicCapitalRatio": 7.210154006316952
},
"2020": {
"obs_EconomicCapitalRatio": 7.984729054440954
},
"2021": {
"obs_EconomicCapitalRatio": 3.7120049615170845
},
"2022": {
"obs_EconomicCapitalRatio": 1.227031168154277
}
},
"0000822370": {
"2013": {
"obs_EconomicCapitalRatio": 16.953206263457304
},
"2014": {
"obs_EconomicCapitalRatio": 12.503291998490209
},
"2015": {
"obs_EconomicCapitalRatio": 0.9501448579961315
},
"2016": {
"obs_EconomicCapitalRatio": 13.956093492017365
},
"2017": {
"obs_EconomicCapitalRatio": 3.983601278513772
},
"2018": {
"obs_EconomicCapitalRatio": 1.715303466761049
},
"2021": {
"obs_EconomicCapitalRatio": 1.1111050021413131
},
"2022": {
"obs_EconomicCapitalRatio": 0.25056198404886904
}
},
"0000887151": {
"2016": {
"obs_EconomicCapitalRatio": 3.851922974427995
},
"2017": {
"obs_EconomicCapitalRatio": 3.076097907239819
}
},
"0001069899": {
"2014": {
"obs_EconomicCapitalRatio": 0.8935879204520644
},
"2015": {
"obs_EconomicCapitalRatio": 0.9508600960375623
},
"2016": {
"obs_EconomicCapitalRatio": 0.793610361831243
},
"2017": {
"obs_EconomicCapitalRatio": 1.016798789211543
},
"2018": {
"obs_EconomicCapitalRatio": 0.9354751915827592
},
"2019": {
"obs_EconomicCapitalRatio": 0.6931133060887299
},
"2020": {
"obs_EconomicCapitalRatio": 0.49350298466545506
},
"2021": {
"obs_EconomicCapitalRatio": 0.5200930672010649
},
"2022": {
"obs_EconomicCapitalRatio": 0.313936991934562
}
},
"0001104506": {
"2013": {
"obs_EconomicCapitalRatio": 6.239386499572907
},
"2014": {
"obs_EconomicCapitalRatio": 5.559776850126781
}
},
"0001125345": {
"2013": {
"obs_EconomicCapitalRatio": 7.803881980904605
},
"2014": {
"obs_EconomicCapitalRatio": 8.424909912013891
},
"2015": {
"obs_EconomicCapitalRatio": 5.284021545136552
},
"2016": {
"obs_EconomicCapitalRatio": 3.9013252707834996
},
"2017": {
"obs_EconomicCapitalRatio": 3.1599055119679273
},
"2018": {
"obs_EconomicCapitalRatio": 2.527222996513196
},
"2019": {
"obs_EconomicCapitalRatio": 2.6990521646869077
},
"2020": {
"obs_EconomicCapitalRatio": 5.983826636156595
},
"2021": {
"obs_EconomicCapitalRatio": 4.738597933159698
},
"2022": {
"obs_EconomicCapitalRatio": 1.7374711486845418
},
"2023": {
"obs_EconomicCapitalRatio": 2.7508258106149883
},
"2024": {
"obs_EconomicCapitalRatio": 0.9955773842653965
},
"2025": {
"obs_EconomicCapitalRatio": 0.44188357025285224
}
},
"0001130598": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.8760307150595883
}
},
"0001176309": {
"2013": {
"obs_EconomicCapitalRatio": 18.96374780999439
},
"2015": {
"obs_EconomicCapitalRatio": 6.853734582183693
},
"2016": {
"obs_EconomicCapitalRatio": 2.526336074927299
},
"2017": {
"obs_EconomicCapitalRatio": 4.125791873249401
},
"2018": {
"obs_EconomicCapitalRatio": 1.7197718408127676
},
"2019": {
"obs_EconomicCapitalRatio": 3.430129084485662
},
"2020": {
"obs_EconomicCapitalRatio": 3.471973647944272
},
"2021": {
"obs_EconomicCapitalRatio": 7.578119224307776
},
"2023": {
"obs_EconomicCapitalRatio": 0.6042175137645596
},
"2024": {
"obs_EconomicCapitalRatio": 1.0805057222764693
}
},
"0001177648": {
"2013": {
"obs_EconomicCapitalRatio": 8.112576671408831
},
"2014": {
"obs_EconomicCapitalRatio": 11.458921414358276
},
"2015": {
"obs_EconomicCapitalRatio": 4.739370496323121
},
"2016": {
"obs_EconomicCapitalRatio": 4.347583184663215
},
"2017": {
"obs_EconomicCapitalRatio": 6.320430181270734
},
"2018": {
"obs_EconomicCapitalRatio": 6.28232019258115
},
"2019": {
"obs_EconomicCapitalRatio": 4.868766833283514
},
"2020": {
"obs_EconomicCapitalRatio": 3.31097125848491
},
"2021": {
"obs_EconomicCapitalRatio": 6.40068695232658
},
"2022": {
"obs_EconomicCapitalRatio": 4.51700389556921
},
"2023": {
"obs_EconomicCapitalRatio": 0.5518999495160052
}
},
"0001295947": {
"2013": {
"obs_EconomicCapitalRatio": 1.234083101191435
},
"2017": {
"obs_EconomicCapitalRatio": 0.6751705902222275
},
"2018": {
"obs_EconomicCapitalRatio": 0.5002811341605694
},
"2019": {
"obs_EconomicCapitalRatio": 0.702931364694115
},
"2020": {
"obs_EconomicCapitalRatio": 0.5977205081707389
},
"2021": {
"obs_EconomicCapitalRatio": 1.12929687903751
},
"2022": {
"obs_EconomicCapitalRatio": 1.0708172655863475
},
"2023": {
"obs_EconomicCapitalRatio": 1.1593510793678938
},
"2024": {
"obs_EconomicCapitalRatio": 1.5607829762146974
}
},
"0001422142": {
"2018": {
"obs_EconomicCapitalRatio": 2.0166717971745087
},
"2019": {
"obs_EconomicCapitalRatio": 1.0673470561314449
},
"2020": {
"obs_EconomicCapitalRatio": 2.074347492998886
},
"2021": {
"obs_EconomicCapitalRatio": 5.79141032727474
},
"2022": {
"obs_EconomicCapitalRatio": 2.893564453874418
},
"2023": {
"obs_EconomicCapitalRatio": 0.6359938686600423
},
"2024": {
"obs_EconomicCapitalRatio": 1.6662710669263088
}
},
"0001422143": {
"2015": {
"obs_EconomicCapitalRatio": 3.369248096829516
},
"2016": {
"obs_EconomicCapitalRatio": 3.1625897198124835
},
"2017": {
"obs_EconomicCapitalRatio": 8.25384480595116
},
"2018": {
"obs_EconomicCapitalRatio": 4.985778240350756
},
"2019": {
"obs_EconomicCapitalRatio": 4.867052264367894
},
"2020": {
"obs_EconomicCapitalRatio": 5.976791842622965
},
"2021": {
"obs_EconomicCapitalRatio": 3.5394127480171993
},
"2022": {
"obs_EconomicCapitalRatio": 3.261053122473768
}
},
"0001430306": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 0.7326351572316913
},
"2025": {
"obs_EconomicCapitalRatio": 1.2786182495279823
}
},
"0001434868": {
"2013": {
"obs_EconomicCapitalRatio": 4.990914676628872
},
"2014": {
"obs_EconomicCapitalRatio": 9.726111733017273
},
"2015": {
"obs_EconomicCapitalRatio": 3.3754092489620873
},
"2016": {
"obs_EconomicCapitalRatio": 2.2034935943965324
},
"2017": {
"obs_EconomicCapitalRatio": 10.321430770156113
},
"2018": {
"obs_EconomicCapitalRatio": 11.344584986079722
},
"2019": {
"obs_EconomicCapitalRatio": 7.5531542464423955
},
"2020": {
"obs_EconomicCapitalRatio": 1.9574243547929262
},
"2021": {
"obs_EconomicCapitalRatio": 0.30890702629983063
},
"2022": {
"obs_EconomicCapitalRatio": 1.0976268299515959
},
"2023": {
"obs_EconomicCapitalRatio": 0.6167576764568707
},
"2024": {
"obs_EconomicCapitalRatio": 0.8127698162651695
},
"2025": {
"obs_EconomicCapitalRatio": 1.505606914542882
}
},
"0001438533": {
"2013": {
"obs_EconomicCapitalRatio": 4.338907006980449
},
"2014": {
"obs_EconomicCapitalRatio": 2.2438108045252743
},
"2015": {
"obs_EconomicCapitalRatio": 1.9909044593386087
},
"2016": {
"obs_EconomicCapitalRatio": 1.9465652604480188
},
"2017": {
"obs_EconomicCapitalRatio": 2.3240419148596247
},
"2018": {
"obs_EconomicCapitalRatio": 1.6932986955759188
},
"2019": {
"obs_EconomicCapitalRatio": 1.2469359762444685
},
"2020": {
"obs_EconomicCapitalRatio": 2.7955623418513964
},
"2021": {
"obs_EconomicCapitalRatio": 2.987538852042171
},
"2022": {
"obs_EconomicCapitalRatio": 1.990765953595929
},
"2023": {
"obs_EconomicCapitalRatio": 0.966461297382591
},
"2024": {
"obs_EconomicCapitalRatio": 2.3819207475662103
},
"2025": {
"obs_EconomicCapitalRatio": 6.058174443400131
}
},
"0001439222": {
"2013": {
"obs_EconomicCapitalRatio": 6.010792545649196
},
"2014": {
"obs_EconomicCapitalRatio": 14.427215733512456
},
"2015": {
"obs_EconomicCapitalRatio": 10.152840121937325
},
"2016": {
"obs_EconomicCapitalRatio": 5.1377806433858195
},
"2017": {
"obs_EconomicCapitalRatio": 6.359322116960603
},
"2018": {
"obs_EconomicCapitalRatio": 5.099084201225455
},
"2019": {
"obs_EconomicCapitalRatio": 4.9771337691935384
},
"2020": {
"obs_EconomicCapitalRatio": 4.619781227945105
},
"2021": {
"obs_EconomicCapitalRatio": 2.3379954495073885
},
"2022": {
"obs_EconomicCapitalRatio": 2.240306141532274
},
"2023": {
"obs_EconomicCapitalRatio": 2.421286069721265
},
"2024": {
"obs_EconomicCapitalRatio": 2.226980796611712
},
"2025": {
"obs_EconomicCapitalRatio": 2.1892605948265986
}
},
"0001447028": {
"2014": {
"obs_EconomicCapitalRatio": 4.137390561672009
},
"2015": {
"obs_EconomicCapitalRatio": 0.5718949329772033
},
"2016": {
"obs_EconomicCapitalRatio": 0.7939316007515166
},
"2017": {
"obs_EconomicCapitalRatio": 1.8297281847793387
},
"2018": {
"obs_EconomicCapitalRatio": 1.6735901287268171
},
"2021": {
"obs_EconomicCapitalRatio": 4.5460396854681004
},
"2022": {
"obs_EconomicCapitalRatio": 2.950860947004616
},
"2023": {
"obs_EconomicCapitalRatio": 4.256969558004361
},
"2024": {
"obs_EconomicCapitalRatio": 7.315003596033688
}
},
"0001488039": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 1.464336515563814
},
"2019": {
"obs_EconomicCapitalRatio": 1.8789726658392594
},
"2020": {
"obs_EconomicCapitalRatio": 0.31720077467551944
},
"2021": {
"obs_EconomicCapitalRatio": 3.084746010229382
},
"2022": {
"obs_EconomicCapitalRatio": 1.1138704020398191
}
},
"0001498382": {
"2013": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 3.577001255121189
},
"2021": {
"obs_EconomicCapitalRatio": 6.072430958497425
},
"2022": {
"obs_EconomicCapitalRatio": 68.63174459169403
}
},
"0001503802": {
"2014": {
"obs_EconomicCapitalRatio": 10.568267673318969
},
"2015": {
"obs_EconomicCapitalRatio": 4.234783843903932
},
"2017": {
"obs_EconomicCapitalRatio": 3.9041353963426646
},
"2018": {
"obs_EconomicCapitalRatio": 2.2353114096595594
},
"2019": {
"obs_EconomicCapitalRatio": 4.452252617312478
},
"2020": {
"obs_EconomicCapitalRatio": 4.039306074089596
},
"2021": {
"obs_EconomicCapitalRatio": 1.4804850726715195
},
"2022": {
"obs_EconomicCapitalRatio": 0.6665063990066935
}
},
"0001509261": {
"2013": {
"obs_EconomicCapitalRatio": 5.086219265656686
},
"2014": {
"obs_EconomicCapitalRatio": 6.0707381417572925
},
"2015": {
"obs_EconomicCapitalRatio": 4.985934370337063
},
"2016": {
"obs_EconomicCapitalRatio": 6.283976228503316
},
"2017": {
"obs_EconomicCapitalRatio": 6.795295310951352
},
"2018": {
"obs_EconomicCapitalRatio": 1.3518936383405822
},
"2019": {
"obs_EconomicCapitalRatio": 3.0683180651136253
},
"2020": {
"obs_EconomicCapitalRatio": 16.80130407778926
},
"2021": {
"obs_EconomicCapitalRatio": 2.4576320665776623
},
"2022": {
"obs_EconomicCapitalRatio": 0.9410206800819028
}
},
"0001510964": {
"2013": {
"obs_EconomicCapitalRatio": 14.68082349336576
},
"2014": {
"obs_EconomicCapitalRatio": 7.935457650084689
},
"2015": {
"obs_EconomicCapitalRatio": 0.40491650603475937
},
"2016": {
"obs_EconomicCapitalRatio": 1.4697979619780515
},
"2017": {
"obs_EconomicCapitalRatio": 2.555887871177016
},
"2018": {
"obs_EconomicCapitalRatio": 18.640806572937688
},
"2019": {
"obs_EconomicCapitalRatio": 2.5922748033763816
},
"2020": {
"obs_EconomicCapitalRatio": 1.9188970641079883
},
"2021": {
"obs_EconomicCapitalRatio": 0.7811896639092076
},
"2022": {
"obs_EconomicCapitalRatio": 0.34310972374923965
}
},
"0001516551": {
"2015": {
"obs_EconomicCapitalRatio": 4.119831509212193
},
"2016": {
"obs_EconomicCapitalRatio": 7.634612941564023
},
"2017": {
"obs_EconomicCapitalRatio": 4.691264869308869
},
"2018": {
"obs_EconomicCapitalRatio": 5.017589306013457
},
"2019": {
"obs_EconomicCapitalRatio": 14.945189639139171
},
"2020": {
"obs_EconomicCapitalRatio": 4.395640268516184
},
"2021": {
"obs_EconomicCapitalRatio": 3.8168424336686164
},
"2022": {
"obs_EconomicCapitalRatio": 1.1601060857746122
},
"2023": {
"obs_EconomicCapitalRatio": 2.7796492108229773
},
"2024": {
"obs_EconomicCapitalRatio": 2.1016027261151256
},
"2025": {
"obs_EconomicCapitalRatio": 1.4748690162029767
}
},
"0001534525": {
"2017": {
"obs_EconomicCapitalRatio": 1.4490394659367776
},
"2018": {
"obs_EconomicCapitalRatio": 1.7484343180061497
},
"2019": {
"obs_EconomicCapitalRatio": 0.6382098530180732
},
"2020": {
"obs_EconomicCapitalRatio": 1.7628676846384046
},
"2021": {
"obs_EconomicCapitalRatio": 1.7651874702486943
},
"2022": {
"obs_EconomicCapitalRatio": 0.543535154049098
},
"2023": {
"obs_EconomicCapitalRatio": 0.9367081985114467
},
"2024": {
"obs_EconomicCapitalRatio": 1.6132142321110672
},
"2025": {
"obs_EconomicCapitalRatio": 1.0385019129814923
}
},
"0001535955": {
"2013": {
"obs_EconomicCapitalRatio": 3.80951395842458
},
"2014": {
"obs_EconomicCapitalRatio": 4.484665187952989
},
"2015": {
"obs_EconomicCapitalRatio": 9.666698677538678
},
"2016": {
"obs_EconomicCapitalRatio": 4.874530917876101
},
"2017": {
"obs_EconomicCapitalRatio": 4.6990766813576395
},
"2018": {
"obs_EconomicCapitalRatio": 1.7078513542217602
},
"2019": {
"obs_EconomicCapitalRatio": 0.5361184010136972
},
"2020": {
"obs_EconomicCapitalRatio": 5.216460021131948
},
"2021": {
"obs_EconomicCapitalRatio": 3.08629287481249
},
"2022": {
"obs_EconomicCapitalRatio": 1.8362438163077024
},
"2023": {
"obs_EconomicCapitalRatio": 1.214237420839552
},
"2024": {
"obs_EconomicCapitalRatio": 2.1281845992346944
},
"2025": {
"obs_EconomicCapitalRatio": 2.6318924774286794
}
},
"0001551152": {
"2013": {
"obs_EconomicCapitalRatio": 2.830790180578059
},
"2014": {
"obs_EconomicCapitalRatio": 3.433454015057143
},
"2015": {
"obs_EconomicCapitalRatio": 1.9423485332421722
},
"2016": {
"obs_EconomicCapitalRatio": 1.7976357034299837
},
"2017": {
"obs_EconomicCapitalRatio": 2.4973235713716044
},
"2018": {
"obs_EconomicCapitalRatio": 2.4285136647028804
},
"2019": {
"obs_EconomicCapitalRatio": 1.9353808052892818
},
"2020": {
"obs_EconomicCapitalRatio": 1.6600659528716244
},
"2021": {
"obs_EconomicCapitalRatio": 2.207745471098879
},
"2022": {
"obs_EconomicCapitalRatio": 3.004369768582203
},
"2023": {
"obs_EconomicCapitalRatio": 2.896346731964981
},
"2024": {
"obs_EconomicCapitalRatio": 3.4184774378859855
},
"2025": {
"obs_EconomicCapitalRatio": 4.486019242804715
}
},
"0001559053": {
"2013": {
"obs_EconomicCapitalRatio": 6.274475527995295
},
"2014": {
"obs_EconomicCapitalRatio": 3.555240237199364
},
"2015": {
"obs_EconomicCapitalRatio": 10.781347415563726
},
"2016": {
"obs_EconomicCapitalRatio": 6.262097250121002
},
"2017": {
"obs_EconomicCapitalRatio": 4.853544935160512
},
"2018": {
"obs_EconomicCapitalRatio": 1.203722221822252
},
"2019": {
"obs_EconomicCapitalRatio": 2.234599621041635
},
"2020": {
"obs_EconomicCapitalRatio": 2.1603142399661874
},
"2024": {
"obs_EconomicCapitalRatio": 2.690037933050509
},
"2025": {
"obs_EconomicCapitalRatio": 2.7366970621221456
}
},
"0001580149": {
"2020": {
"obs_EconomicCapitalRatio": 16.645305521172176
},
"2022": {
"obs_EconomicCapitalRatio": 11.007711429755684
},
"2023": {
"obs_EconomicCapitalRatio": 1.7609395614375387
},
"2024": {
"obs_EconomicCapitalRatio": 2.1427383390745054
}
},
"0001585364": {
"2014": {
"obs_EconomicCapitalRatio": 1.797467911617485
},
"2016": {
"obs_EconomicCapitalRatio": 0.8588285460560211
},
"2017": {
"obs_EconomicCapitalRatio": 1.1182437890174832
},
"2018": {
"obs_EconomicCapitalRatio": 0.5289068467907572
},
"2019": {
"obs_EconomicCapitalRatio": 0.6971525678852332
},
"2020": {
"obs_EconomicCapitalRatio": 0.5723944883354882
},
"2021": {
"obs_EconomicCapitalRatio": 0.5576594937896573
},
"2022": {
"obs_EconomicCapitalRatio": 0.4367027339465495
},
"2023": {
"obs_EconomicCapitalRatio": 0.4500543240745834
},
"2024": {
"obs_EconomicCapitalRatio": 0.43153707026666605
},
"2025": {
"obs_EconomicCapitalRatio": 0.25459107099964257
}
},
"0000894158": {
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.45840814733792534
},
"2019": {
"obs_EconomicCapitalRatio": 0.7458799373449941
},
"2020": {
"obs_EconomicCapitalRatio": 1.2450476388168137
},
"2021": {
"obs_EconomicCapitalRatio": 1.104415694485011
},
"2022": {
"obs_EconomicCapitalRatio": 0.158159831871509
},
"2023": {
"obs_EconomicCapitalRatio": 0.2288718953647814
}
},
"0001005286": {
"2014": {
"obs_EconomicCapitalRatio": 1.7964608968568716
},
"2015": {
"obs_EconomicCapitalRatio": 1.3881882041224352
},
"2016": {
"obs_EconomicCapitalRatio": 1.6000760916448888
},
"2017": {
"obs_EconomicCapitalRatio": 1.3934041904536012
},
"2018": {
"obs_EconomicCapitalRatio": 1.274525956308206
},
"2019": {
"obs_EconomicCapitalRatio": 0.8782635756660979
},
"2020": {
"obs_EconomicCapitalRatio": 0.7241950199416594
},
"2021": {
"obs_EconomicCapitalRatio": 0.8085732734578128
},
"2023": {
"obs_EconomicCapitalRatio": 0.7946687239882525
}
},
"0001081938": {
"2014": {
"obs_EconomicCapitalRatio": 24.798158649712516
},
"2018": {
"obs_EconomicCapitalRatio": 3.0340184485227577
},
"2019": {
"obs_EconomicCapitalRatio": 4.094288661085645
},
"2020": {
"obs_EconomicCapitalRatio": 1.400630499064566
},
"2022": {
"obs_EconomicCapitalRatio": 0.22856186348027485
},
"2023": {
"obs_EconomicCapitalRatio": 0.02085915706496507
},
"2024": {
"obs_EconomicCapitalRatio": 0.274704453126574
},
"2025": {
"obs_EconomicCapitalRatio": 0.15591606480719788
}
},
"0001157601": {
"2014": {
"obs_EconomicCapitalRatio": 4.341188952805879
},
"2018": {
"obs_EconomicCapitalRatio": 6.488683448986104
},
"2019": {
"obs_EconomicCapitalRatio": 6.067750596961241
},
"2020": {
"obs_EconomicCapitalRatio": 10.865689025506962
},
"2021": {
"obs_EconomicCapitalRatio": 8.130161003271429
},
"2022": {
"obs_EconomicCapitalRatio": 17.64314754873853
},
"2023": {
"obs_EconomicCapitalRatio": 10.491030513883619
},
"2024": {
"obs_EconomicCapitalRatio": 10.157226400900424
},
"2025": {
"obs_EconomicCapitalRatio": 13.989437963906283
}
},
"0001178253": {
"2014": {
"obs_EconomicCapitalRatio": 3.6521598876967274
},
"2015": {
"obs_EconomicCapitalRatio": 2.8445582088352213
},
"2017": {
"obs_EconomicCapitalRatio": 1.8020299925753376
},
"2018": {
"obs_EconomicCapitalRatio": 0.5211327320508553
},
"2019": {
"obs_EconomicCapitalRatio": 0.8852073910277948
},
"2020": {
"obs_EconomicCapitalRatio": 0.8514995515209948
},
"2021": {
"obs_EconomicCapitalRatio": 1.6132436985084486
},
"2022": {
"obs_EconomicCapitalRatio": 0.5986303702132718
}
},
"0001253689": {
"2022": {
"obs_EconomicCapitalRatio": 3.563091100578236
},
"2023": {
"obs_EconomicCapitalRatio": 5.536842666003607
}
},
"0001297184": {
"2014": {
"obs_EconomicCapitalRatio": 2.1269462487249093
},
"2015": {
"obs_EconomicCapitalRatio": 2.65513432698816
},
"2016": {
"obs_EconomicCapitalRatio": 3.5203039587929785
},
"2017": {
"obs_EconomicCapitalRatio": 3.1242555268336623
},
"2018": {
"obs_EconomicCapitalRatio": 2.7752269134021916
},
"2019": {
"obs_EconomicCapitalRatio": 2.4411844945872296
},
"2020": {
"obs_EconomicCapitalRatio": 2.217148801257373
},
"2021": {
"obs_EconomicCapitalRatio": 2.4283466270366865
},
"2022": {
"obs_EconomicCapitalRatio": 2.8741219144747516
},
"2023": {
"obs_EconomicCapitalRatio": 2.4367223036504586
}
},
"0001343009": {
"2014": {
"obs_EconomicCapitalRatio": 11.135576808625036
},
"2015": {
"obs_EconomicCapitalRatio": 29.204850072482998
},
"2017": {
"obs_EconomicCapitalRatio": 57.14357766254051
},
"2018": {
"obs_EconomicCapitalRatio": 21.073064451886307
},
"2019": {
"obs_EconomicCapitalRatio": 1.6521169122003325
},
"2020": {
"obs_EconomicCapitalRatio": 25.04805838183159
},
"2021": {
"obs_EconomicCapitalRatio": 5.575010777304091
},
"2022": {
"obs_EconomicCapitalRatio": 2.222389581523738
},
"2023": {
"obs_EconomicCapitalRatio": 0.25153193883875463
}
},
"0001393434": {
"2014": {
"obs_EconomicCapitalRatio": 9.723762656180517
},
"2015": {
"obs_EconomicCapitalRatio": 3.6396014649500734
},
"2016": {
"obs_EconomicCapitalRatio": 4.245367407321326
},
"2017": {
"obs_EconomicCapitalRatio": 3.1586602946560784
},
"2018": {
"obs_EconomicCapitalRatio": 3.098624810304815
},
"2019": {
"obs_EconomicCapitalRatio": 2.3784652282637255
},
"2020": {
"obs_EconomicCapitalRatio": 6.806910043019627
},
"2021": {
"obs_EconomicCapitalRatio": 3.3165392530152924
},
"2022": {
"obs_EconomicCapitalRatio": 1.6004878747764422
},
"2023": {
"obs_EconomicCapitalRatio": 1.5903378431512945
}
},
"0001401914": {
"2014": {
"obs_EconomicCapitalRatio": 3.9749108988053177
},
"2015": {
"obs_EconomicCapitalRatio": 1.7793294237143362
},
"2016": {
"obs_EconomicCapitalRatio": 0.647193872144733
},
"2021": {
"obs_EconomicCapitalRatio": 4.188590883783982
},
"2022": {
"obs_EconomicCapitalRatio": 1.899653309523115
},
"2023": {
"obs_EconomicCapitalRatio": 1.3773038942544311
},
"2024": {
"obs_EconomicCapitalRatio": 1.1054306529956048
}
},
"0001404281": {
"2014": {
"obs_EconomicCapitalRatio": 5.641429299848193
},
"2021": {
"obs_EconomicCapitalRatio": 0.7230097507704459
},
"2022": {
"obs_EconomicCapitalRatio": 0.6498330155428738
}
},
"0001404644": {
"2014": {
"obs_EconomicCapitalRatio": 3.112438741240614
},
"2015": {
"obs_EconomicCapitalRatio": 3.66314659749228
},
"2016": {
"obs_EconomicCapitalRatio": 4.666188054215424
},
"2017": {
"obs_EconomicCapitalRatio": 4.472501841321298
},
"2018": {
"obs_EconomicCapitalRatio": 1.2201436186914152
},
"2022": {
"obs_EconomicCapitalRatio": 0.2718573870509964
},
"2023": {
"obs_EconomicCapitalRatio": 1.1061815689134848
},
"2024": {
"obs_EconomicCapitalRatio": 1.861957314482675
}
},
"0001437402": {
"2014": {
"obs_EconomicCapitalRatio": 4.926661749470438
},
"2015": {
"obs_EconomicCapitalRatio": 7.937166009598443
},
"2016": {
"obs_EconomicCapitalRatio": 5.864265172195904
},
"2017": {
"obs_EconomicCapitalRatio": 3.5416783481777787
},
"2018": {
"obs_EconomicCapitalRatio": 0.8694093294722323
},
"2019": {
"obs_EconomicCapitalRatio": 2.97619547684202
},
"2020": {
"obs_EconomicCapitalRatio": 4.502454051781784
},
"2021": {
"obs_EconomicCapitalRatio": 1.167873651644269
},
"2022": {
"obs_EconomicCapitalRatio": 3.1398158634339004
},
"2023": {
"obs_EconomicCapitalRatio": 6.850181889159298
},
"2024": {
"obs_EconomicCapitalRatio": 3.222650149881341
},
"2025": {
"obs_EconomicCapitalRatio": 3.367464199027977
}
},
"0001485003": {
"2023": {
"obs_EconomicCapitalRatio": 1.5632126082991586
},
"2024": {
"obs_EconomicCapitalRatio": 0.4148454443859101
}
},
"0001517022": {
"2014": {
"obs_EconomicCapitalRatio": 4.010819223234276
},
"2015": {
"obs_EconomicCapitalRatio": 4.8237243575533135
},
"2016": {
"obs_EconomicCapitalRatio": 1.4730434380249977
},
"2017": {
"obs_EconomicCapitalRatio": 2.3876562009982942
},
"2018": {
"obs_EconomicCapitalRatio": 0.48055421021598477
},
"2019": {
"obs_EconomicCapitalRatio": 1.3494051436213654
},
"2020": {
"obs_EconomicCapitalRatio": 0.8291826353614926
},
"2021": {
"obs_EconomicCapitalRatio": 0.870633819197869
},
"2022": {
"obs_EconomicCapitalRatio": 0.2233559190516168
},
"2023": {
"obs_EconomicCapitalRatio": 0.875991209192467
},
"2024": {
"obs_EconomicCapitalRatio": 1.6501753585300492
},
"2025": {
"obs_EconomicCapitalRatio": 1.219065982409421
}
},
"0001517681": {
"2014": {
"obs_EconomicCapitalRatio": 0.0
},
"2015": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001527728": {
"2018": {
"obs_EconomicCapitalRatio": 2.302516553080004
},
"2019": {
"obs_EconomicCapitalRatio": 2.3775735808175726
},
"2023": {
"obs_EconomicCapitalRatio": 6.055969830162965
},
"2024": {
"obs_EconomicCapitalRatio": 1.6861727041832997
}
},
"0001540159": {
"2015": {
"obs_EconomicCapitalRatio": 8.276585544563552
},
"2016": {
"obs_EconomicCapitalRatio": 2.6501242318372156
},
"2017": {
"obs_EconomicCapitalRatio": 1.9270691516342444
},
"2018": {
"obs_EconomicCapitalRatio": 0.7880523009856242
},
"2020": {
"obs_EconomicCapitalRatio": 8.152620731319265
},
"2022": {
"obs_EconomicCapitalRatio": 5.054299772437978
},
"2023": {
"obs_EconomicCapitalRatio": 2.854481801541483
},
"2024": {
"obs_EconomicCapitalRatio": 2.1800251672491813
},
"2025": {
"obs_EconomicCapitalRatio": 1.6714362166326928
}
},
"0001574235": {
"2014": {
"obs_EconomicCapitalRatio": 2.0469770380681473
},
"2015": {
"obs_EconomicCapitalRatio": 2.207632602380119
},
"2016": {
"obs_EconomicCapitalRatio": 0.7181712517809893
},
"2017": {
"obs_EconomicCapitalRatio": 2.8167511874971356
},
"2018": {
"obs_EconomicCapitalRatio": 1.626270015339166
},
"2019": {
"obs_EconomicCapitalRatio": 0.5494034407077054
},
"2020": {
"obs_EconomicCapitalRatio": 1.5457787375224854
},
"2021": {
"obs_EconomicCapitalRatio": 0.6892383766578533
},
"2022": {
"obs_EconomicCapitalRatio": 0.49146228292780314
},
"2023": {
"obs_EconomicCapitalRatio": 0.28093937465011043
},
"2024": {
"obs_EconomicCapitalRatio": 4.120047303893817
},
"2025": {
"obs_EconomicCapitalRatio": 3.8419290070237064
}
},
"0001582313": {
"2014": {
"obs_EconomicCapitalRatio": 4.392368429265987
},
"2015": {
"obs_EconomicCapitalRatio": 3.476660776453972
},
"2016": {
"obs_EconomicCapitalRatio": 4.103680140318783
},
"2017": {
"obs_EconomicCapitalRatio": 1.614193722770627
},
"2018": {
"obs_EconomicCapitalRatio": 2.093243843844552
},
"2019": {
"obs_EconomicCapitalRatio": 3.3904067163153058
},
"2020": {
"obs_EconomicCapitalRatio": 4.973343390727814
},
"2021": {
"obs_EconomicCapitalRatio": 5.3605927874064205
},
"2022": {
"obs_EconomicCapitalRatio": 6.135998550200953
}
},
"0001582554": {
"2014": {
"obs_EconomicCapitalRatio": 6.583806821973907
},
"2015": {
"obs_EconomicCapitalRatio": 8.203102613253769
},
"2016": {
"obs_EconomicCapitalRatio": 12.462807120338587
},
"2017": {
"obs_EconomicCapitalRatio": 14.12256248864945
},
"2018": {
"obs_EconomicCapitalRatio": 5.7222806221190705
},
"2019": {
"obs_EconomicCapitalRatio": 12.112346070508153
},
"2020": {
"obs_EconomicCapitalRatio": 5.299472496229888
},
"2021": {
"obs_EconomicCapitalRatio": 6.349425394200524
},
"2022": {
"obs_EconomicCapitalRatio": 4.169448789703781
},
"2023": {
"obs_EconomicCapitalRatio": 3.1366592849168913
},
"2024": {
"obs_EconomicCapitalRatio": 0.3033443877558794
},
"2025": {
"obs_EconomicCapitalRatio": 0.9102057238354853
}
},
"0001583107": {
"2014": {
"obs_EconomicCapitalRatio": 2.524510289086943
},
"2015": {
"obs_EconomicCapitalRatio": 3.5502715758954673
},
"2016": {
"obs_EconomicCapitalRatio": 4.769352639402022
},
"2017": {
"obs_EconomicCapitalRatio": 5.97018939026352
},
"2018": {
"obs_EconomicCapitalRatio": 4.009561421194865
},
"2019": {
"obs_EconomicCapitalRatio": 5.525429130789294
},
"2020": {
"obs_EconomicCapitalRatio": 3.9967540930032373
},
"2021": {
"obs_EconomicCapitalRatio": 3.6474585228242065
},
"2022": {
"obs_EconomicCapitalRatio": 2.371147972942393
},
"2023": {
"obs_EconomicCapitalRatio": 2.7435188030991986
}
},
"0001583648": {
"2015": {
"obs_EconomicCapitalRatio": 4.7747987863209085
},
"2016": {
"obs_EconomicCapitalRatio": 2.596238426600483
},
"2017": {
"obs_EconomicCapitalRatio": 2.7677828179053505
},
"2018": {
"obs_EconomicCapitalRatio": 1.141407671889934
},
"2019": {
"obs_EconomicCapitalRatio": 1.5409437503001444
},
"2020": {
"obs_EconomicCapitalRatio": 1.6540422363874783
},
"2021": {
"obs_EconomicCapitalRatio": 1.8727478616863706
},
"2022": {
"obs_EconomicCapitalRatio": 0.8323592340556023
},
"2023": {
"obs_EconomicCapitalRatio": 0.6057469211723506
}
},
"0000014272": {
"2015": {
"obs_EconomicCapitalRatio": 3.2475450415220855
},
"2016": {
"obs_EconomicCapitalRatio": 2.7259590116089485
},
"2017": {
"obs_EconomicCapitalRatio": 2.650646716670952
},
"2018": {
"obs_EconomicCapitalRatio": 2.199930130401309
},
"2020": {
"obs_EconomicCapitalRatio": 1.114835636149512
},
"2021": {
"obs_EconomicCapitalRatio": 1.2419398460280224
},
"2022": {
"obs_EconomicCapitalRatio": 1.612627956472529
},
"2023": {
"obs_EconomicCapitalRatio": 1.138243408987469
},
"2024": {
"obs_EconomicCapitalRatio": 1.2721676304709277
},
"2025": {
"obs_EconomicCapitalRatio": 1.321169806314478
}
},
"0000873303": {
"2015": {
"obs_EconomicCapitalRatio": 9.668485604102845
},
"2016": {
"obs_EconomicCapitalRatio": 6.233662004332542
},
"2017": {
"obs_EconomicCapitalRatio": 3.924175866378392
},
"2018": {
"obs_EconomicCapitalRatio": 6.339103672060055
},
"2019": {
"obs_EconomicCapitalRatio": 6.823271045904484
},
"2020": {
"obs_EconomicCapitalRatio": 5.29119921898451
},
"2021": {
"obs_EconomicCapitalRatio": 2.9435836473847226
},
"2022": {
"obs_EconomicCapitalRatio": 3.8077405647956177
}
},
"0001128189": {
"2016": {
"obs_EconomicCapitalRatio": 42.5561641662153
},
"2017": {
"obs_EconomicCapitalRatio": 44.12701545013146
},
"2018": {
"obs_EconomicCapitalRatio": 100.30969158981598
},
"2019": {
"obs_EconomicCapitalRatio": 88.26242021178395
},
"2020": {
"obs_EconomicCapitalRatio": 104.06358738597007
},
"2021": {
"obs_EconomicCapitalRatio": 89.94199206829096
},
"2022": {
"obs_EconomicCapitalRatio": 41.60826773992075
},
"2023": {
"obs_EconomicCapitalRatio": 22.90371520612683
},
"2024": {
"obs_EconomicCapitalRatio": 12.311765432860431
}
},
"0001267565": {
"2015": {
"obs_EconomicCapitalRatio": 9.545499460498341
},
"2016": {
"obs_EconomicCapitalRatio": 4.83483609366986
},
"2017": {
"obs_EconomicCapitalRatio": 7.157401045644926
},
"2018": {
"obs_EconomicCapitalRatio": 2.1923205454261003
},
"2019": {
"obs_EconomicCapitalRatio": 2.5638217711610176
},
"2020": {
"obs_EconomicCapitalRatio": 1.1945982442476681
},
"2021": {
"obs_EconomicCapitalRatio": 1.1275846582888194
},
"2022": {
"obs_EconomicCapitalRatio": 0.7166745350456436
},
"2023": {
"obs_EconomicCapitalRatio": 0.9397213313234996
},
"2025": {
"obs_EconomicCapitalRatio": 1.0262046808470957
}
},
"0001281895": {
"2015": {
"obs_EconomicCapitalRatio": 5.0364370997148225
},
"2016": {
"obs_EconomicCapitalRatio": 1.9822646801810113
},
"2017": {
"obs_EconomicCapitalRatio": 0.8946573077218604
},
"2018": {
"obs_EconomicCapitalRatio": 3.5163891482923164
},
"2019": {
"obs_EconomicCapitalRatio": 5.289572624031411
},
"2020": {
"obs_EconomicCapitalRatio": 9.152568054550002
},
"2021": {
"obs_EconomicCapitalRatio": 5.464254934454973
},
"2022": {
"obs_EconomicCapitalRatio": 4.816510052502813
}
},
"0001326732": {
"2015": {
"obs_EconomicCapitalRatio": 4.7370337142113
},
"2016": {
"obs_EconomicCapitalRatio": 3.9967030445270955
},
"2017": {
"obs_EconomicCapitalRatio": 4.202511162476909
},
"2018": {
"obs_EconomicCapitalRatio": 6.073969875839424
},
"2019": {
"obs_EconomicCapitalRatio": 5.83986745888784
},
"2020": {
"obs_EconomicCapitalRatio": 6.222607779114316
},
"2021": {
"obs_EconomicCapitalRatio": 4.9964835227058515
},
"2022": {
"obs_EconomicCapitalRatio": 3.2034867036915506
},
"2023": {
"obs_EconomicCapitalRatio": 2.070616845257262
},
"2024": {
"obs_EconomicCapitalRatio": 2.7552069968217667
},
"2025": {
"obs_EconomicCapitalRatio": 1.9795640740863942
}
},
"0001348911": {
"2015": {
"obs_EconomicCapitalRatio": 0.20211091249350502
},
"2016": {
"obs_EconomicCapitalRatio": 12.845502948864823
},
"2017": {
"obs_EconomicCapitalRatio": 5.386046168520068
},
"2019": {
"obs_EconomicCapitalRatio": 4.363753356040546
},
"2020": {
"obs_EconomicCapitalRatio": 6.251934538262092
},
"2021": {
"obs_EconomicCapitalRatio": 2.3451793339305693
},
"2022": {
"obs_EconomicCapitalRatio": 1.2250090948446972
}
},
"0001372514": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 4.8687372773255175
},
"2020": {
"obs_EconomicCapitalRatio": 2.1345849403381534
},
"2021": {
"obs_EconomicCapitalRatio": 0.8948813852784885
},
"2022": {
"obs_EconomicCapitalRatio": 0.24485864375810124
},
"2023": {
"obs_EconomicCapitalRatio": 0.3888692783137503
},
"2024": {
"obs_EconomicCapitalRatio": 0.4182487345061539
}
},
"0001374690": {
"2015": {
"obs_EconomicCapitalRatio": 20.943435399614355
},
"2016": {
"obs_EconomicCapitalRatio": 15.15781782827369
},
"2017": {
"obs_EconomicCapitalRatio": 20.69114475239754
},
"2018": {
"obs_EconomicCapitalRatio": 29.417509168744573
},
"2019": {
"obs_EconomicCapitalRatio": 8.48372085170697
},
"2020": {
"obs_EconomicCapitalRatio": 5.486558924421429
},
"2021": {
"obs_EconomicCapitalRatio": 4.021593630675525
},
"2022": {
"obs_EconomicCapitalRatio": 2.6954254166627156
}
},
"0001434647": {
"2015": {
"obs_EconomicCapitalRatio": 4.4921423898171
},
"2016": {
"obs_EconomicCapitalRatio": 0.5165262290733772
},
"2017": {
"obs_EconomicCapitalRatio": 0.6848099016426473
},
"2018": {
"obs_EconomicCapitalRatio": 0.865624026468524
},
"2019": {
"obs_EconomicCapitalRatio": 0.24683179633840263
},
"2020": {
"obs_EconomicCapitalRatio": 24.491947700213355
},
"2023": {
"obs_EconomicCapitalRatio": 1.2615329818804297
},
"2024": {
"obs_EconomicCapitalRatio": 2.8610987447081255
},
"2025": {
"obs_EconomicCapitalRatio": 2.3330351772908413
}
},
"0001460702": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 2.2107914692835418
},
"2022": {
"obs_EconomicCapitalRatio": 3.7082246599908757
},
"2023": {
"obs_EconomicCapitalRatio": 0.9723846982305767
},
"2024": {
"obs_EconomicCapitalRatio": 0.8966105358545655
},
"2025": {
"obs_EconomicCapitalRatio": 0.7992021507471163
}
},
"0001501989": {
"2015": {
"obs_EconomicCapitalRatio": 5.593684092339584
},
"2016": {
"obs_EconomicCapitalRatio": 2.619381599651744
},
"2017": {
"obs_EconomicCapitalRatio": 2.3376888954500075
},
"2018": {
"obs_EconomicCapitalRatio": 1.6725413392645991
},
"2019": {
"obs_EconomicCapitalRatio": 1.2386537359077794
},
"2020": {
"obs_EconomicCapitalRatio": 1.036637404678561
},
"2021": {
"obs_EconomicCapitalRatio": 0.9597362946003473
},
"2022": {
"obs_EconomicCapitalRatio": 0.3339390654966768
}
},
"0001506251": {
"2015": {
"obs_EconomicCapitalRatio": 68.18891485061765
},
"2016": {
"obs_EconomicCapitalRatio": 2.7992844910974117
},
"2017": {
"obs_EconomicCapitalRatio": 2.685011457384177
},
"2018": {
"obs_EconomicCapitalRatio": 1.0813813832971078
},
"2020": {
"obs_EconomicCapitalRatio": 2.2591166917938206
},
"2023": {
"obs_EconomicCapitalRatio": 2.159536016547452
},
"2024": {
"obs_EconomicCapitalRatio": 6.035944830417154
}
},
"0001526119": {
"2015": {
"obs_EconomicCapitalRatio": 1.10776532837638
},
"2017": {
"obs_EconomicCapitalRatio": 2.0776084538190913
},
"2018": {
"obs_EconomicCapitalRatio": 1.1626992843450203
},
"2019": {
"obs_EconomicCapitalRatio": 0.7040930043916058
},
"2020": {
"obs_EconomicCapitalRatio": 3.968963717126026
},
"2021": {
"obs_EconomicCapitalRatio": 6.306571084828538
},
"2022": {
"obs_EconomicCapitalRatio": 1.0850427238616216
},
"2023": {
"obs_EconomicCapitalRatio": 1.839270489546306
}
},
"0001527599": {
"2015": {
"obs_EconomicCapitalRatio": 42.38419100270754
},
"2016": {
"obs_EconomicCapitalRatio": 15.55508778937919
},
"2017": {
"obs_EconomicCapitalRatio": 42.78514884794768
},
"2018": {
"obs_EconomicCapitalRatio": 34.08047468923924
},
"2019": {
"obs_EconomicCapitalRatio": 10.248352718914434
},
"2020": {
"obs_EconomicCapitalRatio": 13.415002946338147
},
"2021": {
"obs_EconomicCapitalRatio": 24.718119187681346
},
"2022": {
"obs_EconomicCapitalRatio": 10.796971933946313
}
},
"0001541157": {
"2015": {
"obs_EconomicCapitalRatio": 333.2338112169181
},
"2025": {
"obs_EconomicCapitalRatio": 557.3736464203313
}
},
"0001553643": {
"2015": {
"obs_EconomicCapitalRatio": 1.7338821891929213
},
"2016": {
"obs_EconomicCapitalRatio": 1.1816013242874706
},
"2017": {
"obs_EconomicCapitalRatio": 4.599958387137025
},
"2018": {
"obs_EconomicCapitalRatio": 5.631594568993065
},
"2020": {
"obs_EconomicCapitalRatio": 8.070490617556281
},
"2021": {
"obs_EconomicCapitalRatio": 3.189405967515967
},
"2023": {
"obs_EconomicCapitalRatio": 1.648304465498439
}
},
"0001557746": {
"2016": {
"obs_EconomicCapitalRatio": 6.604216738408072
},
"2017": {
"obs_EconomicCapitalRatio": 5.6131375883934025
},
"2018": {
"obs_EconomicCapitalRatio": 1.7019790590737285
},
"2019": {
"obs_EconomicCapitalRatio": 1.212098674624993
},
"2020": {
"obs_EconomicCapitalRatio": 5.435226457505301
},
"2021": {
"obs_EconomicCapitalRatio": 5.8301042520779305
},
"2022": {
"obs_EconomicCapitalRatio": 6.499861999475928
},
"2023": {
"obs_EconomicCapitalRatio": 0.6170529806766536
}
},
"0001569340": {
"2015": {
"obs_EconomicCapitalRatio": 9.116142223062687
},
"2020": {
"obs_EconomicCapitalRatio": 11.37309540355387
}
},
"0001585608": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001595097": {
"2015": {
"obs_EconomicCapitalRatio": 7.150216686101165
},
"2016": {
"obs_EconomicCapitalRatio": 28.092542245692012
},
"2017": {
"obs_EconomicCapitalRatio": 10.055725124496933
},
"2018": {
"obs_EconomicCapitalRatio": 9.993523112769557
},
"2019": {
"obs_EconomicCapitalRatio": 7.498768621961081
},
"2020": {
"obs_EconomicCapitalRatio": 1.4308728416796583
},
"2021": {
"obs_EconomicCapitalRatio": 1.104648603895476
},
"2022": {
"obs_EconomicCapitalRatio": 0.27635414874298914
}
},
"0001598646": {
"2015": {
"obs_EconomicCapitalRatio": 2.634548670759021
},
"2016": {
"obs_EconomicCapitalRatio": 5.485442013339983
},
"2017": {
"obs_EconomicCapitalRatio": 1.9859162487009006
},
"2018": {
"obs_EconomicCapitalRatio": 2.747774885570393
},
"2019": {
"obs_EconomicCapitalRatio": 4.208753853253404
},
"2020": {
"obs_EconomicCapitalRatio": 3.3886058732353694
},
"2021": {
"obs_EconomicCapitalRatio": 0.5251543288767053
},
"2022": {
"obs_EconomicCapitalRatio": 0.2067192346550029
}
},
"0001607678": {
"2015": {
"obs_EconomicCapitalRatio": 1.9834389723963093
},
"2016": {
"obs_EconomicCapitalRatio": 2.0814310306844765
},
"2017": {
"obs_EconomicCapitalRatio": 7.592782060667528
},
"2018": {
"obs_EconomicCapitalRatio": 3.5884317978740667
},
"2019": {
"obs_EconomicCapitalRatio": 4.005092177058184
},
"2020": {
"obs_EconomicCapitalRatio": 3.3915361928929455
},
"2021": {
"obs_EconomicCapitalRatio": 3.468945823287514
},
"2022": {
"obs_EconomicCapitalRatio": 6.479499566971428
}
},
"0001609809": {
"2015": {
"obs_EconomicCapitalRatio": 12.371324494321517
},
"2016": {
"obs_EconomicCapitalRatio": 1.9421880149134538
},
"2017": {
"obs_EconomicCapitalRatio": 2.5908631473715626
},
"2018": {
"obs_EconomicCapitalRatio": 1.384064290835004
},
"2019": {
"obs_EconomicCapitalRatio": 1.8615650337156782
},
"2020": {
"obs_EconomicCapitalRatio": 8.781524800983108
},
"2021": {
"obs_EconomicCapitalRatio": 2.7321700147524
},
"2022": {
"obs_EconomicCapitalRatio": 1.9955432209497879
}
},
"0001618835": {
"2015": {
"obs_EconomicCapitalRatio": 0.0
},
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 27.260771879425697
},
"2021": {
"obs_EconomicCapitalRatio": 1.304128340362082
},
"2022": {
"obs_EconomicCapitalRatio": 0.14293480962284852
},
"2023": {
"obs_EconomicCapitalRatio": 0.01667205175592019
},
"2024": {
"obs_EconomicCapitalRatio": 0.015834009366340877
},
"2025": {
"obs_EconomicCapitalRatio": 0.023036945432258746
}
},
"0001621221": {
"2019": {
"obs_EconomicCapitalRatio": 2.4753873505624306
},
"2020": {
"obs_EconomicCapitalRatio": 4.264908581177564
},
"2021": {
"obs_EconomicCapitalRatio": 4.02697447143019
},
"2023": {
"obs_EconomicCapitalRatio": 0.6054883871847317
},
"2024": {
"obs_EconomicCapitalRatio": 0.9901373189844184
},
"2025": {
"obs_EconomicCapitalRatio": 0.9241621649519836
}
},
"0001631574": {
"2015": {
"obs_EconomicCapitalRatio": 4.069113217531914
},
"2016": {
"obs_EconomicCapitalRatio": 7.185150465314827
},
"2017": {
"obs_EconomicCapitalRatio": 9.051139386919285
},
"2018": {
"obs_EconomicCapitalRatio": 4.859865684220317
},
"2019": {
"obs_EconomicCapitalRatio": 2.1475345165686233
},
"2020": {
"obs_EconomicCapitalRatio": 1.769382687303525
},
"2021": {
"obs_EconomicCapitalRatio": 1.0659833362894395
},
"2022": {
"obs_EconomicCapitalRatio": 3.2970693329247367
}
},
"0001641489": {
"2015": {
"obs_EconomicCapitalRatio": 1.2552103799603973
},
"2016": {
"obs_EconomicCapitalRatio": 1.3459374903125807
},
"2017": {
"obs_EconomicCapitalRatio": 1.1345479524457975
},
"2018": {
"obs_EconomicCapitalRatio": 1.2383672431029904
},
"2019": {
"obs_EconomicCapitalRatio": 4.491518150513322
},
"2020": {
"obs_EconomicCapitalRatio": 7.976879057591623
},
"2021": {
"obs_EconomicCapitalRatio": 3.9162067227323436
},
"2022": {
"obs_EconomicCapitalRatio": 1.826215242233967
},
"2023": {
"obs_EconomicCapitalRatio": 35.7174631241012
},
"2024": {
"obs_EconomicCapitalRatio": 1.1686335633140843
},
"2025": {
"obs_EconomicCapitalRatio": 2.5435087644018997
}
},
"0000812306": {
"2017": {
"obs_EconomicCapitalRatio": 0.7679844265560579
},
"2018": {
"obs_EconomicCapitalRatio": 1.3238043750261224
},
"2019": {
"obs_EconomicCapitalRatio": 1.553680659218853
},
"2020": {
"obs_EconomicCapitalRatio": 3.951228396195592
},
"2021": {
"obs_EconomicCapitalRatio": 1.0293958339533176
},
"2022": {
"obs_EconomicCapitalRatio": 0.9173385873482564
},
"2023": {
"obs_EconomicCapitalRatio": 0.6230011525278941
}
},
"0001014763": {
"2021": {
"obs_EconomicCapitalRatio": 3.2970328242500426
},
"2022": {
"obs_EconomicCapitalRatio": 0.6373987318483224
},
"2023": {
"obs_EconomicCapitalRatio": 2.2353109180655855
},
"2024": {
"obs_EconomicCapitalRatio": 0.2989579783403101
},
"2025": {
"obs_EconomicCapitalRatio": 0.5564579677349022
}
},
"0001395937": {
"2016": {
"obs_EconomicCapitalRatio": 2.0274181405815592
},
"2017": {
"obs_EconomicCapitalRatio": 2.3708227426577966
},
"2018": {
"obs_EconomicCapitalRatio": 1.7735484369185335
},
"2019": {
"obs_EconomicCapitalRatio": 5.012956899172152
},
"2020": {
"obs_EconomicCapitalRatio": 5.657839182322721
},
"2021": {
"obs_EconomicCapitalRatio": 4.338131466604313
},
"2022": {
"obs_EconomicCapitalRatio": 5.533006676662477
}
},
"0001539029": {
"2016": {
"obs_EconomicCapitalRatio": 3.8001069543615715
},
"2017": {
"obs_EconomicCapitalRatio": 5.511027749062352
},
"2018": {
"obs_EconomicCapitalRatio": 1.0708192486420613
},
"2019": {
"obs_EconomicCapitalRatio": 5.457817849157306
},
"2020": {
"obs_EconomicCapitalRatio": 6.830495344600248
}
},
"0001555280": {
"2016": {
"obs_EconomicCapitalRatio": 3.5294023070229286
},
"2017": {
"obs_EconomicCapitalRatio": 4.26721278609896
},
"2019": {
"obs_EconomicCapitalRatio": 5.830222610803596
},
"2020": {
"obs_EconomicCapitalRatio": 6.2465194766286976
},
"2021": {
"obs_EconomicCapitalRatio": 9.433935491487597
},
"2022": {
"obs_EconomicCapitalRatio": 5.098553510112966
},
"2023": {
"obs_EconomicCapitalRatio": 7.413320323582953
},
"2024": {
"obs_EconomicCapitalRatio": 6.132488673752045
},
"2025": {
"obs_EconomicCapitalRatio": 3.9456146954632536
}
},
"0001579428": {
"2016": {
"obs_EconomicCapitalRatio": 4.731285154323032
},
"2017": {
"obs_EconomicCapitalRatio": 4.395347931767885
},
"2018": {
"obs_EconomicCapitalRatio": 4.458882968102999
},
"2019": {
"obs_EconomicCapitalRatio": 26.65313506898581
},
"2022": {
"obs_EconomicCapitalRatio": 11.82261524078376
}
},
"0001583771": {
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 1.4764049161692996
},
"2020": {
"obs_EconomicCapitalRatio": 0.6820121179955333
},
"2021": {
"obs_EconomicCapitalRatio": 1.6165558445799055
},
"2022": {
"obs_EconomicCapitalRatio": 0.6594129903533573
},
"2023": {
"obs_EconomicCapitalRatio": 0.9993418815360613
},
"2024": {
"obs_EconomicCapitalRatio": 1.36001469804817
},
"2025": {
"obs_EconomicCapitalRatio": 0.43504776570784937
}
},
"0001590560": {
"2017": {
"obs_EconomicCapitalRatio": 3.443816673125471
},
"2018": {
"obs_EconomicCapitalRatio": 5.436808380747137
},
"2019": {
"obs_EconomicCapitalRatio": 10.904943748745998
},
"2020": {
"obs_EconomicCapitalRatio": 7.792438910067191
},
"2021": {
"obs_EconomicCapitalRatio": 1.9302182695305188
},
"2022": {
"obs_EconomicCapitalRatio": 2.290830914690775
},
"2023": {
"obs_EconomicCapitalRatio": 0.4456950008088053
}
},
"0001626878": {
"2016": {
"obs_EconomicCapitalRatio": 7.28422372646887
},
"2017": {
"obs_EconomicCapitalRatio": 3.755245458715203
},
"2019": {
"obs_EconomicCapitalRatio": 1.5759474094123005
},
"2020": {
"obs_EconomicCapitalRatio": 2.345949117862805
},
"2021": {
"obs_EconomicCapitalRatio": 2.433294962975098
},
"2022": {
"obs_EconomicCapitalRatio": 0.7500901950035245
},
"2023": {
"obs_EconomicCapitalRatio": 1.0375765523682057
},
"2025": {
"obs_EconomicCapitalRatio": 0.9328657551171378
}
},
"0001626971": {
"2016": {
"obs_EconomicCapitalRatio": 4.277405407531264
},
"2017": {
"obs_EconomicCapitalRatio": 4.149375012876857
},
"2019": {
"obs_EconomicCapitalRatio": 2.6843077546283682
},
"2020": {
"obs_EconomicCapitalRatio": 2.241320520434651
},
"2021": {
"obs_EconomicCapitalRatio": 1.9728459381286443
},
"2022": {
"obs_EconomicCapitalRatio": 0.9395855641792878
},
"2023": {
"obs_EconomicCapitalRatio": 3.1431390679772337
}
},
"0001636282": {
"2016": {
"obs_EconomicCapitalRatio": 1.911949666807195
},
"2017": {
"obs_EconomicCapitalRatio": 2.7490583145413074
},
"2018": {
"obs_EconomicCapitalRatio": 4.003210640999432
},
"2019": {
"obs_EconomicCapitalRatio": 4.235264567342523
},
"2020": {
"obs_EconomicCapitalRatio": 4.34926970229657
},
"2021": {
"obs_EconomicCapitalRatio": 3.0591140227060354
},
"2022": {
"obs_EconomicCapitalRatio": 0.480811302312216
},
"2023": {
"obs_EconomicCapitalRatio": 0.3451585198947146
},
"2024": {
"obs_EconomicCapitalRatio": 3.4522188932719113
},
"2025": {
"obs_EconomicCapitalRatio": 6.1043163744290645
}
},
"0001638287": {
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 9.290038100241892
}
},
"0001651308": {
"2016": {
"obs_EconomicCapitalRatio": 55.07257988517769
},
"2017": {
"obs_EconomicCapitalRatio": 80.78994328623331
},
"2018": {
"obs_EconomicCapitalRatio": 75.19069906966709
},
"2019": {
"obs_EconomicCapitalRatio": 117.56902263238351
},
"2020": {
"obs_EconomicCapitalRatio": 83.7077839131438
},
"2021": {
"obs_EconomicCapitalRatio": 60.09190503077995
},
"2022": {
"obs_EconomicCapitalRatio": 70.79176203538113
},
"2023": {
"obs_EconomicCapitalRatio": 60.354771279349215
},
"2024": {
"obs_EconomicCapitalRatio": 58.74717564636796
},
"2025": {
"obs_EconomicCapitalRatio": 74.46961209797139
}
},
"0001659617": {
"2016": {
"obs_EconomicCapitalRatio": 0.0
},
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 1.402227694170675
},
"2022": {
"obs_EconomicCapitalRatio": 1.2594041493424097
},
"2023": {
"obs_EconomicCapitalRatio": 0.909656247498064
},
"2025": {
"obs_EconomicCapitalRatio": 13.456130084491564
}
},
"0001680048": {
"2017": {
"obs_EconomicCapitalRatio": 0.2596643535753641
},
"2018": {
"obs_EconomicCapitalRatio": 0.07895219091057175
},
"2019": {
"obs_EconomicCapitalRatio": 0.0501303238990739
},
"2020": {
"obs_EconomicCapitalRatio": 0.03952130469039673
},
"2021": {
"obs_EconomicCapitalRatio": 0.016593300619834713
},
"2022": {
"obs_EconomicCapitalRatio": 0.003244066029327926
},
"2023": {
"obs_EconomicCapitalRatio": 0.06359334012047171
}
},
"0000109657": {
"2020": {
"obs_EconomicCapitalRatio": 1.6846332758244982
},
"2022": {
"obs_EconomicCapitalRatio": 3.276889997621411
},
"2023": {
"obs_EconomicCapitalRatio": 1.0101946437098341
},
"2024": {
"obs_EconomicCapitalRatio": 1.2853889944280936
},
"2025": {
"obs_EconomicCapitalRatio": 1.622201918946696
}
},
"0001173313": {
"2017": {
"obs_EconomicCapitalRatio": 133.7703825988571
},
"2019": {
"obs_EconomicCapitalRatio": 14.62906593991791
},
"2020": {
"obs_EconomicCapitalRatio": 10.431590816230356
},
"2021": {
"obs_EconomicCapitalRatio": 11.24254806221214
},
"2022": {
"obs_EconomicCapitalRatio": 2.569020672124645
},
"2023": {
"obs_EconomicCapitalRatio": 0.8218812740633279
}
},
"0001370053": {
"2017": {
"obs_EconomicCapitalRatio": 13.167988751469355
},
"2018": {
"obs_EconomicCapitalRatio": 6.2142651603584
},
"2019": {
"obs_EconomicCapitalRatio": 1.921164157298367
},
"2020": {
"obs_EconomicCapitalRatio": 2.81203464508538
},
"2021": {
"obs_EconomicCapitalRatio": 2.991710648767185
},
"2022": {
"obs_EconomicCapitalRatio": 2.6017630895148307
},
"2023": {
"obs_EconomicCapitalRatio": 2.2108411190227493
},
"2024": {
"obs_EconomicCapitalRatio": 1.6017455543069687
}
},
"0001377121": {
"2017": {
"obs_EconomicCapitalRatio": 3.914023929056892
},
"2018": {
"obs_EconomicCapitalRatio": 1.9371601789637214
},
"2019": {
"obs_EconomicCapitalRatio": 1.6918961236380876
},
"2020": {
"obs_EconomicCapitalRatio": 4.6012149122973
},
"2021": {
"obs_EconomicCapitalRatio": 8.232979661392296
},
"2022": {
"obs_EconomicCapitalRatio": 3.4935072045172726
},
"2023": {
"obs_EconomicCapitalRatio": 6.698251527915118
}
},
"0001411685": {
"2017": {
"obs_EconomicCapitalRatio": 3.827433625855536
},
"2018": {
"obs_EconomicCapitalRatio": 5.7207627820698495
},
"2019": {
"obs_EconomicCapitalRatio": 3.0027583042272052
},
"2020": {
"obs_EconomicCapitalRatio": 11.917054122105522
},
"2021": {
"obs_EconomicCapitalRatio": 6.12552075504253
},
"2022": {
"obs_EconomicCapitalRatio": 0.4842481960234831
},
"2023": {
"obs_EconomicCapitalRatio": 9.274635539846695
},
"2024": {
"obs_EconomicCapitalRatio": 1.0717075833225695
}
},
"0001412486": {
"2017": {
"obs_EconomicCapitalRatio": 2.460451307469997
},
"2018": {
"obs_EconomicCapitalRatio": 2.5120455856560415
}
},
"0001420565": {
"2017": {
"obs_EconomicCapitalRatio": 5.1023289307496595
},
"2018": {
"obs_EconomicCapitalRatio": 0.5726969681607266
},
"2019": {
"obs_EconomicCapitalRatio": 0.8727951563208037
},
"2020": {
"obs_EconomicCapitalRatio": 4.163633669590643
},
"2021": {
"obs_EconomicCapitalRatio": 1.850461391873863
},
"2022": {
"obs_EconomicCapitalRatio": 16.418427885256513
}
},
"0001509745": {
"2017": {
"obs_EconomicCapitalRatio": 2.4505707185375876
},
"2018": {
"obs_EconomicCapitalRatio": 2.369922122381597
},
"2019": {
"obs_EconomicCapitalRatio": 2.8635571965108215
},
"2020": {
"obs_EconomicCapitalRatio": 4.25639470917342
},
"2021": {
"obs_EconomicCapitalRatio": 4.100610570922096
},
"2022": {
"obs_EconomicCapitalRatio": 1.0865248758170611
},
"2023": {
"obs_EconomicCapitalRatio": 1.9134670273083285
}
},
"0001514946": {
"2017": {
"obs_EconomicCapitalRatio": 73.39159388942399
},
"2018": {
"obs_EconomicCapitalRatio": 7.96001803039942
},
"2022": {
"obs_EconomicCapitalRatio": 0.7094745888114613
},
"2023": {
"obs_EconomicCapitalRatio": 0.5978697836515268
}
},
"0001528172": {
"2017": {
"obs_EconomicCapitalRatio": 0.019099386123103267
},
"2018": {
"obs_EconomicCapitalRatio": 0.8283695524372952
},
"2019": {
"obs_EconomicCapitalRatio": 142.77801500563763
},
"2020": {
"obs_EconomicCapitalRatio": 0.05812407823255177
},
"2021": {
"obs_EconomicCapitalRatio": 0.11790771971716654
}
},
"0001534120": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 1.1778632103795506
},
"2023": {
"obs_EconomicCapitalRatio": 131.79765640599854
},
"2024": {
"obs_EconomicCapitalRatio": 1.1101645179123487
}
},
"0001566044": {
"2018": {
"obs_EconomicCapitalRatio": 1.317547784011202
},
"2019": {
"obs_EconomicCapitalRatio": 2.6616596600295654
},
"2020": {
"obs_EconomicCapitalRatio": 3.9600248195471717
},
"2021": {
"obs_EconomicCapitalRatio": 1.3698621993549591
},
"2022": {
"obs_EconomicCapitalRatio": 0.32575957408979317
},
"2023": {
"obs_EconomicCapitalRatio": 0.6649149421403918
},
"2024": {
"obs_EconomicCapitalRatio": 1.012622254166815
},
"2025": {
"obs_EconomicCapitalRatio": 0.909971665771834
}
},
"0001589150": {
"2017": {
"obs_EconomicCapitalRatio": 1.5939039321287882
},
"2021": {
"obs_EconomicCapitalRatio": 5.815418147348666
},
"2022": {
"obs_EconomicCapitalRatio": 3.3803374988335997
},
"2023": {
"obs_EconomicCapitalRatio": 0.9680986000563736
}
},
"0001595248": {
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 2.2975715784653983
},
"2025": {
"obs_EconomicCapitalRatio": 0.6890334170541527
}
},
"0001615219": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.4266213271995585
},
"2023": {
"obs_EconomicCapitalRatio": 0.8817239426328813
},
"2024": {
"obs_EconomicCapitalRatio": 1.0538230226625522
}
},
"0001645469": {
"2019": {
"obs_EconomicCapitalRatio": 25.93457561963354
},
"2020": {
"obs_EconomicCapitalRatio": 7.94561875748812
},
"2021": {
"obs_EconomicCapitalRatio": 3.8337806849507885
},
"2022": {
"obs_EconomicCapitalRatio": 3.7394488995043447
},
"2023": {
"obs_EconomicCapitalRatio": 1.237974920283715
},
"2024": {
"obs_EconomicCapitalRatio": 3.90769690668125
},
"2025": {
"obs_EconomicCapitalRatio": 6.343918823471869
}
},
"0001671584": {
"2017": {
"obs_EconomicCapitalRatio": 0.0
},
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001682639": {
"2018": {
"obs_EconomicCapitalRatio": 2.2837564752113586
},
"2019": {
"obs_EconomicCapitalRatio": 7.0391953952305535
},
"2020": {
"obs_EconomicCapitalRatio": 5.154502189305028
},
"2021": {
"obs_EconomicCapitalRatio": 5.026111355492541
},
"2022": {
"obs_EconomicCapitalRatio": 2.5051335831758266
},
"2023": {
"obs_EconomicCapitalRatio": 3.079128218817466
}
},
"0001698530": {
"2018": {
"obs_EconomicCapitalRatio": 8.357163676148797
},
"2019": {
"obs_EconomicCapitalRatio": 2.9887187823059307
},
"2020": {
"obs_EconomicCapitalRatio": 2.483895035470864
},
"2021": {
"obs_EconomicCapitalRatio": 0.3380830254064559
},
"2022": {
"obs_EconomicCapitalRatio": 0.36138827407151963
},
"2023": {
"obs_EconomicCapitalRatio": 0.5142840533526112
},
"2024": {
"obs_EconomicCapitalRatio": 3.239869857320238
}
},
"0001701108": {
"2017": {
"obs_EconomicCapitalRatio": 3.249938964861851
},
"2018": {
"obs_EconomicCapitalRatio": 1.533993943015218
},
"2019": {
"obs_EconomicCapitalRatio": 2.918587726691467
},
"2020": {
"obs_EconomicCapitalRatio": 6.327245808454878
},
"2021": {
"obs_EconomicCapitalRatio": 3.5665420006235404
},
"2022": {
"obs_EconomicCapitalRatio": 0.9629564817040931
}
},
"0000818686": {
"2018": {
"obs_EconomicCapitalRatio": 0.32514906136361227
},
"2019": {
"obs_EconomicCapitalRatio": 0.2178319843684473
},
"2020": {
"obs_EconomicCapitalRatio": 0.23675779404262848
},
"2021": {
"obs_EconomicCapitalRatio": 0.21886047552551496
},
"2022": {
"obs_EconomicCapitalRatio": 0.25601351138535516
},
"2023": {
"obs_EconomicCapitalRatio": 0.2979363623480095
},
"2024": {
"obs_EconomicCapitalRatio": 0.6887107587567836
}
},
"0001205922": {
"2018": {
"obs_EconomicCapitalRatio": 3.558545253032523
},
"2019": {
"obs_EconomicCapitalRatio": 14.107889173710923
},
"2020": {
"obs_EconomicCapitalRatio": 3.848820391735063
},
"2021": {
"obs_EconomicCapitalRatio": 6.534633254036944
},
"2022": {
"obs_EconomicCapitalRatio": 5.585500529255729
}
},
"0001398733": {
"2018": {
"obs_EconomicCapitalRatio": 2.0335208694788927
},
"2019": {
"obs_EconomicCapitalRatio": 1.6769019425473788
},
"2020": {
"obs_EconomicCapitalRatio": 2.480994835552515
},
"2021": {
"obs_EconomicCapitalRatio": 1.556911477192337
},
"2022": {
"obs_EconomicCapitalRatio": 0.41985375789917745
},
"2023": {
"obs_EconomicCapitalRatio": 1.2066939811949051
},
"2024": {
"obs_EconomicCapitalRatio": 2.4787610336985555
},
"2025": {
"obs_EconomicCapitalRatio": 4.105635682704048
}
},
"0001401040": {
"2019": {
"obs_EconomicCapitalRatio": 9.581231195149424
},
"2020": {
"obs_EconomicCapitalRatio": 11.44489460295306
},
"2021": {
"obs_EconomicCapitalRatio": 3.9817759093568927
},
"2023": {
"obs_EconomicCapitalRatio": 3.74479963887114
},
"2024": {
"obs_EconomicCapitalRatio": 8.787097452657084
},
"2025": {
"obs_EconomicCapitalRatio": 12.966407842541559
}
},
"0001426800": {
"2018": {
"obs_EconomicCapitalRatio": 3.2715032567189795
},
"2019": {
"obs_EconomicCapitalRatio": 2.656833630410397
},
"2020": {
"obs_EconomicCapitalRatio": 1.2260807054391023
},
"2021": {
"obs_EconomicCapitalRatio": 1.012923367531431
},
"2022": {
"obs_EconomicCapitalRatio": 1.0245394097639269
}
},
"0001513525": {
"2018": {
"obs_EconomicCapitalRatio": 15.29204527391044
},
"2019": {
"obs_EconomicCapitalRatio": 7.422992112609702
},
"2020": {
"obs_EconomicCapitalRatio": 9.195160674374737
},
"2023": {
"obs_EconomicCapitalRatio": 0.8112821129859077
}
},
"0001570562": {
"2018": {
"obs_EconomicCapitalRatio": 2.4644934958280946
},
"2019": {
"obs_EconomicCapitalRatio": 1.6526450097941916
},
"2020": {
"obs_EconomicCapitalRatio": 0.504423451769479
},
"2021": {
"obs_EconomicCapitalRatio": 1.6900619644881842
},
"2022": {
"obs_EconomicCapitalRatio": 2.3100849590901413
},
"2023": {
"obs_EconomicCapitalRatio": 2.8583602912038395
},
"2024": {
"obs_EconomicCapitalRatio": 3.0213055263832986
},
"2025": {
"obs_EconomicCapitalRatio": 1.8769865134086707
}
},
"0001604191": {
"2018": {
"obs_EconomicCapitalRatio": 0.0
},
"2019": {
"obs_EconomicCapitalRatio": 0.0
},
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.6221840865782279
},
"2023": {
"obs_EconomicCapitalRatio": 10.104779725932428
}
},
"0001622229": {
"2019": {
"obs_EconomicCapitalRatio": 0.653173704312413
},
"2020": {
"obs_EconomicCapitalRatio": 1.041837424690067
},
"2021": {
"obs_EconomicCapitalRatio": 2.68914694631765
},
"2022": {
"obs_EconomicCapitalRatio": 4.443547993300266
}
},
"0001655759": {
"2018": {
"obs_EconomicCapitalRatio": 3.2808490818527978
},
"2019": {
"obs_EconomicCapitalRatio": 7.486499358429144
},
"2020": {
"obs_EconomicCapitalRatio": 8.251738168682177
},
"2021": {
"obs_EconomicCapitalRatio": 3.5375048165770537
},
"2022": {
"obs_EconomicCapitalRatio": 1.833701160049044
},
"2023": {
"obs_EconomicCapitalRatio": 2.188090869424132
},
"2024": {
"obs_EconomicCapitalRatio": 1.599250605197483
},
"2025": {
"obs_EconomicCapitalRatio": 1.5230753357527844
}
},
"0001659323": {
"2018": {
"obs_EconomicCapitalRatio": 1.2956470910456483
},
"2019": {
"obs_EconomicCapitalRatio": 0.9991685577319022
},
"2020": {
"obs_EconomicCapitalRatio": 0.7321175401737595
},
"2021": {
"obs_EconomicCapitalRatio": 1.2505648158055298
},
"2022": {
"obs_EconomicCapitalRatio": 0.19588772714124267
}
},
"0001661181": {
"2019": {
"obs_EconomicCapitalRatio": 2.4337172392910094
},
"2020": {
"obs_EconomicCapitalRatio": 3.178293633366289
},
"2021": {
"obs_EconomicCapitalRatio": 3.7505662449012793
},
"2022": {
"obs_EconomicCapitalRatio": 1.067092580296219
}
},
"0001661998": {
"2018": {
"obs_EconomicCapitalRatio": 5.061694686560405
},
"2019": {
"obs_EconomicCapitalRatio": 5.264587553460372
},
"2020": {
"obs_EconomicCapitalRatio": 3.3929572131000203
},
"2021": {
"obs_EconomicCapitalRatio": 1.8249824165964792
},
"2022": {
"obs_EconomicCapitalRatio": 0.5213274307293991
}
},
"0001668243": {
"2019": {
"obs_EconomicCapitalRatio": 6.351614519380273
},
"2020": {
"obs_EconomicCapitalRatio": 5.627440820998476
},
"2021": {
"obs_EconomicCapitalRatio": 1.8434655464148624
},
"2022": {
"obs_EconomicCapitalRatio": 1.0245192387938165
},
"2023": {
"obs_EconomicCapitalRatio": 2.1951516473304666
},
"2024": {
"obs_EconomicCapitalRatio": 1.5615001591597384
},
"2025": {
"obs_EconomicCapitalRatio": 4.298345678378464
}
},
"0001708599": {
"2020": {
"obs_EconomicCapitalRatio": 9.389529401288595
},
"2022": {
"obs_EconomicCapitalRatio": 1.7540810203784016
},
"2023": {
"obs_EconomicCapitalRatio": 1.5714257944094645
},
"2024": {
"obs_EconomicCapitalRatio": 7.338972673386068
}
},
"0001711786": {
"2019": {
"obs_EconomicCapitalRatio": 31.04911251583365
},
"2021": {
"obs_EconomicCapitalRatio": 2.852022738805497
},
"2022": {
"obs_EconomicCapitalRatio": 1.0174342861200536
},
"2023": {
"obs_EconomicCapitalRatio": 1.083925115542916
}
},
"0001720893": {
"2018": {
"obs_EconomicCapitalRatio": 2.031438132927808
},
"2019": {
"obs_EconomicCapitalRatio": 7.684337873792798
},
"2020": {
"obs_EconomicCapitalRatio": 10.558813026558067
},
"2021": {
"obs_EconomicCapitalRatio": 4.729842390339243
},
"2022": {
"obs_EconomicCapitalRatio": 3.5299603687448617
},
"2023": {
"obs_EconomicCapitalRatio": 0.8587140121727126
}
},
"0001723128": {
"2018": {
"obs_EconomicCapitalRatio": 0.415203533677114
},
"2019": {
"obs_EconomicCapitalRatio": 0.18065044713560116
},
"2020": {
"obs_EconomicCapitalRatio": 0.1718239942463209
},
"2021": {
"obs_EconomicCapitalRatio": 0.19469925420081194
},
"2022": {
"obs_EconomicCapitalRatio": 0.08732183232289117
},
"2023": {
"obs_EconomicCapitalRatio": 0.5032006156988483
},
"2024": {
"obs_EconomicCapitalRatio": 0.6880617097541213
},
"2025": {
"obs_EconomicCapitalRatio": 1.0974009973927321
}
},
"0001724521": {
"2018": {
"obs_EconomicCapitalRatio": 3.008208356388294
},
"2019": {
"obs_EconomicCapitalRatio": 3.7292180755241033
},
"2020": {
"obs_EconomicCapitalRatio": 3.8563550492511514
},
"2021": {
"obs_EconomicCapitalRatio": 2.512052521732088
},
"2022": {
"obs_EconomicCapitalRatio": 1.9429558255953299
},
"2023": {
"obs_EconomicCapitalRatio": 2.1356368645167483
},
"2024": {
"obs_EconomicCapitalRatio": 2.0590112050369846
},
"2025": {
"obs_EconomicCapitalRatio": 3.641939566168213
}
},
"0001730430": {
"2018": {
"obs_EconomicCapitalRatio": 1.8816380603461278
},
"2019": {
"obs_EconomicCapitalRatio": 1.660159439750396
},
"2020": {
"obs_EconomicCapitalRatio": 3.045260196566863
},
"2021": {
"obs_EconomicCapitalRatio": 3.055856469183665
},
"2022": {
"obs_EconomicCapitalRatio": 2.032152591371752
},
"2023": {
"obs_EconomicCapitalRatio": 2.091221132933098
}
},
"0001739104": {
"2018": {
"obs_EconomicCapitalRatio": 1.7973732754806913
},
"2019": {
"obs_EconomicCapitalRatio": 1.7481325752317818
},
"2020": {
"obs_EconomicCapitalRatio": 1.0662567361290218
},
"2021": {
"obs_EconomicCapitalRatio": 1.0621834473295215
},
"2022": {
"obs_EconomicCapitalRatio": 0.4773477266025837
},
"2023": {
"obs_EconomicCapitalRatio": 0.6392950171837957
},
"2024": {
"obs_EconomicCapitalRatio": 0.613419169390112
},
"2025": {
"obs_EconomicCapitalRatio": 1.100692110544838
}
},
"0001746466": {
"2018": {
"obs_EconomicCapitalRatio": 4.161873700106537
},
"2019": {
"obs_EconomicCapitalRatio": 2.1735982867865347
},
"2020": {
"obs_EconomicCapitalRatio": 2.357638972989078
},
"2021": {
"obs_EconomicCapitalRatio": 2.3162186799119553
},
"2022": {
"obs_EconomicCapitalRatio": 0.5143186328567134
}
},
"0001534248": {
"2020": {
"obs_EconomicCapitalRatio": 19.16575959466217
},
"2021": {
"obs_EconomicCapitalRatio": 2.3500071338810997
},
"2022": {
"obs_EconomicCapitalRatio": 20.54831421144658
}
},
"0001622244": {
"2019": {
"obs_EconomicCapitalRatio": 59.08664512486836
},
"2020": {
"obs_EconomicCapitalRatio": 3.315685453794312
},
"2021": {
"obs_EconomicCapitalRatio": 2.3576372934404723
},
"2022": {
"obs_EconomicCapitalRatio": 1.4501694306847879
}
},
"0001623526": {
"2019": {
"obs_EconomicCapitalRatio": 7.74739908520579
},
"2020": {
"obs_EconomicCapitalRatio": 12.964685852432778
},
"2021": {
"obs_EconomicCapitalRatio": 6.1805890569330995
},
"2022": {
"obs_EconomicCapitalRatio": 2.0107832271209825
}
},
"0001649904": {
"2019": {
"obs_EconomicCapitalRatio": 6.079937722420159
},
"2021": {
"obs_EconomicCapitalRatio": 3.0156025697181783
},
"2022": {
"obs_EconomicCapitalRatio": 6.556528414134431
},
"2025": {
"obs_EconomicCapitalRatio": 21.653552672060908
}
},
"0001661059": {
"2019": {
"obs_EconomicCapitalRatio": 6.661137772072324
},
"2020": {
"obs_EconomicCapitalRatio": 1.8583391549245685
},
"2021": {
"obs_EconomicCapitalRatio": 1.3036217049364485
},
"2022": {
"obs_EconomicCapitalRatio": 0.3444290342244711
},
"2023": {
"obs_EconomicCapitalRatio": 0.44731514854614707
}
},
"0001680581": {
"2019": {
"obs_EconomicCapitalRatio": 5.7808098137940505
},
"2020": {
"obs_EconomicCapitalRatio": 4.260748062645979
},
"2021": {
"obs_EconomicCapitalRatio": 5.545902455372892
},
"2022": {
"obs_EconomicCapitalRatio": 2.5634132861588323
}
},
"0001690585": {
"2019": {
"obs_EconomicCapitalRatio": 102.2366531448102
},
"2020": {
"obs_EconomicCapitalRatio": 67.62029350291377
},
"2021": {
"obs_EconomicCapitalRatio": 43.073906165303356
},
"2022": {
"obs_EconomicCapitalRatio": 3.8790288898853373
}
},
"0001703647": {
"2019": {
"obs_EconomicCapitalRatio": 3.9689334067178352
},
"2020": {
"obs_EconomicCapitalRatio": 6.751884175181702
},
"2021": {
"obs_EconomicCapitalRatio": 1.5606886586463908
},
"2022": {
"obs_EconomicCapitalRatio": 0.964573573675129
}
},
"0001710340": {
"2019": {
"obs_EconomicCapitalRatio": 10.551165338630362
},
"2020": {
"obs_EconomicCapitalRatio": 11.152305168792797
},
"2021": {
"obs_EconomicCapitalRatio": 5.580918001036222
},
"2022": {
"obs_EconomicCapitalRatio": 4.076857430236477
},
"2023": {
"obs_EconomicCapitalRatio": 4.8694454718614555
},
"2024": {
"obs_EconomicCapitalRatio": 5.113958645322763
},
"2025": {
"obs_EconomicCapitalRatio": 5.65958338479525
}
},
"0001743881": {
"2019": {
"obs_EconomicCapitalRatio": 11.817891342219891
},
"2020": {
"obs_EconomicCapitalRatio": 12.923862718869536
},
"2021": {
"obs_EconomicCapitalRatio": 2.80267550168653
},
"2022": {
"obs_EconomicCapitalRatio": 0.9685514686017004
},
"2025": {
"obs_EconomicCapitalRatio": 7.423081982971124
}
},
"0001755237": {
"2019": {
"obs_EconomicCapitalRatio": 0.6467154509978333
},
"2020": {
"obs_EconomicCapitalRatio": 1.6091658350418265
},
"2021": {
"obs_EconomicCapitalRatio": 2.1222352909850035
},
"2022": {
"obs_EconomicCapitalRatio": 1.8967159585278592
}
},
"0001759425": {
"2019": {
"obs_EconomicCapitalRatio": 6.740158002097331
},
"2020": {
"obs_EconomicCapitalRatio": 3.0273910929081205
},
"2021": {
"obs_EconomicCapitalRatio": 2.050862904586447
},
"2022": {
"obs_EconomicCapitalRatio": 2.387721311230474
},
"2024": {
"obs_EconomicCapitalRatio": 3.573666967858353
},
"2025": {
"obs_EconomicCapitalRatio": 5.932467369373917
}
},
"0001761612": {
"2019": {
"obs_EconomicCapitalRatio": 2.487174279392095
},
"2020": {
"obs_EconomicCapitalRatio": 3.602705733294328
},
"2021": {
"obs_EconomicCapitalRatio": 5.652923697425659
},
"2022": {
"obs_EconomicCapitalRatio": 3.2433037923492805
}
},
"0001768224": {
"2019": {
"obs_EconomicCapitalRatio": 2.494416324374605
},
"2020": {
"obs_EconomicCapitalRatio": 8.691195070865797
},
"2021": {
"obs_EconomicCapitalRatio": 3.784184735102964
},
"2022": {
"obs_EconomicCapitalRatio": 1.4539389804718246
}
},
"0001781983": {
"2019": {
"obs_EconomicCapitalRatio": 11.417820453559177
},
"2020": {
"obs_EconomicCapitalRatio": 9.845984775457229
},
"2021": {
"obs_EconomicCapitalRatio": 2.165256182243437
},
"2022": {
"obs_EconomicCapitalRatio": 1.0867464139946783
},
"2023": {
"obs_EconomicCapitalRatio": 1.0559407672736314
}
},
"0001783183": {
"2019": {
"obs_EconomicCapitalRatio": 4.508790694494323
},
"2020": {
"obs_EconomicCapitalRatio": 5.193042395538745
},
"2021": {
"obs_EconomicCapitalRatio": 3.9761973177993113
},
"2022": {
"obs_EconomicCapitalRatio": 2.265079167617603
}
},
"0001808898": {
"2020": {
"obs_EconomicCapitalRatio": 2.1143833140342334
},
"2021": {
"obs_EconomicCapitalRatio": 1.9672621564562023
},
"2022": {
"obs_EconomicCapitalRatio": 1.0124988074946555
},
"2023": {
"obs_EconomicCapitalRatio": 1.9162068530827412
}
},
"0000921299": {
"2020": {
"obs_EconomicCapitalRatio": 6.037695737495577
},
"2021": {
"obs_EconomicCapitalRatio": 2.0679100904341126
},
"2022": {
"obs_EconomicCapitalRatio": 2.3772951556496356
}
},
"0001444192": {
"2020": {
"obs_EconomicCapitalRatio": 1.8212668931042104
},
"2021": {
"obs_EconomicCapitalRatio": 1.601910280914289
}
},
"0001453687": {
"2020": {
"obs_EconomicCapitalRatio": 1.885318991628831
},
"2021": {
"obs_EconomicCapitalRatio": 2.583586463141516
},
"2022": {
"obs_EconomicCapitalRatio": 1.37528869806314
},
"2023": {
"obs_EconomicCapitalRatio": 0.2969628497898465
},
"2024": {
"obs_EconomicCapitalRatio": 1.0950299982334744
},
"2025": {
"obs_EconomicCapitalRatio": 0.4954362901108546
}
},
"0001468639": {
"2020": {
"obs_EconomicCapitalRatio": 41.71486278196386
},
"2021": {
"obs_EconomicCapitalRatio": 91.93342781717148
},
"2022": {
"obs_EconomicCapitalRatio": 58.302482661739276
}
},
"0001472012": {
"2020": {
"obs_EconomicCapitalRatio": 4.454862991960487
},
"2021": {
"obs_EconomicCapitalRatio": 5.523992589733809
},
"2022": {
"obs_EconomicCapitalRatio": 2.422759521127661
},
"2023": {
"obs_EconomicCapitalRatio": 4.280267182756013
},
"2024": {
"obs_EconomicCapitalRatio": 4.585594760034545
}
},
"0001477845": {
"2020": {
"obs_EconomicCapitalRatio": 10.403516812427029
},
"2021": {
"obs_EconomicCapitalRatio": 6.81015427205511
},
"2022": {
"obs_EconomicCapitalRatio": 4.367600605808978
},
"2023": {
"obs_EconomicCapitalRatio": 9.447126381813128
}
},
"0001549595": {
"2020": {
"obs_EconomicCapitalRatio": 6.056262987617507
},
"2021": {
"obs_EconomicCapitalRatio": 4.328866026019691
},
"2022": {
"obs_EconomicCapitalRatio": 1.9390477295987234
},
"2023": {
"obs_EconomicCapitalRatio": 1.8453547894611453
},
"2024": {
"obs_EconomicCapitalRatio": 3.4698470832360737
},
"2025": {
"obs_EconomicCapitalRatio": 3.516804360887202
}
},
"0001571934": {
"2020": {
"obs_EconomicCapitalRatio": 1.9367055523471661
},
"2021": {
"obs_EconomicCapitalRatio": 3.0562030121239125
},
"2022": {
"obs_EconomicCapitalRatio": 0.3571391225015261
},
"2023": {
"obs_EconomicCapitalRatio": 0.3055024340497261
}
},
"0001593899": {
"2020": {
"obs_EconomicCapitalRatio": 4.982388173173559
},
"2021": {
"obs_EconomicCapitalRatio": 1.7889261352116168
},
"2022": {
"obs_EconomicCapitalRatio": 1.1023371148257655
}
},
"0001599298": {
"2020": {
"obs_EconomicCapitalRatio": 7.253437136286895
},
"2021": {
"obs_EconomicCapitalRatio": 3.630304594545802
},
"2022": {
"obs_EconomicCapitalRatio": 1.3285352790419083
},
"2023": {
"obs_EconomicCapitalRatio": 11.018534843177335
},
"2024": {
"obs_EconomicCapitalRatio": 55.96920150546034
},
"2025": {
"obs_EconomicCapitalRatio": 31.41912147041661
}
},
"0001600620": {
"2021": {
"obs_EconomicCapitalRatio": 9.703248034518616
},
"2022": {
"obs_EconomicCapitalRatio": 2.374302612487517
},
"2023": {
"obs_EconomicCapitalRatio": 3.7093327061713572
},
"2024": {
"obs_EconomicCapitalRatio": 3.588324024493516
},
"2025": {
"obs_EconomicCapitalRatio": 4.595182884458584
}
},
"0001636651": {
"2020": {
"obs_EconomicCapitalRatio": 3.065681924492594
},
"2021": {
"obs_EconomicCapitalRatio": 2.117481637967616
},
"2022": {
"obs_EconomicCapitalRatio": 1.3598528063187154
},
"2023": {
"obs_EconomicCapitalRatio": 2.4106470615597217
},
"2024": {
"obs_EconomicCapitalRatio": 1.2035985474563016
}
},
"0001664710": {
"2020": {
"obs_EconomicCapitalRatio": 11.15743911511553
},
"2021": {
"obs_EconomicCapitalRatio": 9.823255567688177
},
"2022": {
"obs_EconomicCapitalRatio": 7.868704196501648
},
"2023": {
"obs_EconomicCapitalRatio": 5.476382983993136
},
"2024": {
"obs_EconomicCapitalRatio": 2.0694873777143337
},
"2025": {
"obs_EconomicCapitalRatio": 3.3872065454063467
}
},
"0001672619": {
"2020": {
"obs_EconomicCapitalRatio": 32.27703889816523
},
"2021": {
"obs_EconomicCapitalRatio": 4.815995993435351
}
},
"0001676725": {
"2020": {
"obs_EconomicCapitalRatio": 1.910906464785605
},
"2021": {
"obs_EconomicCapitalRatio": 3.888299033936247
},
"2022": {
"obs_EconomicCapitalRatio": 3.8187736139631454
}
},
"0001677077": {
"2021": {
"obs_EconomicCapitalRatio": 134.03651058526592
},
"2022": {
"obs_EconomicCapitalRatio": 10.957841768849988
},
"2023": {
"obs_EconomicCapitalRatio": 1.445083947343951
},
"2024": {
"obs_EconomicCapitalRatio": 3.3768356960216277
}
},
"0001678660": {
"2020": {
"obs_EconomicCapitalRatio": 29.852580691842824
},
"2021": {
"obs_EconomicCapitalRatio": 3.7897608225132036
},
"2022": {
"obs_EconomicCapitalRatio": 1.9743198737884817
}
},
"0001680367": {
"2020": {
"obs_EconomicCapitalRatio": 11.337515983150187
},
"2021": {
"obs_EconomicCapitalRatio": 2.2396700444705333
},
"2022": {
"obs_EconomicCapitalRatio": 0.8695375359442132
},
"2023": {
"obs_EconomicCapitalRatio": 3.2164383492063244
},
"2025": {
"obs_EconomicCapitalRatio": 4.095392329748731
}
},
"0001695473": {
"2020": {
"obs_EconomicCapitalRatio": 4.669797408223305
},
"2021": {
"obs_EconomicCapitalRatio": 4.255756953222455
},
"2022": {
"obs_EconomicCapitalRatio": 0.9977644045203846
},
"2023": {
"obs_EconomicCapitalRatio": 1.937291648646682
},
"2024": {
"obs_EconomicCapitalRatio": 1.1364421533009899
}
},
"0001699382": {
"2020": {
"obs_EconomicCapitalRatio": 12.848011118817782
},
"2021": {
"obs_EconomicCapitalRatio": 5.929521083876715
},
"2022": {
"obs_EconomicCapitalRatio": 2.715854942883037
}
},
"0001720580": {
"2020": {
"obs_EconomicCapitalRatio": 2.81568620431054
},
"2021": {
"obs_EconomicCapitalRatio": 2.6874207501034557
},
"2022": {
"obs_EconomicCapitalRatio": 1.8902049958954465
}
},
"0001725160": {
"2020": {
"obs_EconomicCapitalRatio": 10.979229591790343
},
"2021": {
"obs_EconomicCapitalRatio": 13.702353859771764
},
"2022": {
"obs_EconomicCapitalRatio": 3.3174172620290943
},
"2023": {
"obs_EconomicCapitalRatio": 3.089962409485199
},
"2024": {
"obs_EconomicCapitalRatio": 0.8290663394065225
}
},
"0001726711": {
"2020": {
"obs_EconomicCapitalRatio": 0.0
},
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001728328": {
"2020": {
"obs_EconomicCapitalRatio": 4.577471381356152
},
"2021": {
"obs_EconomicCapitalRatio": 3.271531063244177
},
"2022": {
"obs_EconomicCapitalRatio": 0.17978140318971794
},
"2023": {
"obs_EconomicCapitalRatio": 0.23825555809900759
},
"2024": {
"obs_EconomicCapitalRatio": 3.88013069052814
}
},
"0001742927": {
"2020": {
"obs_EconomicCapitalRatio": 7.287951365168326
},
"2022": {
"obs_EconomicCapitalRatio": 5.5409080631952605
},
"2023": {
"obs_EconomicCapitalRatio": 4.613513866544896
},
"2024": {
"obs_EconomicCapitalRatio": 3.7878517832107255
},
"2025": {
"obs_EconomicCapitalRatio": 3.1156774432362093
}
},
"0001746473": {
"2020": {
"obs_EconomicCapitalRatio": 5.857802788342808
},
"2021": {
"obs_EconomicCapitalRatio": 4.3773197207660886
},
"2022": {
"obs_EconomicCapitalRatio": 4.726552714214153
},
"2023": {
"obs_EconomicCapitalRatio": 3.7010006534345026
},
"2024": {
"obs_EconomicCapitalRatio": 3.333291209670626
},
"2025": {
"obs_EconomicCapitalRatio": 0.5568651663918129
}
},
"0001763950": {
"2020": {
"obs_EconomicCapitalRatio": 11.355252435808278
},
"2021": {
"obs_EconomicCapitalRatio": 2.1722035078289954
},
"2022": {
"obs_EconomicCapitalRatio": 1.9693754788301854
},
"2023": {
"obs_EconomicCapitalRatio": 1.9424356466155677
},
"2024": {
"obs_EconomicCapitalRatio": 2.3113357750235837
},
"2025": {
"obs_EconomicCapitalRatio": 4.7509364652543695
}
},
"0001787306": {
"2020": {
"obs_EconomicCapitalRatio": 7.791943253314391
},
"2021": {
"obs_EconomicCapitalRatio": 3.910142729960259
},
"2022": {
"obs_EconomicCapitalRatio": 2.524778961577347
},
"2023": {
"obs_EconomicCapitalRatio": 0.8833479379113233
},
"2024": {
"obs_EconomicCapitalRatio": 6.317635141059226
},
"2025": {
"obs_EconomicCapitalRatio": 10.417323618496392
}
},
"0001787400": {
"2020": {
"obs_EconomicCapitalRatio": 12.296919314685818
},
"2021": {
"obs_EconomicCapitalRatio": 3.3411289373909545
},
"2022": {
"obs_EconomicCapitalRatio": 0.9793904296250519
}
},
"0001792044": {
"2020": {
"obs_EconomicCapitalRatio": 2.8519194602188337e-08
},
"2021": {
"obs_EconomicCapitalRatio": 0.3023160057060142
},
"2022": {
"obs_EconomicCapitalRatio": 0.2882186828643058
},
"2023": {
"obs_EconomicCapitalRatio": 0.3069370365291023
},
"2024": {
"obs_EconomicCapitalRatio": 0.4330347985069521
},
"2025": {
"obs_EconomicCapitalRatio": 0.46088319499372177
}
},
"0001799788": {
"2020": {
"obs_EconomicCapitalRatio": 30.42976875216127
},
"2021": {
"obs_EconomicCapitalRatio": 24.51891800687105
},
"2022": {
"obs_EconomicCapitalRatio": 26.799867229313154
},
"2023": {
"obs_EconomicCapitalRatio": 37.84356462519523
},
"2024": {
"obs_EconomicCapitalRatio": 56.6613741545884
},
"2025": {
"obs_EconomicCapitalRatio": 36.68280029973951
}
},
"0001802665": {
"2020": {
"obs_EconomicCapitalRatio": 5.468950647202746
},
"2021": {
"obs_EconomicCapitalRatio": 7.357291711352325
},
"2022": {
"obs_EconomicCapitalRatio": 6.968809248214065
},
"2023": {
"obs_EconomicCapitalRatio": 3.318508034292695
}
},
"0001802768": {
"2020": {
"obs_EconomicCapitalRatio": 1.5083605602075743
},
"2021": {
"obs_EconomicCapitalRatio": 1.2404006192636492
},
"2022": {
"obs_EconomicCapitalRatio": 1.3215216000222363
},
"2023": {
"obs_EconomicCapitalRatio": 1.0095920224940342
},
"2024": {
"obs_EconomicCapitalRatio": 0.8300691833941843
},
"2025": {
"obs_EconomicCapitalRatio": 1.1156824324208434
}
},
"0001810182": {
"2020": {
"obs_EconomicCapitalRatio": 14.62861782260423
},
"2021": {
"obs_EconomicCapitalRatio": 4.550269504823056
},
"2022": {
"obs_EconomicCapitalRatio": 2.487207345201067
}
},
"0001818794": {
"2020": {
"obs_EconomicCapitalRatio": 5.4526504778285885
},
"2021": {
"obs_EconomicCapitalRatio": 2.641862011132604
},
"2022": {
"obs_EconomicCapitalRatio": 3.6937309216583993
}
},
"0001819576": {
"2021": {
"obs_EconomicCapitalRatio": 3.8709267163294454
},
"2022": {
"obs_EconomicCapitalRatio": 4.761078308530657
},
"2023": {
"obs_EconomicCapitalRatio": 7.8453765509689095
}
},
"0001822462": {
"2020": {
"obs_EconomicCapitalRatio": 4.751909233181428
},
"2021": {
"obs_EconomicCapitalRatio": 1.6675293224063918
},
"2022": {
"obs_EconomicCapitalRatio": 0.6272968813672785
},
"2023": {
"obs_EconomicCapitalRatio": 0.8280520764862019
},
"2024": {
"obs_EconomicCapitalRatio": 0.8980197292338962
}
},
"0001280776": {
"2021": {
"obs_EconomicCapitalRatio": 3.3340617426522416
},
"2022": {
"obs_EconomicCapitalRatio": 0.7059338103397217
},
"2023": {
"obs_EconomicCapitalRatio": 1.666027643790281
},
"2024": {
"obs_EconomicCapitalRatio": 2.945386156378902
},
"2025": {
"obs_EconomicCapitalRatio": 2.5033241416493146
}
},
"0001419041": {
"2021": {
"obs_EconomicCapitalRatio": 1.4209741119297001
},
"2022": {
"obs_EconomicCapitalRatio": 0.9297002390649902
}
},
"0001452804": {
"2022": {
"obs_EconomicCapitalRatio": 3168.512429183764
}
},
"0001490978": {
"2025": {
"obs_EconomicCapitalRatio": 2.117089071809597
}
},
"0001574094": {
"2021": {
"obs_EconomicCapitalRatio": 5.150953517551173
},
"2022": {
"obs_EconomicCapitalRatio": 4.409128500339078
},
"2023": {
"obs_EconomicCapitalRatio": 3.3439971517133937
},
"2024": {
"obs_EconomicCapitalRatio": 5.205257127532486
}
},
"0001601485": {
"2021": {
"obs_EconomicCapitalRatio": 1.415639197764491
},
"2022": {
"obs_EconomicCapitalRatio": 0.8165700887487293
},
"2023": {
"obs_EconomicCapitalRatio": 2.5601919164746474
},
"2024": {
"obs_EconomicCapitalRatio": 1.6178696291329993
},
"2025": {
"obs_EconomicCapitalRatio": 5.583320492672247
}
},
"0001637715": {
"2021": {
"obs_EconomicCapitalRatio": 2.6119057182116054
},
"2022": {
"obs_EconomicCapitalRatio": 0.9188554177683708
}
},
"0001641281": {
"2021": {
"obs_EconomicCapitalRatio": 0.9512093355759328
},
"2022": {
"obs_EconomicCapitalRatio": 0.3446517584862095
}
},
"0001645460": {
"2021": {
"obs_EconomicCapitalRatio": 7.119845614894133
},
"2022": {
"obs_EconomicCapitalRatio": 1.6334346042316759
}
},
"0001660334": {
"2021": {
"obs_EconomicCapitalRatio": 3.9992043021661643
},
"2022": {
"obs_EconomicCapitalRatio": 4.416390192021974
},
"2025": {
"obs_EconomicCapitalRatio": 2.233302684760354
}
},
"0001671858": {
"2021": {
"obs_EconomicCapitalRatio": 1.3161514949634543
},
"2022": {
"obs_EconomicCapitalRatio": 2.0094306464423357
}
},
"0001683553": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001684144": {
"2021": {
"obs_EconomicCapitalRatio": 2.325411279249918
},
"2022": {
"obs_EconomicCapitalRatio": 1.1047721659202565
},
"2023": {
"obs_EconomicCapitalRatio": 1.5634931168213562
}
},
"0001689375": {
"2021": {
"obs_EconomicCapitalRatio": 3.4050607267756394
},
"2022": {
"obs_EconomicCapitalRatio": 3.277871231738275
},
"2023": {
"obs_EconomicCapitalRatio": 1.4420649053685184
},
"2024": {
"obs_EconomicCapitalRatio": 2.091201556950649
},
"2025": {
"obs_EconomicCapitalRatio": 1.8060770649526663
}
},
"0001689548": {
"2021": {
"obs_EconomicCapitalRatio": 5.257153136894679
},
"2022": {
"obs_EconomicCapitalRatio": 1.4008110546579007
},
"2023": {
"obs_EconomicCapitalRatio": 48.6720633206395
},
"2024": {
"obs_EconomicCapitalRatio": 5.492877727846892
},
"2025": {
"obs_EconomicCapitalRatio": 13.798237590422602
}
},
"0001703057": {
"2021": {
"obs_EconomicCapitalRatio": 5.128698575879268
},
"2022": {
"obs_EconomicCapitalRatio": 3.148047741990266
},
"2023": {
"obs_EconomicCapitalRatio": 1.8105113718561898
},
"2024": {
"obs_EconomicCapitalRatio": 1.023568114995679
},
"2025": {
"obs_EconomicCapitalRatio": 1.218246727455875
}
},
"0001710072": {
"2021": {
"obs_EconomicCapitalRatio": 5.066391448451008
},
"2022": {
"obs_EconomicCapitalRatio": 2.735818420050592
},
"2023": {
"obs_EconomicCapitalRatio": 3.2535404403961716
},
"2024": {
"obs_EconomicCapitalRatio": 10.977887819024053
}
},
"0001716947": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.28645113019466883
},
"2023": {
"obs_EconomicCapitalRatio": 1.1047546706759725
},
"2024": {
"obs_EconomicCapitalRatio": 41.079123913525216
},
"2025": {
"obs_EconomicCapitalRatio": 0.656978176046888
}
},
"0001736243": {
"2021": {
"obs_EconomicCapitalRatio": 6.565093390600356
},
"2022": {
"obs_EconomicCapitalRatio": 7.884893700132662
},
"2023": {
"obs_EconomicCapitalRatio": 9.335254148753522
}
},
"0001750284": {
"2021": {
"obs_EconomicCapitalRatio": 2.511734257269554
},
"2022": {
"obs_EconomicCapitalRatio": 0.8463406216798857
}
},
"0001752828": {
"2021": {
"obs_EconomicCapitalRatio": 1.6228382618914432
},
"2022": {
"obs_EconomicCapitalRatio": 0.5793503252191476
},
"2024": {
"obs_EconomicCapitalRatio": 0.3913511061415067
},
"2025": {
"obs_EconomicCapitalRatio": 0.2903284139304872
}
},
"0001761918": {
"2021": {
"obs_EconomicCapitalRatio": 6.429819762928459
},
"2022": {
"obs_EconomicCapitalRatio": 1.6612816937900394
}
},
"0001768446": {
"2021": {
"obs_EconomicCapitalRatio": 3.163784830589746
},
"2022": {
"obs_EconomicCapitalRatio": 1.0700868561112922
}
},
"0001782223": {
"2021": {
"obs_EconomicCapitalRatio": 2.111294265873082
},
"2022": {
"obs_EconomicCapitalRatio": 0.3323020132912376
}
},
"0001785530": {
"2021": {
"obs_EconomicCapitalRatio": 3.1720410978971088
},
"2022": {
"obs_EconomicCapitalRatio": 0.5601135472074897
},
"2023": {
"obs_EconomicCapitalRatio": 0.9462244042196647
},
"2024": {
"obs_EconomicCapitalRatio": 0.7704248818211188
}
},
"0001790340": {
"2021": {
"obs_EconomicCapitalRatio": 5.672639281594998
},
"2022": {
"obs_EconomicCapitalRatio": 1.708970518177094
},
"2023": {
"obs_EconomicCapitalRatio": 3.80062421348927
},
"2024": {
"obs_EconomicCapitalRatio": 2.1236015682286755
},
"2025": {
"obs_EconomicCapitalRatio": 3.4114869322297863
}
},
"0001798749": {
"2021": {
"obs_EconomicCapitalRatio": 2.7499402452773416
},
"2022": {
"obs_EconomicCapitalRatio": 9.087261432076014
},
"2023": {
"obs_EconomicCapitalRatio": 7.725094101880131
}
},
"0001806952": {
"2021": {
"obs_EconomicCapitalRatio": 2.7658237776442247
},
"2022": {
"obs_EconomicCapitalRatio": 1.4549797893575631
},
"2023": {
"obs_EconomicCapitalRatio": 1.2100115484779883
},
"2024": {
"obs_EconomicCapitalRatio": 0.5879123817937689
},
"2025": {
"obs_EconomicCapitalRatio": 3.361295963504125
}
},
"0001807120": {
"2021": {
"obs_EconomicCapitalRatio": 5.110273773093571
},
"2022": {
"obs_EconomicCapitalRatio": 2.9091935322443994
}
},
"0001810560": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
}
},
"0001811063": {
"2021": {
"obs_EconomicCapitalRatio": 4.4594460489134535
},
"2022": {
"obs_EconomicCapitalRatio": 1.156596156073967
}
},
"0001815903": {
"2021": {
"obs_EconomicCapitalRatio": 0.9315853262360096
},
"2022": {
"obs_EconomicCapitalRatio": 1.8389462883029757
},
"2023": {
"obs_EconomicCapitalRatio": 0.11262634902034269
}
},
"0001815974": {
"2021": {
"obs_EconomicCapitalRatio": 13.860591563674177
},
"2022": {
"obs_EconomicCapitalRatio": 8.012390333548375
},
"2023": {
"obs_EconomicCapitalRatio": 9.79937517371494
},
"2024": {
"obs_EconomicCapitalRatio": 17.533372649206587
}
},
"0001816590": {
"2022": {
"obs_EconomicCapitalRatio": 3.469069793877861
},
"2023": {
"obs_EconomicCapitalRatio": 3.181819330791114
},
"2024": {
"obs_EconomicCapitalRatio": 1.9976368353893532
}
},
"0001816736": {
"2021": {
"obs_EconomicCapitalRatio": 1.5673969847038716
},
"2022": {
"obs_EconomicCapitalRatio": 17.946181285719497
}
},
"0001817713": {
"2021": {
"obs_EconomicCapitalRatio": 4.222290083037995
},
"2022": {
"obs_EconomicCapitalRatio": 2.4602137482729134
}
},
"0001818844": {
"2021": {
"obs_EconomicCapitalRatio": 5.108939352094039
},
"2022": {
"obs_EconomicCapitalRatio": 0.9600408848841279
},
"2023": {
"obs_EconomicCapitalRatio": 5.086933153035263
}
},
"0001819133": {
"2021": {
"obs_EconomicCapitalRatio": 2.9059148447166874
},
"2022": {
"obs_EconomicCapitalRatio": 2.1709711795560804
}
},
"0001819411": {
"2021": {
"obs_EconomicCapitalRatio": 3.076434388579569
},
"2022": {
"obs_EconomicCapitalRatio": 2.4217228765908048
},
"2023": {
"obs_EconomicCapitalRatio": 2.6616627665067916
}
},
"0001821825": {
"2021": {
"obs_EconomicCapitalRatio": 0.9514939785370281
},
"2022": {
"obs_EconomicCapitalRatio": 0.9005471267937213
},
"2023": {
"obs_EconomicCapitalRatio": 0.2657689617152537
},
"2024": {
"obs_EconomicCapitalRatio": 0.2860582314552151
},
"2025": {
"obs_EconomicCapitalRatio": 0.14698366747611746
}
},
"0001823239": {
"2021": {
"obs_EconomicCapitalRatio": 3.324821543814707
},
"2022": {
"obs_EconomicCapitalRatio": 1.0187043552243467
},
"2023": {
"obs_EconomicCapitalRatio": 0.7979658106136953
},
"2024": {
"obs_EconomicCapitalRatio": 1.079141954197552
},
"2025": {
"obs_EconomicCapitalRatio": 0.82289065119173
}
},
"0001824293": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 1.766930002257645
},
"2025": {
"obs_EconomicCapitalRatio": 0.18999951389172234
}
},
"0001828673": {
"2021": {
"obs_EconomicCapitalRatio": 3.034524794547648
},
"2022": {
"obs_EconomicCapitalRatio": 2.4330632068491176
}
},
"0001829635": {
"2021": {
"obs_EconomicCapitalRatio": 0.0
},
"2022": {
"obs_EconomicCapitalRatio": 0.0
},
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 7.880452829308091
}
},
"0001829802": {
"2021": {
"obs_EconomicCapitalRatio": 2.1770565929437673
},
"2022": {
"obs_EconomicCapitalRatio": 0.6635101635348523
}
},
"0001840233": {
"2021": {
"obs_EconomicCapitalRatio": 3.411233264533946
},
"2022": {
"obs_EconomicCapitalRatio": 0.7416409577746491
},
"2023": {
"obs_EconomicCapitalRatio": 0.36062284533159966
}
},
"0001840904": {
"2021": {
"obs_EconomicCapitalRatio": 5.634686356849057
},
"2022": {
"obs_EconomicCapitalRatio": 2.701176549058382
}
},
"0001857044": {
"2021": {
"obs_EconomicCapitalRatio": 2.126214716188324
},
"2022": {
"obs_EconomicCapitalRatio": 0.8140410650242103
},
"2023": {
"obs_EconomicCapitalRatio": 1.748806858580108
},
"2024": {
"obs_EconomicCapitalRatio": 1.7037172495363144
},
"2025": {
"obs_EconomicCapitalRatio": 0.5309387175287837
}
},
"0001858685": {
"2021": {
"obs_EconomicCapitalRatio": 2.0565299498420657
},
"2022": {
"obs_EconomicCapitalRatio": 0.6194003825807052
},
"2023": {
"obs_EconomicCapitalRatio": 0.17770193395364212
},
"2024": {
"obs_EconomicCapitalRatio": 0.395556793187993
},
"2025": {
"obs_EconomicCapitalRatio": 0.3598275158539455
}
},
"0001861560": {
"2021": {
"obs_EconomicCapitalRatio": 5.488287614155773
},
"2022": {
"obs_EconomicCapitalRatio": 5.949742697006308
}
},
"0001861657": {
"2022": {
"obs_EconomicCapitalRatio": 1.1921959530489235
},
"2023": {
"obs_EconomicCapitalRatio": 1.4108271541154638
},
"2024": {
"obs_EconomicCapitalRatio": 1.0148133307016274
}
},
"0001863127": {
"2021": {
"obs_EconomicCapitalRatio": 3.6689204765827528
},
"2022": {
"obs_EconomicCapitalRatio": 2.3778352646735605
}
},
"0001865494": {
"2021": {
"obs_EconomicCapitalRatio": 1.984167670127024
},
"2022": {
"obs_EconomicCapitalRatio": 0.912960344779015
}
},
"0001867096": {
"2021": {
"obs_EconomicCapitalRatio": 1.1827520422190887
},
"2022": {
"obs_EconomicCapitalRatio": 0.5343457845599805
},
"2023": {
"obs_EconomicCapitalRatio": 0.8876602074616373
},
"2024": {
"obs_EconomicCapitalRatio": 1.5068427753479947
},
"2025": {
"obs_EconomicCapitalRatio": 3.213363246006965
}
},
"0001873835": {
"2022": {
"obs_EconomicCapitalRatio": 3.612121626948463
},
"2023": {
"obs_EconomicCapitalRatio": 9.546066891374704
},
"2024": {
"obs_EconomicCapitalRatio": 3.6907687937165123
},
"2025": {
"obs_EconomicCapitalRatio": 3.2771052417139117
}
},
"0001231457": {
"2023": {
"obs_EconomicCapitalRatio": 20.58658297936221
},
"2024": {
"obs_EconomicCapitalRatio": 3.8012970654339866
},
"2025": {
"obs_EconomicCapitalRatio": 12.487756265058431
}
},
"0001575142": {
"2023": {
"obs_EconomicCapitalRatio": 0.46157616565160214
},
"2024": {
"obs_EconomicCapitalRatio": 137.2589511115023
},
"2025": {
"obs_EconomicCapitalRatio": 0.20558168607917748
}
},
"0001690080": {
"2023": {
"obs_EconomicCapitalRatio": 0.24947006630043778
}
},
"0001704292": {
"2025": {
"obs_EconomicCapitalRatio": 23.99537244484833
}
},
"0001719406": {
"2023": {
"obs_EconomicCapitalRatio": 2.8107941259243874
},
"2024": {
"obs_EconomicCapitalRatio": 1.2123808991964091
},
"2025": {
"obs_EconomicCapitalRatio": 3.256314248115792
}
},
"0001728117": {
"2023": {
"obs_EconomicCapitalRatio": 0.7082923364427968
},
"2024": {
"obs_EconomicCapitalRatio": 0.6442715394449453
}
},
"0001729427": {
"2023": {
"obs_EconomicCapitalRatio": 0.0
},
"2024": {
"obs_EconomicCapitalRatio": 1.3765743708780394
},
"2025": {
"obs_EconomicCapitalRatio": 0.6059397013669012
}
},
"0001771910": {
"2024": {
"obs_EconomicCapitalRatio": 0.4591204113571571
},
"2025": {
"obs_EconomicCapitalRatio": 1.0509994743294888
}
},
"0001834105": {
"2024": {
"obs_EconomicCapitalRatio": 1.0074543225769161
},
"2025": {
"obs_EconomicCapitalRatio": 5.449758180736699
}
},
"0001847903": {
"2023": {
"obs_EconomicCapitalRatio": 3.1551998397667322
},
"2024": {
"obs_EconomicCapitalRatio": 5.9799791062469065
}
},
"0001860657": {
"2023": {
"obs_EconomicCapitalRatio": 0.22728545269121814
},
"2024": {
"obs_EconomicCapitalRatio": 0.2806654262934393
},
"2025": {
"obs_EconomicCapitalRatio": 1.2323411898099832
}
},
"0001873875": {
"2023": {
"obs_EconomicCapitalRatio": 456.5184457750075
},
"2024": {
"obs_EconomicCapitalRatio": 2.550487370004812
}
},
"0001904286": {
"2023": {
"obs_EconomicCapitalRatio": 5.895620284301549
},
"2024": {
"obs_EconomicCapitalRatio": 9.85535789993241
},
"2025": {
"obs_EconomicCapitalRatio": 10.827874200411674
}
},
"0001610820": {
"2024": {
"obs_EconomicCapitalRatio": 3.431083357476488
},
"2025": {
"obs_EconomicCapitalRatio": 1.1485388588887744
}
},
"0001625297": {
"2025": {
"obs_EconomicCapitalRatio": 3.599845897191032
}
},
"0001677940": {
"2025": {
"obs_EconomicCapitalRatio": 1.9832255110904602
}
},
"0001679628": {
"2024": {
"obs_EconomicCapitalRatio": 88.34065319613647
},
"2025": {
"obs_EconomicCapitalRatio": 5.844019823713041
}
}
}
}